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Abstract 
 
Lymphocytes express antigen receptors which are formed by re-arrangement of gene 
segments. Mutations acquired during this process, predominantly in the 
complementarity determining regions (CDRs), result in generation of non-germline 
sequences.  Through analysing the CDR3 sequence, this study attempts to determine 
whether editing of the lymphocyte repertoire is present in an HLA-dependant manner. 
 
Data presented demonstrates a decrease frequency of CDR3-derived HLA-A2 binding 
peptides in HLA-A2+ donors (0.03% (SYFPEITHI) and 0.35% (BIMAS)) compared 
with HLA-A2- donors (0.24% (SYFPEITHI, p=0.01) and 0.54% (BIMAS, p=0.19)). 
Trends similar to those seen in HLA-A2 were observed in other HLA alleles as well 
suggesting that there may be a process by which potentially dangerous B cell 
populations are edited from the B cell repertoire.  Similar analysis of the TCR CDR3 
did not reveal any such process in all of the HLA alleles tested suggesting that there is 
no immunoediting of the T cell repertoire.  
 
Simultaneously, this study attempts to determine the processing and presentation of 
CDR3-derived peptides at the cell surface using lymphocyte antigen receptor models 
containing CDR3-encoded viral epitopes.  The apparent presence of these peptides on 
the cell surface leads to the hypothesis that antibodies enter the antigen processing 
pathway and potentially deliver an immunogenic peptide to a target cell.  Using 
antibodies specific for B cells, this study has shown that cells labelled with an 
antibody-peptide complex are targeted and lysed by cytotoxic CD4+ T cells in a 
peptide-specific manner. The use of such technology in antibody immunotherapy may 
be of considerable therapeutic benefit.  
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Chapter 1 - Introduction 
 
 
1.1 The Immune System 
The immune system is a complex network consisting of many different cell types and 
soluble factors. Conventionally, it has been divided into two distinct sections, the 
innate and the adaptive immune systems, however, there is considerable overlap 
between these two systems and they function seamlessly in concert with each other.   
 
The innate immune system is often seen as the first line of defence against invading 
pathogens and consists of cells which recognise proteins and molecules only present 
on pathogens, termed pathogen associated molecular patterns.  It also consists of 
many soluble factors such as lipid mediators of inflammation (prostaglandins and 
leukotrienes) and the kinin system (bradykinins), which help to prevent the spread of 
invading pathogens.  Although the innate immune system is very quick to react to the 
presence of pathogens within the body, sometimes it is not enough to prevent the 
pathogen spreading throughout the body.  Within 48-96 hours after infection, the 
adaptive immune system begins to play an active role in controlling the invading 
pathogen.  The adaptive immune system consists of soluble factors as well as two 
distinct cell types, B cells and T cells.  The soluble factors mainly comprise of 
cytokines, small proteins produced by cells involved in signalling and cell maturation, 
and antibodies - secreted by stimulated B cells.  The adaptive immune system is 
extremely sensitive and specific for invading pathogens, and can recognise either 
short, processed peptide fragments or whole, unprocessed proteins.  As well as 
differences in the kinetics of the different innate and adaptive immune response, they 
differ in terms of magnitude, with the adaptive arm able to generate stronger and 
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faster secondary immune responses, a hallmark of immunological memory.  The 
innate immune system is set before birth and cannot be altered and therefore, every 
challenge with the same antigen will mount a similar immune response.  However, the 
adaptive immune system has the ability to retain memory B and T cells, generated 
after the first immune response against the pathogen, which can be called upon the 
next time the host is infected with the same pathogen.  This results in a faster, 
stronger, and therefore more effective, immune response on subsequent re-exposure to 
a given pathogen, typically aborting infection. 
 
1.2 Adaptive Immune Responses 
1.2.1 B Cells 
B cells are generated and mature in the bone marrow and those which develop 
earliest, typically expressing CD5 and produce IgM natural antibodies, are termed B1 
cells.  The surface immunoglobulin expressed by these B1 cells is thought to 
recognise receptors on many common pathogens, but with a lower affinity for their 
antigen (Hayakawa et al., 1999 and Youinou et al, 1999) and are thought to be less 
diverse than the other B cells. 
 
B2 cells (termed B cells from here on), which lack CD5 expression, develop slightly 
later and are the B cells that produce the majority of the IgG, IgA and IgE antibodies 
found in the body.  B cells recognise antigen, either conformational or linear epitopes, 
through their surface immunoglobulin receptor.  Mature, naïve B cells co-express IgM 
and IgD on the cell surface but can switch their immunoglobulin heavy chain to IgA, 
IgE or IgG after stimulation with their cognate antigen and before they become 
memory B cells.  Upon activation and maturation, B cells become antibody producing 
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cells termed plasma cells.  The antibody produced by the B cell contains exactly the 
same specificity as the surface immunoglobulin receptor.  There are a few differences 
between the two including the absence of a transmembrane region and short 
cytoplasmic tail in the secreted antibody and the presence of a joining (J) chain which 
links multiple IgM and IgA antibodies into multimeric structures.  Antibodies 
function in many different ways, dependent upon the heavy chain used, to prevent the 
spread and to aid in the killing of the pathogen.   
 
Antibodies may also limit pathogen infection by binding to pathogen receptors and 
neutralising secreted toxins.  In addition, antibodies potently opsonise invading 
pathogens leading to killing via phagocytosis or through complement dependent 
cytotoxicity (CDC).  Furthermore, another mechanism to control viral infections is 
termed antibody dependant cellular cytotoxicity (ADCC) whereby infected host cells 
are coated by viral-specific antibodies and lead to engagement with cytotoxic 
lymphocytes such as natural killer (NK) cells. 
 
1.2.2 T Cells 
T cells are derived from haematopoietic stem cells generated in the bone marrow 
which then migrate to the thymus as common lymphoid progenitors.  Unlike B cells, 
the T cell receptor is only expressed in a surface bound form.  T cells can be classified 
according to the TCR receptor family used, either αβ or γδ. αβ T cells recognise their 
cognate antigen, peptide bound to either MHC class-I or II, through their T cell 
receptor (TCR) whereas γδ T cells are thought to recognise non-peptidic ligands such 
as bacterial lipids (Pfeffer et al, 1990) which could be presented by CD1c (Leslie et 
al, 2002). MHC class-I (Spits et al, 1990), MHC class-II (Bosnes et al, 1990), the 
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MHC class-I like molecule CD1c (Faure et al, 1990) and the non-classical MHC-I 
molecules MICA and MICB (Groh et al, 1998) are thought to present non-peptide 
ligands to γδ T cells.  αβ T cells are further classified into groups determined by 
which MHC class molecule they recognise and which surface co-receptor they 
express.  T cells which recognise peptide-loaded MHC class-I molecules are known 
as “cytotoxic” T lymphocytes (CTLs) and express the CD8 co-receptor.  Those T cells 
which recognise peptide-loaded MHC class-II molecules are referred to as “helper” T 
cells (TH) and these express the CD4 co-receptor.  For CTLs, lysis of the target cell 
can be achieved by degranulation of cytotoxic granules containing perforin and 
granzymes, or by mobilisation of CD178 (Fas ligand (FasL)) to the surface of the 
CTL.  FasL binds to CD95 (Fas), expressed on the target cell, and causes activation of 
the caspase pathway leading to apoptosis of target cell (Podack, 1995).  CD8
+
 T cells 
also secrete a variety of cytokines, such as interferon γ (IFN-γ), which promotes 
antigen processing in all cells thus preventing the spread of infection (Mosmann et al, 
1997).   
 
Helper T cells secrete cytokines and can either help to amplify different components 
of or down-regulate the immune response when they recognise their peptide bound to 
MHC class-II.   Helper T cells can be further divided into different subsets depending 
on which cytokines are secreted.  T helper 1 cells (TH1) are generally thought to be 
pro-inflammatory cells helping to amplify the T cell response and secreting 
interleukin 2 (IL-2) and IFN-γ.  T helper 2 cells (TH2) secrete IL-4, IL-5 and IL-6 and 
are thought to be anti-inflammatory cells which help to amplify the humoral B cell 
response.  Regulatory T helper cells (Treg) are thought to suppress activation of other 
T cells by production of IL-10 and transforming growth factor-β (TGF-β) (Zheng et 
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al, 2004) as well as by cell-to-cell contact (Takahashi et al, 1998).  More recently 
identified are the TH17 subset of helper T cells - defined by their production of IL-17, 
are thought to play a major role in autoimmunity and inflammation (Rouvier et al, 
1993; Betteli et al, 2007).  The most recent subset of CD4
+
 T cells, follicular T helper 
cells (TFH), would appear to play a dominant role in controlling T-dependant B cell 
immune responses (Velardi et al, 1986; Vinuesa et al, 2005).  Although TH cells are 
primarily thought to produce cytokines and aid in the generation of the immune 
response, there are reports that have demonstrated cytotoxic activity from CD4
+
 T 
cells (Wagner et al, 1977, Swain et al, 1981, Tite & Janeway Jr, 1984, Nakamura et 
al, 1986, Williams & Engelhard, 1997 and Appay et al, 2002). 
 
1.2.3 Co-Stimulation of Lymphocytes 
Naïve T cells require at least 2 signals to become activated, „Signal 1‟ through the T 
cell receptor and „Signal 2‟ via co-stimulatory molecules (Figure 1.1).  These signals, 
which come from professional antigen presenting cells, prevent T cells from 
becoming non-functional.  The best characterised co-stimulation signal is the 
interaction of CD28 with CD80 (B7.1) and CD86 (B7.2).  These have been shown to 
stimulate the clonal expansion of T cells and blocking CD80 and CD86 using 
antibodies leads to inhibition of T cell expansion (Gonzalo et al., 2001).  After 
activation, T cells begin to express further co-stimulatory markers including CD154 
(CD40 ligand) which helps to drive the expansion of T cells.  Interaction of CD154 
with its ligand CD40 stimulates the T cell and also stimulates the antigen presenting 
cell to upregulate co-stimulatory molecules (Grewal et al, 1995).  Another set of co-
stimulatory molecules are CD137 (4-1BB) on T cells and CD137 ligand (4-1BBL) on 
the APC.  Similar to CD40, interaction of 4-1BB with its ligand produces stimulatory  
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Figure 1.1 Co-stimulation of T cells
Naïve T cells require co-stimulation from professional antigen presenting cells for activation. 
Engagement of TCR and peptide-MHC is known as signal 1 and the co-stimulatory signals 
are known as signal 2. Interaction of ligands activates T cells and stimulates the T cell 
immune response. CD80/CD86 can interact with two different ligands, CD28, an immuno-
stimulatory signal, and CD152, an immuno-inhibitory signal. The interaction with CD152 
takes place with a much higher affinity and is a mechanism in place to dampen the T cell 
immune response. 
CD278
TCR
CD154 CD137
CD134
CD152
CD275
CD28
MHC-
Peptide
CD40 CD137 
Ligand
CD134 
Ligand
T Cell
APC
CD80 CD86CD80 CD86
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signals for both the T cell and the APC (DeBenedette et al., 1995).  A third related co-
stimulation protein expressed on T cells is CD278 (inducible co-stimulator (ICOS)) 
which binds to CD275 (ICOS ligand) on APCs.  Interaction of ICOS with is ligand is 
thought to stimulate T cell growth (Gonzalo et al., 2001).  CD134 (OX40), and its 
ligand CD134 ligand (4-1BB ligand), also participate in promoting T cell activation 
and survival (Gramaglia et al, 1998).   
 
CD80 and CD86, as well as binding CD28 also bind to CD152 (cytotoxic T 
lymphocyte antigen 4 (CTLA-4)).  CTLA-4 has a similar structure to CD28 but binds 
to CD80/CD86 with a greater affinity (Green, 2000) and therefore sequesters 
CD80/CD86 molecules during a T cell immune response.  CTLA-4 is known to limit 
the proliferation of T cells and prevents lymphoproliferative disorders, as seen in mice 
lacking functional CTLA-4 (Khattri et al, 1999).  Absence of co-stimulatory signals 
can lead to peripheral tolerance through induction of an anergic state.   
 
1.3 Lymphocyte Development 
1.3.1 T Cell Development and Selection 
T cells are derived from the common lymphoid progenitor which is initially produced 
in the bone marrow before migrating to the thymus to differentiate further (Figure 1.2 
A).  Lymphoid progenitor cells enter the thymic cortex as CD4
-
/CD8
-
, double 
negative (DN) cells.  After entry into the thymus, T cell receptor (TCR) β-chain gene 
re-arrangement occurs along with the pre-TCRα chain.  At this stage, only those T 
cells with in-frame gene re-arrangement will be permitted to continue to develop in 
the cortex (Raulet et al, 1985).  Cells that successfully re-arrange the TCR move 
deeper into the cortex and begin to express CD4 and CD8 termed double positive 
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Common lymphoid 
progenitor
Progenitor T cell
Double negative 
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Mature Naive 
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Figure 1.2 B and T Lymphocyte development
B and T lymphocytes develop in either the thymus (T cells) (A) or bone marrow (B cells) (B) 
(Okkenhaug and Vanhaesebroeck, 2003) from the common lymphoid progenitor. Antigen 
receptors are produced in many stages which allows continuous testing of the receptor to ensure 
that only lymphocytes with functional receptors continue to develop. All lymphocytes undergo 
stringent selection processes to prevent self recognition before they are fully developed. Mature 
naïve T cells exit the thymus and immature B cells exit the bone marrow to populate the 
periphery.
A
B
Common lymphoid 
progenitor
Late Pro B cell Pre B cell Immature 
B cell
B1 cell
B2 cell
Early Pro B cell
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(DP) T cells.  The  newly produced DP T cells now undergo the processes of positive 
and negative selection, termed thymic education, before they will be permitted to 
leave the thymus and populate the periphery.  There is a remarkable amount of 
cellular waste produced during the development of lymphocytes and it has been 
suggested that 97-99% of all T cells generated fail to make it past the selection stage 
within the thymus (Egerton et al, 1990 and Goldrath & Bevan, 1999).  Within the 
thymus, T cells are highly motile and interact with peptide-MHC complexes on 
thymic stromal cells, still within the cortex, through their TCR (Bousso et al, 2002).  
During this stage, known as positive selection, T cells are programmed to die unless 
they are given survival signals by the stromal cells.  T cells which interact with a high 
affinity for self-peptide-MHC complexes are given signals to die by apoptosis.  T 
cells which do not recognise peptide-MHC complexes do not receive any survival 
signals and are left to “die by neglect”.  However, T cells which interact weakly with 
the peptide-MHC complexes are given survival signals by the stromal cells.  These T 
cells further differentiate to become single positive T cells (SP) depending on which 
MHC class they recognise, T cells recognising MHC class-I lose CD4 expression and 
retain CD8 expression whereas T cells recognising MHC class-II molecules lose CD8 
expression and retain CD4 expression.  After differentiation into SP T cells, they 
begin to migrate from the thymic cortex towards the medulla where they will undergo 
the second round of selection, termed negative selection. 
 
The primary function of negative selection is to remove from the repertoire T cells 
which contain a TCR reactive against a self protein.  Allowing self-reactive T cells to 
escape the thymus could result in the induction of autoimmunity and negative 
selection mostly prevents this from happening.  It has previously been shown that SP 
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T cells spend ~12 days within the thymic medulla before they are permitted to exit the 
thymus (Egerton et al, 1990).  During this time, the thymic epithelial cells present self 
peptides in complex with MHC class-I and class-II molecules (Volkmann et al, 1997).  
T cells which recognise self-peptides in complex with MHC molecules are given 
signals to die by apoptosis and are therefore deleted from the T cell repertoire.  
However, T cells which do not recognise any self peptides within the thymus mature 
in the thymic medulla and can then populate the periphery.  Although positive and 
negative selection is not 100% efficient, very few self-reactive T cells survive and 
reach the periphery, which helps to prevent the induction of auto-immune reactions.   
 
1.3.2 B Cell Development and Selection 
B cells are also derived from the common lymphoid progenitor (Figure 1.2 B) and 
mature within the bone marrow before migrating to the periphery.  B cell precursors 
were discovered in 1991 (Hardy et al, 1991 and Li et al, 1996) and the earliest cells in 
the lineage were termed pre-pro B cells.  At the stage of pre-pro-B cells, there is no 
recombination of immunoglobulin genes (Allman et al, 1999) and therefore, early 
development of B cells would appear to happen independently of the 
immunoglobulin.  During the early stages of development, B cells begin rearranging 
their B cell receptor beginning with the recombination between heavy chain diversity 
(D) and junction (J) regions to form a D-J region.  Recombination of the variable (V) 
region to the DJ rearrangement follows to form the V-DJ gene with the B cells now 
termed pro-B cells (Hardy et al, 1991 and Li et al, 1996).  Late pro-B cells are 
prevented from further development unless they can express a functional heavy chain 
which can associate with the surrogate light chain to form the pre-B cell receptor (pre-
BCR).  B cells expressing a functional heavy chain are selected for further growth and 
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development whereas those cells expressing a non-functional heavy chain or a heavy 
chain that cannot associate with the surrogate light chain do not receive any further 
signals and will “die by neglect”.  It has been suggested that nearly half of all heavy 
chains produced cannot associate with the surrogate light chain (ten Boekel et al, 1997 
& Kenya et al, 1995).  The B cells move into the pre-B cell stage after the successful 
production of the pre-BCR and the production of surrogate light chain ceases 
(Grawunder et al., 1995).  However, it is not known how they enter mitosis and 
progress down the pathway of their development.  During mitosis, the expression of 
gene rearrangement machinery is downregulated until the cells stop proliferating 
when it is upregulated again.  The light chain loci become accessible and this allows 
the cells to begin producing light chains that can attempt to associate with the 
functional heavy chain.  During light chain rearrangement, allelic exclusion occurs 
allowing the expression of only one light chain therefore preserving the single 
specificity of the B cell.  Pairing of the heavy chain with the newly synthesised light 
chain results in the generation of surface-bound IgM and this is a marker of an 
immature B cell.  Importantly for this study, there is no published evidence of MHC 
class I protein expression in early B cell development. 
 
It has been suggested that 50-75% of B cells contain a surface IgM that can cross-
react with self proteins (Rousseau et al, 1989, Souroujon et al, 1988, Striebich et al, 
1990 & Wardemann et al, 2003).  Therefore, similar to T cells, B cells must undergo a 
process of selection to remove the auto-reactive B cells before they populate the 
periphery.  B cells which survive the selection process in the bone marrow become 
mature naïve B cells and migrate to the peripheral lymphoid system.  Previous studies 
have shown that B cells reactive against self proteins including double-stranded DNA 
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(Gay et al, 1993 and Chen et al., 1995) and membrane proteins from red blood cells 
(Okamoto et al., 1992) are deleted whilst still in the bone marrow.  From these 
studies, it has been suggested that for B cells to be deleted in this selection process 
within the bone marrow, there must be cross-linking of the surface immunoglobulin 
followed by a strong signal from the immunoglobulin complex.  Furthermore, 
signalling via a single immunoglobulin molecule is not thought to lead to deletion of 
the B cell (Nemazee & Burki, 1989).  It is thought that although the B cell has 
recognised self protein, there is an intermediate stage in the development where the B 
cell can be rescued from death, possibly by TH cells (Hartley et al., 1993).  Signalling 
in the B cell is modulated by CD45, a membrane bound phosphatase, partly by de-
phosphorylating the negative regulatory tyrosine kinase (Chan et al, 1994 and 
Trowbridge & Thomas, 1994).  It has been shown that CD45-deficient B cells do not 
make the transition from immature to mature B cells after the selection process 
(Cyster et al., 1996).   
 
1.4 Tolerance 
Immunological tolerance prevents the recognition of self and therefore prevents 
autoimmune reactions.  Tolerance is achieved through two distinct processes termed 
central and peripheral tolerance.  Central tolerance is achieved during the selection of 
T cells within the thymus and for B cells by a poorly understood process within the 
bone marrow.  The autoimmune regulator gene (AIRE) is present in the thymus and 
this regulates the expression of many self proteins in the thymus for expression on 
MHC molecules.  Mutations in AIRE have been shown to lead to defects in the 
thymic selection process resulting in the peripheral migration of self-reactive T cells 
(Anderson et al., 2002 & Liston et al, 2003).  However, it is unlikely that AIRE can 
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induce presentation of every possible self-antigen to T cells and therefore, there is the 
potential for some auto-reactive lymphocytes to escape from the bone marrow or 
thymus and populate the periphery. This requires further mechanisms to prevent auto-
immune reactions and is collectively termed peripheral tolerance.   
 
1.4.1 Peripheral T cell tolerance 
In the thymus, T cells undergo positive selection where TCRs which cannot recognise 
MHC molecules are deleted whereas those which can recognise MHC molecules 
develop further and begin the process of negative selection.  One of the problems with 
negative selection is the requirement for thymic epithelial cells to express every 
possible self antigen in complex with MHC molecules so that every possible self-
reactive T cell can be deleted 
 
Naïve T cells which recognise their cognate antigen on the surface of a cell, other than 
a professional antigen presenting cell, which does not express the correct co-
stimulatory molecules are not activated but they are found in a state of 
unresponsiveness, or anergy.  The lack of co-stimulation, usually provided by 
professional antigen presenting cells, means that the peptide recognised by the T cell 
may be a self-peptide expressed by a healthy cell and therefore the healthy cell is 
saved due to the T cell becoming anergic.  This will then prevent the self-protein 
specific T cell from circulating and recognising the same peptide presented by another 
healthy cell, thus, preventing the induction of an auto immune reaction.   
 
Weakly auto-reactive B cells that survived the selection pressure within the bone 
marrow are excluded from the lymphoid follicles by other, non-auto-reactive B cells 
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and are rapidly eliminated (Cyster et al, 1994).  Further mechanisms of peripheral 
tolerance include generating a state of immunological ignorance and deletion of 
circulating T cells. Immunological ignorance occurs when self-protein specific T cells 
co-exist with their cognate antigen without becoming activated by it and can be a 
major barrier in immunotherapy. Deletion of self-reactive T cells in the periphery 
occurs after peptide-specific encounter (Carlow et al, 1992) but a recent study 
suggests that the induction of tolerance is not dependent on deletion of circulating T 
cells (Lees et al, 2006). 
 
Peripheral tolerance also mediated by specialised tolerogenic CD4
+
 T cells known as 
regulatory T cells (Treg).  Treg actively suppress the immune response and help to 
prevent the induction of autoimmunity although the mechanism by which this is 
achieved is as yet unknown (Walsh et al, 2004).  It may be due to cell-to-cell contact 
between the Treg and the activated T cell or it may be due to the expression of 
suppressive cytokines such as TGF-β and IL-10 by the Treg (Zheng et al, 2004) 
therefore generating a localised suppressive environment which prevents the 
activation of the T cell.  Whatever the mechanism of action, it has been shown 
previously that a lack of Treg cells results in an increased incidence of autoimmune 
reactions (Sakaguchi et al, 1995).   
 
One other method of peripheral tolerance is barrier tolerance, whereby T cells are not 
permitted to enter immunologically privileged sites within the body such as the testis, 
brain and developing foetus (Janeway et al, 2005).  These areas can be protected by 
several mechanisms including the induction of apoptosis by Fas-FasL interaction 
(Griffith et al, 1995) and blood-tissue-barrier which has tight junctions between 
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endothelial cells providing a physical barrier which prevents the T cells from crossing 
(Cines et al, 1998).  All of these methods of peripheral tolerance are present because 
although the selection of T cells in the thymus is very good, it is not perfect and self-
reactive T cells can mature and populate the periphery. 
 
1.5 The T Cell Receptor and Structure 
T cell receptors (TCRs) are heterodimeric, membrane bound proteins composed of the 
α (or γ) chain and the β (or δ) chain with 95% of peripheral blood T cells expressing 
an alpha-beta (αβ) TCR and the other 5% expressing the gamma-delta γδ TCR (Figure 
1.3 A).  The αβ T cell subset can be further separated into CD4+ (helper) and CD8+ 
(cytotoxic) T cells.  The protein chains are divided into the extracellular, 
transmembrane and (a short) intracellular cytoplasmic domains and demonstrate 
sequence variation at the amino terminus compared with a highly conserved sequence 
elsewhere.  This difference in sequence variation led to the classification of these 
regions as variable (V) and constant (C) regions.  These regions are similar in 
structure to the V and C regions which are found within immunoglobulin molecules.  
The V region of the TCR also contains three protein loops of hypervariable sequence, 
known as complementarity determining regions (CDR) 1-3. 
 
T cells recognise short peptide sequences in complex with a membrane-bound protein 
known as major histocompatibility complex (MHC) molecules (Davis et al., 1998).  
The TCR protein forms loops at the end of which are the three CDR regions which 
form the antigen binding component of the TCR.  The hypervariability of the protein 
loops, which interact with the peptide-MHC complex, provides the T cell repertoire 
with its extensive diversity.  The CDR1 & 2 regions provide less variability than the 
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Figure 1.3 Structure of T cell receptor and B cell receptor
The T cell receptor (A) consists of 2 protein chains, the α and β chains. Both proteins are 
divided into two distinct domains depending on their sequence, the variable and constant 
regions. The variable region from the α and β chains forms the peptide-MHC binding and 
idiotype regions. The B cell receptor (B) consists of 4 protein chains, 2 identical heavy 
chains and 2 identical light chains. The heavy chains are formed of 4 domains, 3 constant 
domains and 1 variable domain, whereas the light chain consists of only 2 domains, 1 
constant domain and 1 variable domain. The combination of the variable domains from both 
heavy and light chain form the antigen binding domain and idiotype region. Both receptors 
have a very short cytoplasmic and intracellular region as well, which is absent on the 
secreted form of B cell receptor (immunoglobulin).
CH1 CH1
CH2 CH2
CH3 CH3
VH VH
CL CL
VL VL
A B
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CDR3 region and it is known that normally, the protein loops encoding the CDR1 & 2 
regions largely bind to the MHC molecule (Wu et al, 2002).  Accordingly, the CDR3 
protein loop interacts and mediates recognition of the peptide whislt the CDR1 and 2 
protein loops mediate binding to the polymorphic HLA alleles. CD8
+
 T cells 
recognise short peptides presented by MHC class-I molecules, which are expressed on 
the surface of all nucleated cells.  CD4
+
 T cells recognise peptides which are slightly 
longer and are complexed with MHC class-II molecules.  MHC class-II expression is 
restricted to professional antigen presenting cells such as dendritic cells, macrophages 
and B cells, although many cell types will also express class-II if exposed to IFNγ 
(Loughlin et al, 1993; Mach et al, 1996).  TCRs interact with the protruding loops of 
the MHC molecule as well as the peptide presented and therefore are MHC restricted 
as well as peptide specific.   
 
The TCR bears a very short cytoplasmic domain, insufficient to mediate signal 
transduction.  Therefore, the TCR associates with the CD3 complex of proteins 
(Figure 1.4 A) that allow signal transduction.  The complex consists of CD3γ, CD3ε, 
two molecules of CD3δ and a homodimer of a disulphide linked CD3δ chain 
(Tunnacliffe, 1998).  The CD3γ chain associates with one of the CD3δ chains and the 
CD3ε chain associates with the other CD3δ chain.  Upon TCR ligation and either 
CD4 or CD8 signalling, an immune synapse forms between the T cell and the target 
cell.  Co-stimulatory molecules (Figure 1.1) are recruited to the synapse and CD45 
(tyrosine phosphatase) is excluded from the synapse due to its large size (Graf et al, 
2007).  Aggregation of the receptor complex within the immune synapse after TCR 
engagement leads to downstream signalling.  Lck kinase is recruited to the complex 
(Iwashima et al, 1994; van Oers et al, 1996) and phosphorylation of the immuno-
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Figure 1.4 Signalling complexes from B and T lymphocytes
The CD3 complex (A) (de Felipe, 2004), consisting of CD3γ, CD3ε, two molecules of CD3δ and a 
homodimer of a disulphide linked CD3δ, enables T cell signalling after TCR engagement. 
Downstream phosphorylation of the immuno-tyrosine activating motif leads to activation of the T 
cell. The signalling complex found on B cells (B) consists of an Igα chain linked by a disulphide 
bridge to the Igβ chain. Each of these proteins contains a single immuno-tyrosine activating motif 
(ITAM, yellow) that enables signalling when the B cell receptor has been ligated with antigen.
αβ
B
A
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tyrosine activation motifs (ITAMs) contained within cytoplasmic tails of the CD3 
chains occurs (Samelson & Klausner, 1992), leading to activation of the T cell.  The 
removal of CD45 from the immunological synapse is important as the phosphatase 
activity of this molecule would prevent the kinase activity of Lck, preventing 
activation of the T cell. 
 
1.6 The B Cell Receptor and Structure 
Immunoglobulin can exist as either membrane bound or secreted protein with the only 
difference being the presence of a transmembrane and short cytomplasmic region at 
the C-terminus on the membrane bound form (Wall & Kuehl, 1983).  Although the 
cytoplasmic tail of the Ig consists of only 3 amino acids (lysine-valine-lysine) (Reth et 
al, 1987), it has been demonstrated that the tail is very important in the signalling of 
IgM (Parikh et al, 1991).  The immunoglobulin is a tetrameric complex formed from 
four protein chains with two identical heavy chains bound to two identical light chains 
(Kabat, 1976) (Figure 1.3 B).  The heavy chains are formed of 4 distinct domains with 
variability seen in the domain closest to the amino terminus, termed the variable (V) 
region, with little variability seen in the 3 domains following it, termed the constant 
(C) regions.  The light chains are formed of two distinct domains with a variable 
region at the amino terminus and a constant region at the carboxy terminus.  The 
variable regions from both chains combine to produce the antibody binding region.  
Akin to T cells, the variable regions contain 3 hypervariable regions (CDR1-3) within 
them.  These regions generate the area of the antibody that specifically binds to the 
antigen by forming protein loops that are extended at the leading edge of the protein.  
The extreme variability of these regions leads to the diversity seen in the antibody 
repertoire.  The heavy chains can be divided into 5 isotypes depending on their use of 
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constant regions, Igα (IgA), Igδ (IgD), Igε (IgE), Igγ (IgG) and Igμ (IgM).  There are 
2 further sub-classes of IgA and 4 further sub-classes of IgG with each of the different 
sub-classes resulting in different effector functions.  The light chains are derived from 
two different isotypes, either Igκ or Igλ.  Mature naïve B cells express both IgM and 
IgD at the cell surface, however, after activation of the B cell they can undergo a 
process known as class-switching in the germinal centre (Dong et al, 2001) whereby 
the antibody expresses a different heavy chain, IgA, IgG or IgE.  Activated B cells 
lose expression of IgD and mature further to plasma cells which can produce large 
amounts of antibody.  Immunoglobulin of the IgA isotype can be found as a dimer 
linked by the joining (J) chain and immunoglobulin of the IgM isotype can be found 
as a pentamer also linked by a J chain (Koshland, 1975). 
 
Similar to the TCR, surface-bound immunoglobulin contains a very small cytoplasmic 
region which cannot mediate signal transduction.  The surface Ig is associated with 
two molecules Igα (CD79a) and Igβ (CD79b) which can transmit the activation 
signals the cell requires (Torres et al, 1996) (Figure 1.4 B).  The Igα and Igβ 
molecules exist as a disulphide-linked heterodimer and they contain a longer 
cytoplasmic tail which encodes for ITAMs, similar to those found on CD3 (Samelson 
& Klausner, 1992).  Downstream signalling by phosphorylation of the ITAMs on Igα 
and Igβ leads to activation of the B cell.  Improper activation of B cells, without the 
co-stimulation of Igα and Igβ, can lead to anergy (a state of unresponsiveness) or 
apoptosis of the B cell. 
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1.7 Antigen Receptor Gene Rearrangement 
T cell receptors (TCRs) are encoded in germline DNA in gene segments with those 
encoding the α-chain located on chromosome 14 and those encoding the β-chain 
located on chromosome 7.  These segments encode for many constant (C), variable 
(V) and joining (J) segments for the α-chain and β-chain and an extra diversity (D) 
segment within the β-chain (Table 1.1).  Similar to the genes encoding the TCRs, the 
BCRs are encoded in germline DNA within gene segments found on different 
chromosomes.  The immunoglobulin (Ig) heavy chain gene locus is located on 
chromosome 14 whereas the Ig light chain kappa (κ) locus is found on chromosome 2 
and the light chain lambda (λ) locus is found on chromosome 22.   There are many 
gene segments which encode for variable, constant and joining regions for the Ig 
heavy chain and Ig light chain and, similar to the TCR β-chain, an extra diversity 
region in the Ig heavy chain (Table 1.2).  These gene segments can be utilised to form 
a full length, functional Ig heavy chain (Early et al, 1980).  Although these gene 
segments are some distance away from each other, they are joined together to form 
full length antigen receptors (Hozumi & Tonegawa, 1976).  It is thought that the 
arrangement of gene segments for TCRs is at least 60-80 million years old (Klein, J. 
Immunology, 2
nd
 Ed, 1997).   
 
1.7.1 Lymphocyte Antigen Receptor Re-Arrangement 
Formation of a full length antigen receptor occurs by somatic recombination whereby 
a single gene segment from each region (V, (D), J and C) is joined together with the 
intervening segments being excised.  For example, gene rearrangement for the TCR 
β-chain begins with the Dβ1 segment joined to one of 6 Jβ1 segments or the Dβ2 
segment is joined to one of 7 Dβ2 segments to form DβJβ.  One of the 48 Vβ segments
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1
2
50
13
0
2
45
48
TCRα
TCRβ
ConstantJoiningDiversityVariableLocus
Table 1.1 Gene segments found in the T cell receptor loci
T cell receptors are generated using gene segments with a single variable, diversity (in the β
chain only), joining and constant segments forming a full length TCR. Recombination of gene 
segments during T cell development produces a functional TCR expressed at the surface of the T 
cell ready for thymic selection.
Homo sapiens immunoglobulin and T cell receptor genes - Accessed 13 Oct 2010 - IMGT 
website (http://www.imgt.org/IMGT_GENE-DB/GENElect?Query=4.2+&species=Homo+sapiens)
9
1
4-5
6
5
5
23
0
0
50
43
33
IgH
Igκ
Igλ
ConstantJoiningDiversityVariableLocus
Table 1.2 Gene segments found in the immunoglobulin loci
B cell recptors are also generated using gene segments with a single variable, diversity (in IgH 
only), joining and constant segments forming a full length BCR. Similar to TCR production, 
recombination of Ig gene segments occurs during B cell development and allows selection of B 
cells in the bone marrow.
Homo sapiens immunoglobulin and T cell receptor genes - Accessed 13 Oct 2010 - IMGT 
website (http://www.imgt.org/IMGT_GENE-DB/GENElect?Query=4.2+&species=Homo+sapiens)
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is then selected to join the DβJβ to form Vβ-DβJβ, with intervening Vβ segments 
excised.  The Vβ-DβJβ is then linked to one of two β-chain constant regions to form 
the transcript for a full length TCR β-chain (Figure 1.5).  The re-arrangement of V, D 
and J gene segments, and the insertion and deletion of nucleotides that accompanies 
the re-arrangement, forms the CDR regions within the antigen receptors.  
Lymphocytes must be able to distinguish between vast numbers of proteins presented 
to them and therefore it is important that the most variable part of the antigen 
receptors bind to the antigenic protein/peptide.  CDRs 1 & 2, found within the 
variable region, exhibit a small amount of variability but it is the CDR3 region which 
has the greatest variability (Gauss & Lieber, 1996).  Therefore, antigen receptor 
diversity is largely generated by the joining of these segments (Weigert et al, 1980).  
The formation of the full length TCR α-chain and the Ig heavy and light chains occurs 
in much the same way although the TCR α-chain and Ig light chain do not contain a 
diversity region. 
  
To produce full length, functional receptors, the gene segments between those 
selected to form the antigen receptor need to be excised.  V, D and J gene segments 
are flanked by conserved heptamer or nonamer DNA sequences which act as a signal 
to ensure that gene segments are only joined in a functional manner (Grawunder et al, 
1998).  The heptamer-spacer-nonamer sequence is known as the recombination signal 
sequence (RSS) (Sakano et al, 1979) and a gene segment flanked by a 12bp spacer 
can only recombine with a gene segment flanked by a 23bp spacer (Figure 1.6).  The 
RSS can be recognised by a collection of specific enzymes known as VDJ 
recombinases, which includes recombination activating genes 1 and 2 (RAG1 and 
RAG 2).  These two enzymes induce DNA cleavage in such a way that all of the 
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Figure 1.5 Re-arrangement of gene segments to form a full length T cell receptor
One Vα gene segment is joined to a single Jα gene segment with excision of DNA between 
the two gene segments. The Vα-Jα is then joined to the Cα gene segment to form the full 
length transcript which is then spliced and translated. The β-chain is very similar with the 
only difference is the Vβ gene segment is joined to one of the Dβ gene segments before 
being joined to one of the Jβ gene segments to for the Vβ-Dβ-Jβ recombination. This will 
then join to one of the two Cβ gene segments to form the full length transcript, which will 
then be spliced and translated. The two protein chains will then pair together and transport 
to the surface of the T cell (Janeway et al, 6th Ed).  
 
12bp 23bp
heptamernonamer
12bp 23bpTCRα
V
TCRα
J
12bp
heptamernonamer
12bp 12bpTCRβ
V
TCRβ
J
12bp
23bp23bp TCRβ
D
Figure 1.6 12/23 rule in re-arrangement of V, D and J gene segments
The V, D and J gene segments are separated by specific sequences that mean only one 
single V region, flanked by a recombinant signal sequence (RSS) encoding 12bp can be 
joined to one single J region, flanked by a RSS encoding for 23bp, for TCRα. For TCRβ, one 
V region, flanked by a RSS with 12bp, can be joined to one D region, flanked by 23bp, and 
one J region, flanked by 12bp. This prevents incorrect gene segment re-arrangement such 
as a V region joining to a J region in TCRβ because both of these segments are flanked by 
12bp spacers. A single V region can only join to a single J region after the V region has been 
joined to a D region (Adapted from Janeway et al, 6th Ed).
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intervening segments are removed and the selected segments are brought together 
(Oettinger et al, 1990).  Cleavage of the DNA causes hairpin loops which can be 
cleaved by RAG1 and 2 (Shockett & Schatz, 1999) generating DNA overhangs on 
both strands which form palindromic (P) nucleotides.  The addition of further 
nucleotides onto the DNA overhangs (N nucleotide insertion) is facilitated by the 
enzyme terminal deoxynucleotidyl transferase (TdT) and cells lacking TdT have a 
lack of N insertions with a corresponding lack of diversity (Komori et al, 1993).  
Pairing and ligation of the DNA overhangs occurs with removal of unwanted 
nucleotides and finally, DNA synthesis fills the spaces on both strands to re-form 
double stranded DNA (Figure 1.7).   
 
1.7.2 Generating the Antigen Receptor Diversity 
The gene segments encoded can generate 2200-2300 different α-chains and between 
950-1250 different β-chains, allowing for the production of ~3x106 receptors when 
the TCRα and β chains are paired.  This figure is far smaller than the theoretical 
maximum of 10
12
 TCR pairings (comprised of 10
4
 α-chains and 108 β-chains) 
(IMGT).  Regarding the BCR, the gene segments alone could generate 5200-6300 
different Ig heavy chains, 155-175 different Ig kappa chains and 116-165 different Ig 
lambda chains, therefore generating a potential maximum of 2x10
6
 antibodies.  
Similarly to TCRs, the number of potential antibodies is far below the actual number 
of 10
12
 antibodies thought to be the theoretical maximum (consisting of 10
7
 IgH 
chains, 6x10
4
 Ig lambda chains and 4x10
4
 Ig kappa chains) (http://imgt.cines.fr).   
 
One of the reasons for the increase in this theoretical number of antigen receptors is N 
region insertions which slightly alters the amino acid sequence of Ig/TCRs and 
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Figure 1.7 Generation of N and P insertions
Recombination signal sequences are brought together and RAG1 and 2 generate hairpins at both 
ends of the DNA. Cleavage of the hairpin loops generates palindromic (P) nucleotide overhangs 
with further insertion of N-nucleotides by terminal deoxynucleotidyl transferase (TdT). The 
additional nucleotides pair together and the DNA double-strand is reformed by synthesis and 
ligation of nucleotides (Janeway et al, 6th Ed). 
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therefore alters the specificity as well.  The actual number of functional antigen 
receptors present in the lymphocyte repertoire has not been identified although 
estimates suggest there are around 25x10
6
 unique, functional TCRs (Arstila et al., 
1999) and a similar number of antibodies as well.  This is much lower than the 
theoretical maximum, although both antibodies and TCRs will be lost due to protein 
misfolding and deletion in the thymus or bone marrow for receptors which recognise 
self proteins.  The insertions and/or deletions mean that the DNA encoding these 
receptors is non-germline and therefore could potentially be immunogenic.  
 
1.7.3 Other Mechanisms for Generating Diversity 
T cells cannot mutate their T cell receptors as the mutations may result in the TCR 
losing specificity for the MHC molecule or peptide.  Therefore, after generation by 
gene re-arrangement, the sequence of the TCR is fixed and absolute (Davis & 
Bjorkman, 1988).  However, B cells are able to mutate the sequence of their antigen 
receptor in an attempt to generate antibodies with a higher affinity for the antigen in a 
process termed somatic hypermutation. 
 
Somatic hypermutation occurs after B cells have become activated and requires T cell 
help (Lenschow, Walunas, & Bluestone, 1996).  Point mutations are introduced 
amongst the variable region of the heavy and light chains but not amongst the 
constant region of either chain (Mckean et al., 1984).  The mutations cause changes to 
the interaction between antibody and antigen, allowing the B cell to produce 
antibodies with a higher affinity for the antigen.  This gives rise to the phenomenon 
known as affinity maturation.  Although the end point is an antibody with a higher 
affinity for antigen, there will be many mutations that cause the antibody to recognise 
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the antigen with a lower affinity or will abolish recognition completely.  These B cells 
will be deleted whereas those with a higher affinity will differentiate further.  The 
mutations that cause somatic hypermutation are not completely random and are 
concentrated within “hotspots” throughout the V region, including the CDRs (Betz et 
al, 1993).   
 
1.8 MHC-Peptide Complexes 
1.8.1 MHC Class-I Structure 
MHC class-I-peptide complexes consist of a 45kDa glycosylated transmembrane 
protein heavy chain, which is non-covalently bound to a 12kDa soluble protein, beta-
2-microglobulin (β2m), and a small peptide (usually 8-10 amino acids in length) 
(Figure 1.8 (A)).  The MHC heavy chains are located on chromosome 6 at 3 different 
loci named human leukocyte antigen (HLA) -A, -B and -C.  They are highly 
polymorphic with more than 300 different heavy chains known, 80 alleles for HLA-A, 
180 alleles for HLA-B and 40 alleles for HLA-C (Bodmer et al., 1997).  Every 
individual expresses six HLA alleles, two from each locus.  The MHC class-I heavy 
chain protein is made up of 3 domains (α1 - α3) which, when folded produces a groove 
containing six pockets (A-F), into which a small peptide can bind (Figure 1.9 A).  
Every MHC class-I allele contains a slightly different binding groove which can 
accommodate a restricted set of amino acid side chains depending on which allele is 
expressed (Falk et al, 1991).  Therefore, allele specific peptide binding motifs can be 
designed depending on which amino acid residues bind to the different pockets.  
HLA-A*0201 is a MHC class-I allele which has been extensively studied and has a 
peptide binding motif containing a leucine or isoleucine residue at position 2 and a 
valine or leucine residue at position 9 (Drijfhout et al, 1995).  MHC class-I 
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Figure 1.8 Structure of MHC class I and II
MHC class I molecules are composed of 2 disulphide-linked protein chains and a bound 
peptide (A). The heavy chain consists of 3 domains, α1-α3 (Green), with the peptide binding 
groove made from both α1 and α2 domains. The α3 domain interacts with β2 microglobulin
(β2m, Yellow) and once completely formed, the β2m and peptide (Red) stabilise the heavy 
chain in the correctly folded conformation. MHC class II molecules are also composed of 2 
disulphide linked protein chains and a bound peptide (B). Each of the 2 chains consists of 
two domains α1-α2 (Grey) and β1-β2 (Blue) with the peptide binding groove formed from the 
α1 and β1 domains containing the peptide (Red).  
Figure 1.9 Peptide binding to MHC class I and II
Peptides are bound to MHC molecules through interactions of the amino acid side-chain of 
the peptides with pockets in the peptide-binding cleft in the MHC molecule. The peptide 
binding cleft in MHC class I molecules (A) is closed at both ends and can only accommodate 
peptides between 8 and 11 amino acids long. The second amino acid interacts with the first 
binding pocket and the final amino acid interacts with the last binding pocket. The peptide-
binding cleft in MHC class II molecules (B) is open-ended and as a results can bind to 
peptides which vary in length from 13 amino acids to 25-30 amino acids. The central core of 
amino acids in each of the peptides binds to the peptide-binding cleft in a similar fashion to 
the MHC class I binding peptides with the amino acid side-chains interacting with the 
pockets formed in the MHC class II molecule.
A
B
 30 
polymorphism results in the differential expression of peptides, from the same 
antigen, dependent on which MHC class-I alleles are expressed between individuals.  
Therefore, all protein antigens will contain a large number of antigenic peptides, 
recognised by the cellular immune response through binding to different MHC class-I 
alleles.  Although the peptide binding groove on MHC class-I molecules is enclosed 
at both ends, there are peptides longer than 10 amino acids known to bind to MHC 
class-I alleles (Collins et al, 1995 and Takahashi et al, 1999).  Studies using X-ray 
crystallography have shown that the amino terminal residues still bind to the A-pocket 
and the carboxy terminal residue still binds to the F-pocket.  However, the residues in 
the middle of the peptide are forced to bulge out of the peptide binding groove due to 
the limited space available (Guo et al., 1992).   
 
1.8.2 Assembly of MHC Class-I 
The MHC heavy chain protein (α1-α3) is synthesised in the endoplasmic reticulum 
(ER) where it is inserted into the membrane.  The newly synthesised protein binds to 
calnexin to aid in the folding process and to prevent the protein from mis-folding and 
aggregating (Degen & Williams, 1991).  Calnexin is not an absolute requirement at 
this stage of assembly as calnexin-deficient cell lines continue to express MHC class-I 
at the cell surface (Balow et al, 1995 and Scott & Dawson, 1995).  Once folded, the 
heavy chain protein binds to β2m and this heterodimer binds to calreticulin, which 
aids in stabilising and folding of the heavy chain:β2m complex (Sadasivan et al, 
1996).  However, MHC class-I molecules can fold correctly in the absence of 
calreticulin (J.  Neefjes & H.  Ploegh, 1992) suggesting that this chaperone is also 
non-essential but may improve efficiency of peptide loading.  The heavy chain:β2m 
heterodimer interacts with another chaperone protein, tapasin, which cross-links the 
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heavy chain:β2m protein complex with the transporter associated with antigen 
processing (TAP) complex (Ortmann et al, 1994 and Suh et al., 1994).  Contrary to 
the other chaperones in the MHC class-I assembly pathway, tapasin appears to be 
essential for the correct folding of MHC class-I complexes but not for the folding of 
any other protein within the ER (Sadasivan et al, 1996).  Tapasin is also important in 
loading peptides with a lower affinity onto MHC class-I (Zarling et al, 2003). By 
stabilising the peptide-free MHC class-I complex, it allows lower binding peptides 
more time to bind to the peptide binding groove.  Cells deficient in tapasin 
demonstrate a decreased expression of MHC class-I molecules at the cell surface 
probably due to the inability of the MHC class-I molecule binding to TAP (Grandea 
III et al, 1995) with those that are expressed containing a peptide with a high affinity 
for MHC class-I (Zarling et al, 2003).  Therefore, it is thought that tapasin has a 
similar function in HLA class-I assembly as HLA-DM has in MHC class-II assembly 
(Brocke et al, 2002).  Another chaperone protein required in the assembly of HLA 
class-I molecules is endoplasmic reticulum protein of 57kDa (ERp57).  It is thought 
that this chaperone is required for assembly and although its function is unknown, it is 
thought that it either aids in the MHC class-I complex refolding or it may trim longer 
peptides, which have been transported into the ER via TAP, for loading onto MHC 
class-I (Hughes & Cresswell, 1998, Lindquist et al, 1998 and Morrice & Powis, 
1998).  Once bound to TAP, the MHC class-I heterodimer waits to bind to a peptide 
which has been transported into the ER via the TAP complex.  Once loaded, the 
newly formed MHC class-I heterotrimeric complex is released from TAP (Ortmann et 
al, 1994 and Suh et al., 1994) and is transported from the ER via the golgi complex to 
the cell surface.  MHC molecules rely on the peptide to stabilise the whole complex 
and only MHC molecules which contain a peptide and are stable will be transported to 
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the cell surface.  To prevent build up of peptides within the ER, those which are not 
loaded onto MHC class-I molecules are transported back across the ER membrane 
back into the cytosol where they are broken down, although this transport is not 
mediated by TAP (Roelse & Neefjes, 1994).  All nucleated cells express MHC class-I 
molecules on their surface, meaning that an array of endogenous proteins can be 
expressed at the surface of every one of these cells for surveillance by CD8
+
 T cells.  
Under normal circumstances, CD8
+
 T cells do not recognise any “self” peptides 
which are expressed by MHC class-I molecules. 
 
Continual expression of MHC class-I molecules, presenting peptides from self 
proteins, is essential for cells to survive as it has been previously demonstrated that 
cells lacking MHC class-I molecules on the surface are a target for NK cell mediated 
lysis (Kaufman et al, 1993).   MHC class-I molecules also act as a key component of 
an immune response as it allows all cells to present non-self (antigenic) peptides on 
the surface of the cell.  This is one of very few mechanisms by which an infected cell 
can alert the immune response that it is harbouring intracellular pathogens or has 
become malignant and that it should be targeted for CD8
+
 T cell mediated lysis to 
prevent further spread.  However, MHC class-I expression is such a vital component 
of the anti-viral immune response, viruses (and tumours) have developed 
sophisticated techniques, at every stage of the antigen processing and presentation 
pathway, to try to down-modulate the expression of viral (antigenic) peptides in 
complex with MHC class-I at the cell surface.  Epstein Barr virus encodes for Epstein 
Barr nuclear antigen-1 (EBNA-1) which contains a glycine-alanine repeat which 
interferes with the processing of antigenic peptide and subsequently the expression of 
peptides (Levitskaya et al., 1995).  Cytomegalovirus (CMV) encodes for the 
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glycoprotein US3 which retains the MHC class-I complex in the ER (Ahn et al., 1996 
and Jones et al., 1996), thus preventing expression at the cell surface. 
 
1.8.3 MHC Class-II Structure 
There are 3 major families of MHC class-II molecules; HLA-DP, -DQ and -DR which 
are encoded within the MHC II loci on chromosome 6 (alongside the MHC class-I 
genes) (Monaco, 1993).  MHC class-II molecules are heterodimers of two 
transmembrane glycoprotein heavy chains, the α-chain of approximately 33-35kDa 
and the β-chain of approximately 25-30kDa (Brown et al, 1993).  The two chains are 
both divided into four domains, two extracellular domains (α1-α2 and β1-β2) of 90-100 
amino acids each, a transmembrane domain of 20-25 amino acids and a short 
intracellular domain of 10-15 amino acids (Cresswell, 1994) (Figure 1.8 B).  The α1 
and β1 domains form the peptide binding groove similar to that found in MHC class-I 
molecules except the groove in MHC class-II molecules is open ended allowing 
longer peptides to bind to the MHC class-II complex.  The longer peptides, 13-25 
residues in length (Hunt et al., 1992, Newcomb & Cresswel, 1993 and Rudensky et al, 
1991), fall over the edge of the peptide binding groove and hang down the side of the 
molecule (Figure 1.9 B).  The α2 and β2 domains each contain an internal disulphide 
bond which links the two heavy chains (Kappes & Strominger, 1988).  The structure 
of the peptide binding groove of MHC class-II was predicted on the basis of sequence 
similarities between the α1- α2 domains of MHC class-I and the α1 and β1 domains of 
MHC class-II (Brown et al., 1988) with x-ray crystallography confirming the 
prediction (Brown et al., 1993).   
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The invariant chain (Ii) is a transmembrane protein 216 amino acids in length with a 
molecular weight ~31-33kDa.  In the absence of MHC class-II molecules, the Ii exists 
as a trimer although it has been suggested that the Ii exists as a hexamer (Marks et al, 
1990).  The Ii is thought to bind to the MHC class-II peptide binding groove of free 
MHC class-II heterodimers, stabilising the protein complex and preventing premature 
binding of peptide.   
 
1.8.4 MHC Class-II Assembly 
The α and β chains of MHC class-II are synthesised in the ER and integrate into the 
membrane of the ER where the Ii is also integrated after its synthesis.  Within hours, 
three newly synthesised α-chains and three β-chains associate with the Ii trimer to 
form a nonamer (Lamb & Cresswell, 1992).  To prevent peptides from binding to the 
MHC class-II complex, the peptide binding cleft is filled with a region of the Ii 
(Riberdy et al, 1992 and Sette et al., 1992).  The Ii also appears to have a role in 
stabilising the MHC class-II complex.  In mice, a deficiency in the Ii leads to poor 
expression of MHC class-II molecules at the surface of the cell and large 
accumulation of MHC class-II within the ER (Bikoff et al., 1993, Lamb et al, 1991 
and Schaiff et al, 1992).  The MHC class-II complex is stabilised with calnexin in a 
mechanism similar to MHC class-I assembly. It is thought that calnexin is important 
in the association of MHC class-II heavy chains with the Ii trimer (Anderson & 
Cresswell, 1994).  Only when the nonamer has been fully formed is the complex 
exported from the ER through the golgi complex (Anderson & Cresswell, 1994), 
where they can then be found in endosomal pathway (Arunachalam et al, 1994, Lamb 
et al, 1991, Lotteau et al., 1990 and  Romagnoli et al, 1993) within the MHC class-II 
containing compartment (MIIC) (Peters et al, 1991 & Neefjes et al, 1990).  In order to 
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load peptides, first the Ii must be removed from the peptide binding groove.  It is 
thought that this is done by proteolysis of the Ii as addition of chloroquine (a 
lysomotropic reagent) inhibits Ii dissociation (Nowell & Quaranta, 1985) and prevents 
MHC class-II expression at the cell surface.  The degradation of Ii chain appears to 
utilise different proteases including cathepsins B, L and S.  Cells treated with 
leupeptin (an inhibitor of cathepsins) caused accumulation of Ii intermediates 
suggesting that cathepsins are important and that Ii is degraded in stages (Neefjes & 
Ploegh, 1992, Roche & Cresswell, 1991 and Stebbins et al, 1995).  The last piece of 
the Ii to be removed is the class-II associated invariant chain peptide (CLIP) which 
occupies the peptide binding groove and is removed by cathepsin S (Riese et al., 
1996, Riese et al., 1998 and Villadangos et al, 1997).  HLA-DM is a molecule which 
has a vital role in the exchange of peptides in the peptide binding groove.  HLA-DM 
deficient lines express MHC class-II at the surface of the cell but all of the class-II 
complexes contain CLIP (Riberdy et al, 1992, Sette et al., 1992 and Mellins et al., 
1994).  It is thought that HLA-DM stabilises the MHC class-II complex during the 
removal of CLIP and the subsequent time it takes to load another peptide into the 
groove (Kropshofer et al, 1997 and Vogt et al, 1996).  HLA-DM therefore appears to 
function as a peptide exchanger of MHC class-II molecules.  Once loaded with an 
exogenous peptide, the heterotrimeric complex can then be transported and expressed 
at the surface of the cell for recognition by CD4
+
 T cells. 
 
Whereas MHC class-I molecules are expressed on all nucleated cells, the expression 
of MHC class-II molecules is much more tightly regulated and only specialised 
antigen presenting cells (APCs) express MHC class-II molecules.  This means that 
only a select few cell types can initiate a CD4
+
 T cell immune response to a pathogen.  
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MHC class-II is constitutively expressed on professional APCs but can be induced on 
other cell types using IFN-γ (Loughlin et al, 1993 and Mach et al, 1996). 
 
1.9 Antigen Processing  
Antigen processing is classically defined in two separate pathways processing either 
endogenous or exogenous protein.   
 
1.9.1 Endogenous Processing - MHC Class-I 
Endogenous proteins are degraded and digested into smaller peptide fragments by the 
20S proteasome, a 700kDa protein complex composed of two rings of outer α 
subunits and two rings of inner β subunits (Groll et al, 1997).   The rings form a 
channel, into which proteins are fed and are then digested into shorter peptide 
fragments ready for further processing (Löwe et al., 1995).  The 20S proteasome is 
specific and cannot cleave proteins at every residue.  It is restricted to cleaving 
proteins at the carboxy terminus of acidic, basic, hydrophobic, branched chain and 
small, neutral amino acids (Orlowski et al, 1993 and Cardozo et al, 1994).  The length 
of peptides produced by proteasomal cleavage is very important (Ehring et al, 1996) 
and can have an effect on whether the peptides are further degraded or not (Dolenc et 
al, 1998) with peptides constituting 14 amino acids or greater in length are degraded 
very quick after proteasomal cleavage.  Peptides closer to 9 amino acids in length are 
degraded much slower allowing for the build up of peptides, of an optimum length, 
for MHC class-I loading.  The importance of peptide length after proteasomal 
cleavage suggests that there is a “molecular ruler”, due to the space within the 
proteasome, which aids in the cleavage of peptides of correct length (Wenzel et al, 
1994).  During infection, IFN-γ inducible components LMP2 and LMP7 are produced 
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forming the immunoproteasome (Brown et al, 1991, Glynne et al., 1991, Kelly et al., 
1991 and Ortiz-Navarette et al., 1991).  The inclusion of the LMP2 and LMP7 
subunits slightly alters the peptides generated by cleavage of the proteasome 
(Stohwasser et al, 1996) and it is thought that there is an increased generation of 
peptides which contain a basic or hydrophobic carboxy terminal residue (Heemels & 
Ploegh, 1994, Momburg et al., 1994 & Schumacher et al., 1994).  Many peptidases 
including aminopeptidases (Craiu et al, 1997) and tripeptidyl protease II (TPPII) 
(Geier et al., 1999) have also been shown to be involved in antigen processing, 
“nibbling” the amino residues to reduce the length of peptides to around 8-11 amino 
acids.  A large percentage of newly synthesised proteins are thought to be directed 
towards the proteasome for degradation although there is some debate as to the actual 
figure with reports suggesting anywhere between 30% (Schubert et al., 2000) and 
80% (Reits et al, 2000).  Peptides are then transported into the endoplasmic reticulum 
(ER) via the transporter associated with antigen processing (TAP) (Monaco et al, 
2010 and Spies et al., 1990).  TAP is a heterodimer (TAP1 and TAP2), made up of a 
total of 15 transmembrane subunits, 8 subunits from TAP1 and 7 subunits from TAP2 
(Vos et al, 1999).  TAP binds to peptides in the cytosol and transports them across the 
membrane in an ATP-dependant manner (Higgins, 1992), where they can interact 
with newly synthesised MHC molecules.  MHC molecules which do not contain 
peptides are unstable and as a result are retained within the ER (Demars et al, 1985).  
There have been previous reports demonstrating that an inherited mutation in one of 
the two TAP genes results in low MHC class-I expression at the surface (de La Salle 
et al., 1994), leading to a lower frequency of CD8
+
 T cells.   
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1.9.2 Exogenous Processing - MHC Class-II 
MHC class-II molecules bind peptides predominantly derived from extracellular or 
membrane bound proteins internalized by the class-II-bearing cell (Unanue, 1984).  
The internalised proteins are contained within an endosome/lysosome which is then 
acidified to break down the proteins.  Disruption of the acidification using 
chloroquine can inhibit the antigen processing and presentation functions within the 
cells (Ziegler & Unanue, 1982).  The acidification of the endosome/lysosome is also 
thought to facilitate the removal of CLIP (Riberdy et al, 1992), allowing a newly 
produced peptide to bind to the binding groove.  As well as acidification, there are 
endosomal proteinases, such as cathepsins, which further degrade the protein in the 
acidic environment.  Previous studies have shown that proteinase inhibitors such as 
leupeptin can also inhibit the antigen processing and presentation pathway (Buus & 
Werdelin, 1986 and Takahashi et al, 1989).  It appears that cathepsins S and L are 
essential for antigen processing as mice lacking these proteinases demonstrated a 
restriction in the CD4
+
 T cell repertoire (Nakagawa et al., 1998, Nakagawa et al., 
1999 and Riese et al., 1998) suggesting that there is presentation of peptides in 
complex with MHC class-II but there is a reduction in the peptides presented.  
However, mice lacking cathepsins B and D demonstrated a normal CD4
+
 T cell 
repertoire (Deussing et al., 1998) suggesting that the activity of these proteinases was 
not as important.  Once the proteins have been fully processed, the peptides are ready 
to be loaded onto an MHC class-II molecule.  Antigens can increase the efficiency by 
which they are internalised by binding to specific cell surface receptors such as Fc 
receptors and surface immunoglobulin on B cells or by engaging with complement or 
pathogen receptors such as TLRs.  Internalisation of antigen bound to surface Ig is 
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seen to increase the efficiency of presentation of the antigen by up to 1000-fold 
(Lanzavecchia, 1985).  
 
1.9.3 Cross Presentation 
The two antigen processing pathways may appear distinct but there is considerable 
overlap between them.  Cross presentation was first discovered in 1976 when 
allogenic cells cultured together developed CTLs specific for minor antigens.  This 
could only have occurred if cellular material had been “passed” between the cells 
cultured together (Bevan, MJ, 1976a and Bevan, MJ, 1976b).  Further studies 
managed to determine that cross-presentation occurred only in the professional 
antigen presenting cells (APCs) dendritic cells and macrophages (Kovacsovics-
Bankowski et al, 1993 and Shen et al, 1997) but not B cells (Rock et al, 1993).  Later 
studies attempted to determine how cross presentation occurred, whether it was due to 
passage of whole protein, peptides or nucleic acids.  Immunisation with whole protein 
antigens fail to initiate a CD8
+
 immune response (Kovacsovics-Bankowski et al, 1993 
and Rock & Clark, 1996 & Falo Jr et al, 1995) whereas peptides from heat-shock 
proteins appeared to stimulate CD8
+
 T cells (Udono & Srivastava, 1993).  However, it 
was further determined that whole protein which had been made particulate by 
adsorption to innate particles (1-5nm) could cause cross-presentation using much 
lower protein concentrations (Harding & Song, 1994 and Kovacsovics-Bankowski et 
al, 1993).  Therefore, it is now generally accepted that cellular proteins are the 
predominant form of antigen which is cross-presented.  Once the antigen has been 
internalised by the APC, there appears to be more than one pathway in which the 
exogenous antigen could be loaded onto MHC class-I molecules.  The phagosome-to-
cytosol pathway was first described when it was found that APCs lacking 
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proteasomes or those which were TAP-deficient could not cross present antigen 
(Kovacsovics-Bankowski & Rock, 1995).  This would suggest that the protein had 
been passed across the phagosomal membrane into the cytosol and would therefore 
join the MHC class-I classical processing pathway.  Another pathway, termed the 
vacuolar pathway, was discovered when there was cross presentation which did not 
involve TAP and was insensitive to proteasome inhibitors (Rock, 1996).  This second 
pathway was blocked by the addition of leupeptin (a protease inhibitor) suggesting 
that the activity of proteases is essential (Shen et al, 2004).  The vacuolar pathway 
involves the presence of molecules involved in the MHC class-I processing pathway 
in the membrane of a large vacuole within the cells and the fusion of the phagosome 
with the vacuole (Rock & Shen, 2005).  The fusion of these two compartments would 
bring together the MHC class-I molecules with the protein and peptides required for 
antigen presentation.  Cross presentation would appear to be, potentially, a very 
dangerous concept as it would allow healthy APCs to present antigen to cytotoxic 
CD8
+
 T cells.  These cells could therefore be seen as infected and there could be the 
potential for killing healthy APCs.  However, it is now accepted that cross 
presentation, mediated by CD8
+
 conventional DCs and precursor CD8
-
 CD24
+
 
conventional DCs (Bedoui et al, 2009), is an important mechanism for surveillance by 
the immune system. 
 
1.9.4 Antigen Presentation 
Peptides which bind to MHC class-I are usually very specific in their length due to the 
closed structure of the peptide binding groove with peptides of 8-11 amino acids 
being able to fit into the restricted space.  MHC Class-I molecules are very important 
in viral and intracellular bacterial infections.  It is one of few signals that the cell can 
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use to highlight itself as infected and therefore should be killed to try to prevent the 
spread of the pathogen.  Cells constitutively express MHC class-I molecules and a 
failure to do this could result in the cell being seen as infected or transformed and 
recognised and killed by NK cells.  Some viruses including CMV have been shown to 
down-regulate the expression of MHC class-I on the surface as an evasion mechanism 
to prevent the cell from being seen as infected.   
 
1.10 Peptide Binding Motifs and Computer Algorithms 
MHC molecules are expressed at the cell surface presenting a peptide for T cells to 
survey.  Pockets within the peptide binding groove mean that the MHC molecule 
selects peptides that can fit the most stably into the groove based on the structure and 
hydrophobicity of the amino acid side chains on the peptide (Garrett et al, 1989 and 
Saper et al, 1991) (Figure 1.9).  Peptide binding motifs can be determined by isolating 
peptides from MHC class-I complexes and analysing the peptides that are expressed 
(Falk et al, 1991 and Jardetzky et al, 1991) or by analysing the sequences that are 
supposed to bind to MHC molecules (Romero et al, 1991).  There are amino acids 
within almost every peptide which are invariant for each MHC allele, termed anchor 
residues.  The amino acid side chains are inserted into pockets contained in the 
peptide binding groove which stretch deep into the MHC protein.  The anchor residue 
at position 2 becomes buried deep in pocket A and the residue at position 9 binds to 
pocket F (Saper et al, 1991).  There are other positions within the peptide sequence 
which are important in MHC-binding and although they are not as important as 
anchor residues, they are still important in binding and are termed auxiliary anchors 
(Falk et al, 1991).  However, the peptide-binding motifs are not absolute and there are 
peptides which bind to MHC molecules that do not conform to the peptide-binding 
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motif (Clerici et al., 1991 and Dadaglio et al., 1991).  There are many computer 
algorithms designed to predict the ability of any peptide to bind to MHC molecules, 
two of which (SYFPEITHI and BIMAS) are discussed further. 
 
1.10.1 SYFPEITHI 
SYFPEITHI (Rammensee et al, 1999) uses a scoring system designed to give each 
amino acid residue a score between 0 and 10 with optimal anchors given the highest 
value, sub-optimal amino acids given a low score and amino acids which are 
disadvantageous can be given a negative score.  Using the CMV-derived peptide 
NLVPMVATV, which binds strongly to HLA-A2 as an example, the leucine residue 
at position 2 (an optimal anchor) would give the value 10 whereas the sub-optimal 
residue at position 6, valine, produces a value of 1.  The sum score of amino acids at 
each position gives an overall peptide-binding score, 28 in the case of 
NLVPMVATV.  The algorithm can predict peptide binding for many HLA class-I 
alleles but not as many HLA class-II alleles because of the more variable peptide 
binding groove.   
 
1.10.2 BIMAS 
The results from BIMAS (Parker et al, 1994) predict the half-time of dissociation of 
HLA class-I complexes expressing the peptide, at 37°C and pH 6.5 for HLA-A2, and 
based on the anchor residues expected for other HLA class-I alleles.  Initially, the 
score for each epitope is set to 1 and this is multiplied by the co-efficient of that 
amino acid at each position along the whole of the epitope.  The algorithm is slightly 
different to SYFPEITHI in the fact that it places more emphasis on the anchor 
residues with highly favourable amino acids given a co-efficient markedly higher than 
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1 and the slightly less favourable anchors given a co-efficient of slightly greater than 
1.  Amino acids at anchor positions which are not well tolerated are given a co-
efficient markedly less than 1 and so on.  Using the CMV-derived peptide 
NLVPMVATV as an example again, the optimal anchor residue leucine at position 2 
has a co-efficient of 72 whereas the sub-optimal valine at position 6 has a co-efficient 
of 1.  This results in the half-time for dissociation of this peptide on HLA-A2 being 
159.97 minutes.  Although SYFPEITHI attempts to determine peptide binding for 
HLA class-II molecules, BIMAS can only predict peptide binding for a limited 
number of HLA class-I alleles.   
 
One of the major problems using computer algorithms is the reliance on how accurate 
any of them are.  Previous studies have attempted to determine the accuracy of 
SYFPEITHI and BIMAS by predicting peptides using the computer algorithms and 
then employing the T2 binding assay to determine peptide binding affinities (Gomez-
Nunez et al, 2006).  Using SYFPEITHI, the study calculated false negatives at 14% 
and the false positives at 12% whereas the rate of true positives was measured at 42% 
and the true negatives measured at 32%.  Therefore, the sensitivity and specificity was 
demonstrated as 75% and 73% respectively.  Using BIMAS the study calculated false 
negatives at 8% and false positives at 8% as well whereas the rate of true positives 
was measured at 48% and the true negatives measured at 36%.  As a result of this, the 
sensitivity and specificity was demonstrated as 86% and 82% respectively.  These 
results suggest that the BIMAS algorithm is the better of the two algorithms 
investigated but SYFPEITHI produces similar results as well.  
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Although the study demonstrates the usefulness of both computer algorithms, it is 
important to remember the fallibility of both algorithms when analysing any data sets. 
On average, the programs are 80% accurate and therefore 4 out of 5 peptides will be 
predicted correctly and therefore this is important to consider when analysing the 
results and formulating conclusions. 
 
1.11 Idiotype 
The idiotype is the collection of unique antigenic determinants expressed within the 
variable regions of an Ig or TCR molecule.  The idiotype was the first known tumour 
associated antigen (Janeway et al, 1975) and it was suggested that it could act as a 
tumour-associated antigen for the potential therapy for B and T cell lymphomas 
(Stevenson & Stevenson, 1983).  There have been many studies using the idiotype as 
tumour associated antigen for a variety of lymphomas with varying degrees of 
success.  However, it was “The Network Theory of the Immune System” published by 
Niels Jerne, who later received the Nobel Peace Prize for his work, in 1974 that 
brought the idiotype into the immunotherapy world.  Although this theory is not 
directly relevant to the work shown in this thesis, the idiotype network theory is very 
important in the history of idiotypic studies and therefore important for this thesis. 
 
1.11.1 Idiotype Network Theory 
The network theory of the immune system was first postulated by Niels Jerne in 1974 
(Jerne, 1974) which included the presence of an idiotype network theory.  This theory 
suggests that every idiotope, a unique set of antigenic determinants contained within 
an Ig, can be recognised by a set of paratopes, the antigen binding region of an Ig, and 
that every paratope can be recognised by a set of idiotopes.  Therefore, the expansion 
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of the B cell repertoire is regulated by anti-idiotypic antibodies which recognise 
idiotopes from other antibodies.  It also encompasses the suppression of B cells by T 
cells which recognise the idiotopes within the B cell receptor, suggesting that B cells 
remain functional as long as their idiotype has not been recognised by a T cell.  
Therefore, B cells and T cells regulate the functional repertoire of B cells.  This 
theory is “contradictory” to the well known and accepted clonal theory whereby the B 
cell repertoire is edited of self-reactive clones by recognition of self proteins during 
selection processes.  The clonal theory dictates that each lymphocyte clone arises 
completely independently of all other B cell clones whereas with Jerne‟s “Idiotype 
Network Theory”, all B cell clones share interactions and these can have an influence 
on the development of other clones (Bona & Bonilla, 1996). 
 
The network theory is based on the principle that antigen elicits an antibody response 
which results in production of antibodies against the antigen.  The idiotypic regions of 
the antibody elicit an anti-idiotypic antibody response.  This anti-idiotypic antibody 
contains idiotypic determinants that will then elicit another anti-idiotypic antibody 
response which will then be continually repeated (Figure 1.10).  The immune system 
is said to be in a dynamic state, even in the absence of immunogenic antigen, with 
lymphocytes interacting with one another to generate homeostasis and Jerne 
postulated that this was due to the interaction of idiotopes and paratopes.  The 
network theory was ground-breaking in 1974 and led to further idiotype-based studies 
and on to its use in immunotherapy.  
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Figure 1.10 B cell idiotype network theory
The network theory of the immune system involves the regulation of B cells by antibodies 
that recognise idiotopes on different antibodies. Ab1 recognises antigen X and an immune 
response is generated. Ab2 contains an idiotope which is an exact replica of the antigen, 
recognised by Ag1, on antigen X and is therefore recognised by Ab1. The idiotype of Ab1 is 
recognised by Ab3, resulting in regulation of Ab1 and stimulation of Ab3. The idiotype of Ab5
is also recognised by Ab3 resulting in further stimulation of Ab5. However, the idiotype of Ab3 
is recognised by Ab4 and this results in regulation of Ab3 and stimulation of Ab4. Meanwhile, 
Ab4 is recognised by Ab6, resulting in regulation of Ab4 and stimulation of Ab6. (Adapted from 
Jerne, 1974). 
Ab1 Ab3
Ab2 Ab4
Ab5
Ab6
Ag X
Recognition and 
stimulation
Regulation/ 
Suppression
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1.12 Immune Responses to Idiotype-Derived Epitopes 
1.12.1 T Cell Responses to B Cell Lymphomas 
Previous studies have attempted to determine the possibility of raising a T cell 
response against peptides from the idiotype and also from the BCR as a whole.  
Generating an immune response against idiotype-derived peptides, being tumour cell 
specific, was hoped to result in the clearance of tumour cells without targeting healthy 
non-tumour B cells.  However, every B cell tumour will contain a different idiotypic 
sequence and also may not contain an idiotype-derived epitope suitable for a T cell 
response.  This means that the T cells generated for therapeutic use will be different 
for every patient and there is the possibility that many patients couldn‟t be treated.  
Therefore, in order to broaden the possible applicability of the idiotype-derived 
peptide therapy, studies have focussed on epitopes from within the framework region 
of the tumour BCR (Tobin et al., 2003, Ghiotto et al., 2004 and Widhopf et al., 2004).  
The use of framework region derived epitopes would remove the need for patient-
specific T cell responses to be generated.  However, the use of these epitopes would 
then target healthy B cells from the patient B cell repertoire for T cell mediated 
effects.  This may not be as bad as first thought as Rituximab, a monoclonal antibody 
therapy used in treatment of CLL patients, targets surface-bound CD20 which is 
found on all B cells, including malignant B cells.   
 
Many studies have used a bioinformatic approach to analyse idiotype sequences for 
potential HLA-binding epitopes that could potentially be recognised by T cells.  
Computer algorithms including SYFPEITHI and BIMAS  are used to predict HLA-
binding epitopes from the idiotype sequence (Harig et al., 2001, Hansson et al, 2003 
and Molinier-Frenkel et al., 2005).  Many of the studies attempt to alter the peptide 
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sequence (heteroclitic peptides) to increase the affinity of the peptide for HLA (Harig 
et al., 2001) and have shown that T cells generated against the heteroclitic peptide can 
also recognise the native peptide as well as the tumour cell that the sequence was 
derived from.   
 
1.12.2 Immunotherapy Towards the Idiotype 
Targeting the idiotype could lead to potential therapies against many B cell 
malignancies including B cell chronic lymphocytic leukaemia (CLL), multiple 
myeloma (MM) and follicular lymphoma (FL).  After the idiotype was suggested to 
be a tumour specific antigen with the potential to treat these patients, the problem of 
immunological tolerance was raised. Peripheral tolerance could be caused by cells 
expressing the tumour antigen without the secondary signals required for T cell 
activation, leading to anergy (Matzinger, 1994).   
 
The goal of immunotherapy is to break tolerance and generate both cellular and 
humoral responses against the idiotype and for these responses to be long-lasting.  
The vaccine used and the method of vaccination will have a major effect on the type 
of response that is generated.  It will also have a bearing on whether there is 
immunological memory to the idiotype or whether the immune response is transient.  
CD4
+
 T cells are required to generate long lasting humoral and cellular immunity and 
as a result, the idiotype protein, which is not particularly immunogenic by itself, was 
conjugated to a carrier protein that was immunogenic.  During the initial studies, the 
carrier protein was usually keyhole limpet haemocyanin (KLH), a large immunogenic 
protein composed of many subunits from the keyhole limpet.  The KLH would initiate 
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an inflammatory milieu which would allow generation of an immune response against 
the idiotype protein. 
 
1.12.3 Early Antibody Immunotherapy 
Soon after the idiotype was shown to be a potential therapeutic target, attempts were 
made to target the idiotype using antibody therapies.  Passive immunisation with 
either polyclonal (Hamblin et al, 1980) or monoclonal (Miller et al, 1982 & Lowder et 
al., 1987) antibodies was shown to be effective.  However, generation of antibodies, 
either mono- or polyclonal, was costly and laborious as the therapy had to be tailored 
for each patient.  Thus, although the diversity of the idiotype made it a very useful 
target for therapy, it was also proving to be a significant problem.  Ideally, therapy 
would target a conserved region of the idiotype that was expressed in all patients so as 
to generate a single therapeutic antibody that could be used to treat a large number of 
patients.  However, the diversity generated in the idiotype region suggests that a broad 
specificity antibody therapy against the idiotype may not be possible.   
 
1.12.4 Idiotype Protein Vaccination 
After the success of the antibody therapies, the immunotherapy studies moved on to 
active immunisation using idiotype protein in follicular lymphoma (Table 1.3) 
(Baskar et al, 2004, Weng et al, 2004 and Inogès et al., 2006).  Early B cell lymphoma 
studies in mice using idiotype protein, alone or coupled to KLH, as a vaccine 
demonstrated its ability to suppress B cell tumours and generate protective immunity 
(Kaminski et al, 1987 and George et al, 1988).  However, it appeared that it was anti-
idiotypic antibodies that were induced, and not a cellular response.  Furthermore, a 
study in multiple myeloma demonstrated that immunisation of a healthy donor with  
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myeloma IgG coupled to KLH could generate a cellular Id-specific response, which 
was then taken from the donor and transplanted into the patient.  CD4
+
 idiotype-
specific responses were detected in the patient up to day 60.  This study showed that 
transfer of immunity from an immunised donor to a patient could prove to be an 
alternative method of generating an idiotype-specific response (Kwak et al., 1995).  
However, one of the major issues with this therapeutic strategy is the need for an 
HLA-matched donor and the potential for post-transplant complications.  Later 
studies in MM using the more conventional vaccination with idiotype protein coupled 
to KLH were completed but were not as successful as the FL (Massaia et al., 1999).  
One of the potential issues with vaccinating MM patients is the high-dose 
chemotherapy and stem cell transplant they receive prior to the vaccination.  
However, the presence of T-cell responses to idiotype and KLH proteins suggested 
that the timing of vaccination was not a problem. 
 
The actively induced antibody in follicular lymphoma (FL) studies produced 
protection similar to that achieved by passive immunisation with anti-idiotype 
antibodies (Brown et al., 1989).  Although the outcome of protein vaccination 
appeared to be the same as passive immunisation with antibody, it was demonstrated 
that, in the presence of the whole idiotype protein, the antibody response prevented 
the tumour cell from immune evasion by altering the expression of the idiotype 
(Maloney et al., 1994).  It was further demonstrated that immunisation with idiotype 
protein could potentially generate CD4
+
 T cells which have subsequently been shown 
to be important in the anti-tumour response (King et al., 1998).   
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The pre-clinical studies in humans and mice, which had yielded encouraging results, 
led to a clinical trial using idiotype protein coupled to KLH in patients with follicular 
lymphoma.  The results of the clinical trial were encouraging with 20 of 41 patients 
generating an immune response, predominantly humoral, against the idiotype protein 
contained in the vaccine (Hsu et al., 1997).  Patients generating an immune response 
demonstrated a significantly longer progression-free disease and overall survival 
compared with those patients who failed to mount an anti-idiotype immune response. 
 
After further success vaccinating FL patients with idiotype protein coupled to KLH 
(Bendandi et al., 1999), where 8 of 11 patients converted to molecular remission, 
three multi-centre phase III clinical trials began (Table 1.4).  The first phase III trial to 
begin was instigated by the National Cancer Institute, National Institute for Health 
(USA) and is sponsored by Biovest (BiovaxId).  This began in February 2000 using 
idiotype protein, taken from a biopsy sample of the lymphoma, coupled to KLH as a 
vaccine and KLH alone as control.  Results reported at the 2009 American Society of 
Clinical Oncology suggested that there may be a positive outcome after vaccination 
with the idiotype vaccine. The median time to relapse was 44 months in patients 
administered with the vaccine compared with 30 months in patients given placebo 
(p=0.045) (Schuster et al, 2009).  The other phase III clinical trials used similar 
vaccines sponsored by Favrille (FavId; started in 2004) and Genitope (MyVax®; 
started in November 2000) with the main difference between the trials being the 
patients recruited.  The Biovest trial included patients with stage III or IV FL, 
Genitope recruited patients with stage II - IV FL and the Favrille trial included 
patients with stage I - IV FL (All clinical trial information taken from 
http://.clinicaltrials.gov).  The results from the Genitope study have not yet been 
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Table 1.4 Phase III clinical trials of idiotype vaccination in follicular lymphoma
After successful early phase clinical trials, three phase III clinical trials began using idiotype protein 
vaccination in patients with follicular lymphoma. Table shows details from each of the three trials  
with only two of the three trials ongoing following the cessation of the Favrille sponsored trial. 
Results from the Genitope study are expected soon but results from the Biovest sponsored study 
demonstrated a slightly longer median time to relapse in patients treated with idiotype vaccination 
compared with untreated control patients. Information taken from http://clinicaltrials.gov
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released but are expected in the near future.  However, the clinical trial using FavId 
(Renamed to SpecifId) was stopped in May 2008, after recruiting 349 patients, after it 
failed to show a statistically significant increase in the time to progression (Freedman 
et al, 2009).  
 
1.12.5 Later Protein Vaccination Studies Towards Follicular Lymphoma 
During the course of these phase III clinical trials, further FL patient studies have 
demonstrated similar clinical benefits of idiotype protein vaccination.  The logical 
progression of development of a new treatment is to initiate clinical trials leading 
from phase I to II and finally phase III.  However, there has been doubts raised as to 
whether this is the correct course for the idiotype vaccine trials because every patient 
receives a slightly different vaccine due to their idiotype being different from the next 
patient.  It has been known since the earliest studies that idiotypes vary in their ability 
to stimulate an immune response (Lynch et al, 1972).  Therefore, to address this issue 
in the efficacy of idiotype vaccinations, one study used an innovative method for 
determining clinical efficacy.  It has previously been shown that antibody therapy, 
using Rituximab, with or without chemotherapy in FL patients can induce complete 
responses in patients (Czuczman et al., 1999 & Coiffier et al., 2002).  However, the 
2
nd
 complete response, with a median duration of 13 months, is almost always shorter 
than the 1
st
 complete response and subsequent responses tend to get shorter and 
shorter (Rohatiner & Lister, 2005).  The study by Inogès et al., 2006 demonstrated a 
longer 2
nd
 complete response by patients who generated a humoral and/or cellular 
immune response against the vaccine compared with those who didn‟t generate an 
immune response.  Interestingly, the study by Inogès et al., 2006 also demonstrated 
that all patients with an immune response to the idiotype protein had a longer 2
nd
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response than the median duration (13 months) and it was also longer than the 1
st
 
complete response as well.  Every patient that failed to generate an idiotype-specific 
immune response produced similar results to those seen before with a shorter 2
nd
 
clinical response.  Therefore, these results demonstrate the potential clinical benefit 
associated with idiotype protein vaccination in B cell lymphoma.  The experimental 
outcome of this study suggests that the endpoint of future clinical trials may be better 
suited to looking at duration of complete response in patients treated with the idiotype 
vaccines.  The studies described investigate the vaccination of patients after the 
treatment with chemotherapy generally resulting in minimal residual disease.  This 
would suggest that idiotype specific vaccination is best suited in conjunction with 
chemotherapy regimens.   
 
The results from vaccination studies using idiotype protein suggest that there is a 
possibility in producing a humoral and a CD4
+
 T cell response, which suggests that 
the problem of tolerance is either not present or can be overcome (Hsu et al., 1997 and 
Bendandi et al., 1999).  It also suggests that there was an immune repertoire present in 
patients which had failed to prevent disease progression, but could be stimulated 
using the idiotype protein.  The results from the phase III clinical trials are eagerly 
awaited and may have a large influence on any further work on idiotype protein 
vaccination. 
 
1.12.6 Dendritic Cell Vaccines 
Inducing a primary T cell immune response requires the presentation of antigen by 
dendritic cells (DCs).  There have been many studies determining usefulness of DCs, 
loaded with idiotype protein, processing and presenting idiotype peptides to T cells.  
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However, there are a few drawbacks to using DCs as therapy to treat B cell 
lymphoma.  Although DCs are potent stimulators of immune responses, they can also 
be potent inhibitors as well (Banchereau & Steinman, 1998).  They require maturation 
signals to allow them to stimulate the immune system and it was shown that immature 
DCs pulsed with antigen resulted in tolerance (Dhodapkar et al, 2001).  This may be a 
major issue in MM where recovery of idiotype protein in multiple myeloma is made 
easier by the fact that there is a large amount of idiotype protein in patient serum but 
the presence of idiotype protein, at the time of vaccination, could prove to be 
tolerogenic (Bogen et al, 2000).  Another issue with DCs is the cost and time involved 
in generating them to a suitable clinical grade to allow infusion into patients.  Despite 
these issues, there have been studies investigating the immune response to idiotype-
derived epitopes after vaccination of patients with DCs pulsed with idiotype protein 
and/or KLH in follicular lymphoma (Table 1.5) (Timmerman et al., 2002) and 
multiple myeloma (Reichardt et al., 2003).  The results from both of the pre-clinical 
studies demonstrated the generation of anti-idiotype T cells after vaccination using 
DCs suggesting that there is not a tolerance barrier to overcome.  As a result of this, 
phase I/II clinical trials have begun in an attempt to further study the clinical efficacy 
of DC vaccines in both follicular lymphoma and multiple myeloma.  The phase I/II 
clinical trial in MM patients (Curti et al., 2007) demonstrated the safety of the 
idiotype-pulsed DC vaccine and induced idiotype-specific T cell responses in 8 of 15 
patients vaccinated.  There is another phase I/II clinical trial ongoing to determine the 
safety and potential efficacy of DC vaccines in B cell lymphomas with the trial 
predicted to finish later this year (http://clinicaltrials.gov).  The results of the pre-
clinical studies along with the initial results from the multiple myeloma trial suggest 
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that there is a possibility that DC vaccines could be clinically relevant although much 
will depend on any future data from clinical trials.   
 
1.12.7 DNA Vaccines 
DNA vaccines are known to induce both cellular and humoral immune responses 
against various cancers (Stevenson & Anderson, 1999).  The use of DNA vaccines in 
infectious disease clinical trials have shown encouraging results with vaccination 
generating few side effects and inducing antigen-specific immune responses 
(MacGregor et al., 1998 and Wang et al., 1998).  The DNA sequence for the idiotype 
is incorporated into a DNA plasmid backbone which contains a promoter, usually the 
CMV immediate-early promoter, to drive high level gene expression.  Following 
introduction into the host, the gene of interest is synthesised in the host cells.  Also 
incorporated within the backbone is bacterial DNA, which encodes for pathogen-
associated molecular patterns (CpG motifs), which can stimulate the innate immune 
system, leading to the stimulation of the adaptive immune system (Hoebe et al., 
2006).   
 
DNA vaccines can be introduced via 3 routes; intramuscularly, intradermally or into 
skin cells using a gene gun.  Once administered, the DNA is transfected into cells and 
the synthesis of the gene of interest is initiated.  DNA vaccines administered via the 
intradermal route are thought to transfect skin-derived dendritic cells which then 
process and present antigen to T cells (Akbari et al., 1999 and Porgador et al., 1998).  
DNA vaccines administered by intramuscular route are thought to transfect muscle 
cells.  However, muscle cells do not express the MHC class-II molecules and co-
stimulatory molecules, required to present antigen to and activate CD4
+
 T cells.  It is 
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thought that muscle cells “pass” the newly synthesised protein to professional APCs, 
such as dendritic cells, in a process known as “cross-presentation”.  The result of this 
process means DCs can present the antigen to T cells with the required co-stimulation 
so that they can activate T cells (Corr et al, 1996 and Corr et al, 1999).  Although 
DNA vaccination attempts to induce every arm of the immune system, it 
predominantly induces CD4
+
 T helper cells as well as CD8
+
 cytotoxic T cells 
(Gurunathan et al, 2000).   
 
DNA vaccines allow optimisation of the protein of interest by addition of sequences 
that could target the protein to the required cellular location.  Leader sequences to 
target the idiotype protein to the endoplasmic reticulum where it could be secreted to 
generate a specific antibody response.  Otherwise, the protein could be targeted to the 
cytosol to allow processing in the classical MHC class-I processing pathway (Rice et 
al, 2008).  This targeting of the idiotype protein could prove to be very useful in DNA 
vaccination but could not be used in protein vaccination.   
 
1.12.8 DNA Vaccines Against Idiotype 
The earliest DNA vaccination was developed quickly due to the need to overcome 
difficulties in generating individual, patient-specific protein vaccines (Hawkins et al., 
1994).  It is easier to identify the sequence of the idiotype region of the BCR than it is 
to recover the BCR protein from tumour cells.  One of the first DNA constructs to be 
generated for this work was to encode both the full length IgH and IgL chains under a 
single promoter.  Results from the initial pre-clinical studies showed that this was an 
effective approach, leading to a clinical trial using this method.  However, the results 
of the clinical trial demonstrated only 1 of 12 patients developed a cellular response 
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and no patients developed a humoral response after a single vaccination (Table 1.6) 
(Timmerman, et al., 2002).  There was an increased response after a second round of 
vaccinations with 2 patients producing an antibody response and 4 patients producing 
a cellular response.  However, the responses seen at this stage were not specific and 
were cross-reactive with Id proteins from the other patient tumours.  Despite the 
modest induction of cellular and humoral immune responses, the clinical trial 
demonstrated the potential that idiotype-based DNA vaccination could have in the 
future. 
 
Another construct for DNA vaccination that was developed was the linking of the IgH 
variable region to the IgL variable region, forming the single chain variable fragment 
(scFv) (Hawkins et al., 1994).  The idiotype protein produced by the DNA construct 
retained all of the idiotypic determinants as it could still be recognised by monoclonal 
antibodies.  However, studies investigating the immunogenicity of scFv demonstrated 
that scFv alone was not particularly immunogenic.  Therefore, similar to protein 
vaccination requiring a carrier protein to stimulate a stronger immune response, DNA 
vaccines were engineered using similar technologies.  One of the first proteins used to 
stimulate a stronger immune response to the scFv DNA vaccine was the Fragment C 
(FrC) component from tetanus toxin.  The results of the fusion protein vaccination in 
mice demonstrated a marked increase in the induction of antibodies against the 
idiotype (Spellerberg et al., 1997).  It is thought that the immune response against FrC 
aids in the amplification of the idiotype-specific immune response.  The induction of 
an antibody response requires CD4 TH cell help and because the B cells have been 
transfected with both FrC and the idiotype proteins, the idiotype-specific B cells will 
express peptides from the FrC.  Therefore, the FrC-specific TH cells can recognise and 
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activate the idiotype-specific B cells, indirectly augmenting the idiotype-specific 
antibody response (King et al., 1998).   
 
A clinical trial (UK-007) set up as a pilot study of idiotype-based DNA vaccination of 
follicular lymphoma was completed in 2007.  The study involved the intramuscular 
vaccination of 25 patients with naked DNA encoding for the idiotype scFv coupled to 
FrC (Rice et al, 2008).  The vaccination was well tolerated and an anti-FrC response 
was generated in 18 of 25 patients, albeit slower than conventional protein vaccines 
(Böcher et al, 1999 and Rahman et al., 2000).  Idiotype-specific responses were 
investigated in 16 of the vaccinated patients with 6 demonstrating either cellular 
and/or antibody responses.  However, the responses generated by those patients were 
relatively low and there is a need to improve these responses.  It has been shown that 
the method of DNA introduction could be very important with microparticles (Otten 
et al., 2003) and electroporation (Tollefsen et al., 2002) demonstrating increased 
generation of immune responses.   
 
After the low idiotype-specific responses seen in the clinical trial involving the scFv-
FrC DNA vaccine of FL patients, another potential adjuvant, an agent which can be 
added to a vaccine to stimulate the immune response is the pentameric B subunit from 
the heat labile enterotoxin found in E.  coli (Chen et al., 2009).  Enterotoxin B, in its 
pentameric form, binds to the toxin receptor ganglioside GM1.  The murine study 
demonstrated the scFV vaccine coupled to the toxin subunit could still bind to the 
toxin receptor after synthesis of the protein from the vaccinated plasmid.  Generation 
of idiotype-specific antibody was also demonstrated suggesting that the toxin, used to 
couple the scFV to, has potential in future therapy.   
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Similar to follicular lymphoma, although smaller in scale, DNA vaccines have also 
been tested against multiple myeloma.  Mouse models demonstrated protective 
immunity after scFv DNA vaccination but vaccination with the idiotype protein failed 
to induce the same protective immunity (King et al., 1998).  However, the majority of 
studies into idiotype vaccination in multiple myeloma centred around protein 
vaccination or dendritic cell vaccines.  The myeloma idiotype protein is easier to 
recover from myeloma patients and this may have a bearing on the direction of 
therapy for myeloma in the future. 
 
1.12.9 Generation of Immune Responses to T Cell Lymphoma 
Compared with the volume of studies completed on responses towards the B cell 
idiotype and immunotherapy using this idiotype, there has been very few studies into 
the idiotype contained within the TCR.  This is mainly due to the small number of 
patients who present with T cell lymphoma compared with those who present with B 
cell lymphomas.  However, there has been investigation into T cell idiotypes where 
studies have used various methods to generate T cell responses against the T cell 
idiotype from T cell lymphomas including mycosis fungoides (MF) and cutaneous T 
cell lymphoma (CTCL).  In one study, the determination of synthetic peptide T cell 
epitopes, using combinatorial peptide libraries, which mimics a natural TAA have 
been used to generate a T cell response (Linnemann et al, 2000).  The peptides could 
be used to generate T cell responses in many patients suggesting that there is a natural 
epitope presented by the T cell lymphoma which is mimicked by the synthetic peptide 
which was used.  Other studies have used sequence analysis of the CDR3 region and 
peptide prediction algorithms to discover potential CDR3 epitopes (Berger et al., 1998 
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and Berger et al, 2001).  The generation of T cell responses to synthetic peptides led 
them to believe that there was the possibility that tumour cells could present CDR3-
derived epitopes on their surface.  They went on to elute peptides from the surface of 
CTCL cells and found a novel peptide, which could not be identified using a protein 
database, which was very similar to the sequence of the V region of the T cell 
lymphoma.  Further work studying the sequence of the eluted peptide and T cell 
responses against it demonstrated that there was a possibility that the T cell 
lymphoma may present peptides from the TCR on the cell surface (Berger et al., 
1998).   
 
1.12.10 Immunotherapy Using the TCR Idiotype 
Most of the studies into T cell lymphomas and the TCR idiotype have used adenoviral 
transduction (Wong & Levy, 2000) and, similarly to the B cell work, dendritic cells 
pulsed with tumour cell lysate and used as a vaccine (Gatza & Okada, 2002).  
However, one study has demonstrated this targeted approach against pathogenic T 
cells reactive against idiotype peptides derived from myelin basic protein (MBP) 
reactive T cells (Zang et al, 2000).  A panel of epitopes from the CDR2 and 3 regions 
from MBP-reactive T cells were used to generate anti-idiotypic T cells ex vivo and 
used as a vaccine in patients with MS.  The results demonstrated that T cells reactive 
against the CDR2-derived epitopes were less immunogenic than those generated 
against CDR3-derived epitopes and that these T cells, CD8
+
, could specifically lyse 
autologous MBP-reactive T cells.   
 
Despite apparent progress in the study of the T cell idiotype and the potential for 
future immunotherapy, the problems that apply to the B cell idiotype apply to the T 
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cell idiotype as well.  The vast majority of patients who present with T cell lymphoma 
will contain a unique idiotype region and as a result, any therapy produced would be 
patient specific, and therefore could only be used to treat a single patient.  
Consequently, therapy for T cell lymphomas would be more attractive if it wasn‟t 
patient specific.  However, this may mean that the target would not be tumour cell 
specific and could result in the targeting of otherwise healthy T cells.  Although, there 
has been a suggestion that T cell lymphomas express a peptide which is present in 
many patients (Linnemann et al, 2000) and this could prove to be a useful 
immunotherapeutic target. 
 
Immunotherapy targeting the idiotype has moved on dramatically in recent decades 
with many potential vaccines trialled in many common lymphoid malignancies.  The 
results of these trials are, to date, disappointing and this may partly be due to 
tolerance against these antigens.  However, one fundamental issue remains, the 
specificity of each vaccine for every single patient.  This will continue to prove a 
difficult problem to overcome due to the hugely diverse nature of the idiotype region.   
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1.13 The Paradox of the Adaptive Immune System 
The immune system must be able to recognise every conceivable antigen that could 
potentially cause harm and for this there needs to be an extraordinary number of 
receptors specific for each of these antigens.  However, the amount of DNA needed to 
encode for this number of receptors would constitute a large part of the genome, and 
yet the loci for the B cell and T cell antigen receptors are relatively small.  As 
discussed previously, the generation of each antigen receptor occurs from 
recombination of gene segments with deliberate mutations or “mistakes” between the 
segments which can alter the specificity immeasurably.  These apparently random 
mutations give rise to short sequences of DNA which are considered “non-germline”.  
Considering that there are thought to be ~25x10
6
 TCRs (Arstila et al., 1999) and a 
similar number of BCRs, this would imply there is vast antigenic diversity within the 
lymphocyte compartment which could potentially be recognised as non-self by the 
immune response and have the potential to trigger autoimmune reactions.  Moreover, 
because antigen receptor diversity is critical for robust adaptive immunity, this vast 
incurred antigenic diversity becomes a functional prerequisite.   
 
This presents a curious paradox in that if the immune response is tolerant not only to 
germline-encoded self antigens, but also the vast antigenic universe created by antigen 
receptors, then it could become non-functional.  Such a nihilistic state would be self-
defeating and would counter any selective advantage of evolving such an adaptive 
immune response.  Conversely, maintaining the functional integrity of the adaptive 
immune cell repertoire by avoiding tolerance to antigen receptors, particularly 
circulating antibodies, would likely lead to an autoimmune state whereby a small 
number of antibody peptide fragments would be identical to pathogenic epitopes. 
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To circumvent this problem, it could be argued that three possible mechanisms could 
prevent the potential autoimmunity whilst maintaining a useful repertoire of T and B 
cells.  Firstly, lymphocyte antigen receptors may be actively excluded from antigen 
processing thus preventing their presentation at the cell surface.  In this manner, these 
antigen receptors would be treated as exceptional antigens, perhaps through 
possession of signal motifs excluding antigen processing - tolerance through 
ignorance. 
   
Secondly, the immune system could be functionally tolerant towards CDR3-derived 
peptides resulting in prevention of activation of T cells after recognition of CDR3-
derived peptides - tolerance though peripheral mechanism. 
  
Lastly, tolerance could be achieved through immunoediting of the lymphocyte antigen 
receptor repertoire, whereby T or B cell bearing HLA-binding peptides within their 
CDR3 regions would be deleted - tolerant through immuno-editing of the antigen 
receptor repertoire.  Consequently, lymphocytes expressing receptors which do not 
contain CDR3-derived HLA-binding peptides would populate the periphery.  This 
third mechanism is analogous to thymic central tolerance.  
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1.14 Mathematical Model of B Cell Receptor Diversity 
 
In order to demonstrate the potentially dangerous nature of the immune system, due to 
its diversity, a mathematical model of B cells has been created (Figure 1.11). In a 
typical donor, there have been estimates of ~25x10
6
 unique B cells (Arstila et al, 
1999) with an average CDR3 heavy chain consisting of 25 amino acids and an 
average CDR3 light chain consisting of 22 amino acids. Using this conservative 
estimate of the number of unique B cells, every person has ~47 CDR3-derived 9mers 
per B cell and potentially 1.2x10
9
 CDR3-derived peptides from their B cell repertoire 
alone. There is the potential to produce 5.12x10
11
 different nonamer peptides (20 
amino acids at 9 different positions). Therefore, the chance of any given nonamer 
peptide sequence (e.g. AAAAAAAAA) being found in any CDR3 in the entire B cell 
repertoire would be 0.23% (Figure 1.11 A).  One caveat to these calculations, would 
be any observed bias toward the random nature of the B cell CDR3.  In reality, there 
will always be some bias introduced as a consequence of the conserved regions in the 
joining region of the CDR3 meaning that the number of unique peptides in the CDR3 
is possibly as low as 10-12 peptide nonamers in each Ig chain.  Taking this into 
account, there is still 0.11% chance that any given nonamer peptide sequence would 
be found in the B cell CDR3 proteome.  
 
However, it is conceivable to suggest that there are a larger number of unique B cells 
considering there are ~1x10
9
 B cells in the blood alone (~10% B cells in PBMCs; 
2x10
9
 PBMCs per litre producing 0.2x10
9
 B cells per litre and assuming there are ~5 
litres blood per person, there would be 1x10
9
 B cells in the blood alone). If this is true, 
there could be a larger number of unique B cells in humans. Using a less conservative 
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estimate of the number of unique B cells in the body, 2x10
8
, there would be a 1.84% 
chance that any given nonamer peptide sequence would be found in the B cell CDR3 
proteome. 
 
From the perspective of focussing on a given HLA allele such as HLA-A2, every 
possible peptide is thought to have approximately 0.5% chance of binding to HLA-A2 
(Yewdell and Bennink, 1999).  Consequently, there is approximately a 99.5% chance 
that any given peptide will not bind to HLA-A2 (Figure 1.11 B). If it is assumed that 
there are 47 CDR3-derived peptides per B cell, there is ~79% chance that none of the 
CDR3-derived peptides will bind to HLA-A2 (0.995
47
x100%). Therefore, the chance 
that any peptide from the B cell CDR3 will bind to HLA-A2 is ~21%.  Again, this is 
assuming that every peptide within the CDR3 is unique which is unlikely to be true.  
Taking this concern into account, a more conservative estimate might be 10-12 unique 
CDR3-derived peptides in each Ig chain, there is still 11% chance that any peptide 
within the CDR3 will bind to HLA-A2 (or indeed any given HLA Class-I allele).  If 
we now consider that any individual has 6 Class-I alleles then the chances that any 
given peptide within the CDR3 will bind to any of the 6 HLA Class-I alleles will be 
approximately 1-(1-0.11)
6
 = ~51% using the more conservative estimates.   
 
Although the figures described here are purely theoretical, it is perhaps surprising 
how potentially dangerous the antigen receptor diversity could be. Considering these 
figures, it is reasonable to postulate that there would be a survival advantage to evolve 
a mechanism, as yet undefined, which prevents the inclusion of self-HLA-binding 
peptides within the B cell and/or T cell CDR3, thus limiting the risk of developing 
autoimmune disease. 
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Number of B cells: 25,000,000
Length of CDR3: Heavy Chain - 25 amino acids
Light Chain - 22 amino acids
Total - 47 amino acids  47 CDR3-derived peptides
Total number of CDR3-derived peptides: = 25,000,000 x 47
= 1.18x109 peptides
Chances of a CDR3-derived peptide not binding to HLA-A2  = (1 - 0.01)47 x 100 %
= 62%
There is a 62% chance that no CDR3-peptides will bind to an HLA-A2
Therefore, the chance that a CDR3-peptide will bind to MHC   = 1 - 62%
= 38%
There is ~38% chance that a B cell will contain an MHC-binding 
CDR3-derived peptide binding to HLA-A2.
Every peptide is thought to have ~1% chance of binding to an HLA-A2 molecule
Total number of possible peptides = 209
= 5.12x1011
Chance of any peptide being found in the CDR3 = 1.18x109 / 5.12x1011 x100 %
= 0.23%
There is 0.23% chance than an immunogenic or viral peptide could be 
found in the entire BCR CDR3 proteome.
A
B
Figure 1.11 Mathematical model of B cell receptor diversity
The B cell receptor is an extremely diverse protein formed from re-arrangement of gene segments 
with extreme variability between segments which can potentially be non-self protein sequence. This 
re-arrangement is responsible for most of the diversity seen in the repertoire. However, it is also 
the diversity coupled with the potentially non-self sequence that can be very dangerous. A 
mathematical model was developed in order to demonstrate the potential danger of the CDR3 by 
determining the potential for an immunogenic peptide to be contained within the CDR3. The first 
model (A) uses a conservative estimate of the number of unique BCRs present in the immune 
system and estimates the probability that an immunogenic peptide (e.g.viral) could be found within 
the CDR3 of any B cell in a single person.  The second model (B) estimates the probability of a 
peptide from the CDR3 binding specifically to a single HLA allele, in this case HLA-A2.
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1.15 Hypothesis, Aims and Objectives 
B and T cell receptors undergo germline gene segment rearrangement to produce full 
length functional receptors.  However, these insertions and deletions between gene 
segments generate a sequence which is non-germline and could potentially be a 
source of immunogenic peptides.  Current understanding suggests lymphocyte antigen 
receptors undergo two methods of selection in the thymus or bone marrow.   
 
However, in order to prevent an autoimmune reaction, there must be mechanisms in 
place to prevent T cell recognition of these non-self peptides (see section 1.13).  In 
this study it is hypothesised that there is no peripheral tolerance towards non-self 
peptides contained within the CDR3. Therefore, to prevent the initiation of an 
autoimmune reaction there is a third selection process whereby antigen receptors with 
a potentially immunogenic CDR3-derived peptide are deleted from the lymphocyte 
repertoire.  If this hypothesis is true, the observed frequency of HLA-A2 binding 
peptides found within the CDR3 region of an HLA-A2
+
 donor will be decreased 
compared with an HLA-A2
-
 donor.   
 
If the hypothesis is not proven and there are HLA-binding peptides present in the 
CDR3 of HLA-positive donors, a second hypothesis can be tested; HLA-binding 
peptides within the CDR3 of antigen receptors are excluded from Class-I antigen 
processing and not presented at the cell surface.  This second hypothesis could help to 
define the absence of lymphocyte interaction as either tolerance or the prevention of 
antigen processing of CDR3-derived peptides. 
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The aims of this project are: 
 
Investigate the lymphocyte antigen receptor CDR3 sequences and determine the 
presence of immunoediting within the lymphocyte antigen receptor repertoire 
 
Ascertain the presence or absence of naturally processed and presented CDR3-derived 
peptides in B and/or T cells through the development of models of B and T cell CDR3 
antigen processing 
 
These aims would be pursued by sequencing the CDR3 sequences of BCRs and TCRs 
to determine any differences in the frequency of HLA-binding peptides in HLA-
positive and negative donors. Presentation of CDR3-derived peptides would be 
determined by recognition of target cells using peptide-specific T cells and attempts 
made to investigate the antigen processing pathway involved.  
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Chapter 2 - Materials and Methods 
 
2.1 Molecular Biology 
2.1.1 RNA Extraction from PBMCs 
RNA was extracted from healthy laboratory donors with known HLA type (Table 2.1) 
so as to give 5 HLA-A2
+
 and 5 HLA-A2
-
 donors. RNA extraction was completed 
using the RNeasy RNA extraction kit (Qiagen, West Sussex UK). Briefly, 1-2x10
6
 
PBMCs were washed to remove residual serum from the cells. 350μl of buffer RLT + 
1% 2-mercaptoethanol was added to the cells and mixed thoroughly. The cells were 
then homogenised by passing the lysate 5-10 times through a 21G needle fitted to a 
syringe. 350μl of 70% ethanol was added to the homogenised lysate and pipetted onto 
the RNA spin column. This was then spun at 8,000g for 15 seconds and the 
supernatant discarded. 700μl of buffer RW1 was added onto the column, spun again 
and the supernatant discarded. The column was then washed twice with 500μl buffer 
RPE + ethanol with the supernatant discarded each time. The RNA was eluted from 
the column using 30μl of RNAse-free water. This was added to the column and spun 
at 13,000rpm for 1 minute. The RNA yield was then determined by 
spectrophotometry and stored at -20°C until needed. 
 
2.1.2 cDNA Synthesis 
cDNA synthesis was done using the Superscript II First-Strand Synthesis for RT-PCR 
Kit (Invitrogen, Paisley, UK). Briefly, 3μl of RNA was incubated with 1μl of 10mM 
dNTP mix and 1μl of 0.5μg.ml oligo dT primer at 65°C for 5 mins. The RNA/primer 
mix was used for reverse transcription in a 20μl reaction incubated at 42°C for 50mins  
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Table 2.1 HLA Type of laboratory donors for used for sequencing
The donors were chosen so each of the HLA-types investigated contained 5 positive donors 
and 5 negative donors.
A2, B7Id 010
A2Id 009
A2, B8Id 008
A1, A2, B8Id 007
A1, B7 Id 006
B7Id 005
A1, B8Id 004
A1, B7, B8Id 003
A2, B7Id 002
A1, B8Id 001
HLA TypeDonor ID
Table 4.1 HLA Type of Laboratory 
Donors
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containing 2μl 10X RT buffer, 4μl 25mM MgCl2, 2μl 0.1M DTT and 1μl RNAse 
inhibitor. After 2 mins, 50units of Superscript II RT was added to each sample. 
Reactions were terminated by incubation at 70°C for 15 mins and RNAse H was 
added to remove the residual RNA and incubated at 37°C for 20 mins. The presence 
of cDNA was verified by amplification using primers specific for the TCR/BCR.  
 
2.1.3 Amplification of BCR/TCR Transcripts from cDNA 
cDNA was amplified with a panel of primers specific for TCRVB families 1-24 
(Table 2.2) (Invitrogen, Paisley, UK) or primers specific for IgH isotypes IgA, IgG 
and IgM (Table 2.3) (Invitrogen, Paisley, UK). BCRs were amplified from within the 
framework region 1 (FR1) of the variable region to the constant region and the TCRs 
were amplified from the beginning of the variable region to the constant region. 
Amplification of the DNA for both TCR and BCR was 35 cycles of 95°C for 30sec, 
65°C for 30 sec and 72°C for 1 min in reactions containing 10mM dNTPs, 1uM each 
primer and 1 unit of Expand High Fidelity DNA polymerase (Roche, West Sussex 
UK). 50μl of each reaction was loaded onto a 1% TBE (Boric Acid, Tris.HCl and 
EDTA) agarose gel and run for 50 mins at 120V. Bands were visualised by SYBR 
safe gel stain (Invitrogen, Paisley, UK) and the size was determined by comparison to 
a 100bp molecular weight marker (Invitrogen, Paisley UK) (Figure 2.1). This method 
may lead to variation in amplification as the annealing temperature used may be 
optimal for some of the primers but not for the others. The extent of this has been 
minimised and this method has been used previously on many occasions (Kou et al., 
2000 & Yao et al., 2006). 
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Table 2.2. Oligonucleotide primer sequences to amplify the TCR variable region and 
CDR3
Table of all oligonucleotide primers used to amplify the TCR var iable region for both the α and 
β chains including the CDR3 region.  Taken from Okamoto, Y et al, 1994.
ACAACAGTTCCCTGACTTGCA
TCAACCATGCAAGCCTGACCT
TCTCTAGAGAGAAGAAGGAGCGC
ACATATGAGAGTGGATTTGTCATT
ACTTCAGTGAGACACAGAGAAAC
CCCTAACTATAGCTCTGAGCT
AGGCCTGAGGGATCCGTCT
ACCTGAATGCCCCAACAGCTCT
ATTTACTTTAACAACAACGTTCCG
TAAATCTCCAGACAAAGCTCACT
TCCAAAAACTCATCCTGTACCTT
AACAGTCTCCAGAATAAGGACG
AAAGGAGAAGTCTCAGAT
TCCTGAAGACAGGACAGAGCA
TTGGTGAGGGTACAACTGCCA
TCTCTCGAAAAGAGAAGAGGAAT
GTGTCTCTCGACAGGCACAG
AAGAGTCTAAACAGGATGAGTC
ACAGATAGTAAATGACTTTCAGAAA
AGATGAGTCAGGAATGCCAAAG
TCTCAATGCCCCAAGAACGCA
GCTCTGAGGTGCCCCAGAATCTC
CAAAGGAGTAGACTCCACTC
CAGTGACTATCATTCTGAACTG
ATCTCAGAGAAGTCTGAAATAT
CCGAACACTTCTTTCTGCTTTC
TGCTTCTGATGGCTCAAACAC
1
2
3
4
5.1
5.2
6
7
8
9
10
11
12
13.1
13.2
14
15
16
17
18
19
20
21
22
23
24
Cβ
TTGCCCTGAGAGATGCCAGAG
GTGTTCCAGAGGGAGCCATTGCC
GGTGAACAGTCAACAGGGAGA
ACAAGCATTACTGTACTCCTA
GGCCCTGAACATTCAGGA
GTCACTTTCTAGCCTGCTGA
AGGAGCCATTGTCCAGATAAA
GGAGAGAATGTGGAGCAGCATC
ATCTCAGTGCTTGTGATAATA
ACCCAGCTGCTGGAGCAGAGCCCT
AGAAAGCAAGGACCAAGTGTT
CAGAAGGTAACTCAAGCGCAGACT
GCTTATGAGAACACTGCGT
GCAGCTTCCCTTCCAGCAAT
AGAACCTGACTGCCCAGGAA
CATCTCCATGGACTCATATGA
GACTATACTAACAGCATGT
TGTCAGGCAATGACAAGG
TGACACAGATTCCTGCAGCT
TGAGCCCCTTCAGCAACTTAAGG
ATATAAGGCTGGTGAATTGACCTCAAAT
TAAACTGCACGTCATCAAAGACG
ACCACTTCAGACAGACTGTATT
GTAGCATATTAGATAAGAAAGAACTT
ACAACCAGTGCAGAGTCCTC
CTTGTCACTGGATTTAGAGTCTC
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
23
24
25
26
27
28
29
Cα
SequenceVβSequenceVα
Vα: TCR alpha chain variable region; Cα: TCR alpha chain constant region; Vβ: TCR beta chain 
variable region; Cβ: TCR beta chain constant region 
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2.1.4 Molecular Cloning of TCR/BCR transcripts 
The PCR products were purified from the gel by Gel Extraction kit (Qiagen, West 
Sussex, UK) and cloned into pCR TOPO 4 TA vector (Invitrogen, Paisley UK). The 
vector containing the amplified DNA was transformed into TOP10 chemically 
competent E.coli (Invitrogen, Paisley UK) and grown overnight on agar under 
ampicillin selection (100μg/ml). Following overnight incubation, colonies were 
picked, suspended in 50μl LB broth + 100μg/ml ampicillin and grown for 4 hours 
ready for colony PCR. 
 
2.1.5 Colony PCR 
PCR reactions were set up (as previously described) containing 10μM dNTPs, 1μM of 
each primer (M13 forward and M13 reverse) and 1 unit Expand High Fidelity enzyme 
(Roche, UK) and 5μl of bacterial culture. An initial incubation at 95°C for 5mins was 
used to lyse the bacteria and make the plasmid DNA available for amplification. After 
this, the DNA was subject to 35 cycles of 95°C 30sec, 65°C for 30sec and 72°C for 1 
min. A final elongation step of 72°C for 10mins was added to ensure all DNA strands 
were fully elongated. 10μl of each reaction was loaded onto a 1% TBE agarose gel 
and run for 50 mins at 120V. Bands were visualised by SYBR safe gel staining 
(Invitrogen, UK) and the size was determined by comparison to a 100bp molecular 
weight marker (Invitrogen, Paisley UK) (Figure 2.2).  Bacterial cultures resulting in 
positive PCR reactions were added to 5mls LB broth supplemented with 100μg/ml 
ampicillin and grown overnight at 37°C in a shaking incubator. Cultures were pelleted 
and double stranded plasmid DNA was extracted from cell pellets using a Qiaprep 
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Table 2.3. Oligonucleotide primer sequences to amplify the BCR variable region and 
CDR3
Table of oligonucleotide primers used to amplify the BCR from within framework 1 of the Ig 
heavy chain variable region including the CDR3 region. Taken from Fais et al, 1998.
GAGGCTCAGCGGGAAGACCTT
GGGGAAGTAGTCCTTGACCAG
CAGGAGAAAGTGATGGAGTCG
SAGGTRCAGCTGBWGSAGTCNG
IgA
IgG
IgM
FR1
Primer SequenceIsotype
FR1: Framework region 1; S: C/G; R: A/G; B: T/C/G; W: A/T; N: A/C/G/T
 
 
Figure 2.1. Amplification of TCRβ-chain CDR3
cDNA was synthesised from RNA extracted from 
unfractionated PBMCs. The TCR chain was amplified 
using a mixture of V region primers and a single 
constant region primer.  PCR products run on a 1% 
agarose gel and visualised under an ultraviolet light. 
Amplicons of TCR variable regions were expected 
~500-550bp.
500bp
 79 
spin miniprep kit (Qiagen, West Sussex UK) following the manufacturer‟s protocol. 
DNA was stored at -20°C until ready for sequencing. 
 
2.1.6 HLA Typing of Patient DNA Samples 
PCR reactions were set up (as previously described) containing 10μM dNTPs, 1μM of 
each primer (Table 2.4), 1 unit Expand High Fidelity enzyme (Roche, UK) and 1μl 
genomic DNA. DNA was subject to 35 cycles of 95°C 30sec, 65°C for 60sec and 
72°C for 1 min. A final elongation step of 72°C for 10mins was added to ensure all 
DNA strands were fully elongated as described (Tonks et al, 1999). PCR products 
were run on 1% agarose gel and visualised under UV light (Figure 2.3). 
 
2.2 Automated DNA Sequencing 
2.2.1 Functional Genomics 
DNA sequencing was performed using an M13 primer (Invitrogen, UK) and a Bigdye 
Terminator cycle sequencing kit (Applied Biosystems, UK). 200-500ng of double 
stranded plasmid DNA was used as template in the reactions. Cycle sequencing 
reactions consisted of 25 cycles of 96°C for 10 secs, 50°C for 5 secs and 60°C for 4 
mins. Sequencing products are purified by precipitating DNA in an automated system. 
Purified products were run on ABI3700 DNA sequencer.  
 
2.2.2 Polymorphic DNA Technologies 
DNA sequencing was performed using an M13 primer. 600ng of double stranded 
plasmid DNA was used as a template in the reactions. Samples were run in fully 
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Figure 2.2. PCR to amplify the TCRV β chains from individual colonies of bacteria.
The TCR chain β chain CDR3 regions amplified fom the cDNA were cloned into the TA vector and 
transformed into bacterial cells. With each colony containing a single TCR β chain, bacterial 
colonies were picked and grown in 50μl LB + ampicillin. Bacterial cells were used as template for 
the colony PCR to test which colonies had been transfected with the TA vector containing a TCR β
chain within it.  PCR products were run on a 1% agarose gel and visualised under ultraviolet light.  
Bands ~500-550bp were used for sequencing and further work.
500bp
 
 
Table 2.4 PCR primers to determine HLA-A2 type of patients
Primers, taken from Tonks et al, 1999, were used to amplify genomic DNA from paitents
with various B cell lymphomas to determine which patients were HLA-A2+. Dna sent from 
University of Southampton (kind gift from Prof. C Ottensmeier).
GTG GCC CCT GGT ACC CGTA2 Reverse
TCC TCG TCC CCA GGC TCTA2 Forward
SequencePrimer Name
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automated sequencing systems. Sequencing returned was analysed using ChromasPro 
and translated into amino acid sequence using Translate (www.expasy.ch).  
 
2.3 Peptide Prediction Studies Using Syfpeithi and BIMAS 
Sequences of TCR beta chains and Ig heavy chains were determined by reference to 
previously published known TCR and Ig families. CDR3 region sequences were 
determined and used to predict potentially immunogenic epitopes within the CDR3 
using the computer algorithms Syfpeithi (www.syfpeithi.de) and BIMAS 
(http://www-bimas.cit.nih.gov/molbio/hla_bind/) 
 
2.4 Mutagenensis of CDR3 Region of TCR Beta Chain 
A full length T cell receptor beta chain (kindly donated by Lee Machado), within the 
TA vector (Invitrogen, Paisley, UK), was used as a starting point for mutagenesis 
studies. Phosphorylated primers were designed (Table 2.5) to mutate the CDR3 region 
of the TCR β-chain to encode for CMV-derived CD8 T cell epitopes. The PCR was 
performed using Phusion enzyme (New England Biolabs, USA) with the PCR product 
for each set of primers (containing different CDR3-peptides) being run on a 1% 
agarose gel (Figure 2.4). The DNA was re-circularised using DNA ligase (Roche, 
West Sussex, UK), and used for transfection studies. The gene was sequenced to 
demonstrate insertion of the new sequence in the correct orientation (Table 2.6).  
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Figure 2.3 PCR to amplify HLA-A2 to determine HLA-A2 type of patients
DNA from patients with B cell lymphomas was amplified using oligonucleotide primers 
specific for HLA-A2 to determine which of the patients were HLA-A2+ (A). The primers used 
are known to produce a PCR product of ~900bp in HLA-A2+ individuals. Actin was amplified 
as control (B) to demonstrate that the DNA was of good enough quality for PCR 
amplification.
A
B
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2.5 Tissue Culture and Cellular Experiments 
2.5.1 Peptides 
Peptides were synthesized by AltaBioscience (Birmingham UK) or Genscript (New 
Jersey, USA), reconstituted in DMSO at a final concentration of 10mg/ml and stored 
at -20°C. Reference to each peptide is made by the first three amino acids e.g. 
ALCDTGRRAL is designated as ALC and so on. 
 
2.5.2 Isolation of mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood 
samples by Ficoll density gradient centrifugation. Whole blood was diluted 1:1 with 
RPMI 1640 (Gibco, Paisley UK or made in-house from powder ordered from Sigma 
(R6504)) and then layered onto Ficoll (Lymphoprep, Nycomed, Sweden) and spun for 
25min at 1800rpm with the brake off. The lymphocyte layer was then removed with a 
transfer pipette to a fresh sterile tube and resuspended in RPMI. Cells were spun for 
10min at 1600rpm and the supernatant discarded. Cell pellets were resuspended once 
more in RPMI and spun again (this time at 1200rpm). The supernatant was discarded 
and cells were resuspended in RPMI supplemented with 10% foetal calf serum (FCS), 
2mM L-glutamine and 100U/ml penicillin-streptomycin (Sigma, UK). The 
lymphocyte yield was determined using a haemocytometer and a light microscope. 
Cells were then used immediately or cryopreserved. Freezing media contained 90% 
FCS and 10% DMSO (Sigma, UK). 
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Figure 2.4. PCR to amplify the complete TCRβ chain using two different sets of 
primers.
DNA encoding the full length TCR β-chain was used as a template for mutation PCR to 
introduce CMV viral epitopes into the CDR3. Amplified DNA was run on a 1% agarose gel 
and visualised using SYBR safe gel stain under a UV box.  The full length TCR β chain was 
5.5kb in size and the corresponding band cut-out of the gel, purified and used for further 
experimentation. 
5 kb
 
 
Table 2.5. Oligonucleotide primer sequences to introduce viral epitopes in the CDR3
Oligonucleotide primers were designed and synthesised to introduce CMV viral epitopes into 
the CDR3 region.  Amplification of the TCRβ chain using the primer sets would mutate the 
CDR3 to incorporate the viral epitopes.
P-GTGGCTACGGTTGGGCCGGGCACCAGGC
P-CATGGGCACCAGGTTGCTGCTGGCGCAG
P-GTTGCTACGGTTCAGGGGCCGGGCACCA
P-CATGGGCACCAGGTTGCGGGTGCTGGCG
P-AACGGCTTTACGGTGTTGGGGCCGGGCA
P-GCGCTCGTGGGGGCGGCTGCTGGCGCAG
P-GGCGGCGGCGCCATGGGGCCGGGCACCA
P-GGTAACGCGGGGCGTGCTGCTGGCGCAG
P-AGTACCCGTTACGTGGGGCCGGGCACCA
P-GTGGGTGTTGGAATAATCGCTGCTGGCG
NLV forward
NLV reverse
RNLV forward
RNLV reverse
RPH forward
RPH reverse
TPR forward
TPR reverse
DYSN forward
DYSN reverse
Primer sequencePrimer Name
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2.5.3 Cell staining with antibodies and tetramers 
5x10
5 PBMC were incubated with 1μl of antibody at room temperature for 30 minutes 
and washed in MACS buffer (PBS (made in-house from tablets, Oxoid (Hampshire, 
UK) + 2% FCS + 2mM EDTA). Cells were analysed on a Coulter EPICS-XL flow 
cytometer or Becton Dickinson Facs Canto II.  Acquired data was analysed using 
WinMDIv2.8 software (Scripps Institute, California, USA) or FlowJo7 (Celeza 
GmbH, Switzerland). T cell receptor beta chain variable region 7 (TCRVβ7) usage by 
transfected cells was determined by addition of 1μl of TCRVβ7 phycoerythrin-
conjugated antibody (Abcam, Cambridge UK) to 5x10
5
 transfected cells at room 
temperature for 20 mins. Cells were washed in MACS buffer and analysed on a 
Coulter EPICS-XL flow cytometer. 
 
2.5.4 Magnetic selection of antibody-bound PBMCs  
5-10 x10
6
 PBMC were stained with antibody as described earlier, washed and then 
incubated with anti-PE microbeads (Miltenyi Biotech, Surrey UK) for 30min on ice. 
Cells were washed again twice in MACS buffer (PBS (made in-house from tablets, 
Oxoid (Hampshire, UK) containing 0.5% BSA and 2mM EDTA) and resuspended in 
0.5ml cold MACS buffer. A miniMACS MS (Miltenyi Biotec, Germany) separation 
column was placed onto the column holder attached to a magnet. The column was 
washed with 1ml of cold MACS buffer. The cell suspension was added to the column 
and the eluted cells (negatively selected fraction) collected in a tube. The column was 
washed extensively with 3x0.5ml of cold MACS buffer. More washes were 
performed if greater purity was desired (at the expense of yield). The column was 
then removed from the magnet and cells still bound were eluted out with buffer using  
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PEDSALYLCASSPGRWYEQYFGPGTRLTVTEDLKNVFP
PEDSALYLCASSTPRVTGGGAMGPGTRLTVTEDLKNVFP
PEDSALYLCASSRPHERNGFTVLGPGTRLTVTEDLKNVFP
PEDSALYLCASSRNLVPMVATVQGPGTRLTVTEDLKNVFP
PEDSALYLCASSNLVPMVATVGPGTRLTVTEDLKNVFP
Sequence
No Mutation
TPR
RPH
RNLV
NLV
T Cell Clone
Table 2.6. Sequencing of the mutated CDR3 of the full length TCR β-chain
The TCR β-chain was mutated using PCR to incorporate CMV-derived, immunogenic 
peptides within the CDR3 region. The sequencing results shown here confirm the 
presence of the immunogenic peptides within the CDR3 region.
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a sterile plunger. A small aliquot of cells from each fraction could be stained with 
further antibodies (if required) and analysed by flow cytometry.  
 
2.5.5 IFNγ ELISA 
IFNγ release by T cells was determined by using the Human IFNγ ELISA Kit – 
Ready-SET-Go! (Ebiosciences, SanDiego CA, USA). T cell clones or lines were 
washed to remove any residual IFNγ from the culture supernatant and resuspended in 
LCL media (RPMI + 10% FCS + 2mM L-Glutamine) at 10
5
/ml. Target cells were 
pulsed with peptide (10μg/ml) in serum-free media at 37°C for 2hrs and then washed 
to remove excess peptide. Where no peptide was added, the cells were washed and all 
target cells were resuspended in LCL media at 5x10
5
/ml. Normally, 10,000 effector T 
cells and 50,000 target cells per well were used in the stimulation step (E:T ratio 1:5). 
Cell numbers could be increased or decreased depending on available cell numbers. 
100μl of effector cells and 100μl of target cells were added to wells of a 96-well U-
bottomed plate. The plate was incubated at 37°C for 16 hours in 5% CO2.  
 
A 96-well flat bottomed plate was coated with 100μl of IFNγ capture antibody, sealed 
and incubated at 4°C for 12 hours. The plate was washed 5 times (PBS (made in-
house from tablets, Oxoid (Hampshire, UK) + 0.05% Tween 20 (Melford Labs, 
Suffolk, UK)), blocked using 200μl of assay diluent per well and stored at room 
temperature for 1 hour. The plate was washed again as above and 100μl of culture 
supernatant added to the wells from the overnight culture plate. Wells containing 
known amounts of IFNγ were also set up to allow quantitative analysis of the ELISA. 
The plate was sealed and stored at room temperature for 2 hours. After washing (as 
above), 100μl/well of IFNγ detection antibody was added and the plate incubated at 
 88 
room temperature for 1 hour. After washing (as above), 100μl/well avidin-HRP was 
added and the plate incubated at room temperature for 30 mins. The plate was washed 
7 times using wash buffer and 100μl/well TMB added before storing at room 
temperature in the dark for 15 mins to allow for colour development. Colour change 
from colourless to blue was indicative of IFNγ production. To stop the reaction, 
50μl/well 1M phosphoric acid was added and the plate was taken to be read in a 
spectrophotometer at A450.  
 
2.5.6 IFN-γ ELISpot 
The ELISpot wells (Mabtech, France) came pre-coated with anti-IFN-γ antibody and 
were washed once in 200μl RPMI + 10% FCS before use. PBMCs and PBMCs 
depleted of B cells were washed in RPMI + 10% FCS and resuspended at 5x10
5
/ml in 
fresh RPMI + FCS. 200μl of cells were added to each well and 50μl of immune 
complex antibody or 5μl peptide (500μg/ml) was added to individual wells. For the 
positive control, 1μl anti-CD3 (Mabtech, France) was used and 10μl PBS  (made in-
house from tablets, Oxoid (Hampshire, UK) was used for the negative control. The 
plate was covered and incubated at 37°C for 16-18 hours. The cells were flicked off 
and the plated was washed four times with PBS and 200μl PBS + 0.5% FCS was 
added to each well. The plate was incubated for 30 minutes at room temperature 
before being washed four times in PBS. The secondary antibody (alkaline 
phosphatase conjugated) (Mabtech, France) was diluted 1:200 in PBS and 100μl 
added to each well. The plate was incubated at room temperature for 2 hours and 
washed four times in PBS. To each well, 100μl substrate BCIP/NBT (Mabtech, 
France) was added and left to develop for 10-12 minutes at room temperature. The 
wells were extensively washed in tap water to stop the reaction and the wells were left 
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to dry in a cool, dark place. The spots in each well were counted using an ELISpot 
reader. 
 
2.5.7 Generation of Polyclonal Cytotoxic T Lymphocyte  (CTL) lines 
PBMC were isolated in the normal manner from fresh blood. After the second wash 
with RPMI, cells were resuspended in 100μl of RPMI containing 5μg/ml of CMV 
peptide (such as NLV) and incubated for 1-2hrs at 37°C. Cells were then resuspended 
in fresh media at 1x10
6
 cells/ml in 2ml cultures. After 24 hours, the used media was 
removed and fresh media added containing 20IU/ml recombinant IL-2 (Peprotech 
UK).  After a week, fresh T cell media (5ng/ml IL-7 and 5ng/ml IL-15) (Peprotech, 
UK) was added and cultures were re-fed every 3-4 days. These cultures were stained 
with tetramer to determine the expansion and purity of the peptide-specific cytotoxic 
T cells. They were either used within 10-14 days or could be cryopreserved at -80°C 
for future assays. 
 
2.5.8 Generation of Naïve T Cell Response 
2.5.8.1 Production of Dendritic Cells 
Generation of naïve T cell responses followed a previously published protocol (Ho et 
al, 2006). Briefly, unfractionated PBMCs were washed in RPMI + 10% heat 
inactivated AB human serum (Biosera, East Sussex, UK) and resuspended at 5x10
6
 
cells/ml. 1x10
7
 cells were added to each well of a 6 well plate and incubated at 37°C 
for 2 hours. Non-adherent cells were washed off and 3mls of fresh media containing 
800IU/ml GM-CSF (Peprotech, UK) and 1000IU/ml IL-4 (Peprotech, UK) was added 
to the adherent cells in each well and the plate incubated at 37°C overnight. The 
following day, 300μl maturation media (RPMI + 10% AB human serum + 100ng/ml 
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TNF-α (Peprotech, UK) + 100ng/ml IL-1β (Peprotech, UK) + 10,000IU/m IL-6 
(Peprotech, UK) and 10μg/ml prostaglandin-E2 (Peprotech, UK)) was added to each 
well and incubated at 37°C for a further 24 hours. Dendritic cells were harvested in 
wash buffer (PBS (made in-house from tablets, Oxoid (Hampshire, UK) + 0.5% BSA 
(Sigma, UK) + 2mM EDTA (Sigma, UK)) and washed twice in wash buffer. Cells 
were resuspended in RPMI with 10μg/ml peptide of interest and incubated at 37°C for 
2 hours. The peptide loaded DCs were washed twice in RPMI + 10% AB human 
serum and resuspended at 1x10
6
 cells/ml.  
 
2.5.8.2 CD8
+
 T Cells 
Non-adherent cells (described above) were washed in wash buffer and CD8 T cells 
isolated using magnetic selection with anti-CD8 PE antibody (BD Bioscience, UK) 
and anti-PE beads (Miltenyi Biotec, Germany). Isolated CD8
+
 T cells were then 
cryopreserved at -80°C until needed. Cells were thawed and washed in RPMI + 10% 
AB human serum, counted and resuspended at 5x10
6
/ml. 
 
2.5.8.3 Generation of Naïve T Cell Response 
Isolated CD8
+
 T cells were plated out in 1ml at 5x10
6
 cells/ml in a 6 well plate and 
dendritic cells were plated out in 1ml at 1x10
6
 cells/ml. Cells were re-fed after 48 and 
96 hours by removing 1ml of used media and replacing it with 1ml of fresh media 
containing 10ng/ml IL-7 (Peprotech, UK) and 10ng/ml IL-15 (Peprotech, UK). 
 
After 7 days culture, T cell lines were re-stimulated using fresh autologous PBMCs. 
PBMCs were washed in RPMI + 10% AB human serum and resuspended at 1x10
7
/ml 
and peptide-pulsed using 50μl of 500μg/ml peptide. After 2 hours incubation at 37°C, 
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the cells were irradiated using 35Gy. The cells were washed 3 times in RPMI and 
resuspended in RPMI + 10% AB human serum at 1x10
7
 cells/ml. 1ml of used media 
was removed from the T cell lines and 1ml of fresh media plus peptide-pulsed feeder 
cells was added. Cells were re-fed every 2 days with media + cytokines as described 
previously. After 14 days, IFN-γ cytokine secretion assay was performed to determine 
whether there was any peptide-specific response.  
 
2.5.9 IFNγ Cytokine secretion assay (CSA) 
PBMC were stimulated for 3 hours at 37°C with 1μg/ml of the appropriate peptide, in 
2ml cultures at 1x10
6
 PBMC/ml of T cell cloning media (RPMI plus 10% FCS, 1% 
human serum, 2mM L-Glutamine and 100U/ml penicillin-streptomycin solution). 
After the incubation, cells were washed three times with cold MACS Buffer and then 
resuspended in a volume of approximately 80μl. 20μl of IFNγ capture reagent 
(Miltenyi Biotec, Germany) was added to the cells, which were then incubated for 
5min on ice before diluting in warm T cell cloning media to between 0.5 and 1x10
6
 
cells/ml. The cells were incubated at 37°C for 45 min with agitation every 5min. The 
tube was placed in a horizontal position to minimize capture reagent binding in a non-
specific manner. After this, cells were washed twice with cold MACS buffer and 
resuspended in a volume of approximately 80μl.  20μl of PE-conjugated IFN-γ 
detection antibody (Miltenyi Biotech, Germany) was added and cells were incubated 
on ice for 10-15min. Cells were also counter-stained with anti-CD8 at this stage. After 
2 washes with cold PBS, cells were resuspended in 0.5ml MACS buffer and were 
used for cell sorting using the MS columns (Miltenyi Biotec, Germany). Cells 
collected in the positive fraction were counted using a haemocytometer and either 
analysed on the FACS machine or cloned using limiting dilution assay methods. 
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2.5.10 Single Cell Cloning 
2.5.10.1 FACSorting 
PBMC were stained with tetramers and anti-CD8 FITC and then washed with sterile 
MACS buffer prior to sorting using a FACS Vantage cell sorter (Becton Dickinson).  
Cells were sorted using the TurboSort
®
 setup allowing 5,000 events per second to be 
sorted. T cell cloning mix was prepared: 10
6
 irradiated allogeneic PBMC and 10
5
 
irradiated EBV-transformed autologous LCLs/ml., in T cell clining media containing 
50U/ml recombinant IL-2 (Peprotech EC, London UK) and 5ng/ml IL-7. Single 
CD8
pos
 tetramer
pos
 cells were sorted into 96-well plates containing 200μl of cloning 
mix. A 96-well plate containing only cloning mix and no T cells added was used as a 
control. 
 
2.5.10.2 Cloning by Limiting Dilution  
Cells (EBV-transformed LCLs and other B cell types) were counted and seeded into 
LCL growth media (RPMI + 10% FCS + 2mM L-Glutamine + 100U/ml Penicillin + 
100U/ml Streptomycin) at 0 cells per well (1 plate), 0.3 cells per well (12 plates), 3 
cells per well (3 plates) and 30 cells per well (1 plates). After 14-21 days of culture at 
37°C in 5% CO2, growing cultures were expanded to 2ml and seeded in 24-well 
plates. These cultures were re-fed every 3-4 days and expanded when needed.  
 
2.5.11 Rapid Expansion Protocol (REP) 
For expansion of cell numbers, the desired clone was subjected to a REP. On day 1 of 
the REP, 1-2x10
5
 T cells were added to 25ml of REP media (RPMI plus 10% FCS, 
1% Human serum, 2mM L-Glutamine, 25μM 2-mercaptoethanol (Sigma, UK), 
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12.5mM Hepes (Sigma, UK), 30ng/ml OKT3 and 100u/ml penicillin-streptomycin 
solution) containing 25x10
6
 irradiated allogeneic PBMC and 5x10
6
 irradiated 
autologous peptide pulsed LCLs. After 24hr (day 2) IL-2 was added to each REP to a 
final concentration of 50U/ml. On day 4, the cells were resuspended and pelleted by a 
5min spin at 1200rpm. Cells were then resuspended in 25ml of fresh REP media 
containing 50U/ml IL-2 (and no OKT3). Every three to four days afterwards, half the 
media was replaced with fresh media and IL-2. Cytotoxicity assays were performed at 
least four days after stimulation with fresh IL-2. After 15 days the cells were frozen in 
multiple aliquots containing 2x10
6
 cells per vial and stored long-term in liquid 
nitrogen. 
 
2.6 Transfection and transduction of cells  
2.6.1 Mirus Bio – TransIT Jurkat Transfection Reagent 
1.5x10
6
 Jurkat T cells (an immortalised human leukaemic T cell line) were pelleted by 
centrifuging at 1400rpm for 10 mins and resuspended in 2 mls complete media and 
seeded into a single well of a 6-well plate. In an eppendorf, 1-5μl of TransIT reagent 
(MirusBio, Wisconsin, USA) was added dropwise into 200μl OptiMEM serum free 
media, mixed thoroughly and incubated at room temperature for 20 mins. 2μg of 
DNA was added to the diluted TransIT reagent and incubated at room temperature for 
15 mins. The DNA Suspension was then added dropwise into the cells and the plate 
was rocked gently to distribute the complexes evenly. The cells were then incubated 
at 37°C under 5% CO2.  
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2.6.2 Invitrogen – Lipofectamine LTX and PLUS Reagent 
2x10
5
 Jurkat T cells were pelleted and resuspended in 2mls complete media and 
seeded into a single well of a 6-well plate. In an eppendorf, 1-2μg of DNA was 
diluted in 500μl Opti-MEM (Gibco, Paisley, UK) serum free media and mixed 
thoroughly. 1-2μl of PLUS reagent (Invitrogen, Paisley, UK) was added to the diluted 
DNA, mixed thoroughly and incubated at room temperature for 5 mins. 1.5-5μl 
Lipofectamine LTX reagent (Invitrogen, Paisley, UK) was then added to the diluted 
DNA, mixed thoroughly and incubated at room temperature for 30 mins. The 
DNA:Lipofectamine complexes were then added dropwise into the cells in the 6-well 
plate and mixed gently by rocking the plate back and forth. The cells were then 
incubated at 37°C under 5% CO2. The cells were cultured for at least 48 hours before 
testing for transfected protein production. 
 
2.6.3 Lentiviral Transfection and Transduction 
2.6.3.1 Lentiviral vectors  
Bicistronic lentiviral vectors (Clontech, Saint-Germain-en-Laye, France) pLVX-
IRES-puromycin and pLVX-IRES-neomycin (Figure 2.5) were used as well as pTRIP 
(kind gift from Dr P. Balfe).  
 
2.6.3.2 Transfection of Cells to Produce Lentivirus Particles 
Human embryonic kidney-293T cells (HEK-293T) were grown in monolayers in T25 
flasks overnight in 293 media (Dulbecco Modified Eagle Medium (Gibco, UK) 
supplemented with 10% FCS and penicillin/streptomycin). Lipofectamine LTX 
transfection reagent (Invitrogen, Paisley, UK) was used to transfect the HEK-293T 
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Figure 2.5 Lentiviral Expression Vectors Used for Transduction 
The Rituximab-NLV antibody, containing the mutated CDR3 region to include the 
CMV-derived peptide, was originally in the pLVX-IRES vector with the heavy chain 
upstream of the IRES sequence and the light chain downstream of the IRES 
sequence. Soon after, the heavy and light chains were split up and ligated into two 
different vectors to allow for antibiotic selection. The heavy chain was placed into the 
pLVX-IRES-Puromycin vector and the light chain was placed into the pLVX-IRES-
Neomycin vector. 
 
 
Figure 2.6 Production of lentiviral particles used for transductions
The lentivirus vectors (VSV-G, Gag-Pol and expression construct) are transfected into the 
293T or Lenti-X 293T cells. The 293T cells produce the lentiviral particles af ter 24-48 
hours. The virus particles are harvested ready for transduction studies.
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cells. Briefly, dilute 8μg total DNA (4μg Gene of Interest, 1.5μg VSV-G & 2.5μg 
Gag-Pol) in 1000μl OptiMem (Gibco, UK) and incubate at room temperature for 5 
mins (Figure 2.6). Add 10μl PLUS reagent to diluted DNA and incubate at room 
temperature for 10 mins. Add 15μl of Lipofectamine LTX reagent to mixture and 
incubate at room temperature for 30 mins. The cells are prepared for transfection by 
removing the media from the overnight incubation and washing once gently with 
OptiMem. The DNA-reagent mixture is then gently pipetted onto the HEK-293T cells 
and the flask laid flat at 37°C for 4 hours before adding 2mls of fresh HEK-293T cell 
media. The cells are then incubated overnight at 37°C.  
 
After 24hrs, the media is removed and 3mls fresh HEK-293T cell media is gently 
pipetted onto the cells. The cells are then left at 37°C overnight and the media is 
harvested as this will contain the lentivirus particles. Fresh media is again pipetted 
onto the cells and incubated overnight at 37°C. The media, containing more lentivirus 
particles, is then harvested and added to the initial harvest. The media is then spun at 
2000rpm for 10 mins to remove any cell debris from the harvest before being 
aliquoted into 1ml tubes and frozen at -80°C until required.  
 
2.6.3.3 Alternative Method to Transduce Cells Using Lentivirus  
After transfecting the packaging cell and prior to production of lentivirus particles, 
5x10
6
 target cells were washed in RPMI and re-suspended in 3mls RPMI + 10% FCS. 
After removing the spent media from the packaging cell line, the washed target cells 
were added to the packaging cell line and co-cultured for 48 hours at 37°C to allow 
transduction to occur. After 48 hours, transduced target cells were removed form the 
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flask and washed in RPMI and re-suspended in 5mls RPMI + 10% FCS and cultured 
in a 25cm
2
 flask. After a further 48 hours, the cells were tested for protein production. 
 
2.6.3.4 Production of Rituximab-NLV 
DNA encoding the heavy and light chain of Rituximab was taken from DrugBank 
(http://www.drugbank.ca/drugs/DB00073, v2.5, accessed 19 November 2009) and the 
heavy chain CDR3 region mutated to incorporate the CMV epitope NLVPMVATV. 
DNA encoding the Rituximab sequence was ordered from GenScript (New Jersey, 
USA).   
 
In order to produce lentiviral particles containing the DNA encoding mutated 
Rituximab, 3 different methods of transfection were employed. Firstly, DNA 
encoding the heavy chain (2μg) and light chain (2μg) was mixed together before 
adding the transfection reagent LTX to it and incubated for 20 minutes at room 
temperature (A). Lenti-X HEK-293T cells (Clontech, Saint-Germain-en Laye, France) 
were transfected with the DNA-LTX mixture for 30 minutes. 5mls of fresh DMEM + 
10% FCS was added and the cells were incubated overnight at 37°C. The second 
method added the LTX to the heavy chain in one eppendorf and LTX to the light 
chain in another eppendorf. The two mixtures were incubated at room temperature for 
20 minutes and would be mixed in the flask during transfection (B). Lenti-X HEK-
293T cells were transfected with the two DNA-LTX mixtures for 30 minutes. 5mls of 
fresh DMEM + 10% FCS was added and the cells were incubated overnight at 37°C. 
The third method again contained LTX-Heavy chain in one eppendorf and LTX-light 
chain in another eppendorf, again incubated for 20 mintues (C). Two flasks of cells 
were used for transfection, one was transfected with the LTX-heavy chain and the 
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other was transfected with the LTX-light chain. Lenti-X HEK-293T cells were 
transfected with the DNA-LTX mixture for 30 minutes. 5mls of fresh DMEM + 10% 
FCS was added and the cells were incubated overnight at 37°C. After 24 hours, media 
was removed from flasks A and B and 5mls of fresh media was added. The media in 
the two flasks for C were swapped so that the media in the heavy chain flask was 
placed in the light chain flask and the media from the light chain flask was placed in 
the heavy chain flask. This was to ensure that the cells would be infected with DNA 
encoding for both the heavy and light chain. All of the flasks were incubated for a 
further 48 hours at 37°C. The media was removed from all flasks and replaced with 
fresh media containing 2μg/ml puromycin and 250μg/ml G418. Transfected cells 
were incubated for 4 days at 37°C until confluent and the media taken to assay for 
production of Rituximab-NLV by ELISA. Cells were fed with fresh media containing 
antibiotics and IgG depleted FCS and split once per week and the supernatant 
harvested and stored for purification.  
 
2.6.3.5 Purification of Rituximab-NLV 
Media containing Rituximab-NLV was spun at 3000rpm for 30-60 minutes to 
concentrate it to 1ml using 10kDa centrifugal filtration (Sartorius, Germany). This 
was then purified using either Protein A or Protein G columns (GE Healthcare, UK). 
After washing the column in PBS (made in-house from tablets, Oxoid (Hampshire, 
UK), the media was added to the beads and incubated at room temperature for 5 
minutes. The column was spun at 13,000rpm for 30 seconds and the flow through 
discarded. The column was washed in 500μl PBS, spun again at 13,000rpm for 30 
seconds, the flow through discarded and repeated two further times. The antibody was 
eluted from the column by adding 125μl 0.1M acetic acid (Sigma, UK) and 
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incubating for 3 minutes at room temperature. The column was spun for 30 seconds at 
13,000rpm and the elution process repeated using another 125μl 0.1M acetic acid. 
The eluate was then buffered using 250μl 0.2M Na2CO3 (Sigma, UK) and stored at 
4°C.  
 
The purification of Rituximab-NLV was tested by ELISA using a mouse anti-human 
IgG antibody and an anti-mouse-HRP conjugated antibody (eBiosciences, UK). 
Purified Rituximab-NLV was coated on a 96 well flat bottomed plate (Nunc, 
Germany) at 37°C for 60 minutes. The plate was washed in PBS tween/PBS and the 
wells were blocked with 2% BSA (eBiosciences, UK) for 60 minutes at room 
temperature. After washing, the mouse anti-human IgG antibody (Sigma, UK) was 
diluted 1:500 in PBS and added to each well. The plate was incubated at room 
temperature for 60 minutes and washed. The second antibody anti-mouse HRP was 
diluted 1:500, added to each well and incubated at room temperature for 60 minutes. 
The plate was washed extensively before addition of TMB and the plate was left to 
allow blue colour to develop for 10-15 minutes. After colour had developed, 10% HCl 
was added to each well to stop the reaction and the wells were read using the GloMax 
96 well plate luminometer (Promega, UK).  
 
2.6.3.6 Formation of an Immune Complex 
Heating 
Rituximab-NLV was heated to 65°C for 10-30 minutes to induce unfolding and 
aggregation of the protein. The antibody was then incubated at 37°C for 15 minutes 
before being used for further work. 
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Anti-Kappa Antibody 
In order to form a complex which is closer to physiological conditions, an anti-kappa 
antibody (Generated in-house and kind gift from Dr Margaret Goodall) was used to 
cross-link the kappa light chain used by Rituximab. Equal amounts of Rituximab-
NLV and anti-kappa antibody were mixed and incubated for 30 minutes at room 
temperature. The antibody complex was then ready to use for further work. 
 
2.6.3.7 Concentration of Lentivirus Particles 
Lentiviral particles were concentrated using Lenti-X concentrator (Clontech, Saint-
Germain en Laye, France). After spinning the lentiviral supernatant to remove cellular 
debris, the supernatant is diluted 3 parts supernatant to 1 part Lenti-X concentrator 
and mixed gently. The mixture is incubated at 4°C for 1 hour before being spun at 
1500g for 45 mins. The supernatant is removed and the pellet is resuspended in fresh 
DMEM + 10% FCS and aliquoted before being stored at -80°C. 
 
2.6.3.8 Transduction of PBMCs and Cell Lines with Lentivirus 
1x10
6
 PBMCs or various cell lines per virus transduction were spun down and re-
suspended in RPMI (Prepared in-house from powder ordered from Sigma (R6504)) + 
10% FCS + penicillin/streptomycin (Sigma, UK) at 100μl per virus transduction. 
100μl of cells were added to individual wells of a 24-well plate. 500-1000μl of virus 
cell supernatant (stored as described previously) was added to the cells and incubated 
at 37°C for 4-6 hours. 1.5mls of fresh RPMI media was added on top of the 
transductions and the cells were incubated at 37°C for at least 48 hours and they could 
then be tested for protein expression. 
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2.7 Conjugation of Peptide to Antibody 
2.7.1 Peptide Tagging Antibodies 
Antibody clone BU69 (Generated in-house, kind gift from Dr Margaret Goodall, 
500μg/ml), anti-CD70, was used to attach the peptides ordered from GenScript, UK 
(Table 5.1).  BU69 (500μg) was mixed with 1.2mg Sulfosuccinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate (SMCC (Sigma; Dorset, UK)) 
previously dissolved in 400μl PBS and incubated at room temperature for 1 hour. 
Excess SMCC was removed from the antibody using a protein G column (GE 
Healthcare, UK). Briefly, the protein G column was washed in PBS and the antibody 
allowed to bind to the protein G beads for 5 minutes. The column was washed 3 times 
with PBS to remove the excess SMCC and the antibody eluted with 2x 125μl 0.1M 
acetic acid. The eluted antibody-peptide complex was buffered with 250μl 0.2M 
Na2CO3. Peptides were dissolved in DMSO to 10mg/ml and 2μl of peptide was added 
to 1μl TCEP to reduce the cysteinylated peptides and incubated at room temperature 
for 10 mins. 100μl of SMCC-antibody was added to each of the peptides and 
incubated at room temperature for 2 hours. To remove excess peptide from the 
antibody complex, the complexes were purified using the protein G column again. 
The complexes were eluted in acetic acid and buffered with Na2CO3 again before 
being stored at 4°C.  
 
2.7.2 Staining Cells with Peptide-Tagged Antibodies 
Target cells were stained with 10μl biotinylated peptide conjugated antibody for 30 
minutes at room temperature, washed and 1μl streptavidin-PE added (Invitrogen. 
Paisley, UK). After incubating at room temperature for 20 minutes, the cells were 
washed and analysed on the flow cytometer to ensure that the conjugated antibody 
 102 
could bind to cells (Figure 2.7). For T cell recognition, 1x10
5
 target cells were seeded 
into 96 well V-bottom plates, spun down and washed before being re-suspended in 
100μl media. 25-50μl peptide tagged antibody was added to the cells and incubated at 
room temperature for 30 mins. The cells were then washed in RPMI and spun down 
with the supernatant discarded. The antibody-coated cells were re-suspended in 200μl 
RPMI + FCS and incubated overnight (~14hrs) before the cells were used for T cell 
recognition using IFN-gamma ELISA and/or FACS Killing Assay.
 
 
2.7.3 FACS-Based Cell Targeting Assay 
1x10
5 target cells were separated into two tubes with one population stained with 10μl 
anti-CD45 APC-Cy7 (Becton Dickinson, UK) and the second population stained with 
10μl anti-CD45 FITC (Becton Dickinson, UK). The cells were incubated at room 
temperature for 30 minutes before being washed twice in RPMI. The cells previously 
stained with anti-CD45 APC-Cy7 were stained with the peptide-tagged antibody and 
incubated at room temperature for 30 minutes before being washed twice in RPMI. 
The two cell populations were mixed and seeded into a single well of a 96 well V-
bottom plate in 100μl media. 1x104 peptide specific T cells were washed in RPMI and 
resuspended in 100μl media before being added to the same well. The cells were left 
for 6 hours at 37°C before being washed in RPMI and moved into FACS tubes. The 
cultured cells were stained with anti-CD4 APC to discriminate the effectors (CD4
+
) 
from the targets (CD4
-
). The cells were then washed and run on the flow cytometer.  
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Figure 2.7 Staining cells using peptide conjugated CD20
Cells were stained with either commercially available anti-CD20 (A) or peptide-conjugated 
rituximab (B). After 30 mins, the antibodies were washed off and streptavidin-PE added for 
20 mins. The cells were washed and analysed using the flow cytometer.  Results 
demonstrate the ability of the peptide-conjugated Rituximab to bind to the B cells showing 
that the conjugation of the peptides does not interfere with the antibody binding domain.
A B
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2.7.4 Staining Target Cells with Peptide-Conjugated Secondary Antibody 
In order to test a number of antibodies easily, an anti-mouse IgG secondary antibody 
conjugated with the viral peptide (as previously discussed) was used. Briefly, target 
cells were stained with a primary antibody, not previously conjugated with a peptide, 
for 30 mins at room temperature. After washing once in PBS (made in-house from 
tablets, Oxoid (Hampshire, UK), the target cells were stained with the secondary 
antibody conjugated with the viral peptide. After incubation for 30 mins at room 
temperature, the cells were washed in PBS (made in-house from tablets, Oxoid 
(Hampshire, UK)  and antibody-coated cells were re-suspended in 200μl RPMI + FCS 
and incubated overnight (~14hrs) before the cells were used for T cell recognition 
using IFN-gamma ELISA (eBiosciences, UK) and/or FACS Cell Targeting Assay.
 
 
2.7.5 Quantification of Protein Concentration 
Protein concentration was quantified using the Qubit assay (Invitrogen, Paisley, UK). 
To make the test buffer for each sample, 199μl buffer was added to 1μl of protein 
assay reagent. Firstly, 3 standard protein solutions were used to calibrate the machine. 
10μl of each standard solution was added to 190μl test buffer and incubated at room 
temperature for 15 minutes. The samples were then read using the Qubit fluorimeter 
to calibrate the machine. Five microlitres of the protein solution to test was added to 
195μl of test buffer and incubated for 15 minutes. The samples were then read on the 
Qubit fluorimeter which could then produce the concentration of protein in each 
sample. 
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2.8 Statistical Analysis 
Results were analysed and presented using GraphPad Prism 5 (version 5.01). For 
comparisons between donors in HLA-positive and HLA-negative cohorts, chi-squared 
test was used.  For comparisons between unpaired data sets, an unpaired t-test was 
performed. All p values were considered significant if less than 0.05. Apart from 
discussions with supervisors, no further statistical support was sought.  
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3. Immunoediting of the B Cell Receptor Repertoire 
 
 
3.1 Introduction 
B cells can express B cell receptors on the cell surface, which may contain potentially 
immunogenic peptides within the “non-self” CDR3. These peptides could potentially 
initiate an immune response if they were to be presented at the surface of the B cell in 
complex with MHC molecules. Unlike T cells, B cells can express membrane-bound 
receptors and secrete soluble B cell receptors (immunoglobulin). Therefore, if the 
receptor contained potentially immunogenic peptides within the CDR3, secreted 
antibodies containing these peptides could be taken up by many cells (dendritic cells 
for instance) and initiate immune responses against them by priming the immune 
system to the CDR3 of a B cell receptor leading to autoimmune responses against B 
cells.  
 
I set out to test the hypothesis that B cells bearing BCRs containing HLA-binding 
peptides within their CDR3s are not subject to peripheral immunological tolerance 
and are deleted in what could possibly be a further round of B cell selection after 
selection in the bone marrow.  If there is no peripheral immunological tolerance 
towards non-germline encoded CDR3-derived peptides, in an HLA-A*0201
+
 
individual (henceforth denoted HLA-A2), any B cells bearing BCRs containing 
potential HLA-A2 binding peptides would be deleted. However, B cells bearing 
BCRs containing peptides binding non-self HLA alleles would survive because the 
host simply would not and could not target them (Figure 3.1). Such a model would 
predict for a decreased frequency of HLA-A2 binding peptides within the CDR3s of 
B cell receptors taken from HLA-A2
+
 donors compared with the frequency from A2
-
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No Peripheral Immunological Tolerance Present
Peripheral Immunological Tolerance Present
No HLA-A*0201+ peptides
HLA-A*0201+ peptides
HLA-A2+
HLA-A2-
Figure 3.1 Molecular hypothesis for deletion of B cells containing predicted HLA-
A*0201 peptides within their CDR3
If there is no immunological peripheral tolerance, a B cell from an HLA-A*0201+ individual
containing potential A2-binding peptides derived from the CDR3 region would undergo
deletion as the peptide could be presented on the surface of the B cell in complex with HLA-
A2. This would result in a decreased frequency of HLA-A2 binding peptides within the CDR3
region of HLA-A2+ donors compared with HLA-A2- donors. However, if there is
immunological tolerance towards CDR3-derived peptides, the frequency of HLA-A2 binding
peptides in HLA-A2+ donors would be similar to that from HLA-A2- donors.
HLA-A*0201+ peptides
HLA-A2+
HLA-A2-
HLA-A*0201+ peptides
Ig Heavy Chain
Ig Heavy Chain
Ig Heavy Chain
Ig Heavy Chain
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donors. There are two alternative competing hypotheses which would satisfy the lack 
of any immunoediting of the peripheral BCR repertoire.  Firstly, tolerance against 
BCRs akin to any other self antigen would be subject to peripheral immunological 
tolerance.  Secondly, it is conceivable that BCRs do not access the antigen processing 
machinery of B cells and are thus privileged antigens resulting in antigenic ignorance.  
Therefore, there would be no need for B cells containing potential HLA-A2 binding 
peptides within the CDR3 to be edited from the B cell repertoire, meaning CDR3-
derived peptides could not be presented at the surface of the B cell in complex with 
HLA.  Consequently, B cells which contain potential A2-binding peptides could 
populate the periphery along with B cells which do not (Figure 3.2). Such models 
would therefore predict the frequency of HLA-A2 binding peptides within the CDR3s 
of BCRs from an HLA-A2
+
 donor to be similar to the frequency seen in HLA-A2
-
 
donors as a result.   
 
3.2 Cloning the CDR3 of B Cell Receptors 
For the purpose of this work, the Ig heavy chain was used as this has an extra region 
within the CDR3, providing increased variability. Therefore, the presence of HLA-
binding peptides may be increased in the Ig heavy chain when compared to the Ig 
light chain but the study could possibly be extended to include the Ig light chain. 
Previous studies suggest that the majority of predicted peptides found within the Ig 
heavy chain are found within the CDR3 (Hansson et al, 2003). After amplifying the 
DNA using an oligonucleotide primer specific for the BCR framework region 1 and a 
second primer specific for the constant region, positive bands were seen at ~550bp 
(Figure 3.3). The band, containing many different Ig heavy chains from the 
framework region 1 to the constant region, was cut out and the DNA was purified 
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Figure 3.2 Cellular hypothesis for deletion of B Cells containing predicted HLA-
A*0201 peptides within their CDR3
If there is no peripheral immunological tolerance, a B cell from an HLA-A*0201+ individual 
containing potential A2-binding peptides derived from the CDR3 region (Red) would undergo 
deletion, by anti-idiotype-specific T cells (Green), as the peptide could be presented on the 
surface of the B cell in complex with HLA-A2. BCRs which do not contain a potential HLA-A2 
binding peptide within the CDR3 region (Black) would populate the periphery. Therefore, 
peripheral tolerance towards CDR3-derived peptides would result in a decreased frequency 
of HLA-A2 binding peptides within the CDR3 region of HLA-A2+ donors. However, if there is 
immunological tolerance, or antigenic ignorance, towards CDR3-derived peptides, the B 
cells containing a BCR with a CDR3-derived peptide would be allowed to populate the 
periphery and the anti-idiotype-specific T cells would not recognise the B cells. Therefore, 
the frequency of HLA-A2 binding peptides, within the CDR3 region, in HLA-A2+ donors 
would be similar to that from HLA-A2- donors.
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500bp
1000bp
Figure 3.3 PCR to amplify all BCRs using cDNA generated from PBMCs
cDNA was synthesised from RNA, extracted from unfractionated PBMCs, and used as template 
DNA with one primer corresponding to the Ig framework region 1 within the variable region and a 
second set of primers which corresponded to the constant regions of IgA, IgG and IgM. After 
amplification, the PCR was run on a 1% gel and bands visualised using a transilluminator. 
Amplicons which were visualised at 500-550bp were excised and used for further 
experimentation.  
500bp
1000bp
500bp
1000bp
Figure 3.4 Colony PCR to determine BCR amplification
After ligating amplified BCR DNA into the TA cloning vector and transforming E. coli, colonies 
which had grown were tested for transformation of plasmid DNA encoding BCR DNA. Bacterial 
transformation produced >100 colonies, 20-40 of which were grown in 50μl LB + ampicillin for 4 
hours. Bacterial cells were used as template DNA for PCR amplification using the M13 primer set 
found within the TA cloning vector. After amplification, PCR reactions were run on a 1% agarose 
gel and visualised using a transilluminator. Positive colonies contain a band of DNA ~550-650bp.
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from the agarose gel. After TA cloning, colonies containing DNA encoding for BCRs 
were screened using colony PCR with amplicons running to a size of ~600-650bp 
(Figure 3.4) deemed positive and the DNA used for sequencing. The nucleotide base 
sequence was checked against known B cell receptor variable region sequences to 
determine the CDR3 sequence and to prevent analysis of repeated sequences. 
 
3.3 HLA Peptide Prediction Algorithms 
The extracted DNA was sequenced and the CDR3 determined for 109 BCRs from 
HLA-A2
+
 donors and 125 BCRs from HLA-A2
-
 donors. CDR3 sequences were 
analysed for the presence or absence of potential HLA-binding peptides using two 
different peptide binding matrix-based algorithms, SYFPEITHI (Rammensee et al, 
1999) and BIMAS (Parker et al, 1994). Peptide prediction using SYFPEITHI depends 
on motif-based matrices relying on the presence of specific amino acid residues at the 
anchor positions and therefore these results may not be indicative of peptide affinity 
for HLA. However, peptide prediction using BIMAS uses the time taken for 
dissociation of the peptide from HLA and is therefore indicative of peptide affinity. 
These algorithms have been used in previous studies investigating the B cell and T 
cell CDRs (Trojan et al., 2000 & Hansson et al, 2003) and are generally regarded as 
the most reliable programs for this process. In order to determine the thresholds used 
to separate peptides that bind to HLA from those which do not, receiver operator 
curve (ROC) analysis was used. The accuracy of a test such, as the computer 
algorithms used in this study, can be evaluated using ROC analysis, known HLA-
binding peptides and peptides expected not to bind to HLA. 
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3.4 Performance Analysis of HLA-A2 predictive algorithms 
Peptides known to bind to HLA-A2 were sourced from the immune peptide database 
(IEDB; www.immunpeptide.org) and their binding scores determined using both 
SYFPEITHI and BIMAS. Random peptide sequences were generated, as non-binding 
HLA-A2 peptides, and their scores determined using both computer algorithms as 
well. These figures were plotted together to attempt to determine what the thresholds 
should be for both of the computer algorithms used in the analysis of my data set. The 
ROC analysis depends on both sensitivity and specificity and in this case, sensitivity 
can be defined as the proportion of true positive results of the total number of positive 
results (true positive + false negative). Specificity can be defined as the proportion of 
true negative results of the total number of negative results (true negative + false 
positive). Increasing the criterion value of the test will increase the specificity by 
decreasing the false positives but the sensitivity will decrease as well as there will be 
an increase in false negative results. Decreasing the criterion value of the test will 
increase the sensitivity as the number of true positives will increase but decrease the 
specificity by increasing the number of false positive results (Figure 3.5, taken from 
www.medcalc.be/manual/roc.php (Version 11.4)).  It is important to select a threshold 
which provides the highest incidence of true positive and true negative results whilst 
maintaining the lowest incidence of false positive and false negative results.  
 
3.4.1 SYFPEITHI - HLA-A2-Binding peptides 
Analysing the data set (HLA-A2-binding peptides from IEDB) using SYFPEITHI, the 
cross-over of the curve for peptides that do bind and the curve for peptides that do not 
bind is ~18 (Figure 3.6). This score is lower than the threshold used in previous 
publications and may include too many false positive results. The ROC curve 
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Figure 3.5 Generation and interpretation of receiver operator characteristic
The use of receiver operator characteristic is to try and determine the thresholds which should be 
set for the analysis of my data set. The graph shows the display of test results from patients 
without the disease and those with the disease and the possible outcomes of a test to determine 
whether the patient has the disease. By increasing the criterion value, the number of false positive 
results is reduced although there is a corresponding increase in the number of false negatives. This 
means there is an increase in specificity, due to the decrease in false positives, but there is a 
decrease in the sensitivity, due to the increase in false negati ves. By decreasing the criterion value, 
there is an increase in sensitivity as there is an increase in the true positive results but there is also 
an increase in false positive results meaning there is a decrease in specificity. There is a need to 
balance the sensitivity of the test with the specificity. 
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Figure 3.6 Receiver operator characteristic analyses of HLA-A2 using SYFPEITHI 
and BIMAS
Two peptide data sets, A2-binders and A2-non binders, were analysed using both 
computer algorithms BIMAS and SYFPEITHI. The scores generated from the two data 
sets were plotted to determine the thresholds to be set for analysis of the TCR and BCR 
data sets (A) and the peptide prediction algorithms tested for their specificity and 
sensitivity using receiver operator curve (ROC) analysis (B).
AUC = 0.987 AUC = 0.972
A
B
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produced an area under the curve (AUC) of 0.987 using GraphPad Prism 5 (version 
5.01).  The data set was analysed using a peptide binding threshold of 18 but this may 
be set too low and may not be used in all analysis. The presence of false positive 
peptides present could alter the results from the data set and I decided to also 
determine the SYFPEITHI score that would provide the maximum specificity. 
Although this would have an impact on the sensitivity, the peptides returned would 
almost definitely bind to HLA molecules. The curve for non-binding peptides reaches 
zero at 22, therefore in order to look at 100% specificity the SYFPEITHI score of 22 
was also used for analysis.  
 
3.4.2 BIMAS - HLA-A2 Binding peptides 
The same data set from IEDB was analysed using BIMAS and the cross-over of the 
curve for the peptides that do bind and the curve for the peptides that do not bind is ~5 
minutes (Figure 3.6). Although this is lower than previous publications, the BIMAS 
score that provides the maximal sensitivity as well as the maximal specificity would 
be greater than 5. The ROC curve produced an AUC of 0.972 using calculations by 
GraphPad Prism 5 (version 5.01).  The data set was therefore analysed using a 
BIMAS binding threshold of greater than 5 to accommodate peptides with a lower 
affinity for HLA molecules. Similar to the SYFPEITHI analysis, I also wanted to 
determine the BIMAS score which would give the maximum specificity regardless of 
the sensitivity so that there would be little chance of any peptides returned being non-
binders. Greater than 20 minutes, there is only 1 non-binding peptide (269 mins) and 
therefore, the BIMAS score with the maximum specificity would be greater than 20 
minutes. The data set was analysed using a threshold of 20 minutes to accommodate 
peptides with a higher affinity for HLA molecules. 
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EDTAVYYCARGLPGDIVVVPAAIGGYYFDYWGQGTLVTVSSGSASAPT 
Figure 3.7 Sequence analysis of the BCR
PCR products which contained a band ~600bp (Figure 3.4) were sequenced and analysed for the 
CDR3 sequence. The data returned for the sequencing is processed using the ChromasPro
sequencing program which turns the coloured peaks (A: Green, C: Blue, G: Black and T: Red) into 
the nucleotide base sequence (A). The base sequence is then translated into the amino acid 
sequence encompassing the variable region (blue) leading into the CDR3 regions (red) which 
incorporates the diversity and joining regions (green). The 3’ oligonucleotide primer is situated 
within the constant region of the Ig heavy chain and this results in the truncated sequence of the β-
chain (pink) (B).
A
B
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3.5 Frequency of Predicted HLA-A2-Binding Peptides from 
BCR CDR3 
BCRs were sequenced from within the first framework region (FR1) of the variable 
region to the beginning of the constant region, incorporating the CDR3 (Figure 3.7). 
The sequence shows the end of the variable region moving into the diversity region 
followed by the joining region and finishes with the beginning of the constant region. 
Peptides were considered CDR3-derived when at least 1 amino acid was found within 
the CDR3 similar to previous published work (Hansson et al, 2003). Initially, the 
donor sequences were analysed for the presence or absence of HLA-A2 binding 
peptides within the CDR3s. A total of 109 BCRs from HLA-A2
+
 donors and 125 
BCRs from HLA-A2
-
 donors, resulting in a total of over 8000 potential 9 amino acid 
peptides (3700 for HLA-A2
+
 donors and 4600 for HLA-A2
-
 donors), were analysed. 
The CDR3 sequences were analysed using two different HLA binding prediction 
algorithms, SYFPEITHI and BIMAS and the same thresholds discussed previously.  
 
3.5.1 SYFPEITHI - High Scoring Peptides 
The SYFPEITHI algorithm (version 1.0) was employed with a binding threshold of 
22 in an attempt to analyse peptides that would almost definitely bind to HLA-A2. 
There was a statistically significant increase in the frequency of potential HLA-A2 
binding peptides contained within the CDR3s of HLA-A2
-
 donors (0.24%) in 
comparison with those from the HLA-A2
+
 cohort (0.03%) (χ2=6.43, p=0.01) (Figure 
3.8). This result suggests that there is potentially no peripheral tolerance towards B 
cells expressing HLA-A2 binding peptides within the CDR3 in an HLA-A2
+
 donor. 
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Figure 3.8 Frequency of HLA-A2 peptides present in the CDR3 of BCRs in HLA-A2+ and A2-
healthy donors
Amplified BCRs from healthy donors (separated into A2+ and A2- cohorts) were sequenced from 
unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding peptides using the SYFPEITHI 
algorithm. Data is represented as a percentage of the peptides from both donor cohorts analysed 
where peptide binding was defined by a score of 22 or above.  Error bars denote mean + standard 
error mean.  Data was analysed using chi-squared test to determine statistical significance, * 
P<0.05.
*
Figure 3.9 Frequency of high affinity HLA-A2 peptides present in the CDR3 of BCRs in 
HLA-A2+ and A2- Healthy Donors
Amplified BCRs from healthy donors (separated into A2+ and A2- cohorts) were sequenced 
from unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding peptides using the 
BIMAS algorithm. Data is represented as a percentage of all peptides analysed where peptide 
binding was defined by a score of 20 or above. Error bars denote mean + standard error mean. 
Data was analysed using chi-squared test to determine statistical significance.
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Therefore, the data shown suggests that there may be editing of the BCR repertoire to 
remove potentially dangerous BCRs containing peptides predicted to bind to HLA-A2 
from within the CDR3. Consequently, there may not be peripheral tolerance towards 
these peptides. The peptides were then analysed using the BIMAS algorithm to 
determine whether similar results were seen. 
 
3.5.2 BIMAS - High Scoring Peptides 
The BIMAS algorithm (originally accessed 10 August 2006 and not updated since) 
was then used with a peptide binding threshold of 20 in an attempt to include peptides 
that would almost definitely bind to HLA-A2 only. There is also a decrease in the 
frequency of peptides predicted to bind to HLA-A2 present in the CDR3 of BCRs in 
HLA-A2
+
 (0.35%) when compared with the HLA-A2
-
 cohort (0.54%) (χ2=1.70, 
p=0.19) (Figure 3.9). Despite these results showing no statistical significance, they 
demonstrate a similar trend to those found when using the SYFPEITHI algorithm. 
Therefore, these results may show the presence of an immunoediting process in B 
cells although further studies would be needed to confirm this.  
 
3.5.3 SYFPEITHI & BIMAS - Lower Scoring Peptides 
After determining that there was a decrease in the percentage of peptides predicted to 
bind to HLA-A2 using the higher threshold from both computer algorithms, peptides 
predicted to bind to HLA-A2 at the lower threshold (using a threshold of 18) were 
investigated as well. Using SYFPEITHI with a peptide binding threshold of 18, there 
was still a decrease in the percentage of peptides predicted to bind to HLA-A2 from 
HLA-A2
+
 donors (4.84%) compared with those from the A2
-
 donors (5.16%) 
although this result was not statistically significant (χ2=0.43, p=0.40) (Figure 3.10). 
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Figure 3.10 Frequency of HLA-A2 peptides present in the CDR3 of BCRs in HLA-A2+ and A2-
Healthy Donors
Amplified BCRs from healthy donors (separated into A2+ and A2- cohorts) were sequenced from 
unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding peptides using the SYFPEITHI 
algorithm. Data is represented as a percentage of all peptides analysed where peptide binding was 
defined by a score of 18 or above. Error bars denote mean + standard error mean. Data was 
analysed using chi-squared test to determine statistical significance.
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Figure 3.11 Frequency of high and low affinity HLA-A2 peptides present in the CDR3 of 
BCRs in HLA-A2+ and A2- Healthy Donors
Amplified BCRs from healthy donors (separated into A2+ and A2- cohorts) were sequenced from 
unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding peptides using the BIMAS 
algorithm.  Data is represented as a percentage of all peptides analysed where peptide binding 
was defined by a score of 5 or above. Error bars denote mean + standard error mean. Data was 
analysed using chi-squared test to determine statistical significance, * P<0.05.
*
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The results demonstrate a similar percentage decrease between the two cohorts when 
compared with the results using the higher threshold although the total percentage of 
peptides predicted to bind is very high and has increased to ~5%. These results 
suggest that using the lower threshold may provide similar trends to the higher 
threshold, but the results may be somewhat hidden by the large percentage of false 
positive results. Therefore, further analysis using SYFPEITHI will be limited to using 
the higher threshold of 22. 
 
Using the BIMAS algorithm, the percentage of peptides predicted to bind to HLA-A2 
with a low affinity (using a threshold of half-time for dissociation >5), combined with 
the high affinity peptides, demonstrated a statistically significant increase from the 
HLA-A2
-
 cohort (1.61%) compared with the HLA-A2
+
 cohort (0.97%) (χ2=6.48, 
p=0.01) (Figure 3.11). Therefore, the results produced with BIMAS using the lower 
threshold suggest that there could be immunoediting of the B cell repertoire to remove 
HLA-A2 binding peptides from within the B cell CDR3 of HLA-A2
+
 donors.  
 
Analysis of the peptide sequences predicted to bind to HLA-A2 by both algorithms 
shows that the single peptide predicted to bind to HLA-A2 by SYFPEITHI in the A2
+
 
donors was also predicted to bind to HLA-A2 by BIMAS as well (Appendix A2). 
However, BIMAS also predicted a further ten peptides to bind to HLA-A2 that 
SYFPEITHI did not. In the A2
-
 donors, 8/28 peptides were predicted to bind to HLA-
A2 by both algorithms compared to 3/28 predicted by SYFPEITHI alone and 17/28 
by BIMAS alone (Appendix Table A2). These results show that although there is 
some cross-over between the two prediction algorithms, the results obtained from 
both are not identical reflecting the differences in their programming. 
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3.6 Frequency of BCRs Containing HLA-A2 Binding Peptides 
Although not significant, the above results suggest that there may be an 
immunoediting process in the B cell repertoire based on the frequency of predicted 
HLA-A2 binding peptides. However, the increased frequency seen in HLA-A2
-
 
donors could be the result of skewed data where one or two B cells contain a BCR 
with a large number of peptides within its CDR3 sequence, accounting for the 
difference in peptide frequency. In order to determine if the frequency of HLA-
binding peptides is evenly distributed in the data set, the frequency of BCRs 
containing more than one HLA-A2 binding peptide was investigated. A similar 
decrease in the frequency of BCRs containing an HLA-A2 binding peptide would 
strengthen the argument that there is possibly editing of B cells.  Using SYFPEITHI, 
there is an increased frequency of BCRs containing an HLA-A2 binding peptide in 
HLA-A2
-
 donors (1.6%) compared with HLA-A2
+
 donors (0.0%) (Figure 3.12). A 
similar trend is seen in the BIMAS analysis using both the high and low thresholds 
with an increased frequency seen in HLA-A2
-
 donors 1.6% (20) and 16.0% (5) 
compared with HLA-A2
+
 donors 0.0% (20) and 3.7% (5). 
 
Although many of the results do not demonstrate statistical significance, the trends 
seen suggest that B cells from HLA-A2
+
 donors, containing CDR3-derived peptides 
predicted to bind to HLA-A2, are edited from the B cell repertoire.  However, in 
HLA-A2
-
 donors, those B cells expressing a receptor which contains a peptide 
predicted to bind to HLA-A2 are not deleted simply because the peptides cannot be 
presented at the cell surface. Taken together, these results suggest that the original 
hypothesis may be true and therefore there is a possibility that there is no 
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Figure 3.12 Frequency of BCRs containing more than one HLA-A2 binding peptide 
BCRs from healthy donors (separated into A2+ and A2- cohorts) were analysed to determine the 
frequency of those containing more than one HLA-A2 binding peptide using both peptide prediction 
algorithms. Data is represented as a percentage of all peptides analysed where peptide binding 
was defined by a score of 22 or above using SYFPEITHI (A), a score of 20 or above using BIMAShi
(B) and a score of 5 or above using BIMASlo (B). This was done in an attempt to determine 
whether there was skewed data in the previous analysis of the peptide prediction data due to a 
single BCR containing a large number of HLA binding peptides within the CDR3. 
A B
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peripheral tolerance towards B cells expressing a BCR containing CDR3-derived 
peptides predicted to bind to HLA-A2.  
 
3.7 Performance Analysis of HLA-A1, -B7 and -B8 predictive 
algorithms 
The donors were also chosen to provide an equal number of donors who were positive 
or negative for HLA-A1, -B7 and -B8 (five donors for the HLA
+
 cohort and five 
donors for the HLA
-
 cohort). However, in order to analyse the data to determine the 
presence or absence of CDR3-derived peptides, thresholds for these HLA alleles had 
to be set. As discussed earlier, in the context of setting the threshold for HLA-A2 
(section 3.4, page 109), receiver operator curve analysis was used with a set of 
peptides taken from IEDB (Figure 3.13).  AUCs for each HLA allele and computer 
algorithm were calculated using GraphPad Prism 5 (version 5.01). 
 
3.7.1 SYFPEITHI 
Analysing the peptides using SYFPEITHI, the thresholds were set where no randomly 
generated peptide sequences, used as those which do not bind to HLA, were predicted 
to bind to the HLA allele. Above this threshold, it is possible that almost every 
peptide would bind to HLA and this would provide data with 100% specificity for 
each of the alleles. However, in setting the threshold this high, it is conceivable HLA-
binding peptides with a lower score could be overlooked. Unfortunately, it is not 
possible to include the lower scoring peptides without including some of the higher 
scoring non-binding peptides and for this analysis, it was more important to analyse 
peptides that would almost definitely bind to HLA. Therefore, the thresholds were set  
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Figure 3.13 ROC analysis to determine thresholds for HLA-A1, -B7 and -B8
Data sets for HLA-binders and HLA-non binders for the chosen alleles, were analysed 
using both computer algorithms BIMAS and SYFPEITHI. The scores generated from 
the two data sets were plotted to determine the thresholds to be set for analysis of the 
TCR and BCR data sets and the computer algorithm for each allele and each peptide 
prediction algorithm determined by ROC analysis (inset).
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at 25 for HLA-A1, 22 for HLA-B7 and 21 for HLA-B8. There was no lower threshold 
set as previous data using HLA-A2 had shown that lowering the threshold produced a 
large number of peptides that were unlikely to bind to HLA-A2 and therefore the real 
A2-binding peptides were hidden. It would be highly likely that the same would occur 
with the other HLA alleles analysed and therefore only the higher thresholds were 
used for analysis. 
 
3.7.2 BIMAS 
Analysing the same data using the BIMAS computer algorithm, the upper threshold 
was again set to the time where no randomly generated peptides bound to the HLA 
alleles. This resulted in the thresholds set as 12 for HLA-A1, 16 for HLA-B7 and 12 
for HLA-B8. The lower thresholds were set to 5 for all HLA types as most of the 
HLA-binding peptides produced a score of greater than 5 and there were very few 
non-binding peptides with a score greater than 5. This score would provide the 
maximum sensitivity and maximum specificity for each of the HLA alleles.  
 
3.8 Broader Analysis of HLA-Binding Peptides  
Once the results for HLA-A2 had been completed, the sequences were analysed using 
non-HLA-A2 alleles, HLA-A1, -B7 & -B8 to determine if the results seen with HLA-
A2 were consistent across the other HLA types tested.  
 
3.8.1 SYFPEITHI – High Scoring Peptides 
Using SYFPEITHI, with the peptide binding thresholds previously described (section 
3.7.1), the number of HLA-binding peptides in donors within the HLA positive 
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cohorts was slightly decreased compared with the HLA negative donors in all of the 
other HLA types (Figure 3.14). Similarly to HLA-A2, there is a small increase in the 
peptides predicted to bind to HLA-B7 in the HLA-B7
-
 cohort (0.05%) compared with 
the HLA-B7
+
 cohort (0.00%) (χ2=2.06, p=0.15). Analysis of the peptides predicted to 
bind to HLA-B8 showed a decreased percentage in HLA-B8
+
 donors (0.19%) 
compared with the HLA-B8
-
 donors (0.24%, χ2=0.24, p=0.61). Again, there is a 
decrease in the peptides predicted to bind to HLA-A1 in the HLA-A1
+
 cohort (0.37%) 
compared with the HLA-A1
-
 cohort (0.47%) (χ2=0.44, p=0.51). None of the above 
results were statistically significant but the trend suggests that the hypothesis could be 
true for all of the HLA types tested. Although further work may be required to 
generate statistically significant data, the results presented suggest there may be 
selective depletion of B cells containing CDR3-derived peptides in the HLA alleles 
tested. 
 
3.8.2 BIMAS – High Scoring Peptides 
Using the second peptide prediction algorithm BIMAS, with the higher binding 
thresholds to incorporate peptides with a higher binding affinity for HLA, there is a 
general trend seen with all three HLA types with a small increase in the percentage of 
predicted peptides in the HLA negative donors compared with the HLA positive 
donors (Figure 3.15). Analysis of all three HLA alleles demonstrated similar results 
with an increase in A1
-
 donors (1.75%) compared with the A1
+
 donors (1.64%) 
(χ2=0.16, p=0.69), an increase in B7- donors (0.59%) compared with B7+ donors 
(0.238%) (χ2=0.23, p=0.63) and also an increase in B8- donors (1.84%) compared 
with B8
+
 donors (1.77%) (χ2=0.05, p=0.82). Although none of the results are 
statistically significant, the trend shown in all HLA types is similar to that seen when 
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Figure 3.14 Frequency of peptides predicted to bind to HLA-A1, -B7 or -B8 present 
in the CDR3 of BCRs
BCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A1, -B7 and -B8-
binding peptides using the SYFPEITHI algorithm.  Data is represented as a percentage of 
all peptides analysed where peptide binding was defined by thresholds 25 for HLA-A1, 22 
for HLA-B7 and 21 for HLA-B8. Error bars denote mean + standard error mean. Data was 
analysed using chi-squared test to determine statistical significance.
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Figure 3.15 Frequency of high affinity peptides predicted to bind to HLA-A1, -B7 or -B8 
present in the CDR3 of BCRs.
BCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for high affinity HLA-A1, -B7 
and -B8-binding peptides using the BIMAS algorithm. Data is represented as a percentage of 
all peptides analysed where peptide binding was defined by threshold of 12 for HLA-A1, 16 or 
HLA-B7 and 12 for HLA-B8. Error bars denote mean + standard error mean. Data was 
analysed using chi-squared test to determine statistical significance.
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analysing HLA-A2 with a decreased percentage of peptides in the HLA positive 
cohorts. Therefore, these results suggest that there may be an absence of peripheral 
tolerance towards these peptides and if this is the case that there could be editing of 
the B cell repertoire to remove some of these potentially dangerous B cells in all of 
the alleles tested.  
 
3.8.3 BIMAS – Lower Scoring Peptides 
When the BIMAS threshold was reduced to >5, to include the peptides with lower 
affinity for HLA, there was no difference between the percentage of peptides 
predicted to bind to HLA in the HLA positive and HLA negative cohorts for HLA-A1 
and HLA-B7 (Figure 3.16). The percentages from each cohort were almost identical 
with 1.75% and 1.84% for A1
+
 and A1
-
 (χ2=0.01, p=0.92), 1.21% and 1.20% for B7+ 
and B7
-
 (χ2=0.00, p=0.96) and 2.73% and 2.82% for B8+ and B8- donors (χ2=0.00, 
p=0.95).  
 
Analysing the sequences of the peptides predicted to bind to these HLA alleles 
demonstrates that the majority of peptides predicted to bind to HLA alleles by 
SYFPEITHI are also predicted to bind by BIMAS with a few exceptions. However, 
the majority of peptides predicted to bind to HLA alleles by BIMAS are not predicted 
to bind by SYFPEITHI (Appendix A2). This suggests that the SYFPEITHI algorithm 
is more stringent in what it determines as a peptide that can bind to a given HLA 
allele. Despite the differences in the peptides predicted to bind to HLA, the trends 
produced by both algorithms are similar demonstrating a small decrease in frequency 
of HLA-binding peptides from the CDR3 of HLA
+
 donors. 
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Figure 3.16 Frequency of high and low affinity peptides predicted to bind to HLA-A1, -
B7 or -B8 present in the CDR3 of BCRs.
BCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for high affinity HLA-A1, -B7 
and -B8-binding peptides using the BIMAS algorithm. Data is represented as a percentage of 
all peptides analysed where peptide binding was defined by threshold of 5 for all HLA alleles. 
Error bars denote mean + standard error mean. Data was analysed using chi-squared test to 
determine statistical significance.
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Figure 3.17 Percentage of BCRs containing more than one HLA-binding peptide in the 
other HLA types investigated
BCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
analysed to determine the frequency of those containing more than one HLA-binding peptide 
in the other HLA alleles investigated using both peptide prediction algorithms SYFPEITHI (A) 
and BIMAS (B).  This was done in an attempt to determine whether there was skewed data in 
the previous analysis of the peptide prediction data due to a single BCR containing a large 
number of HLA binding peptides within the CDR3.  Data is represented as a percentage of all 
peptides analysed where peptide binding was defined for both algorithms as previously 
discussed.
A B
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3.8.4 Frequency of BCRs Containing HLA-Binding Peptides 
After showing that there was a decreased frequency of BCRs containing an HLA-A2 
binding peptide in HLA-A2
+
 donors, I wanted to determine whether the same was true 
in the other HLA alleles investigated. Using SYFPEITHI, the frequency of BCRs 
containing more than one peptide for all HLA alleles was increased in the HLA-
negative donors compared with the HLA-positive donors (Figure 3.17). Using 
BIMAS to analyse the same data, the HLA-A1 and -B8 donors demonstrated similar 
results to SYFPEITHI at both the lower and upper threshold with the HLA-negative 
donors containing an increased frequency of BCRs than the HLA-positive donors. 
However, the frequency of BCRs in HLA-B7 was very similar between the HLA-
positive and HLA-negative donors. These results are very similar to the previous 
results from BIMAS investigating the frequency of peptides where there was little 
difference in all HLA types between the HLA-positive and HLA-negative donors. 
 
The above results suggest that there may depletion of B cells, possibly due to the 
absence of peripheral tolerance and presence of potential HLA-binding peptides 
within the sequence of the BCR. The possibility of editing of the B cell repertoire may 
be HLA-specific as the results are strongest in HLA-A2
+
 donors but aren‟t as 
pronounced in HLA-A1, -B7 and B8 positive donors. Although the results for the 
other HLA types demonstrated a small decrease in the frequency of peptides predicted 
to bind to the HLA molecules in the HLA positive and HLA negative cohorts, the 
trends seen are similar to the results from HLA-A2. There is a suggestion that this 
phenomenon may occur in these HLA types, although this is only the case when 
studying peptides with high affinity and excluding the peptides with a lower affinity. 
Therefore, the results shown suggest that donors with HLA-A1, -B7 and -B8 alleles 
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may selectively delete B cells which contain a peptide predicted to bind with a high 
affinity for HLA-A1, -B7 and -B8 although further studies would be needed to 
demonstrate statistical signficance.  
 
Overall, the results from both computer algorithms might suggest that there is no 
peripheral tolerance towards B cells and that this is not unique to HLA-A2 although 
much of the data is not statistically significant. However, results from BIMAS 
investigating peptides with a lower affinity for HLA in these alleles suggest that there 
may be peripheral tolerance towards these peptides as there is a similar frequency of 
peptides in HLA-positive donors compared with the HLA-negative donors. This is 
different to that seen in HLA-A2 where there was a statistically significant decrease in 
peptides predicted to bind to HLA-A2 in HLA-A2
+
 donors.  
 
3.9 Frequency of CDR3-Derived HLA-A2-Binding Decamer 
Peptides 
HLA-A2 molecules can incorporate longer peptides comprised of 10 amino acids, as 
well as the more conventional 9 amino acids in the peptide binding groove (Collins et 
al, 1995 and Takahashi et al, 1999). As a result of this, the frequency of CDR3-
derived decamer peptides predicted to bind to HLA-A2 in A2
+
 and A2
-
 donors was 
investigated. Using the SYFPEITHI prediction algorithm and a peptide-binding 
threshold of 22 to incorporate peptides that are most likely to bind to HLA-A2 only, 
the frequency of predicted HLA-A2 binding peptides was decreased in A2
+
 donors 
(0.35%) compared with the frequency in A2
-
 donors (0.57%) (χ2=2.05, p=0.15) 
(Figure 3.18).  
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Figure 3.18 Frequency of HLA-A2 decamer peptides present in the CDR3 of BCRs 
in HLA-A2+ and A2- Healthy Donors
BCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding 
peptides of 10 amino acids using the SYFPEITHI algorithm.  Data is represented as a 
percentage of all peptides analysed where peptide binding was defined by a score of 22 
or above. Error bars denote mean + standard error mean.  Data was analysed using chi-
squared test to determine statistical significance.
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Although these results were not statistically significant, the results for the 10 amino 
acid peptides, with a higher affinity for HLA-A2, showed the same trend for HLA-A2 
as that seen with the nonamer peptides. The trend seen with both sets of results 
produced by both lengths of peptides suggests that there may be a true decrease in the 
frequency of potentially immunogenic peptides predicted to bind to HLA-A2 from the 
BCR CDR3s of HLA-A2
+
 donors.  
 
3.10 Immunoediting of the B Cell Repertoire 
Data described so far suggest that there could be a depletion of B cells containing 
HLA-binding peptides within the CDR3 of BCRs. The next step in studying this 
depletion was to try and determine at what stage of the B cell maturation this 
depletion occurs. If this is true, the depletion could occur at almost any stage during 
the life and maturation of the B cell. One possible scenario is that this potential 
editing occurs during the maturation of naïve B cells into memory B cells because at 
this stage B cells undergo somatic hypermutation and affinity maturation which could 
remove B cells with potential HLA-A2 binding peptides from the B cell repertoire. 
Naïve and memory B cells differ in their expression of the surface bound molecule 
CD27, a member of the tumour necrosis factor superfamily of receptors which binds 
to CD70 (Maurer et al., 1992 and Agematsu et al, 2000). Naïve B cells lack 
expression of CD27 (CD27
-
) whereas memory B cells express CD27 (CD27
+
) (Klein 
et al, 1998) and therefore can be separated into naïve and memory subsets by CD27 
selection. During this stage of maturation, B cells undergo somatic hypermutation and 
affinity maturation which could remove B cells with potential HLA-A2 binding 
peptides from the B cell repertoire. The hypothesis tested was that the editing of the B 
cell repertoire, seen in HLA-A2 donors, occurs at the stage of B cell activation and 
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generation of memory B cells. There are two possible outcomes testing this 
hypothesis. Firstly, the frequency of peptides found in memory B cells is similar to 
that in naïve B cells and in this scenario, the editing will have occurred prior to 
activation of B cells. Secondly, the frequency of HLA-A2 binding peptides in naïve B 
cells will be increased compared with memory B cells demonstrating removal of these 
peptides during the activation of naïve B cells and the formation of memory B cells.  
 
3.11 Separation of PBMCs into Naive and Memory B Cells 
In order to test this new hypothesis, B cells were magnetically selected from PBMCs, 
from an HLA-A2
+
 donor, into CD27
+
 and CD27
-
 fractions using an anti-CD27 PE 
antibody and anti-PE bead magnetic selection. The cells were separated using two 
columns to improve the purity of the selected cells with >97% of cells selected 
staining positive for CD27 by flow cytometry (Figure 3.19 A). The cells in both 
positive and negative fractions of the separation will contain B cells, T cells and other 
leukocytes and therefore, in order to determine the sequences of only the B cells, 
DNA from the cells was amplified using the same oligonucleotide primers as 
previously described (Table 2.2). After running the PCR amplification of the CD27
-
 
fraction, strong bands could be seen ~500bp for the IgM primers (Figure 3.19 B). 
However, bands could be seen for both IgA and IgG (which should not be there as B 
cells in this fraction should be naïve and therefore they wouldn't have undergone 
class-switching) suggesting that the separation was not 100% effective and even a 
small number of memory B cells (CD27
+
) contaminating the fraction would be 
responsible for this as PCR is extremely sensitive. Further evidence for this is the fact 
that the bands for these “rogue” amplifications are fainter than the bands seen for 
IgM. Similarly, after running the PCR amplifications from the CD27
+
 cells on the 
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Pre Selection Negative Fraction Positive Fraction
Figure 3.19. CD27 Selection of PBMCs from an HLA-A2+ donor using MACS magnetic 
separation and PCR amplification of B cell receptors
Unfractionated PBMCs from a single HLA-A2+ donor were stained with CD27-PE antibody to 
separate naïve B cells (CD27-) from memory B cells (CD27+), washed and incubated with anti-
PE microbeads. After extensive washing, the cells were run through two magnetic sorting 
columns and the fractions analysed on the flow cytometer (A). RNA was extracted from the 
CD27- (naïve) and CD27+ (memory) B cell fractions and cDNA synthesised as previously 
described. This was used as template DNA for PCR amplification using a V-region primer and 
all three of the BCR constant region primers (IgA, IgG and IgM) (B). 
CD27-
IgA IgG IgM
CD27+
IgA IgG IgM
A
B
CD27 CD27 CD27
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same gel, bands could be seen for all 3 Ig heavy chain constant regions. This may 
again be due to the fact that the separation of cells was not 100% effective and again, 
the expected IgA and IgG bands appeared stronger than the “rogue” IgM bands. As 
CD27
-
 naive B cells should only contain IgM expressing B cells, the PCR product 
using IgM primers was collected. Similarly, the CD27
+
 memory B cells should have 
undergone class switching and therefore the majority will express either IgA or IgG. I 
collected the PCR products amplified with the IgA or IgG specific primers for the 
constant regions. The amplified DNA from both subsets (A2
+
/CD27
+
 & A2
+
/CD27
-
) 
was purified and the BCRs separated using the TA cloning kit as described 
previously. A few different plasmids containing a single BCR for each of the subsets 
were sequenced locally to confirm the presence of IgA, IgG or IgM in the correct 
subsets prior to sequencing a large number of these. The initial sequencing results 
returned the correct sequences from the correct subsets (Table 3.1) with only the 
CDR3 of IgM
+
 B cells being sequenced from the CD27
-
 subsets and both the CDR3s 
of IgA
+
 and IgG
+
 B cells being sequenced from the CD27
+
 subsets. This meant that 
the molecular biology work had been successful and the remaining BCRs could be 
sequenced. 
 
There were 96 purified BCR CDR3s from each of the subsets sent for sequencing. 
Analysis of these results will focus on the comparison of HLA-A2 binding peptides 
between CD27
+
 and CD27
-
 B cells in the A2
+ 
donor. In testing the hypothesis that 
editing of the B cell repertoire occurs at the stage of activation and class-switching, 
there are two possible outcomes. Firstly and bearing in mind that the B cell repertoire 
from A2
+
 individuals has already been edited, if there is a decreased frequency of the 
remaining HLA-A2 binding peptides in memory B cells compared with the frequency  
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CDR3 Sequence
A2+ CD27-
IgM+
SEDTAVYYCALNTYYYGSGSYYGYWGQGTLVTVSSGSASAPTL
A2+ CD27+
IgA+ IgG+
DTAFYYCARIHCGVGICYWDWGQGTLVTVSSASTKGPS
DTAVYYCARRSDIWHAFDPWGPGTMVTVSSASTKGPS
DTGTYYCARGGGQTWGQGVLVTVSSASTKGPS
Table 3.1 Examples from CDR3 sequencing from the B Cell subsets
BCRs were sequenced from each of the four purified B cell subsets. The sequences 
shown begin with the 3’ region of the variable region, leading into the CDR3 region 
(underlined) and then moving into the 5’ region of the constant region.
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of HLA-A2 binding peptides in naïve B cells, this would suggest that the selective 
depletion of B cells containing a potentially immunogenic peptide within the CDR3 
occurs after activation of B cells and before a pool of memory B cells is formed. 
Secondly, if there is a similar frequency of HLA-A2 binding peptides from the 
CDR3s of both the memory and naïve B cells in an A2
+
 individual, this would suggest 
that the editing of the B cell repertoire occurs at earlier developmental stages, possibly 
still within the bone marrow or earlier in the lymph node. Sequences returned 
provided 83 sequences that were CD27
-
 IgM CDR3s, providing 2903 potential 
peptides (9 amino acids in length), and 90 sequences from the CD27
+
 IgA/G, 25 of 
which were IgA and 65 were IgG, providing 3019 peptides. The sequences of the 
memory B cells demonstrated that all sequences had been somatically hypermutated 
whereas the naïve B cell sequencing data demonstrated two sequences that had been 
somatically hypermutated and these sequences were removed from the data set. 
 
3.12 Analysis of Predicted HLA-A2-Binding Peptides in Naïve 
and Memory B Cells 
3.12.1 SYFPEITHI - High Scoring Peptides 
Using the SYFPEITHI prediction algorithm and a predicted HLA-A2 binding cut-off 
of 22 as used previously, the frequency of potential HLA-A2 binding peptides in 
CD27
-
 IgM
+
 naïve B cells (0.10%) from an A2
+
 donor was slightly decreased 
compared with the memory B cells (0.20%) (χ2=0.89, p=0.35) (Figure 3.20). This 
result suggests that there has been no editing of the repertoire at this stage and that 
there is possibly positive selection of BCRs containing potential HLA-A2 binding 
peptides in the memory B cells. This may also suggest that the process of somatic 
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Figure 3.20 Frequency of HLA-A2 peptides present in the CDR3 of BCRs in an HLA-A2+
Healthy Donor 
BCRs from naïve and memory B cells from a single HLA-A2+ donor were sequenced and the 
CDR3 analysed for HLA-A2-binding peptides using the SYFPEITHI algorithm.  Data is 
represented as a percentage of all peptides analysed where peptide binding was defined by a 
score of 22 or above.  Data was analysed using the chi-squared test to determine statistical 
significance.
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Figure 3.21 Frequency of high and low affinity HLA-A2 peptides present in the CDR3 of 
BCRs
BCRs from naïve and memory B cells from a single HLA-A2+ donor were sequenced and the 
CDR3 analysed for high affinity (A) and high and low affinity (B) HLA-A2-binding peptides 
using the BIMAS algorithm.  Data is represented as a percentage of all peptides analysed 
where peptide binding was defined by a score of 20 or above for high affinity peptides and 5 
or above for low affinity peptides.  Data was analysed using the chi-squared test to determine 
statistical significance.
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hypermutation and/or affinity maturation may increase the frequency of peptides 
contained within the CDR3 of memory B cells. This would therefore mean that if 
there is immune editing in A2
+
 individuals it occurs at an earlier stage of B cell 
maturation as described before and that the potential editing of the B cell repertoire 
does not occur as B cells become activated and mature into memory B cells.  
 
3.12.2 BIMAS - High Scoring Peptides 
In order to validate the data from the SYFPEITHI prediction algorithm, the same data 
was analysed using the BIMAS prediction algorithm as well. Initially, I used a peptide 
dissociation half-life of 20 minutes to incorporate peptides with a high affinity for 
HLA-A2. There is little difference between the frequency of HLA-A2 binding 
peptides found within the CDR3 of naïve and memory B cells in the HLA-A2
+
 donor 
(0.41% to 0.46%) (χ2=0.09, p=0.77), although the results from the memory B cells are 
slightly increased similar to that seen in the results returned from SYFPEITHI (Figure 
3.21 A). Similar to the results generated from SYFPEITHI, this result suggests that 
somatic hypermutation and/or affinity maturation increase the frequency of HLA-A2 
binding peptides within the CDR3 of memory B cells compared with naïve B cells. 
This would further suggest that the potential process of immune editing of the B cell 
repertoire would occur before the generation of mature naïve B cells.  
 
3.12.3 BIMAS - Lower Scoring Peptides 
The data set was re-analysed using a lower peptide-binding threshold of 5 to 
determine the frequency of predicted peptides with a low affinity as well as those with 
a high affinity for HLA-A2. Results from the HLA-A2
+
 donor demonstrate an 
increased frequency of peptides from memory, CD27
+
 B cells predicted to bind to 
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HLA-A2 (1.52%) compared with peptides predicted to bind to HLA-A2 from CD27
-
 
naïve B cells (1.02%) (χ2=2.40, p=0.12) (Figure 3.21 B). The result for peptides with 
high and low affinity for HLA-A2 suggest that, similarly to the results from 
SYFPEITHI, there is an increased frequency of peptides within the CDR3 of B cells 
after they have undergone somatic hypermutation and affinity maturation. 
 
The results suggest that if editing of the B cell repertoire does occur, it would already 
have occurred before the B cells have reached the peripheryand that rather than the 
decrease in frequency of HLA-A2 binding peptides in the memory B cell subset as 
outlined in the hypothesis, there is actually an increase in the frequency of HLA-A2 
binding peptides in the memory B cell subset. The results from the BIMAS algorithm 
would appear to validate the previous results which were produced from the 
SYFPEITHI algorithm. In relation to the suggested hypothesis, the potential process 
of immune editing of the B cell repertoire does not appear to occur at this stage of B 
cell maturation and would probably occur at an earlier stage of B cell development.  
 
3.13 Immunoediting of the B Cell Lymphoma Repertoire 
The previous results suggested that there may be editing of the B cell repertoire to 
remove BCRs containing CDR3-derived peptides in healthy donors. If this is true, 
there would have to be a process in B cells whereby the majority of B cells containing 
these peptides are removed in healthy volunteers. Since our group has a particular 
interest in haematological malignancies, it was very interesting to me to find out 
whether there could be a selection process occurring in patients with various B cell 
lymphomas. This led me to test the hypothesis that there may not be peripheral 
tolerance towards CDR3-derived peptides expressed by B cells from patients with B 
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cell lymphomas and therefore, patients will undergo immunoediting of the B cell 
repertoire. In order to test this hypothesis, 38 genomic DNA samples (15 HLA-A2
+
 
and 23 HLA-A2
-
) from patients with multiple myeloma (MM), follicular lymphoma 
(FL) and primary central nervous system lymphoma (PCNSL) were analysed, kindly 
donated by Prof. C. Ottensmeier (University of Southampton). 
 
3.13.1 Analysis of Predicted HLA-A2 Binding Peptides in B Cell Lymphoma 
3.13.1.1 SYFPEITHI 
The peptide data set from the patient samples was initially analysed using the 
SYFPEITHI prediction algorithm with a threshold of 22 to investigate the peptides 
with a high binding affinity for HLA-A2. There was an increased frequency of 
potential HLA-A2 binding peptides contained within the CDR3s of B cells sequenced 
from the HLA-A2
-
 patient cohort (0.4%) (Figure 3.22) compared with those from the 
A2
+
 patients (0.0%) (χ2=1.98, p=0.16). This result suggests that there could be editing 
of the B cell repertoire in patients with B cell lymphomas although there would need 
to be an increased data set to determine statistically if such a process does occur. 
 
3.13.1.2 BIMAS 
Subsequently, the same data set was analysed using the BIMAS peptide prediction 
algorithm using a threshold of 20, to incorporate peptides with a high affinity for 
HLA-A2. Similarly to the results produced by SYFPEITHI, there was an increased 
frequency of potential HLA-A2 binding peptides within the CDR3s of B cells from 
HLA-A2
-
 patients (1.06%) compared with those from the HLA-A2
+
 patients (0.20%) 
(χ2=3.10, p=0.08) (Figure 3.23). This result again suggests that there may be a 
mechanism, present in B cells, to delete cells which contain a peptide predicted to 
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Figure 3.22 Frequency of HLA-A2 peptides present in the CDR3 of BCRs in HLA-A2+
and A2- patients
CDR3 from BCRs, from patients with various B cell malignancies, which had been 
previously sequenced were analysed for HLA-A2-binding peptides using the SYFPEITHI 
algorithm.  Data is represented as a percentage of all peptides analysed where peptide 
binding was defined by a score of 22 or above.  Data was analysed using the chi-squared 
test to determine statistical significance.
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bind to HLA-A2 within the CDR3 in HLA-A2
+
 patients. However, inclusion of 
potential peptides predicted to bind to HLA-A2 with a low affinity as well produces 
similar results as those generated from SYFPEITHI. There is a decreased frequency 
of potential HLA-A2 binding peptides in the CDR3s of B cells from HLA-A2
-
 
patients (1.85%) compared with the HLA-A2
+
 patients (2.20%) (χ2=0.19, p=0.66) 
(Figure 3.23).  
 
If the results incorporating the peptides with lower affinity for HLA-A2 are included, 
these results suggest that there is no editing of the B cell repertoire to remove B cells 
which contain a peptide predicted to bind to HLA-A2. Therefore, there could be 
peripheral tolerance towards CDR3-derived peptides by T cells, which could 
recognise the peptide if it was presented by HLA-A2 molecules at the surface of the B 
cell. However, if the results from the peptides with a higher affinity for HLA-A2 are 
true, there would appear to be no peripheral tolerance towards the CDR3-derived 
peptides and therefore there is the possibility that there could be a process of editing 
the B cell repertoire to remove these potentially dangerous B cells before they have 
the potential to cause an auto-immune reaction. Peptide prediction analysis from 
healthy donors and patients suggest there is a decrease in the frequency of HLA-A2 
binding peptides, albeit not statistically significant, contained within the CDR3 of the 
BCR in HLA-A2
+
 donors. Initially, CDR3-derived peptides were going to be targeted 
to generate a naïve T cell response. However, this work was not carried out because 
there is a low frequency of peptides predicted to bind to HLA-A2 contained within the 
CDR3 of BCRs and although it would be possible to locate a potential peptide to 
generate a naïve T cell response against, it would prove too difficult and time 
consuming. Therefore, even though this work can be undertaken in the future, it was 
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Figure 3.23 Frequency of high and low affinity HLA-A2 peptides present in the 
CDR3 of BCRs in HLA-A2+ and A2- patients
CDR3 from BCRs, from patients with various B cell malignancies, which had been 
previously sequenced were analysed for high and low affinity HLA-A2-binding peptides 
using the.  Data is represented as a percentage of all peptides analysed where peptide 
binding was defined by a score of 20 or above for high affinity peptides and 5 or above 
for low affinity peptides. Data was analysed using the chi-squared test to determine 
statistical significance.
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not carried out at the time. Instead, an attempt was made to generate a model to 
investigate the antigen processing of CDR3-derived peptides in order to understand 
further whether these peptides are presented or not at the cell surface in the context of 
HLA molecules (discussed later).  
 
3.14 Discussion 
In this chapter, the hypothesis tested was that there is no peripheral tolerance directed 
towards CDR3-derived peptides from the B cell receptor in an HLA-A2 setting. If this 
hypothesis is true, there would be editing of the B cell repertoire to remove BCRs 
containing HLA-A2 binding peptides in an HLA-A2
+
 donor as the presentation of 
these non-self peptides could result in the initiation of an auto-immune reaction. If 
editing of the B cell repertoire does occur as a result of the presence of CDR3-derived 
peptides, there would be a decreased frequency of HLA-A2 binding peptides in an 
HLA-A2
+
 donor compared with an HLA-A2
-
 donor. An HLA-A2
-
 donor would not 
need to remove the HLA-A2 binding peptides from the CDR3 as they do not express 
HLA-A2 and therefore the peptide would not be presented at the cell surface.  
 
The results for HLA-A2 demonstrated a decreased frequency of CDR3-derived 
nonamer peptides in HLA-A2
+
 donors compared with HLA-A2
-
 donors although the 
differences seen were not statistically significant. This suggests that there could be 
editing of the B cell repertoire to remove B cells which express a BCR containing 
HLA-A2 binding peptides and that there could be a lack of peripheral tolerance 
towards these peptides, proving the original hypothesis is true. The results from 
analysis using two different HLA-peptide binding prediction algorithms demonstrated 
a decreased frequency (although not statistically significant) demonstrating that the 
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results seen are not due to any artefacts in the programming of the prediction 
algorithms. Similarly, when CDR3-derived decamer peptides were analysed using 
SYFPEITHI, there was a decreased frequency of peptides found within the CDR3 
from HLA-A2
+
 donors compared with HLA-A2
-
 donors. The results from this second 
peptide analysis would appear to support the initial results that there could be a 
process of editing of the B cell repertoire based on CDR3 sequence and therefore that 
there is possibly decreased peripheral tolerance towards CDR3-derived peptides in an 
HLA-A2 setting.  
 
Similar results are seen in 3 other HLA alleles tested (HLA-A1, -B7 and -B8) 
although the decreased frequency of HLA-binding peptides in HLA-positive donors 
compared with HLA-negative donors is less striking than in HLA-A2. The results for 
these alleles may become stronger if a larger data set was used by sequencing more 
BCRs from HLA positive and negative donors. These results suggest that there may 
be a process of immunoediting seen in B cells which removes CDR3-derived peptides 
which could bind to any of the HLA alleles found in any donor.  The removal of these 
peptides could be very important in B cells due to the secretion of antibody which 
would also contain the CDR3-derived peptide. Antibodies can move throughout the 
body and could be taken up by many different cell types including dendritic cells, 
macrophages and other B cells via cell-surface expressed receptors e.g. Fc receptors. 
If antibodies contained CDR3-derived peptides that could bind to an HLA allele 
expressed by the cells, there is the possibility that they could process the antibody and 
present these peptides on their surface. Consequently, CD8 T cells which recognise 
the CDR3-derived peptide could generate an autoimmune response against the 
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parental B cell.  If the results seen are true, removal of these peptides from the CDR3 
by a process of immunoediting would prevent the chances of this happening. 
 
These may be very significant results suggesting that there may be a third selection 
process in the maturation process of B cells, alongside positive and negative selection, 
whereby B cells must express self peptides from the CDR3 of the BCR and those with 
a potentially immunogenic peptide are deleted before they can populate the periphery. 
The potential deletion of these B cells, possibly by CDR3-peptide-specific T cells 
resident in the bone marrow (Figure 3.2), may prevent potentially harmful 
autoimmune reactions once these B cells have matured into plasma cells and have 
begun producing antibodies.  
 
The CDR3-derived peptide data shown above is completely dependent on the two 
computer algorithms used and, as such, any errors in the computer algorithm would 
result in errors in the data set. The two algorithms used were picked predominantly 
because they are the most well known, are thought to be the best characterised and 
have been used in many previous publications (Hansson et al, 2003; Zirlik et al, 2006 
& Strothmeyer et al, 2010).  Other algorithms have been used (Harig et al, 2001) but 
the majority of prediction studies have used BIMAS and SYFPEITHI. Although the 
prediction algorithms are used extensively they are not 100% accurate and therefore 
the data should be viewed accordingly.  There is some reassurance in the fact that 
many of the peptides predicted to bind to HLA in SYFPEITHI are also predicted to 
bind to HLA by BIMAS. However, the reverse is not true with the majority of 
peptides predicted to bind to HLA by BIMAS not predicted to bind to HLA by 
SYFPEITHI.  This may be due to the thresholds used to analyse the data and as the 
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two computer algorithms are not linked in any way and do not use a similar scoring 
system, this could account for some of the differences seen.  
 
Although attempts were made to use appropriate thresholds by using receiver operator 
curve analysis for each HLA allele and algorithm, the thresholds used are open to 
debate.  Previous publications have relied on thresholds (Hansson et al, 2003), similar 
to the results shown here, whereas other publications have avoided the use of 
thresholds by analysing a percentage of the highest scoring peptides regardless of 
score (Strothmeyer et al, 2010).  It could be reasonably assumed that changing the 
threshold would alter the results but there is a difference in changing the frequency of 
peptides predicted to bind and changing the results so there is no longer a difference 
in the frequency.  Attempts were made to analyse the data set using different 
thresholds to try and solve this problem.  In every case, changing the thresholds for 
any given HLA allele resulted in a change to the frequency of peptides predicted to 
bind to HLA. However, in many cases, especially using SYFPEITHI, the overall 
results remained the same with a decrease in the frequency of HLA-binding peptides 
in HLA
+
 donors compared with HLA
-
 donors although changing the threshold often 
resulted in a change to the significance of the result.  This was not the case for all 
HLA alleles tested but it possibly goes some way to demonstrate that changing the 
threshold does not alter the outcome dramatically but does alter the significance of the 
result. From the list of CDR3-derived peptides predicted to bind to the HLA alleles, 
tested, none of them were found to be the same as pathogenic epitopes. This may not 
be surprising if there truely is editing of the B cell repertoire as it would be suggested 
that pathogenic epitopes in the CDR3 would be edited from the repertoire, preventing 
an immune response being generated against the CDR3-derived peptides. 
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Statistical support was received from supervisors and experienced staff but it may be 
of interest to seek further statistical support in an effort to determine what could be 
done to show statistical significance regarding the CDR3-derived peptide editing. 
 
One question that arose as a consequence of these results was: at what stage of B cell 
maturation could the process of immunoediting of B cells occur? Theoretically, the 
editing could occur at any stage of maturation of B cells and one potential stage is 
during the activation of naïve B cells in the periphery. During activation B cells 
undergo somatic hypermutation and affinity maturation, losing expression of the cell 
surface glycoprotein CD27 (Agematsu et al, 2000). Naïve B cells were separated from 
activated B cells by magnetic selection of CD27 to test the hypothesis: does 
immunoediting of the B cell repertoire occur during activation of B cells.  
 
Testing this hypothesis using HLA-A2 as the model, there was a slightly increased 
frequency of peptides found within the CDR3 of memory B cells compared with 
naïve B cells. The results were similar when using both peptide prediction algorithms 
and suggest that they are not due to an artefact from one of the algorithms. The result 
suggests that the hypothesis being tested is false and that if immunoediting of B cells 
does occur, it is before the cells are mature naïve B cells, possibly occurring during 
selection of B cells in the bone marrow. This could be another possibility of where the 
potential immunoediting could occur because B cells undergo positive and negative 
selection at this stage and therefore it would be possible for the B cells to undergo a 
further round of selection at this stage dependant on the sequence of the CDR3. This 
theory is given further credence by the presence of a large number of memory CD8
+
 T 
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cells in the bone marrow (Slifka et al, 1997 and Cavanagh et al., 2005) which are 
activated but not through recent stimulation with antigen (Di Rosa & Santoni, 2002). 
In this theoretical model, B cells which had already passed positive and negative 
selection would present peptides from their CDR3 on the surface to bone marrow 
resident CD8
+
 T cells. Those B cells containing a CDR3-derived peptide recognised 
by the resident T cells would be killed and those without a CDR3-derived peptide 
would pass this round of selection and could populate the periphery. Further work 
could be undertaken into the presence of MHC class II peptides present in the CDR3 
of BCRs. MHC class II work is made more difficult due to the variation in length of 
peptide and therefore the prediction of peptides which bind. However, previous 
studies suggest the presence of CD4
+
 T cells in the bone marrow as well (Di Rosa & 
Santoni, 2003) and these may have a role in shaping the B cell repertoire as well. 
 
The increased frequency of peptides found in the CDR3 of memory B cells compared 
with naïve B cells is very surprising. It would be expected that once the HLA-A2 
binding peptides had been edited from the CDR3 region, they would not be found 
later in the life and maturation of B cells. This increased frequency of HLA-A2 
binding peptides in memory B cells may be due to the effects of somatic 
hypermutation and/or affinity maturation as these processes, which occur at this stage 
of B cell maturation, are thought to be random events (Wilson et al., 1998). This 
means that they may introduce amino acids into the CDR3 resulting in a new HLA-
binding peptide. If the immunoediting scenario is true and the immune system has 
gone to great lengths to remove potentially hazardous B cells from the repertoire, why 
would mature memory B cells be allowed to mutate their BCR to contain HLA-A2 
binding peptides? Expression of CDR3-derived peptides may result in killing of the B 
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cell due to recognition by circulating T cells. However, expression of these peptides at 
the surface of the B cell may lead to interaction with T cells which aids in the 
activation of the B cell or possibly to prolong the life of a memory B cell. Further 
investigation of this phenomenon may lead to some interesting and surprising results. 
 
As our group is interested in lymphoma, the next hypothesis tested suggested that a 
process of immunoediting could occur in the malignant B cell repertoire. DNA from 
patients with B cell lymphomas including multiple myeloma, follicular lymphoma 
and primary central nervous system lymphoma were HLA-A2 typed and the CDR3 
sequence analysed for HLA-A2 binding peptides. There was a decreased frequency of 
HLA-A2 binding peptides (although not statistically significant) found within the 
CDR3 of HLA-A2
+
 donors compared with HLA-A2
-
 donors. The results were similar 
when using the two different peptide prediction algorithms again suggesting that the 
results are not an artefact of either algorithm. These results suggest that there could be 
a process of immunoediting of the BCR in B cell lymphomas, proving the hypothesis 
true. If there is a process of immunoediting, it would also mean that there would 
probably be no peripheral tolerance towards CDR3-derived peptides in patients, 
meaning that the B cells could be targeted if immune responses could be mounted to 
CDR3-derived peptides (Hsu et al., 1997 and Bendandi et al., 1999). However, the 
apparent lack of CDR3-derived peptides in BCRs from HLA-A2
+
 patients with B cell 
lymphoma suggests that CDR3-derived peptides, known to be targeted after idiotype 
vaccination (Bertinetti et al., 2006 & Navarrete et al., 2008) in a percentage of 
patients, may not be a useful CD8
+
 T cell target for the majority of patients. If the 
BCRs from B cell lymphomas do not contain HLA-binding peptides within the 
CDR3, there would be no peptide for CD8 T cells to target.  
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These results could have a significant impact on potential anti-idiotype therapies 
available for patients and may explain why many of the idiotype based therapies and 
vaccine trials have such poor efficacy (Timmerman et al, 2002; Levy et al, 2008). If 
this is the case, it would mean that the idiotype, one of the best defined tumour 
antigens, would be very difficult to target. However, the small number of patients 
makes analysis of the data set very difficult, but both computer algorithms produce 
similar results suggesting that there is authenticity regarding these results. In order to 
prove that the patient samples do or do not edit B cells, dependent on their CDR3 
sequence, the number of patients in both the A2
+
 and A2
-
 cohort would need to be 
increased in an attempt to show statistical significance. 
 
3.15 Conclusion 
In this chapter, the hypothesis that there was no peripheral tolerance towards CDR3-
derived peptides from the BCR and therefore there was the requirement of 
immunoediting of the B cell repertoire to prevent an autoimmune reaction was tested. 
There was a decreased frequency of HLA-binding CDR3-derived peptides in HLA-
positive donors compared with HLA-negative donors (although not statistically 
significant). This suggests that there may be a process of immunoediting of the B cell 
repertoire to remove potentially dangerous B cells.  Furthermore, there could also be a 
similar process of immunoediting of malignant B cells in patients with various B cell 
lymphomas.  Despite attempts to identify the timing of this apparent immunoediting, 
it was discovered that if immunoediting does occur, it would probably have taken 
place before B cells mature into naïve B cells and exit the bone marrow. 
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4. Immunoediting of the T Cell Receptor Repertoire. 
 
 
4.1 Introduction 
T cell receptors (TCR) could contain peptides within the “non-self” CDR3, which 
could potentially initiate an immune response if they were to be presented at the 
surface of the T cell in complex with MHC molecules. There has been no previously 
published study to determine the presence or absence of CDR3-derived peptides in 
patients or healthy donors.  
 
The first hypothesis tested was that T cells bearing TCRs containing HLA-binding 
peptides within their CDR3s are not subject to peripheral immunological tolerance 
and are edited out of the T cell repertoire by anti-CDR3 peptide derived specific T 
cells after positive and negative selection has occurred in the thymus, describing a 
pathway in terms of how the final T cell repertoire is defined. Deletion of these T 
cells would only allow T cells expressing receptors which do not contain HLA-
binding peptides within the CDR3 to populate the periphery (Figure 4.1). In this 
model, there would be a decreased frequency of CDR3-derived HLA-binding peptides 
in HLA-positive donors compared to that of HLA-negative donors (Figure 4.2). There 
are two competing hypotheses which would explain the lack of editing in the T cell 
repertoire. Firstly, peripheral tolerance towards the peptides presented from the T cell 
receptor, similar to peripheral tolerance against any self-peptide, could protect the T 
cell, meaning that there would be no functional CDR3-specific T cells populating the 
periphery, having been deleted in the thymus  or  tolerised  in  the  periphery.    
Secondly,  the  TCR  could  be  prevented  from  
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Figure 4.1 Cellular hypothesis for deletion of T cells containing predicted HLA-A*0201 
peptides within their CDR3
If there is no peripheral immunological tolerance, a T cell from an HLA-A*0201+ individual 
containing potential A2-binding peptides derived from the CDR3 region (Red) would undergo 
deletion, by anti-idiotype-specific T cells (Green), as the peptide could be presented on the 
surface of the T cell in complex with HLA-A2. TCRs which do not contain a potential HLA-A2 
binding peptide within the CDR3 region (Black) would populate the periphery. Therefore, 
peripheral tolerance towards CDR3-derived peptides would result in a decreased frequency 
of HLA-A2 binding peptides within the CDR3 region of HLA-A2+ donors. However, if there is 
immunological tolerance, or antigenic ignorance, towards CDR3-derived peptides, the T 
cells containing a TCR with a CDR3-derived peptide would be allowed to populate the 
periphery and the anti-idiotype-specific T cells would not recognise the T cells. Therefore, 
the frequency of HLA-A2 binding peptides, within the CDR3 region, in HLA-A2+ donors 
would be similar to that from HLA-A2- donors.
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No Peripheral Immunological Tolerance Present
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No HLA-A*0201+ peptides
HLA-A*0201+ peptides
HLA-A2+
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Figure 4.2 Molecular hypothesis for deletion of T cells containing predicted HLA-
A*0201 peptides within their CDR3
If there is no immunological peripheral tolerance, a T cell from an HLA-A*0201+ individual 
containing potential A2-binding peptides derived from the CDR3 region would undergo 
deletion as the peptide could be presented on the surface of the T cell in complex with HLA-
A2. This would result in a decreased frequency of HLA-A2 binding peptides within the CDR3 
region of HLA-A2+ donors compared with HLA-A2- donors. However, if there is 
immunological tolerance towards CDR3-derived peptides, the frequency of HLA-A2 binding 
peptides in HLA-A2+ donors would be similar to that from HLA-A2- donors.
HLA-A*0201+ peptides
HLA-A2+
HLA-A2-
HLA-A*0201+ peptides
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entering the antigen processing pathway, in a form of antigenic ignorance, to prevent 
the expression of CDR3-derived peptides at the cell surface. In these models, shown 
in Figure 4.1, where there is a form of peripheral tolerance towards these peptides, the 
frequency of potentially immunogenic peptides within the CDR3 in HLA-positive 
donors would be similar to the frequency in HLA-negative donors (Figure 4.2).  
 
4.2 Amplification of T Cell Receptors 
The TCR β-chain contains an extra, diversity region within the CDR3 and as a result 
is thought to have more variation in its CDR3 compared to the α-chain. As a result of 
this, it is possible that there is an increased incidence of HLA-binding peptides within 
the CDR regions of the TCR β-chain compared with the TCR α-chain. Therefore, this 
work initially focussed on the TCR β-chain and could potentially investigate the 
CDR3 of the TCR α-chain in the future.  
 
4.3 Frequency of Predicted HLA-A2 Binding Peptides from 
TCR CDR3 
TCRs were sequenced from the beginning of the variable region to the beginning of 
the constant region, incorporating the CDR3 (Figure 4.3). The sequence shows the 
end of the variable region moving into the diversity region followed by the joining 
region, comprising the CDR3. The sequence finishes with the beginning of the 
constant region.  
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Figure 4.3. Sequencing the CDR3 of a TCRβ chain
The data returned for the sequencing is processed using the ChromasPro sequencing 
program which turns the coloured peaks (A: Green, C: Blue, G: Black and T: Red) into the 
nucleotide base sequence. The base sequence is then translated into the amino acid 
sequence encompassing the variable region (orange) leading into the CDR3 regions (blue) 
which incorporates the diversity and joining regions. The 3’ oligonucleotide primer is situated 
within the constant region of the TCR β-chain and this results in the truncated sequence of the 
β-chain (green).
NAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHYSVGAGITDQG
EVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASSRQGRLGYTFGSGTRLTVVEDLNKVF
PPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEV
V Beta 6.5
CDR3 Region (Including D Beta 1.1 & J Beta 1.2)
C Beta 1
A
B
 163 
4.3.1 SYFPEITHI – High Scoring Peptides 
Initially, the HLA-A2 positive and negative cohorts were analysed for the presence or 
absence of CDR3-derived peptides that could bind to HLA-A2. 92 TCRs from five 
HLA-A2
+
  donors and 82 TCRs from five HLA-A2
-
 donors, resulting in a total of 
over 5000 potential 9 amino acid peptides (2971 for HLA-A2
+
  donors and 2668 for 
HLA-A2
-
 donors), were analysed. Using the SYFPEITHI algorithm, there was no 
decreased incidence of predicted HLA-A2 binding peptides in HLA-A2
+
 donors when 
compared with HLA-A2
-
 donors as was first hypothesised. Surprisingly, there was 
actually a statistically significant increase in HLA-A2 binding peptides in HLA-A2
+
 
donors with the CDR3s derived from A2
+
 donors containing almost 2% HLA-A2 
binding peptides compared with only 1.24% from the A2
-
 donors (χ2=4.53, p=0.01) 
(Figure 4.4 A). The results are very surprising and would appear to suggest that TCRs 
containing HLA-A2 binding peptides are in some way being positively selected 
during T cell maturation. The results are the opposite to the original hypothesis 
proposed and would appear contradictory to what would have been expected as the 
presence of HLA-binding peptides in the TCR could lead to the presentation of those 
peptides on the surface of T cells.  
 
4.3.2 SYFPEITHI – Lower Scoring Peptides 
Previously, a lower threshold of 18 was also used when analysing the BCR to 
determine if the results were similar to that of the higher threshold. The results were 
similar but there was a high degree of background with non-binding peptides found 
within the A2-binding results.  The lower threshold was used again in the analysis of
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Figure 4.4 Frequency of predicted HLA-A2 binding peptides from in HLA-A2+ and 
HLA-A2- donors
TCRs from healthy donors (separated into HLA-A2+ and HLA-A2- cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding 
peptides using the SYFPEITHI algorithm.  Data is represented as a percentage of all 
peptides analysed where peptide binding was defined by a score of 22 or above (A) or 
18 and above (B). Error bars denote mean + standard error mean. Data was analysed 
using chi-squared test to determine statistical significance where * P<0.05.
* BA
Figure 4.5. Frequency of high affinity HLA-A2 binding peptides from the CDR3 of 
the TCR β-chain
TCRs from healthy donors (separated into HLA-A2+ and HLA-A2- cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding 
peptides using the BIMAS algorithm.  Data is represented as a percentage of all 
peptides analysed where peptide binding was defined by a score of 20 or above (A) or 5 
and above (B). Error bars denote mean + standard error mean. Data was analysed 
using chi-squared test to determine statistical significance.
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TCR sequences to determine if similar results were seen. There is a similar trend 
where HLA-A2
+
 donors contain an increased percentage of HLA-A2-binding peptides 
(4.21%) compared with the HLA-A2
-
 donors (3.45%) although this result is not 
statistically significant (χ2=2.19, p=0.14) (Figure 4.4 B). However, the frequency of 
peptides returned using the lower threshold is very high compared with the higher 
threshold and although the results appear similar, there seems to be a lot of false 
positive peptides in the A2-binding peptides and as a results of this, the lower 
threshold was discarded.  
 
The result generated using the higher threshold was very surprising, demonstrating an 
increased frequency of HLA-A2 binding peptides in HLA-A2
+
 donors. In order to try 
to authenticate this result, the CDR3 sequences were analysed with the second HLA-
binding algorithm, BIMAS. 
 
4.3.3 BIMAS - High Scoring Peptides 
Using the BIMAS algorithm, similar results are seen with an increase in the frequency 
of high affinity HLA-A2 binding peptides (BIMAS threshold of 20) in the HLA-A2
+
 
cohort (4.04%) compared with the HLA-A2
-
 donors (3.60%) (Figure 4.5 A).  
Although these results were not statistically significant (χ2=0.74, p=0.39) they suggest 
that there is peripheral tolerance towards CDR3-derived peptides and consequently, 
no editing of the T cell repertoire.  
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4.3.4 BIMAS – Lower Scoring Peptides 
Incorporating the peptides with a lower affinity for HLA-A2 (shown in BIMAS by a 
half-time for dissociation greater than 5), the percentage of HLA-A2 binding peptides 
in HLA-A2
+
 donors is again increased (5.12%) compared with the HLA-A2
-
 donors 
(4.24%) (Figure 4.5 B), although again the results are very high and not statistically 
significant (χ2=2.43, p=0.12). The results using the BIMAS HLA-binding algorithm 
also suggest that TCRs, containing HLA-A2 binding peptides, may be positively 
selected because there is an increased incidence of HLA-A2 binding peptides seen in 
the A2
+
 donors compared with the A2
-
 donors. It would appear that the affinity of the 
peptides for HLA-A2 does not alter the incidence in HLA-A2 binding peptides 
because there is a similar increased incidence of HLA-A2 binding peptides when 
incorporating those with a lower affinity.  
 
Analysis of the peptide sequences predicted to bind to HLA-A2 by both algorithms 
shows that the majority of peptides predicted to bind to HLA-A2 by SYFPEITHI in 
the A2
+
 donors are also predicted to bind to HLA-A2 by BIMAS as well, 14/26 
(Appendix Table A4). However, BIMAS also predicted a further eight peptides to 
bind to HLA-A2 that SYFPEITHI did not and SYFPEITHI predicted a further five 
peptides that BIMAS did not predict. Similar results were seen after analysing the A2
-
 
donors, 12/17 peptides were predicted to bind to HLA-A2 by both algorithms 
compared to 3/17 predicted by BIMAS alone and 2/17 by SYFPEITHI alone 
(Appendix Table A4). Similar to the results seen when analysing the BCR peptides, 
the results show that although there is some cross-over between the two prediction 
algorithms, the results obtained from both are not identical reflecting the differences 
in their programming. 
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4.4 Frequency of TCRs Containing HLA-A2 Binding Peptides 
The above results appear to show no editing of the T cell repertoire based on the 
sequence from the CDR3. However, the increased frequency of HLA-A2 binding 
peptides in HLA-A2
+
 donors could be a result of many peptides contained within a 
few TCRs. Therefore, the frequency of TCRs containing an HLA-A2 binding peptide 
was determined in order to demonstrate that there was no editing of T cells. 
 
Using SYFPEITHI, there is an increased frequency of TCRs containing more than 1 
HLA-A2 binding peptide in HLA-A2
+
 donors (3.3%) compared with HLA-A2
-
 
donors (2.4%) (Figure 4.6 A). These results correspond to the similar increase in 
CDR3-derived peptide frequency from HLA-A2
+
 donors compared with HLA-A2
-
 
donors. Using the BIMAS algorithm, there is a higher frequency of peptides predicted 
to bind to HLA-A2, at the upper and lower thresholds, compared to SYFPEITHI but 
there is still an increased frequency of TCRs containing more than 1 HLA-A2 binding 
peptide in HLA-A2
+
 donors using both thresholds (29.3% and 54.3%) compared with 
HLA-A2
-
 donors (19.5% and 36.%) (Figure 4.6 B). 
 
These two algorithms are the most heavily used in many previous publications and 
because the results from SYFPEITHI are confirmed using BIMAS, it would suggest 
that the results are a true reflection of HLA-binding peptides within the CDR3 of 
TCRs.  
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Figure 4.6. Frequency of TCRs containing more than one HLA-A2 binding 
peptide.
TCRs from healthy donors (separated into HLA-A2+ and HLA-A2- cohorts) were 
analysed to determine the frequency of those containing more than one HLA-A2 binding 
peptide using both peptide prediction algorithms. Data is represented as a percentage of 
all peptides analysed where peptide binding was defined by a score of 22 or above 
using SYFPEITHI (A), a score of 20 or above using BIMAShi (B) and a score of 5 or 
above using BIMASlo (B). This was done in an attempt to determine whether there was
skewed data in the previous analysis of the peptide prediction data due to a single TCR 
containing a large number of HLA binding peptides within the CDR3. 
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Figure 4.7 Frequency of predicted HLA-binding peptides from other HLA-types in 
healthy donors
TCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) 
were sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A1, -B7 
and -B8-binding peptides using the SYFPEITHI algorithm. Data is represented as a 
percentage of all peptides analysed where peptide binding was defined by thresholds 25 
for HLA-A1, 21 for HLA-B7 and 22 for HLA-B8. Error bars denote mean + standard error 
mean. Data was analysed using chi-squared test to determine statistical significance 
where * P<0.05.
*
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4.5 Broader Analysis of HLA Binding Peptides 
After the surprising results from the HLA-A2 donors, the sequenced CDR3s were re-
analysed for other HLA alleles, HLA-A1, -B7 and –B8 to see if the results were 
consistent over different HLA alleles. The thresholds used for this analysis are the 
same as previously discussed. 
 
4.5.1 SYFPEITHI – High Scoring Peptides 
Analysis of the peptides produced using the higher thresholds for the other HLA types 
using SYFPEITHI produced interesting results as well. For HLA-A1, similar results 
were found where the number of potential HLA-binding peptides was significantly 
increased in the HLA-A1
+
 donors (0.39%) compared with those from the A1
-
 donor 
(0.07%) (Figure 4.7) (χ2=6.44, p=0.01). Analysis of the HLA-B7 donors also 
demonstrated an increased incidence of CDR3-derived HLA-B7 peptides in B7
+
 
donors (1.36%) compared with B7
-
 donors (0.99%) although this result was not 
statistically significant (χ2=1.68, p=0.20). These results would appear to corroborate 
the previous results seen with potential HLA-A2 binding peptides and again suggest 
that the TCRs with a potential HLA-binding peptide within the CDR3 are being 
positively selected. However, analysis of HLA-B8 binding peptides in B8
+
 and B8
-
 
donors showed the opposite to the other HLA types studied with a small increase in 
the percentage of HLA-B8 binding peptides in the B8
-
 donors (1.50%) compared with 
the B8
+
 donors (1.04%) (Figure 4.7), although this result was not statistically 
significant (χ2=2.34, p=0.13).   
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4.5.2 BIMAS – High Scoring Peptides 
The same data set was used with the BIMAS HLA-binding prediction algorithm to 
again try to authenticate the results seen with the SYFPEITHI algorithm. The same 
thresholds were used as previously set, to detect the presence of high affinity peptides 
within the CDR3. There is an increased incidence of HLA-binding peptides from 
HLA-A1
+
 and -B7
+
 donors (1.43% & 1.88) when compared with those from the HLA-
A1
-
 and B7
-
 (1.23% & 1.44%) (Figure 4.8 A) although the increase seen here is not 
statistically significant (χ2=0.45, p=0.50 & χ2=1.70, p=0.19). However, using the 
algorithm for HLA-B8, there was an increased frequency of CDR3-derived peptides 
in HLA-B8
-
 donors (1.61%) compared with the HLA-B8
+
 donors (1.21%) (χ2=1.62, 
p=0.20) (Figure 4.8 A). The differences seen here are similar to those seen when 
analysis of the higher affinity peptides was completed with SYFPEITHI suggesting 
that those results may be verified by this BIMAS data.  
 
4.5.3 BIMAS – Lower Scoring Peptides  
Incorporating lower affinity peptides (Threshold of 5) in the study as well 
demonstrates similar results to those from the study of low affinity peptides only 
when analysed with SYFPEITHI. There is an increased frequency of predicted HLA-
binding peptides from HLA-A1
+
 and -B7
+
 donors (3.69% and 2.36%) compared with 
those of HLA-A1
-
 and B7
-
 (3.55% and 2.09%) (χ2=0.09, p=0.77 & χ2=0.48, p=0.49) 
(Figure 4.8 B). Although the difference between the two cohorts was smaller than 
previously seen, the trend remains the same when investigating the lower affinity 
peptides as well. Similarly to the previous  
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Figure 4.8. Frequency of high and low affinity HLA-binding peptides from the CDR3 
of the TCR β-Chain
TCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for high affinity (A) and 
low affinity (B) HLA-A1, -B7 and -B8-binding peptides using the BIMAS algorithm.  Data is 
represented as a percentage of all peptides analysed where peptide binding was defined 
by thresholds 12 for HLA-A1, 16 for HLA-B7 and 12 for HLA-B8 (A) and 5 for all alleles 
(B). Error bars denote mean + standard error mean. Data was analysed using chi-squared 
test to determine statistical significance.
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HLA-B8 results, there was a decreased frequency of CDR3-derived peptides in the 
HLA-B8
+
 donors (1.08%) compared with the HLA-B8
-
 donors (1.54%) (χ2=2.31, 
p=0.13) (Figure 4.8 B). 
 
4.6 Frequency of TCRs Containing CDR3-Derived Peptides 
After showing that there was an increased frequency of TCRs containing more than 1 
HLA-A2 binding peptide in HLA-A2
+
 donors, the other HLA alleles were 
investigated to determine whether there was a similar difference in frequency. Using 
SYFPEITHI the results in Figure 4.9 demonstrate that there are no TCRs which 
contain more than one peptide using the algorithms for HLA-A1 and –B7. Similar to 
the previous results, HLA-B8
+
 donors demonstrate a decreased frequency of TCRs 
containing at least one CDR3-derived HLA-binding peptide (0.0%) compared with 
the HLA-B8
-
 donors (1.2%).  
 
Using BIMAS, similar trends can be seen, using either the higher or lower thresholds, 
with the HLA-positive donors in –A1 and -B7 demonstrating an increased frequency 
of TCRs compared with the HLA-negative donors (Figure 4.9). The trend seen 
previously with –B8 can also be seen here with an increased frequency of TCRs in 
HLA-B8
-
 donors (1.2% (high) and 13.6% (low)) compared with HLA-B8
+
 donors 
(1.1% (high) and 7.5% (low)) using both the higher and lower BIMAS thresholds.  
 
These results suggest that there is peripheral tolerance towards CDR3-derived 
peptides from TCRs in all HLA alleles tested except HLA-B8. Therefore, there is 
selection pressure on TCRs based on CDR3 sequence but instead of selecting TCRs 
without any 
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Figure 4.9 Frequency of TCRs containing more than one HLA-binding peptide in the 
other HLA types investigated
TCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
analysed to determine the frequency of those containing more than one HLA-binding 
peptide in the other HLA alleles investigated using both peptide prediction algorithms 
SYFPEITHI (A) and BIMAS (B). Data is represented as a percentage of all peptides 
analysed where peptide binding was defined for both algorithms as previously discussed. 
This was done in an attempt to determine whether there was skewed data in the previous 
analysis of the peptide prediction data due to a single BCR containing a large number of 
HLA binding peptides within the CDR3. 
A B
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HLA-binding peptides within the CDR3 as was first hypothesised, TCRs are actually 
selected to contain an HLA-binding peptide within their CDR3, except from those in 
the HLA-B8
+
 cohort. This is due to the fact that for both algorithms tested, there was 
an increased incidence of CDR3-derived peptides from HLA positive donors 
compared with HLA negative donors. 
 
4.7 Frequency of CDR3-Derived HLA-A2 Binding Decamer 
Peptides 
The above results are for CDR3-derived peptides which are 9 amino acids long, 
however, it is well known that a significant percentage of HLA class I peptides can be 
increased in length to 10 amino acids (Collins et al, 1995 and Takahashi et al, 1999). 
Therefore, a second analysis of the sequences of TCR CDR3s was performed to 
determine whether the results seen in HLA-A2 donors for peptides which were 9 
amino acids in length was repeated in peptides which are 10 amino acids in length.  
 
Using SYPEITHI, there was a statistically significant increase in the higher affinity 
peptides, 10 amino acids in length, predicted to bind to HLA-A2 in TCRs from HLA-
A2
+
 donors (1.24%) compared with HLA-A2
-
 donors (0.56%) using a threshold of 22 
(χ2=7.17, p=0.01) (Figure 4.10), similar to that seen in the above results for peptides 9 
amino acids in length. Although this result does not validate all of the previous results 
for all of the different HLA types, the similarities in the different analyses gives a 
degree of confidence that the results are authentic and not a mathematical artefact due 
to the HLA peptide prediction algorithms.  
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Figure 4.10 Frequency of predicted HLA-A2 binding decamer peptides from HLA-A2+
and HLA-A2- donors
TCRs from healthy donors (separated into HLA-positive and HLA-negative cohorts) were 
sequenced from unfractionated PBMCs and the CDR3 analysed for HLA-A2-binding peptides 
of 10 amino acids using the SYFPEITHI algorithm.  Data is represented as a percentage of 
all peptides analysed where peptide binding was defined by a score of 22 or above. Error 
bars denote mean + standard error mean.  Data was analysed using chi-squared test to 
determine statistical significance where * P<0.05.
*
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4.8 T Cell Response to CDR3-Derived Peptides 
The above results show the presence of potentially immunogenic HLA-binding 
peptides within the CDR3s of TCR β-chains from healthy donors in several HLA 
alleles. Even though these data disproved the original hypothesis where a decreased 
percentage of HLA-binding peptides contained within the TCRs of HLA-positive 
donors compared with HLA-negative donors was expected, this led to the 
development of a second hypothesis, that the CDR3-derived peptides could be 
processed and presented on MHC class I molecules on the surface of the T cells and 
therefore I could generate an immune response towards them. Firstly, a peptide 
contained within the CDR3 of a TCR was required so it could be targeted. CD8
+
 T 
cells were cloned using CMV peptides as antigens to allow growth of T cell clones 
and the TCR α & β-chains sequenced to find a potentially immunogenic peptide 
within the CDR3. Previously, Winter et al., 2003 had determined that T cell responses 
could be generated towards peptides from the V region as well as the CDR3 of T cells 
from CTCL patients. Further work demonstrated the ability of these T cells to 
recognise and lyse autologous CTCL cells in a peptide-MHC I dependent manner. 
Once a TCR expressing an HLA-binding peptide had been discovered an immune 
response against the idiotype-derived peptide was mounted. HLA-A2 was used for 
this work as the algorithm for peptide prediction is the most robust of the HLA alleles 
that have been studied.  
 
4.8.1 TCR CDR3-Derived HLA-A2 Binding Peptides 
Five T cell clones were grown from two different HLA-A2
+
 donors, with T cells 
specific for a number of CMV-derived peptides. Sequencing analysis of the TCR α & 
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β chains demonstrate the presence of an HLA-A2 binding peptide, ALCDTGRRAL, 
within the TCRα chain of the ELR-specific T cell clone from donor DB (Table 4.1). 
This peptide, which scored 24 in the SYFPEITHI-derived HLA A2 algorithm but only 
scored 17.5 using the BIMAS-derived algorithm, was considered the best candidate. 
However, whilst sequencing the TCR alpha and beta chains for this clone, I realised 
that there was a possibility that the T cells were not clonal. The TCR from the ELR 
“clone” contained two different TCR beta chain sequences (Table 4.1) which suggests 
that this particular T cell could have at least two different T cell clones growing 
together in culture. In order to confirm this finding I used the flow cytometer to stain 
the T cells for the different V-beta chain usage to determine whether there was more 
than one TCR beta chain variable (TCRVβ) chain being used by the T cells. If there 
was staining for more than one TCRVβ chain in the whole T cell culture, this would 
confirm that there was more than one T cell clone growing. The sequencing results 
suggest that the ELR1 “clone” contains one T cell using the TCRVβ17.2 variable 
region and another T cell using the Vβ14 variable region and therefore the antibody 
staining should follow these results. However, the sequencing results may not have 
picked up all of the different T cell CDR3s and there could be more than two different 
T cells in the culture. The T cells were stained using all 24 TCRVβ antibodies and the 
results showed that the ELR1 T cell clone was 7.1% positive for Vβ17.2 and 90% 
positive for Vβ14 (Figure 4.11 A) with no staining for the other Vβ antibodies. These 
results suggest that there are only two T cell clones growing together in the culture 
which correlates with the results from the sequencing. In order to have a 
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SAVYLCASRGVGSPLHFGNGTRLTVTEDLNKVFPPELR 1 β-Chain (A)
SAMYFCASSDRGQPQHFGDGTRLSILNIQNPDPA
ELR1 α-Chain 
(Vβ17.2+)
SAVYFCASSQEFPPRANTGELFFGEGSRLTVLEDLKNVTPR 2 β-Chain
SAMYLCASSIDSFNEQFFGPGTRLTVLEDLKN RPH 1 α-Chain
SAVYICAVNTGNQFYFGTGTSLTVIPNIQNPDPA
TAFYLCASSIDPLRVGPNGDSPLHFGNGTRLTVTEDLNKNV
SAMYYCALCDTGRRALTFGSGTRLQVQPNIQNP 
TSVYFCASPDYGDNEQFFGPGTRLTVLEDLKNV 
SATYLCAVKATNYGQNFVFGPGTRLSVLPYIQNPDPA
SAMYLCASSLEQVRPYEQYFGPGTRLTVTEDLKNV
Sequence
TPR 2 α-Chain
ELR 1 β-Chain (B)
ELR 1 α-Chain 
(Vβ14+)
NLV 1 β-Chain
NLV 1 α-Chain
VTE 2 β-Chain
T Cell Clone
Table 4.1. Sequencing TCR α and β chains from CMV-specific CD8+ T cell clones
DNA encoding the TCR α or β-Chain from CMV-specific CD8 T cell clones were 
sequenced. The sequence above shows the variable region, through the CDR3 region 
(underlined) and into the constant region. The sequences could then be used to 
determine the presence of HLA-A2 binding peptides within the CDR3 region using 
SYFPEITHI and BIMAS. The ELR1 Clone was found to be made of two different clones 
and therefore contains two sequences for the alpha and beta chains. The two clones 
could be selected using magnetic beads (Figure 4.11).
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clonal T cell culture, I attempted to separate the two T cell clones using the TCR 
Vβ17.2 antibody, which was conjugated with FITC, and anti-FITC microbeads. The 
two T cell clones were isolated using magnetic selection over two columns to try to 
ensure the purity was as high as possible so that the Vβ14+ T cells are only in the 
negative fraction and the Vβ17.2+ T cell are only in the positive fraction. The results 
of the T cell selection/separation showed that, after running the cells over two 
columns, the two T cell clones were separated and very pure (Figure 4.11 B-D) with 
99.6% of the CD8 T cells in the positive fraction also staining positive for 
TCRVβ17.2 and less than 0.1% in the negative fraction.  This result allowed the 
determination of which T cell clone the CDR3-derived HLA-A2 binding peptide 
(ALCDTGRRAL) belonged to. After growing both T cell clones, the alpha chains of 
both the Vβ14+ and the Vβ17.2+ cells were sequenced and it was determined that the 
Vβ14+ cells contained the TCR alpha chain with the HLA-A2 binding peptide, 
ALCDTGRRAL (Table 4.1).  
 
4.8.2 CDR3-Derived Peptide-Specific T Cells 
Previously, studies had generated T cell responses against peptides from the Ig 
framework regions (Trojan et al., 2000). The specificity of the TCR from the T cell 
clone where the peptide was found did not concern me as this T cell will eventually 
become the target for any T cells generated against the CDR3-derived peptide. The 
peptide was predicted to bind to HLA-A2, with a binding score produced by 
SYFPEITHI of 24, so a CD8 T cell response could be generated against it using 
previously discussed methods (Ho et al, 2006).  Dendritic cells were generated from 
PBMCs, from an HLA-A2
+
 donor, and stained after 3 days with antibodies to markers 
expressed on mature dendritic cells (CD80, CD83 and CD86). The 
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Figure 4.11 Antibody staining and magnetic selection of TCRVβ at the surface of 
ELR1 cells
ELR1 T cells were stained with a panel of antibodies to determine their β-chain variable 
region usage. Cells were stained with antibodies specific for individual TCRVβ regions as 
well as with anti-CD8 (FITC or PE) for 30 minutes before being washed and analysed on 
the flow cytometer (A). ELR1 T cells were stained with the Vβ17.2-FITC antibody for 30 
minutes and washed before addition of anti-FITC microbeads. Cells were washed 
extensively and were then separated using two magnetic columns to separate the antibody 
stained cells from the cells not stained with antibody. Cells pr ior to separation (B) and the 
negative (C) and positive (D) fractions were then analysed on the flow cytometer. 
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Figure 4.12 Antibody staining of dendritic cells matured for 3 days 
PBMCs were plated out and adherent cells were matured into dendritic cells using 
cytokines and growth factors over 3 days (Ho et al, 2006). Dendritic cells were stained on 
day 3 with antibodies to determine their maturation state. The cells were incubated with 
antibodies against CD80 (Black), CD83 (Blue) and CD86 (Green) for 30 minutes. After 
washing, the cells were analysed on the flow cytometer. 
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CD80
CD83
CD86
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cells stained with antibodies were positive (Figure 4.12) with all three of them 
staining more than 85% of the dendritic cells. These results strongly suggest that the 
cells are dendritic cells and have matured using the cytokine cocktail described. 
Dendritic cells were used to generate a naïve T cell response against the CDR3-
derived peptide. After 3 rounds of stimulation, T cells were cloned (as described in 
the materials and methods) and 10 T cell clones recognised peptide-pulsed PBMCs 
shown by release of IFN-γ (Figure 4.13 A) whilst not recognising unpulsed PBMCs 
suggesting that these clones are specific for the CDR3-derived peptide. The peptide 
was predicted to bind to HLA-A2 but peptide binding studies have not confirmed this 
possibly in part due to the cysteine residue at position 3. This amino acid contains the 
reactive sulphydryl group that can either be in a reduced or oxidised state. Cysteine 
residues could form a dimer (cystine), joined by a disulphide bridge, and this may 
alter the presentation of the peptide to the CD8
+
 T cells. The peptide will act 
differently in each of its two states which makes determining HLA restriction 
difficult. A B cell line, JY (A2, B7 and Cw7 homozygous), was used to further 
determine the HLA-restriction of the CDR3-derived peptide.  JY cells, pulsed with 
ALCD peptide, were strongly recognised by the T cell clones using an IFN-γ ELISA 
whereas unpulsed JY cells were not recognised (Figure 4.13 B). This data 
demonstrates the specificity of the T cell clones for the ALCD peptide and helps to 
narrow the HLA restriction as well. Recognition of the peptide-pulsed JY cells means 
the peptide can only bind to A2, B7 or Cw7. The peptide is unlikely to bind to HLA-
B7 due to the presence of leucine at position 2, generally regarded as an anchor for 
HLA-A2 whereas HLA-B7 binding peptides generally prefer proline at position 2. 
This is seen in the HLA-B7 peptide prediction 
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Figure 4.13. Recognition of peptide pulsed target cells by ALC clones 
Initially 10 clones thought to be specific for the CDR3-derived peptide ALC were tested for 
reactivity using IFN-γ ELISA. Autologous PBMCs were pulsed with ALC peptide (PBMC + 
Pep) or left unpulsed (PBMC) and after washing, target cells were incubated with the ALC-
specific T cells overnight with unpulsed PBMCs acting as a negative control. The media was 
taken to assay for IFN-γ by ELISA (A). Four surviving T cell clones were used to test for 
reactivity against ALC to help ascertain the HLA-restriction of the peptide. Cells from the B 
cell line JY were pulsed with ALC peptide (JY + ALC) or left unpulsed (JY) and after washing, 
the target cells were incubated with the ALC-specific T cells overnight with unpulsed JY cells 
acting as a negative control. The media was taken to assay for IFN-γ by ELISA (B). Error 
bars denote mean + standard error mean. 
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score of 14 from SYFPEITHI which tends to suggest that this peptide won‟t bind to 
HLA-B7. However, HLA-B7 prediction from BIMAS suggests that the peptide may 
indeed bind with a score of 12.00 compared with only 17.52 for HLA-A2. 
SYFPEITHI doesn‟t have a prediction algorithm for HLA-Cw7 so it is not possible to 
determine potential binding of the ALCD peptide. However, BIMAS contains a 
prediction algorithm for HLA-Cw7, scoring ALCD 1.01, suggesting that the peptide 
does not bind to HLA-Cw7. These results suggest that the peptide used binds to HLA-
A2 and not to HLA-B7 or HLA-Cw7 but this may need verification. 
 
4.8.3 Recognition of Parental T Cell Clone by Peptide-Specific T Cells 
One of the hypotheses tested, that runs throughout all of this work, was whether or not 
a peptide originally found within the CDR3 of a TCR could be processed by a T cell 
and expressed on the surface of the cell in complex with MHC class I molecules. 
Originally, a proteomic approach using mass spectrometry was going to be employed 
in an attempt to determine the presence of the CDR3-derived peptide on the cell 
surface. However, the number of T cells required to do this was very high (~10
9
) and 
despite lengthy attempts to generate this number of T cells, it wasn‟t possible. 
Therefore, to test this hypothesis ALC-specific T cells were cultured with the original 
T cell clone to determine whether there was recognition of the ELR T cell clone by 
the ALC-specific T cell clone. The ALC peptide used to generate CD8 T cell clones 
was originally discovered in one of the TCR α-chains from the Vβ14+ fraction 
(Vβ17.2- fraction) of the T cell “clone” ELR1. Previously, I determined that the ALC-
specific T cell clones and line recognise peptide strongly, by generating a large IFN-γ 
response, and don‟t recognise JY cells that have not been pulsed with peptide. In 
order to determine the presence of the ALC peptide on the cell surface in complex 
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with an HLA molecule, a second, more sensitive method, was used. ALC specific T 
cells and the ELR1 Vβ14+ T cell clone were co-cultured to test whether the ELR1 
target cells express the ALCD peptide on the surface of the cell which could be 
detected by the ALC-specific T cells. The ELR T cell clone that was Vβ17.2+, and 
therefore did not contain the ALC peptide within the α-chain, was also used as a 
control target cell that is almost identical to the ELR1 target cell. After 24 hours co-
culture, the culture supernatant was taken and tested for IFN-γ with the presence of 
IFN-γ demonstrating recognition of ALC peptide at the cell surface. An initial 
experiment to demonstrate recognition of the ELR-specific T cell clone by the ALC-
specific T cells showed a low IFN-γ response when the two cells were cultured 
together, (Figure 4.14) demonstrating T cell recognition. There is an increased amount 
of IFN-γ released in this experiment by the clone recognising the parental T cell 
expressing the TCR containing the ALC peptide compared with all of the controls 
although the amount of IFN-γ produced was lower than previous experiments where 
the ALC-specific T cells recognised peptide-pulsed target cells. This result suggests 
that the ALCD peptide is expressed on the surface of the target T cells, although at a 
lower number of peptide-MHC complexes than when the PBMCs or JY cells were 
peptide-pulsed because there was a decrease in IFN-γ production when the ALCD-
specific T cells were cultured with the ELR1 T cells.  
 
Both target and responder T cells could potentially produce IFN-γ and it was 
important to test both cell lines for spontaneous IFN-γ release. There is a very low 
background release of IFN-γ by both cell lines, however, the amount of IFN-γ 
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Figure 4.14. Recognition of ELR1 T cell clone by the ALC-specific T cell clone
The ELR1 T cell clone contains the ALC peptide within the TCR α-chain whereas the 
ELR Vβ17.2 T cell clone does not contain the ALC peptide within its sequence. Two T 
cell clones, either ALC + ELR 1 or ALC + ELR Vβ17.2 were incubated together overnight 
to determine whether the ALC-specific T cells could recognise the ELR1 or ELRVβ17.2 T 
cells and the media taken for IFN-γ ELISA. Peptide-pulsed T cells (ELR + pep & ELR 
Vβ17.2 + pep) or cell lines (Jurkat A2 + pep) were used as control. In order to 
demonstrate there wasn’t spontaneous release of IFN-γ, the T cell clones were cultured 
on their own (ELR1 only and ALC only) overnight and the media assayed. Error bars 
demonstrate mean + standard error mean, n=3.  Data was analysed using unpaired t-test 
to determine statistical significance.
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produced by the co-culture of the two cell lines produced a significant increase in 
IFN-γ. This would suggest that the IFN-γ release could be specific for ALC peptides, 
in complex with HLA, present on the surface of the ELR T cell clone. The ELR T cell 
clone was derived from an HLA-A2
+
 donor who was also HLA-B8 but not HLA-B7. 
This would suggest that the ALC peptide was probably presented on the cell surface 
by HLA-A2 as we already know the peptide is restricted through either A2 or B7. 
Since the cells used don‟t contain HLA-B7 or HLA-Cw7, this would suggest that the 
peptide is indeed presented by HLA-A2.  
 
Although the peptide pulsed LCLs (acting as positive control) were not recognised by 
the peptide specific T cells, the results suggest that there is recognition of 
endogenously processed CDR3-derived peptides. This would suggest that potentially 
immunogenic CDR3-derived peptides gain access to the MHC class I processing 
pathway. These experiments were repeated to prove that there was an IFN-γ response 
towards the ELR1 T cell clone but, whilst trying to produce further data, the ALCD-
specific T cell clones and lines died so no further work was possible with this part of 
the project.  
 
4.9 HLA and TCR Expression on Jurkat-A2 Cells 
Initially, experiments were focused on the immortalised Jurkat T cell line, which was 
HLA-B7
+
 but HLA-A2
-. I had to use a T cell to introduce the TCR β-chain into as 
there would need to be an endogenous TCR α-chain to pair with the newly introduced 
β-chain. This would allow the mutated TCR β-chain to be expressed at the surface of 
the cell as a fully intact TCR and would mean that the TCR would be degraded in the 
same manner as a normal TCR. One of the most important considerations in 
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establishing this model was to reach as close to physiological conditions as possible 
so the results would be indicative of what happens in functional T cells. The Jurkat T 
cell line that we were given (Dr V. Engelhard, University of Virginia) had already 
been transduced with HLA-A2 so I had an immortal T cell line that was HLA-A2
+
.  
The cells were stained with BB7.2-PE (anti-HLA-A2 antibody) and BB7.1-PE (anti-
HLA-B7 antibody) in order to confirm that the cells growing were the same HLA type 
as expected (Figure 4.15 A). The Jurkat-A2 cells were strongly positive for both 
HLA-A2 and -B7, demonstrating that the cells could be confidently used for future 
experiments. As mentioned before, in order for the TCR β-chain, that is going to be 
introduced into the cells, to be expressed at the cell surface, it must pair with an 
endogenous α-chain. The staining (Figure 4.15 B) demonstrates the expression, albeit 
slightly low, of TCRαβ protein at the surface of the cell. This confirms that there is an 
endogenous α-chain that the introduced TCR β-chain could pair with and therefore be 
expressed at the surface. The Jurkat T cell line is a CD4 T cell line which already 
contains a T cell receptor. The T cell receptor used for mutagenensis studies contained 
the TCR variable region TCRVβ7. It was important to first ensure that the Jurkat T 
cell receptor was TCRVβ7 negative. Using the TCRVβ7 antibody (Abcam, 
Cambridge, UK) conjugated to phycoerythrin demonstrated that the Jurkat T cell line 
is TCRVβ7 negative (Figure 4.15 C). PBMCs, which will contain a small percentage 
of T cells expressing TCRVβ7, were used as a positive control to test that the 
antibody does bind with 4.2% staining positive as expected. These results confirm that 
if the mutated T cell receptor β-chain is introduced into the cell, antibody staining 
could be used to test for the expression at the surface of the T cells.  
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Figure 4.15. Flow cytometric staining Jurkat A2 cells 
Jurkat A2 cells were stained with antibodies against surface HLA-A2 and HLA-B7 (A) for 
30 minutes, washed and analysed on the flow cytometer. Jurkat A2 cells and PBMCs 
were stained with either an isotype control antibody or an antibody against surface 
TCRαβ expression for 30 minutes, washed and analysed on the flow cytometer (B).
PBMCs and Jurkat A2 cells were stained with the TCRVβ7-PE antibody for 30 minutes, 
washed and analysed on the flow cytometer (C).
Isotype Jurkat A2 PBMC
A
B
C
Jurkat A2 - HLA-A2 Jurkat A2 - HLA-B7Jurkat A2 - Unstained
TCR αβ 80%26%TCR αβ TCR αβ
TCRVβ7
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4.10 Introduction of Foreign DNA into Cells 
Initially, I had to decide which method was the easiest and most reproducible method 
for inserting DNA encoding the T cell receptors into the cell of interest. The methods 
tested were standard transfection, with an array of different transfection reagents, 
transfection leading to stable integration, using a specially prepared kit from 
Invitrogen, nucleofection, using the Amaxa system, and transduction, using lentiviral 
vectors. After determining which of the protocols generated the best results, further 
experimental work would proceed with this method.  
 
4.10.1 Green Fluorescent Protein 
Initially, green fluorescent protein (GFP) was used as an easy way to detect protein 
for my first attempts using Jurkat T cells. Once GFP expression was detected in Jurkat 
T cells, the same protocol could be used to introduce the TCR DNA. Although 
standard transfection of Jurkat A2 cells using Lipofectamine LTX (and the PLUS 
reagent) or Lipofectamine 2000 didn‟t work, a different transfection reagent, TransIT, 
demonstrated encouraging results (Figure 4.16). TransIT is specifically tailored for 
Jurkat T cells as they have been described as a cell line that is difficult to transfect. 
Flow cytometric analysis of the transfected cells showed 1-2% of cells were GFP-
positive after 24hrs which increased to 6-10% after 96 hours in Jurkat A2 T cells. 
After 7 days less than 1% of the transfected cells were GFP positive demonstrating 
the loss of expression of GFP after 7 days and suggesting that the expression seen 
after 96 hours was transient and not stable. Although the cells lost expression of GFP, 
this method was considered for introduction of mutated TCR DNA into the Jurkat A2 
cells.   
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4.10.2 Nucleofection 
Jurkat cells are very difficult to transfect and nucleofection is considered to be a 
useful method in transferring DNA into cells which are difficult or impossible to 
transfect. Based on electroporation, nucleofection uses a combination of factors 
including voltage and time to make cells porous and allow transfer of DNA into the 
cell. Using this method, the conditions are completely dependant on the cell type, not 
the type of nucleic acid being used. Unlike other transfection methods, the cells do not 
need to be actively dividing when DNA is being transferred into the cells. 
 
Nucleofection of Jurkat A2 cells was performed using the pcDNA3.1/Hygromycin 
vector. Using the Amaxa nucleofector the conditions used for nucleofection of Jurkat 
A2 cells could not be obtained. However, 48 hours post-nucleofection, the cells were 
analysed for GFP expression using the flow cytometer. Less than 0.5% expressed 
GFP demonstrating that nucelofection did not transfer DNA efficiently into the Jurkat 
A2 cells. Therefore, transfection of DNA using nucleofection as a method for 
introducing the mutated TCR DNA into Jurkat A2 cells ceased. 
 
4.10.3 Flp-In Transfection 
GFP contained within the pcDNA5 vector and transfected into Jurkat A2 T cells 
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24 hrs 96 hrs 7 days
Figure 4.16. Expression of green fluorescent protein at the surface of Jurkat A2 
cells
Green fluorescent protein (from two different plasmids) was transfected into Jurkat A2 
cells using the TransIT transfection reagent (MirusBio). Cells were analysed on the flow 
cytometer after 24 hours when there was little GFP expression. After 96 hours, both of the 
transfected cell lines demonstrated an increased percentage of GFP staining (black and 
green) compared with the untransfected control cells (red). However, staining after 7 days 
demonstrated the loss of GFP from both transfected cell lines.
Untransfected
GFP 1
GFP 2
 
Figure 4.17 GFP expression in Jurkat-Flp In after transfection using Flp-In system
The Jurkat-Flp In cells were transfected with the pcDNA5/Hygro plasmid containing 
GFP. 48 hours after transfection, the cells were analysed on the FACS machine and 
~4% of transfected cells were GFP positive (Green) compared with the untransfected
control (Red).  Expression of GFP was lost soon after. 
Untransfected
GFP
 192 
demonstrated 4% GFP-positive cells (Figure 4.17) when tested 48 hours post-
transfection. The cells were grown in media containing 300ug/ml hygromycin to try 
to select the transfected cells. However, when analysed again on the flow cytometer 
after 7 days, no cells survived suggesting that the hygromycin selection had killed all 
of the cells and that the protein production seen after 3 days was transient. Therefore, 
due to the inability of this system to generate and select stable transfectants, it was not 
used in any further work.  
 
4.11 Expression of GFP by Lentivirus 
Lentiviral trasnduction (Bai et al., 2003) began by attempting to generate pTRIP-GFP 
lentiviral particles, using different transfection reagents (Lipofectamine 2000, 
Lipofectamine LTX, GeneJuice and NanoJuice) to transfect 293T cells in order to 
determine which transfection reagent produces the most lentiviral particles. After 
generating the virus particles, Jurkat A2 cells were transduced with each of the GFP-
viruses and after 48 hours, the cells were analysed on the flow cytometer (Figure 4.18 
A-B). The greatest percentage of GFP-transduced cells was seen in the Lipofectamine 
LTX transfection reagent (99.5%) when compared with the untransduced control 
cells. Lipofectamine 2000 (42%) and NanoJuice (18%) also produced GFP-positive 
cells although at a lower percentage and GeneJuice didn‟t produce any GFP-positive 
cells. This suggested that the Lipofectamine LTX reagent, along with the PLUS 
reagent, was the best protocol to produce lentivirus particles in 293T cells. Previously, 
the problem encountered was the transient nature of the protein production following 
introduction of the gene of interest. Therefore, the transduced cells were cultured to 
allow quantitation of GFP expression over the following months to determine 
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Figure 4.18. Expression of GFP after lentiviral transduction of Jurkat A2 cells
GFP lentivirus was produced in HEK-293T cells transfected with different transfection 
reagents and the lentivirus particles used to transduce Jurkat A2 cells (A-B). Cells were 
transduced with virus from flasks of 293T cells transfected with Lipofectamine LTX (A: 
Green), Lipofectamine 2000 (A: Blue), NanoJuice (B: Green) or GeneJuice (B:Blue). 
Untransduced Jurkat-A2 cells (Red) were used as control cells. Cells transduced with GFP 
lentiviral particles produced from either NanoJuice (C), Lipofectamine 2000 (D) or 
Lipofectamine LTX (E) were analysed on the flow cytometer 4 times over 10 weeks. Cells 
were removed from culture, washed and analysed using the flow cytometer.
A B
C D E
Untransfected
GFP - Lipofectamine
2000
GFP - Lipofectamine
LTX
Untransfected
GFP - GeneJuice
GFP - NanoJuice
Untransfected
GFP - 14 days
GFP - 28 days
NanoJuice Lipofectamine 2000 Lipofectamine LTX
GFP - 49 days
GFP - 70 days
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whether the introduction of the DNA was transient or stable. The Jurkat T cell line, 
transduced with lentiviruses produced with the various reagents, were cultured and the 
percentage of GFP-producing cells determined. The cells were tested every few weeks 
and the percentages of GFP-positive cells were noted to see whether the cells 
continued to produce the protein. Up to 10 weeks after transduction, similar 
percentages of cells were still expressing GFP (Figure 4.18 C-E) suggesting that the 
transduction produces stable integration of the gene of interest. Following the results 
with pTRIP-GFP viruses, pLVX-IRES-Puromycin lentivirus particles containing GFP 
were generated using standard 293T cells. The transfection was done using the 
Lipofectamine LTX and PLUS reagent, which were used for all subsequent 
transductions.  
 
4.12 Expression of GFP in Selectable Lentivirus 
Previously, the selection of transfected cells was unsuccessful and in order to test the 
pLVX lentiviral system, I transduced Jurkat A2 cell line and HEK-293T cells with 
pLVX-IRES-Puromycin virus containing GFP. After 48 hours, the cells were 
analysed on the flow cytometer to determine the transduction efficiency using the new 
lentivirus with the pTRIP-GFP virus, used previously, as a control (Figure 4.19 A-B). 
The Jurkat A2 cell line transduced with the pLVX-GFP virus contained 6% GFP 
positive cells compared with the mock transduced cells whereas the HEK-293T cells 
transduced with the pLVX-GFP virus contained 21% GFP positive cells compared 
with the untransduced control cells. The pTRIP-GFP virus produced an increased 
percentage of GFP positive Jurkat-A2 and HEK-293T cells (74% and 92%) 
demonstrating that the transduction efficiency of the 
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A B
Figure 4.19 Transduction and selection of Jurkat-A2 and HEK-293T cells with pLVX-
IRES-puromycin lentivirus containing GFP
Jurkat-A2 cells (Blue) and HEK-293T cells (Green) were transduced with GFP lentiviral 
particles (A-B). The lentivirus was produced from Lipofectamine LTX transfected HEK-293T 
cells using either pLVX-IRES-Puromycin (A) or pTRIP (B). The cells were washed and 
analysed on the flow cytometer 28 hours after transduction. The cells transduced with the 
pLVX-IRES-Puromycin virus (A) were grown in media containing 1μg/ml puromycin. After 5 
days culture the HEK-293T cells (C) and Jurkat-A2 cells (D) transduced with the pLVX-IRES-
Puromycin virus were washed and assayed for GFP expression using the flow cytometer. 
Untransduced cells were used as negative control (C: black and D: red).
C D
Untransfected
Jurkat A2
HEK-293T
GFP pLVX-
IRES-Puromycin GFP pTRIP
Untransfected
Jurkat A2
HEK-293T
Untransfected
GFP + 
Puromycin
Jurkat-A2HEK-293T
Untransfected
GFP + 
Puromycin
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pTRIP-GFP virus is higher than that of the pLVX-GFP virus but the pLVX virus can 
be selected to increase the GFP-positive percentage. Puromycin (1μg/ml) was added 
to the media 48 hours after transduction to try and select the transduced GFP-positive 
cells from the untransduced, GFP negative cells. The HEK-293T cells were then 
analysed on the flow cytometer 3 days after selection began with the percentage of 
GFP-expressing cells increasing from 21% to 62% after 3 days (data not shown). This 
demonstrated the ability of puromycin to select the transduced HEK-293T cells from 
the untransduced cells as expected. After 5 more days of culture, both cell lines were 
analysed on the flow cytometer and the percentage of GFP-expressing HEK-293T 
cells had increased again to 99.2% (Figure 4.19 C-D) whereas the percentage of GFP-
expressing Jurkat A2 cells had increased to 57% compared with the mock transduced 
control cells. Therefore demonstrating that the population of transduced cells can be 
selected using puromycin so there are very few untransduced cells surviving in the 
puromycin-supplemented media. After demonstration that the pLVX virus system 
worked well with GFP in HEK-293T cells and that the transduced cells could be 
selected very easily with puromycin, this method of introducing DNA into Jurkat A2 
cells was used as well. 
 
Following attempts to introduce GFP into cells using 4 different methods, the two 
methods that demonstrated the largest increase in GFP expression in Jurjat A2 cells 
were standard transfection, using the TransIT reagent, and transduction using 
lentivirus. Experiments moved on in an attempt to introduce the mutated TCR DNA 
into the same cell line using each of these methods.  
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4.13 Expression of T Cell Receptor β–Chain by Transfection 
Using the MirusBio TransIT reagent to transfect Jurkat A2 cells, they stained positive 
for TCRVβ7 after 2 days (range 5.7-12.2%) (Figure 4.20 A). The results suggested 
that the T cell receptor had reached the surface in a small percentage of cells which 
was expected as transfection is known to have a very low efficiency. Importantly, this 
result demonstrated that the mutations made to the T cell receptor β-chain did not 
alter the ability of the T cell receptor to fold properly and pair with the endogenous 
TCR α-chain. Upon culture, the expression of the TCR β-chain was lost after 5 days 
(Figure 4.20 B). This would appear to suggest that the transfection of DNA was 
transient and this is probably the reason it was lost after such a short period of time. 
As standard transfection wasn‟t producing stable protein expression, a new method of 
introducing the TCR DNA was used.  
 
4.14 Expression of TCR in Jurkat-A2 Cells 
4.14.1 Standard Transduction of Lentivirus 
The Jurkat-A2 cell line was transduced with unconcentrated virus containing each of 
the mutated TCRs (Table 2.6) as well as the unmutated TCR as a positive control. 
After 48 hours culture, cells were stained with an antibody specific for TCRVβ7 to 
determine the presence of the protein at the cell surface. The initial results (Figure 
4.21) were very disappointing demonstrating that there was little or no expression of 
the mutated TCR protein at the surface of any of the transduced cells (Range 0.03% - 
0.41%). After these poor results viruses containing the TCRs with NLVPMVATV 
and DYSNTHSTRYV in the CDR3 were produced and concentrated up to 50x greater 
than the previous lentivirus concentration used. The concentrated virus particles 
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NLV RNLV TPR RPH Unmutated
Figure 4.20. Expression and selection of mutated TCR β-chains at the surface of Jurkat 
A2 cells
Mutated TCR β-chains were transfected into Jurkat A2 cells using the TransIT transfection 
reagent (MirusBio). Cells were stained, 48 hours post transfection, using anti-TCRVβ7-PE 
antibody for 30 minutes. After staining with the antibody, cells were washed and analysed on the 
flow cytometer (A: black). Untransfected cells stained with the same antibody (A: red) were used 
as control cells. Cells were grown in media containing hygromycin (300μg/ml). After 5 days, cells 
were again stained with anti-TCR Vβ7-PE antibody for 30 minutes, washed and analysed using 
the flow cytometer (B).
A
B
Untransfected TCR Vβ7
Untransfected
NLV
RNLV
TPR
RPH
Unmutated
 199 
Figure 4.21 Transduction of Jurkat A2 cells using lentivirus containing mutated 
TCRs
Lentiviral particles containing mutated TCRs were produced by Lipofectamine LTX 
transfection of HEK-293 lenti X cells. Jurkat-A2 cells were transduced with the mutated 
TCR viruses NLV (A, Green), RNLV (A, Blue), TPR (B, Green), RPH (B, Blue) and 
unmutated (C. Green) with mock transduced cells (A-C Red) and isotype stained cells (A-C 
black) acting as negative controls. Cells were stained, 48 hours post-transfection, with the 
anti-TCRVβ7-PE antibody for 30 minutes, washed and analysed using the flow cytometer.
A B
C
Untransfected
NLV
RNLV
TPR
RPH
Untransfected
Untransfected
Unmutated
Isotype Isotype
Isotype
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were stored for each of the mutated TCRs and Jurkat-A2 cells were transduced with 
each of the viruses and assayed for protein production after 48 hours on the flow 
cytometer. The results using the concentrated virus were similar to the previous 
attempts with less than 1% of cells staining positive for the TCR β-chain (data not 
shown). After this result, a new method to transduce Jurkat-A2 T cells was used 
where the T cells were co-cultured with the transfected 293 cells (see materials and 
methods 2.6.3.3). 
 
4.14.2 Co-Culture Transduction 
After culturing the T cells with the transfected 293 cells for 48 hours, the cells were 
separated and stained for analysis on the flow cytometer. The results using the co-
culture transduction (Figure 4.22) were much better than previous results with 4% of 
Jurkat-A2 cells transduced with the NLV-mutated TCR staining positive for TCRVβ7 
(A) and those cells transduced with the DYSN-mutated TCR also stained positive for 
7% (B). After showing that there were positively transduced cells, they were grown in 
puromycin in an attempt to select TCRVβ7 expressing cells.  
 
The Jurkat-A2 cells transduced using the co-culture method were put on antibiotic 
selection using 1μg/ml puromycin. However, 5-7 days after beginning selection there 
were no cells alive suggesting that the cells had still been sensitive to puromycin and 
that the transduction had not been successful. 
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Figure 4.22 Transduction of Jurkat A2 cells using co-culture method
Lenti-X 293T cells were transfected with the mutated TCR DNA containing NLV (A) and 
DYSN (B) and after 72 hours 1x106 Jurkat-A2 cells were added to the flask. The co-culture 
was incubated for 48 hours and Jurkat-A2 cells were removed after 48 hours and stained 
with either an isotype control (A-B blue) or an anti-TCRVβ7 antibody conjugated with 
phycoerythrin (A-B green). Untransduced cells (A-B red) acted as negative controls 
throughout.  The cells were washed and analysed by flow cytometry with standard Jurkat-
A2 cells stained with the antibody as control. 
A B
Untransduced
NLV DYSN
Untransduced
Isotype Isotype
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4.15 Discussion 
In this chapter, the hypothesis tested was that there is no peripheral tolerance towards 
CDR3-derived peptides. Therefore in an HLA-A2
+
 donor, peptides binding to HLA-
A2 would need to be removed to prevent the possibility of T cells expressing the 
CDR3-derived peptides at the cell surface and generating an autoimmune reaction. In 
this scenario, an HLA-A2
-
 donor would not need to remove any HLA-A2 binding 
peptides as they would not contain the HLA-A2 molecule required to present the 
peptide at the cell surface. If immunoediting does occur in the T cell repertoire, HLA-
A2
+
 donors would exhibit a decreased frequency of HLA-A2 binding peptides within 
the CDR3 compared with those from HLA-A2
-
 donors.  
 
The results for HLA-A2 demonstrated an increased frequency of CDR3-derived 
nonamer peptides in HLA-A2
+
 donors compared with HLA-A2
-
 donors, suggesting 
the original hypothesis is false. This suggests that there is no immunoediting process 
in the T cell repertoire and therefore suggests that there is peripheral tolerance 
towards these peptides that would prevent induction of an immune reaction if the 
peptides were expressed at the surface of the T cell and recognised by other CD8
+
 T 
cells. Thus, peptides from the TCR CDR3 are similar to other self-peptides which 
cannot be recognised by self T cells. Similar results were produced when CDR3-
derived decamer peptides predicted to bind to HLA-A2 were investigated. The results 
from this second peptide analysis would appear to validate the initial results. All of 
the peptide prediction analysis was consistent using two different peptide prediction 
algorithms suggesting it is not an artefact of either algorithm. Furthermore, the results 
appear to suggest that there is positive selection of T cells expressing a TCR 
containing an HLA-A2 binding peptide within the CDR3. Therefore, why would 
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TCRs from an HLA-A2
+
 donor containing HLA-A2 binding peptides be selected to 
populate the periphery? One reason may be that memory T cells, those which have 
previously encountered antigen and circulate in the periphery looking for the antigen, 
require periodical stimulation for long-term survival and the presentation of CDR3-
derived peptides by memory T cells are recognised by CDR3-peptide specific T cells. 
The “gentle” stimulation of the memory T cell after being recognised by a CDR3-
specific T cell may provide signals or soluble factors that prevent T cell death. This 
theory has foundations in the idiotype network theory first postulated by Niels Jerne 
in 1974 where the idiotype from each lymphocyte can be recognised by and can 
recognise the idiotype from other lymphocytes. In presenting peptides from their 
CDR3, memory T cells may receive periodical stimulation thereby surviving to 
combat infection.  
 
This is a very significant finding suggesting that there may be a selection process 
during the lifecycle of T cells whereby T cells express self peptides from the CDR3 
and those with a potentially immunogenic peptide are positively selected to survive. 
This selection process in T cells could occur very early on in the maturation process 
of T cells in the thymus during positive and negative selection. At this stage of T cell 
development, there is a lot of T cell death in the thymus, normally attributed to 
positive and negative selection, and the 3
rd
 selection process suggested here could 
take place at the same time.  
 
Similar results were also seen in two further HLA alleles tested (HLA-A1 and -B7) 
with HLA-B8 being the only allele tested to produce different results. The results for 
HLA-A1 and -B7 suggest that the selection of TCRs containing HLA-binding 
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peptides is not restricted to HLA-A2 only and therefore gives some credibility to the 
results. However the results for HLA-B8 suggest that the original hypothesis is true, 
that there is immunoediting of the T cell repertoire, as there is a decreased frequency 
of peptides found with the CDR3 sequence from HLA-B8
+
 donors compared with 
HLA-B8
-
 donors. It is unlikely that there is positive selection of TCRs in certain HLA 
alleles and editing of TCRs in other HLA alleles dependent on the sequence of the 
CDR3. Therefore, these results suggest that either the results from HLA-B8 are wrong 
in some way or the results from all of the other alleles tested are wrong. If this were 
the case, the computer algorithms would likely be the problem but the ROC analysis 
for all of the alleles gave similar results and suggests that there are no problems with 
either algorithm for any of the HLA alleles. If the results from the HLA-B8 allele are 
wrong, this may be due to the lack of lysine and/or methionine amino acid residues 
within the CDR3 which are often found in peptides that are predicted to bind to HLA-
B8. If this is the case, the selection process dependent on the CDR3 may be HLA 
allele specific due to the lack of certain amino acids within the CDR3. 
 
After discovering that TCRs from HLA-A2
+
 donors contain an increased frequency of 
HLA-A2 binding peptides, work began to generate an immune response against a 
CDR3-derived peptide from a T cell clone. Previous studies have shown T cell 
responses towards cutaneous T cell lymphoma (CTCL) cells (Bagot et al., 1998). 
However, there has been very little studying the presentation of CDR3-derived 
peptides on the surface of the T cell with Berger et al., 1998 demonstrating the 
potential presentation and CTL response towards a CDR3-derived peptide. After 
generating a naïve T cell response, the hypothesis tested was: peptides contained 
within the CDR3 of TCRs are processed by the MHC class I processing pathway and 
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presented at the cell surface. There was a possibility that the non-self nature of the 
TCR CDR3 would mean that the TCR would be specifically excluded from the MHC 
processing pathways by the cell to prevent the presentation of potentially 
immunogenic peptides. However, results showed that the parental T cell clone could 
be recognised by the peptide-specific T cells generated suggesting that the CDR3-
derived peptide can be processed and presented by HLA-A2 at the cell surface, 
meaning that the hypothesis was true.  
 
However, the results from the experiment were not without problems shown by the 
lack of response towards the positive control peptide-pulsed Jurkat-A2. These cells 
should give a strong IFN-γ response because the peptide should be presented by the 
MHC class I molecules on the surface of the cells but there is a decrease in the IFN-γ 
produced. This is unusual as previous results demonstrated the specificity of the ALC-
specific T cells when the targets were peptide pulsed LCLs. The failure of the positive 
control casts some doubt on the results because essentially the positive control hasn‟t 
worked, it may be explained by the fact that the peptide contains a cysteine which 
could dimerise and alter the recognition of the peptide. There is a possibility that the 
peptide used to generate the T cell clone, and the one present on the ELR specific T 
cell clone, is the reduced peptide whereas the peptide used for the IFN-γ co-culture 
experiment had become oxidised. This would explain why the ALC-specific T cells 
can recognise the ELR T cell clone with the endogenously processed and presented 
ALC peptide but they cannot recognise the exogenously peptide pulsed LCLs. The 
other controls placed in this experiment have shown that there is not a non-specific 
release of IFN-γ in the culture. 
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If the results from the T cell co-culture are true, then not only are the TCRs selected 
so there are more HLA-binding peptides contained within the CDR3, these peptides 
appear to be presented at the cell surface. The expression of these non-self or foreign 
protein peptides further suggest that there is some form of peripheral tolerance 
towards these peptides as theory dictates that they could initiate an autoimmune 
reaction if they are recognised by functional CD8 T cells. Expression of these 
peptides at the cell surface may be a natural part of the processing and presentation of 
self proteins on the cell surface. However, it may be a specific process to present 
CDR3-derived peptides in order to fulfil the immune network theory as described 
previously. The results described here agree with Winter et al., 2003 suggesting that 
CDR3-derived peptides are presented on the surface of T cells.  
 
In order to determine the antigen processing and presentation pathway the TCR 
enters, a model was designed to investigate this. A T cell receptor β-chain was 
mutated to contain known viral peptides within the CDR3 and expressed in a T cell 
line where it could pair with the endogenous α-chain and be expressed at the cell 
surface. Introduction of the mutated TCR into cells did demonstrate the ability of the 
mutated TCR to be expressed at the cell surface. This is a very important result as 
mutation of the TCR could have caused mis-folding and aggregation of the protein, 
preventing pairing of the introduced TCR β-chain with an endogenous α-chain. A 
lentiviral system was set up and, after this method showed long-term stable 
transduction of GFP, was used to transduce Jurkat-A2 cells with the mutated TCRs. 
Standard transduction of Jurkat A2 cells produced poor results with less than 1% of 
cells expressing the TCRVβ7 on the cell surface. Co-culture transduction increased 
the percentage of cells transduced to 6-8%. However, antibiotic selection using 
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puromycin to select positively transduced cells failed to increase the percentage and 
there were no cells alive after 7 days selection. Therefore suggesting that the 
transduction had been transient in nature and had not produced stable integration of 
the protein into the cell genome.  
 
4.16 Conclusion 
In this chapter, the hypothesis that there was no peripheral tolerance towards CDR3-
derived peptides from the TCR and therefore there was the requirement of 
immunoediting of the T cell repertoire to prevent an autoimmune reaction was proven 
false in healthy donors. There was an increased frequency of HLA-binding peptides in 
HLA-positive donors compared with HLA-negative donors analysing the CDR3 for 
nonamer and decamer peptides. A naïve T cell response was generated to a CDR3-
derived peptide which, when cultured with the parental T cell clone, produced an 
IFN-γ response demonstrating the presentation of CDR3-derived peptides at the 
surface of the T cell. An attempt was made to generate a model to study antigen 
processing of CDR3-derived peptides using mutated TCRs containing viral peptides. 
Cells could express the mutated TCRs after lentiviral transduction but the expression 
was lost after only a few days. Repeated attempts to transduce and select the cells 
using antibiotics proved fruitless. 
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5. Antigen Processing and Presentation 
of Peptides Tagged to Antibodies 
 
 
5.1 Introduction 
Work presented in chapter 3 demonstrated that the CDR3 of surface immunoglobulin 
are deficient in HLA-A2 binding peptides in HLA-A2
+
 donors when compared to 
HLA-A2
-
 donors suggesting that there may be an underlying immunoediting process. 
The physiological basis for this potential immunoediting is unclear nor is it clear why 
any editing should exist or why it is only observed in the antigen receptors within the 
B cell compartment and not the T cell compartment.  Some aspects relating to these 
questions are explored further in this chapter. 
 
One key difference between the B cell antigen receptor in contrast to their T cell 
receptor counterparts is that they are secreted in the form of soluble antibodies and 
thus gain access to all tissue compartments.  Moreover, antibodies serve to bind and 
capture antigens, and through interactions with complement and Fc receptors have 
direct access to antigen presenting machinery and thus ideally positioned for T cell 
recognition. 
 
Here it is postulated that there are two theoretical adverse consequences of not editing 
the CDR3 repertoire of B cell antigen receptors.  Both of these are the result of the 
enormous antigenic diversity of the BCR. Firstly, the secretion of an unedited diverse 
antibody repertoire may lead to the development of autoimmune disease in the case 
where a small proportion of antibodies contain, by chance, sequences which are 
identical or very similar to pathogen immunodominant epitopes. In this case T cells 
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would have the potential to destroy bystander cells which uptake antibodies bearing 
epitopes which are close or identical to immunodominant pathogen-derived epitopes. 
Secondly, a competing hypothesis may suggest the reverse: that maintaining 
peripheral tolerance to the entire secreted antibody-derived proteome may abrogate or 
compromise the T cell repertoire by inducing an anergic T cell repertoire or cause 
large-scale deletion of circulating naive T cells. The diversity of lymphocyte receptors 
can be potentially dangerous (previously discussed chapter 1.14) and maintaining 
peripheral tolerance to the antibody-derived proteome may have consequences for the 
ability of T cells to recognise all foreign antigens. 
 
It is difficult to experimentally test each of these hypotheses, but both require 
antibodies as antigens to be efficiently processed and recognised by T cells. 
Therefore, an experimental model was developed whereby antibodies were 
constructed containing immunodominant T cell epitopes.  Due to other work 
performed in the laboratory, T cells specific for cytomegalovirus were readily 
accessible and had been well characterised providing an ideal opportunity to assess 
the immunological consequences of antibodies which contain immunodominant viral 
epitopes. 
 
5.2 Developing a model of peptide-conjugated antibodies 
Initially, a simple model was explored to test whether antibodies bearing 
immunodominant viral T cell epitopes could stimulate cognate T cell responses in 
vitro.  It was reasoned that the position of the viral peptide epitope may not be 
important, as the proteolytic machinery employed in both Class-I and Class-II antigen 
processing pathways lacks location-specificity.  Moreover, some immunoglobulin 
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derived HLA-restricted peptides which have been characterised are derived from the 
multiple regions spanning both heavy and light immunoglobulin chains.   
 
The heterobifunctional molecule sulpho-SMCC was employed to link synthetic 
peptides to antibodies. Sulpho-SMCC contains both an amine-reactive succinimide 
group and a sulphydryl-reactive maleimide group (Figure 5.1) providing a mechanism 
to link cysteine extended peptides to free primary amine groups of the antibody in a 
random manner.  The NHS ester on the sulpho-SMCC reacts with free primary amine 
groups found on lysine residues and the amino terminus of the antibody polypeptide.  
 
The position of the cysteine within the peptide was chosen to limit the susceptibility 
of the peptide-antibody complex to carboxypeptidases present in the cell culture 
media and indeed for future in vivo experiments.  Therefore, by linking the peptide at 
the C-terminus to the antibody would render the antibody-peptide complex resistant to 
carboxypeptidases through steric hindrance. The chemistry used in the peptide 
conjugation is well known and has been used in many previous publications (Walker 
et al, 1995 & Patri et al., 2004).  
 
5.3 Rituximab as a model of antibody-antigen processing. 
Rituximab was used for the initial peptide-conjugations due to its wide therapeutic 
application, and therefore potential future therapeutic use, in the treatment of B cell 
leukaemia and lymphoma.  Rituximab was initially conjugated with the HLA class-I 
CMV peptide NLVPMVATV (Wills et al., 1996) and elongations of this peptide 
(Table 5.1). In order to determine the presence of peptides conjugated to the antibody,  
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Figure 5.1 Mechanism of action of sulfo-SMCC to conjugate a cysteinylated peptide 
to a carrier/antibody
The amine-reactive NHS ester group links sulfo-SMCC to free amine groups on the 
antibody to give the malemide-activated antibody. Addition of a cysteinylated peptide allows 
linkage of the peptide to the malemide group on the sulfo-SMCC via the sulfhydryl group 
from the cysteine residue.  
 
HLA Class I HLA Class II
NLVPMVATVC DYSNTHSTRYVC
RNLVATVPMVC DDYSNTHSTRYVC
RNLVATVPMVQC DDYSNTHSTRYVTC
ARNLVPMVATVC PDDYSNTHSTRYVC
LARNLVPMVATVC IPDDYSNTHSTRYVC
Biotin-EPFRPHERNGFTVL LIPDDYSNTHSTRYVC
Biotin-LIPDDYSNTHSTRYVC
Table 5.1 HLA class I and class II peptides used for conjugation to antibodies
The antibodies were conjugated with the peptides via the cysteine group at the C terminus 
of the peptide. Biotinylated peptides were used to assess the conjugation of peptide to 
antibody using a biotinylation ELISA.  
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a biotinylated peptide was first used to confirm binding of peptide to antibody and a 
readout given by ELISA.  Indeed, Rituximab conjugates bound to plates were shown 
to contain biotin groups confirming successful conjugation using this 
heterobifunctional cross-linking approach (Figure 5.2). This was repeated on multiple 
occasions to ensure the reliability of the protein chemistry. After conjugation of 
peptides, cell labelling was undertaken to determine whether the antibody retained its 
ability to bind to its cellular receptor. Peptide-conjugated Rituximab was shown to 
bind to target cells with a similar frequency as commercial anti-CD20, therefore 
demonstrating that conjugation of peptides does not affect antibody binding. 
 
5.4 T cell recognition of processed peptide-antibody  
B cell LCLs were used as target cells firstly because they express CD20 and secondly 
as professional antigen presenting cells, they can present both class-I and class-II 
peptides on their surface although it has been shown previously that these cells are 
inefficient at cross-presenting exogenous antigens on MHC class-I molecules (Münz 
et al., 2000).  
 
The incubated cells were cultured with peptide-specific CD8
+
 T cells and IFN-γ 
production assayed by ELISA. The initial results for HLA class-I peptides (Figure 
5.3) were very disappointing as there appeared to be no recognition of target cells by 
the effector T cells. The effector T cells were specific for the peptide seen in the 
positive control where cells pulsed with exogenous peptide were recognised very 
strongly, seen by a large increase in the production of IFN-γ.  There was no 
recognition towards any of the peptides tested including those with the elongated 
carboxy and amino termini.  After the poor results seen with the HLA class-I peptides,  
 214 
D
M
SO
B
-R
PH
D
D
YS
_T
PD
D
YS
 1
PD
D
YS
 2
PB
S
0.0
0.5
1.0
1.5
2.0
2.5
A
b
s
o
rb
a
n
c
e
 (
4
5
0
n
m
)
Figure 5.2 Biotinylation ELISA to determine presence of biotinylated peptides 
conjugated to antibody
Peptide-conjugated antibodies were coated to a plate and tested for the presence of biotin. 
Extravidin-peroxidase was added to the wells and TMB used to provide a colour change if 
biotin is present in the well. The plate was read at 450nm using GloMax plate reader.
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Figure 5.3 IFN-γ Recognition of target cells stained with the HLA class I peptide 
conjugated CD20 antibody (Rituximab)
Target cells were stained with Rituximab conjugated with class I peptides (NLV - LARNLV) 
or unconjugated (Rituximab) and used to stain target LCLs. The antibody was washed off 
and the target cells were incubated overnight at 37°C. Peptide-specific CD8 T cells were 
added (E:T ratio – 1:5) and incubated overnight with the supernatant taken to assay for 
IFN-γ production by ELISA. Control wells containing unpulsed target cells (LCL), and T 
cells cultured alone (T cells only) were used to demonstrate that there was no spontaneous 
or non-specific release of IFN-γ. Peptide pulsed target cells cultured with peptide specific T 
cells (pLCL) were used to demonstrate the ability of the target cells to present the NLV 
peptide. Error bars demonstrate mean + standard error mean, n=3. Data was analysed 
using unpaired t-test to determine statistical significance.
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Rituximab was then used for conjugation with an HLA class-II peptide (Table 5.1), a 
DRβ01*07 restricted CMV peptide (Crompton et al, 2008), with similar elongations 
of the carboxy and amino termini as used in the class-I peptides.  After confirming 
conjugation efficiency, LCLs were incubated with the peptide-antibody conjugates.  
Similarly to the HLA class-I peptide-conjugated Rituximab, there was no recognition 
of any of the cells bound by peptide-antibody complexes by the effector T cells after 6 
hours (Figure 5.4).  There was strong recognition of the exogenously peptide pulsed 
LCLs as positive control (1500pg/ml), demonstrating that the CD4
+
 T cells used in the 
assay are functional.  It was thought that this result may be due to the inability of cells 
to internalise Rituximab as previously described (Einfeld et al, 1988).  Therefore, in 
order to re-test the hypothesis, an antibody that is known to internalise was used. 
 
5.5 BU69 as a model of antibody-antigen processing  
BU69 is an anti-CD70 antibody and is internalised rapidly after binding (Israel et al., 
2005 & Adam et al., 2006).  It was one of the antibodies produced in our laboratory 
and CD70 is present on the surface of B cells from various B cell lymphomas 
including ~50% CLL and 33% Follicular lymphoma (Israel et al., 2005). The HLA 
class-I and class-II peptides were attached to the BU69 antibody using the same 
method as previously described and the conjugation was confirmed by ELISA (data 
not shown).  Cell lines from our stocks were incubated with CD70 using a 
commercial antibody to determine surface expression (Figure 5.5 A,B). The LCLs 
stained ~99% positive for anti-CD70 using the commercial antibody and also >85% 
positive when using the biotinylated peptide conjugated to BU69 confirming 
biological reactivity post conjugation. 
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Figure 5.4 IFN-γ recognition of target cells stained with HLA-class II peptide 
conjugated Rituximab 
Target cells were stained with Rituximab conjugated with class I I peptides (DYS1 -
IPDDYSN), control peptide (B-RPH) or unconjugated (DMSO) and used to stain target 
LCLs for 30 minutes. After washing off the antibody, the LCLs were incubated overnight 
before addition of peptide-specific CD4 T cells (E:T ratio 1:5) for 6 hours. The supernatant 
was assayed for IFN-γ production by ELISA. Control wells containing peptide pulsed target 
cells without T cells (Pep pulse only), unpulsed target cells (Untreated only), and target 
cells cultured with peptide-specific T cells (Untreated + T) were used to demonstrate that 
there was no spontaneous or non-specific release of IFN-γ. Peptide pulsed target cells 
cultured with peptide specific T cells (Pep pulse + T) were used to demonstrate the ability 
of the target cells to present the DYSN peptide. Error bars demonstrate mean + standard 
error mean, n=3. Data was analysed using unpaired t-test to determine statistical 
significance.
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Figure 5.5 IFN-γ recognition of target cells stained with HLA-class I peptide 
conjugated BU69 (anti-CD70)
LCLs were stained with commercial anti-CD70 FITC (A) and BU69 conjugated with 
biotinylated peptide (B) for 30 minutes and washed. Streptavidin-PE was added to the 
BU69 antibody and incubated for 30 minutes, washed and analysed on the flow cytometer. 
Target cells were stained with CD70 conjugated with class I peptides (NLV - LARNLV), 
control peptides (His-RPH and Biotin-RPH) or unconjugated (SMCC & DMSO) for 30 
minutes and washed before being incubated overnight. T cells were added (E:T ratio – 1:5) 
and the cell culture incubated overnight before removal of the supernatant to test for 
production of IFN-γ by ELISA (C). Control wells containing T cells cultured alone (T cells 
only), unpulsed target cells (LCL only), and target cells cultured with peptide-specific T cells 
(LCL + T cells) were used to demonstrate that there was no spontaneous or non-specific 
release of IFN-γ. Peptide pulsed target cells cultured with peptide specific T cells (pLCL + T 
cells) were used to demonstrate the ability of the target cells to present the DYSN peptide. 
Error bars demonstrate mean + standard error mean, n=3. Data was analysed using 
unpaired t-test to determine statistical significance * P<0.05, ** P<0.01 and *** P<0.001. 
**
***
*
C
A B
CD70
Streptavidin-PE only
Biotin-RPH conjugated BU69 + 
Streptavidin-PE only
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5.5.1 MHC class-I peptide conjugation 
LCLs were incubated with the BU69 tagged with class-I peptides and cultured with 
peptide-specific CD8
+
 T cells.  There was an IFN-γ response to 3 of the 7 peptides 
tested (Figure 5.5 C). The strongest response was seen with extended peptide 
conjugates, RNLVPMVATVQ and ARNLVPMVATV.  There was no response to the 
BU69 conjugated to irrelevant peptides (RPH) or unconjugated (DMSO) confirming 
responses seen as peptide specific.  Although the IFN-γ responses to the peptide-
tagged BU69 were significantly decreased compared to the IFN-γ response towards 
the peptide-pulsed LCLs (positive control), they are significantly increased against the 
background IFN-γ response. These data suggest B cells can internalise antibody-
bound surface membrane proteins and present the antibody-derived peptide in 
complex with HLA class-I.  
 
5.5.2 MHC class-II peptide conjugation 
After this encouraging result LCLs were assessed for their capacity to present 
antibody-derived HLA class-II restricted peptides.  As expected, there was no 
increase in IFN-γ production when target cells were incubated with BU69 conjugated 
with an irrelevant peptide or without a peptide. However, there was an increase in 
IFN-γ production to 6 of the 7 class-II viral derived peptide antibody conjugates 
(Figure 5.6), with the only peptide not producing an IFN-γ response being the 
naturally processed peptide which had been cysteinylated (DYSNTHSTRYVC). 
Similarly to BU69 conjugated with HLA class-I peptides, the strongest response was 
seen when the cells were incubated with the BU69 conjugated with the peptide which 
had been extended by one amino acid at both ends, (DDYSNTHSTRYVT).  The 
target cells pulsed with exogenous peptide (DYSN) produced a large IFN-γ response  
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Figure 5.6 IFN-γ recognition of target cells stained with HLA-class II peptide 
conjugated BU69 (anti-CD70)
LCLs were stained with BU69 conjugated with class II peptides (LIPDDYS - IPDDYS), 
control peptides (H-RPH and B-RPH) or unconjugated (SMCC and DMSO) for 30 minutes 
and washed before being incubated overnight. T cells were added (E:T ratio – 1:5) and the 
cell culture incubated overnight before removal of the supernatant to test for production of 
IFN-γ by ELISA. Control wells containing peptide pulsed target cells without T cells (pLCL
only), unpulsed target cells (LCL only), T cells cultured alone (T cell only) and target cells 
cultured with peptide-specific T cells (LCL + T cells) were used to demonstrate that there 
was no spontaneous or non-specific release of IFN-γ. Peptide pulsed target cells cultured 
with peptide specific T cells (pLCL + T cell) were used to demonstrate the ability of the 
target cells to present the DYSN peptide. Error bars demonstrate mean + standard error 
mean, n=3. Data was analysed using unpaired t-test to determine statistical significance * 
P<0.05, ** P<0.01 and *** P<0.001. 
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whereas the target cells which were not pulsed with peptide did not produce any IFN-
γ above the background, confirming the peptide-specificity of the CD4+ T cells. 
Similarly to the class-I peptide results, the amount of IFN-γ produced by recognition 
of the cells incubated with the peptide-conjugated BU69 was lower than the peptide-
pulsed LCLs (positive control).  The large increase in IFN-γ suggests that the LCLs 
can process and present MHC class-II peptides linked to the antibody possibly in the 
classical HLA class-II antigen processing pathway. Taken together, these results 
suggest that the earlier hypothesis is true and that peptides conjugated to antibodies, 
subsequently internalised after binding to B cells, can be processed and presented in 
complex with both MHC class-I and class-II.  
 
5.5.3 Free, unconjugated peptide binds to cellular MHC 
During these first few experiments to attach peptides to an antibody, HiTrap desalting 
columns were used to remove excess sulpho-SMCC and excess peptide from the 
peptide-conjugated antibody.  However, it was critical to confirm that the excess 
peptide was completely removed using the desalting column.  If the column was not 
separating the peptide from the antibody-peptide complex, there was the possibility 
that the results seen previously were due to excess peptide binding to surface MHC on 
the target cells and not due to the peptide-conjugated antibody.  Therefore, the 
hypothesis tested was that the recognition of target cells by peptide-specific T cells 
was due to the internalisation of the complex and the processing and presentation of 
the peptide by the target LCL. In order to test this hypothesis, peptides were 
conjugated to the antibody in the presence or absence of sulpho-SMCC.  In order to 
conjugate the peptide to the antibody, the antibody must be activated with sulpho-
SMCC first. If there is no SMCC attached to the antibody, consequently there would 
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be no peptide conjugated to the antibody (Figure 5.1).  The IFN-γ recognition assay 
was repeated with target LCLs incubated with antibody conjugated with peptides in 
the presence or absence of SMCC.  The peptide PDDYS was used as this had 
previously shown a large response.  There was a large increase in IFN-γ release when 
LCLs were incubated with the antibody conjugated to the peptide without SMCC 
compared with the background release (Figure 5.7).  This was presumed to be excess 
cysteinylated peptide, which hadn‟t been removed during the purification step, 
binding to the surface MHC molecules on the LCLs which could then be recognised 
by the T cells, therefore bypassing the antibody conjugation that was being 
investigated.  This suggests that the HiTrap desalting column was not effective at 
removing excess peptide and that the responses seen are due to the excess peptide.  
This may relate to the chromatographic properties of the G25 Superdex
®
 utilised for 
the separation which has a globular exclusion limit of 5,000Da close to the size of any 
disulphide linked peptide dimers which may have formed through peptide oxidation. 
 
However, when the target cells were incubated with the antibody conjugated to the 
peptide in the presence of SMCC, there was further increased IFN-γ release seen 
when compared with that from the conjugation in the absence of sulpho-SMCC. The 
results seen with the antibody conjugated in the presence of SMCC demonstrate an 
increased IFN-γ response compared to the results with the antibody conjugated to 
peptide in the absence of SMCC, which would appear to suggest that the peptide 
conjugated to the antibody is processed and presented by the LCLs. 
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Figure 5.7 IFN-γ recognition of target cells stained with HLA-class II peptide 
conjugated BU69 (anti-CD70) in the presence and absence of sulfo-SMCC
The class II peptide PDDYSN was conjugated to antibodies in the presence and absence 
of sulfo-SMCC.  BU69 conjugated with PDDYSN (PDDYSN) or unconjugated (DMSO) was 
used to stain target cells for 30 minutes. After washing, the target cells were incubated 
overnight. The cells were then cultured with peptide-specific T cells (E:T ratio 1:5) overnight 
and the supernatant assayed for IFN-γ production by ELISA. Control wells containing 
peptide pulsed target cells without T cells (pLCL only), unpulsed target cells (LCL only), T 
cells cultured alone (T cells only) and target cells cultured with peptide-specific T cells (LCL 
+ T cells) were used to demonstrate that there was no spontaneous or non-specific release 
of IFN-γ. Peptide pulsed target cells cultured with peptide specific T cells (pLCL + T cells) 
were used to demonstrate the ability of the target cells to present the DYSN peptide Error 
bars demonstrate mean + standard error mean, n=3. Data was analysed using unpaired t-
test to determine statistical significance .** P<0.01 and *** P<0.001.
**
***
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5.6 Selective affinity chromatography purification 
In order to purify the antibody and remove the excess peptides present, the antibodies 
were purified using more selective affinity chromatography using protein G columns 
instead of the desalting columns. HLA class-II peptides were conjugated to BU69 in 
the presence or absence of SMCC and purified using protein G columns. The peptide-
antibody conjugates were then used to label target cells. The IFN-γ release by T cells 
cultured with the peptide conjugated to PDDYS in the presence of SMCC was 
increased in comparison with the peptide conjugated to antibody in the absence of 
SMCC which was similar to the background level (Figure 5.8). The cells incubated 
with BU69 either conjugated to an irrelevant peptide or unconjugated produced very 
low levels of IFN-γ (~100pg/ml). These results demonstrate that the production of 
IFN-γ is specific only for peptide conjugated to BU69 and the IFN-γ response is not 
due to excess peptide binding to HLA class-II on the surface of the B cells and being 
recognised by the T cells. This demonstrates that the purification of the peptide-
antibody conjugates is very efficient when using the Protein G chromatographic 
methods.  As a direct result of this, all subsequent conjugations of peptide to antibody 
were purified using the protein G columns. 
 
5.7 Purified BU69 as a model of antibody-antigen processing 
The above results seen with purification of class-II peptides conjugated to BU69 
appears to cast doubt over the initial results seen with BU69 conjugated with the 
class-I peptides (Figure 5.5). Therefore, class-I peptides were again conjugated to 
BU69 but purified using the protein G column instead of the desalting columns. The 
previous experiment was repeated, labelling the LCLs with the new peptide-antibody 
conjugates and culturing them with the T cells. There was no increase in IFN-γ  
 224 
D
M
SO
 - 
SM
C
C
D
M
SO
 +
 S
M
C
C
PD
D
YS
N
 - 
SM
C
C
PD
D
YS
N
 +
 S
M
C
C
LC
L
pL
C
L
0
500
1000
1500
IF
N
-y
 (
p
g
/m
l)
Figure 5.8 IFN-γ recognition of target cells stained with HLA-class II peptide 
conjugated BU69 (anti-CD70) purified using protein-A columns
Peptides were conjugated to antibodies in the presence and absence of sulfo-SMCC 
and excess peptide was removed using protein A columns. Target cells were stained 
with the BU69 conjugated to class II peptide (PDDYSN) or unconjugated (DMSO) for 30 
minutes, washed and the cells incubated overnight. Peptide-specific T cells were added 
to the stained cells (E:T ratio - 1:5) and the cells incubated for 6 hours before the 
supernatant was taken to test for IFN-γ by ELISA. Control wells containing unpulsed 
target cells (LCL), were used to demonstrate that there was no spontaneous or non-
specific release of IFN-γ. Peptide pulsed target cells cultured with peptide spefcific T 
cells (pLCL) were used to demonstrate the ability of the target cells to present the DYSN 
peptide. Error bars demonstrate mean + standard error mean, n=3. Data was analysed 
using unpaired t-test to determine statistical significance *** P<0.001. 
***
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production after 6 hours by CD8 T cells towards any of the cells incubated with the 
peptide-antibody conjugates (Figure 5.9). These data suggest that the HLA class-I 
peptides are not efficiently processed and presented by the B cell following antibody 
internalisation and that the previous results were due to excess peptide carry-through 
when using the desalting columns and highlights the importance of employing the 
correct downstream purification steps in separating free peptide from antibody-
peptide complex.  The CD8 T cells were functional as they did strongly recognise and 
produce IFN-γ in response to the exogenously peptide-pulsed LCLs.  These results 
suggest that the HLA class-II restricted epitopes can be cleaved from the antibody and 
processed as a normal exogenous protein whereas the HLA class-I peptides, which 
may need to cross from the endosome to the cytosol, cannot be processed.  
 
All of the previous results suggest that the class-II peptides conjugated to BU69 are 
processed by the target cell and presented to the peptide-specific CD4 T cells. 
However, in order to confirm that the target cells are processing the peptide, the 
antigen processing pathway of incubated cells was investigated using various antigen 
processing inhibitors to try to determine the pathway by which the peptide is 
processed. 
 
5.8 Inhibitory analysis of antigen processing and presentation  
The antigen processing of the class-II peptide conjugated to an antibody leads to 
presentation of the peptide on the surface of the target cell.  It is yet to be ascertained 
how the peptide conjugated to the antibody is processed and therefore the hypothesis 
tested was that the class-II peptide is processed in the classical class-II processing 
pathway after binding to target cells.  Labelled cells were cultured with 3-
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Figure 5.9 IFN-γ Recognition of target cells stained with HLA-class I peptide 
conjugated BU69
HLA class I peptides were conjugated to BU69 and purified using the protein G column to 
remove excess peptide. Target LCLs were stained with BU69 conjugated with class I 
peptides (RNLV_Q & ARNLV) or unconjugated BU69 for 30 minutes and washed before 
being incubated overnight. The target cells were then cultured with peptide-specific T cells 
(E:T ratio 1:5) and the supernatant assayed for IFN-γ production after 6 hours by ELISA. 
Control wells containing peptide pulsed target cells without T cells (Pep pulse only), 
unpulsed target cells (Untreated only), and target cells cultured with peptide-specific T cells 
(Untreated + T) were used to demonstrate that there was no spontaneous or non-specific 
release of IFN-γ. Peptide pulsed target cells cultured with peptide spefcific T cells (Pep 
pulsed + T) were used to demonstrate the ability of the target cells to present the NLV 
peptide. Error bars demonstrate mean + standard error mean, n=3. Data was analysed 
using unpaired t-test to determine statistical significance.
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methyladenine (an inhibitor of autophagy), chloroquine (inhibits lysosomal 
acidification), pepstatin (an inhibitor of aspartyl proteases), lactacystin (a proteasome 
inhibitor), leupeptin (a thiol protease inhibitor) and monensin (disrupts the golgi 
complex and inhibits transport to the plasma membrane) overnight before addition of 
peptide-specific T cells.  The inhibitors were washed off prior to addition of the T 
cells as there was a possibility that the inhibitors may affect the actions of the T cells 
as well as those of the target cells. If this did occur, there may have been a reduction 
in IFN-γ production due to the inability of the T cells to release IFN-γ and not because 
antigen processing in the target cells is being inhibited. The media was assayed after 6 
and 24 hours to determine if there was a reduction in IFN-γ production after culture 
with any of the inhibitors.  
 
Similar to previous results, there was a large increase in IFN-γ production after 6 
hours when the target cells were incubated with the BU69 conjugated to the class-II 
peptide whereas there was no IFN-γ production with the unconjugated BU69 (Figure 
5.10 A). When target cells were incubated overnight in media supplemented with 
pepstatin, 3-methyl adenine or lactacystin there was no difference in the production of 
IFN-γ compared with the untreated cells.  This would suggest that the processing of 
the peptide-antibody conjugate is not autophagy, aspartyl proteases or proteasome 
dependant.  There was a small decrease in the production of IFN-γ when the target 
cells were cultured with leupeptin, demonstrating that the antigen processing of 
peptide-conjugated BU69 is partly dependent on thiol proteases. After cells were 
cultured with media supplemented with chloroquine, there was a significant decrease 
in the production of IFN-γ compared with the untreated cells. This result demonstrates  
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Figure 5.10 IFN-γ production by T cells cultured with target cells stained with 
PDDYS-conjugated BU69 and cultured with antigen processing inhibitors
LCLs were stained with either PDDYS-conjugated BU69 or unconjugated BU69, washed 
and cultured overnight in the presence of antigen processing inhibitors.  After washing, the 
cells were cultured with peptide-specific T cells (E:T ratio - 1:5) for 6 hours (A) and 24 
hours (B) before the supernatant was taken to assay for IFN-γ production. Error bars 
demonstrate mean + standard error mean, n=3. Data was analysed using unpaired t-test to 
determine statistical significance ** P<0.01 and * P<0.05.
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the antigen processing of the peptide-antibody conjugate is dependent on lysosomal 
function.  There was also a significant decrease in the production of IFN-γ when the 
cells were cultured with monensin demonstrating that the processing of the antibody-
peptide conjugate is reliant on passage through the golgi complex to the cell surface.   
 
After 24 hours, the cells incubated with peptide-conjugated BU69 and cultured 
without any antigen processing inhibitors produced IFN-γ compared with those cells 
incubated with the unconjugated BU69 (Figure 5.10 B). When the cells were treated 
with either lactacystin or pepstatin there was only a small reduction in T cell 
recognition.  There was a larger inhibitory effect using leupeptin and 3-methyl 
adenine but the largest decrease was observed using chloroquine.  Paradoxically, 
when the cells were cultured in the presence of monensin, there was an increase in  T 
cell recognition.  
 
It is important to stress that for both the 6 hour and 24 hour studies, after addition of T 
cells the rest of the experiment was performed in the absence of the inhibitors. These 
results suggest that the activity of either chloroquine or leupeptin is not fully 
reversible as the effects are still seen 24 hours after removal of the inhibitor. 
However, the activity of monensin is reversible as there is an increased production of 
IFN-γ at 24 hours compared with that after 6 hours. Interestingly, the increased 
production at 24 hours is increased compared with the untreated control suggesting an 
accumulation of antigenic cargo in the golgi rather than removal.  
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5.9 Response to antibody complex using blocking antibody 
The previous results have demonstrated T cell recognition of target cells which have 
been incubated with peptide-conjugated antibody. In order to confirm that the 
peptides are presented on HLA class-II molecules at the cell surface, the cells were 
also incubated with an antibody to block all HLA-DR molecules on the surface of the 
target cell. The blocking antibody is specific for all HLA-DR alleles and therefore 
will block HLA-DR7 (the allele which presents the DYSN peptide) as well as the 
other HLA-DR allele present in the target cells. If there is a reduction in the amount 
of IFN-γ produced when the blocking antibody is used, this would suggest that the 
peptide is presented by HLA-DR. However, if there is no difference in the amount of 
IFN-γ produced, this would suggest that the peptide is being presented by another 
HLA class-II allele. Target cells incubated with anti-HLA-DR blocking antibody 
demonstrated ~60% decrease in IFN-γ production (Figure 5.11) confirming that the 
peptide is being presented by HLA-DR molecules on the surface of the target cell 
most likely HLA-DR7 as the T cells used are known to be HLA-DR7 restricted.  
 
5.10 Targeted lysis of peptide-antibody incubated target cells 
5.10.1 CD107 mobilisation assay 
Having demonstrated T cell recognition of peptide-conjugated antibody complexes it 
was important to determine whether they could also kill target cells. Data supporting 
antibody-mediated cytoxicity would provide direct evidence that antibody antigenicity 
could cause tissue cytotoxicity.  To test this hypothesis, T cells were analysed for 
recent degranulation using CD107 mobilisation assay. CD107a/b (LAMP1/LAMP2) 
is found within specialised endosomes containing perforin and granzymes which,  
 231 
 
Figure 5.11 IFN-γ recognition of target cells after blocking with anti-HLA-DR 
antibody
LCLs were stained with BU69 conjugated with class II peptides (DDYS_T & PDDYS), 
control peptide (B-RPH) or without peptide (DMSO). After 30 minutes, cells were washed 
and cultured in the presence or absence of 2μg of anti-HLA-DR blocking antibody 
overnight. The blocking antibody was washed off before addition of peptide-specific T 
cells (E:T ratio - 1:5) and the supernatant was assayed for IFN-γ after 6 hours by ELISA. 
Control wells containing peptide pulsed target cells without T cells (+ pep), unpulsed 
target cells (LCL alone), and target cells cultured with peptide-specific T cells (LCL + T) 
were used to demonstrate that there was no spontaneous or non-specific release of IFN-
γ. Peptide pulsed target cells cultured with peptide specific T cells (+ pep + T) were used 
to demonstrate the ability of the target cells to present the DYSN peptide. Error bars 
demonstrate mean + standard error mean, n=3 Data was analysed using unpaired t-test 
to determine statistical significance *** P<0.001. 
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when released by the T cell, kill the target cell (Trapani & Smyth, 2002) Once the 
cytotoxic granules degranulate, CD107 is subsequently located on the surface 
membrane of the responding T cell and has been demonstrated to be a reliable proxy 
for cell cytotoxicity (Betts et al., 2003). However, CD107 is internalised after cells 
have released their granules and therefore for greater assay performance anti-CD107 
antibodies are added to the cells shortly after the antigen has been added to the T cells 
(Betts & Koup, 2004). 
 
After culturing the T cells with the antibody incubated target cells, the T cells were 
incubated with both CD107a (LAMP1) and CD107b (LAMP 2) in order to see if they 
had recently undergone degranulation. The percentage of cells expressing CD107a/b 
at the surface of the T cells when target cells were incubated with antibody either 
unconjugated or conjugated with an irrelevant peptide was very low, less than 2% 
(Figure 5.12). This confirms that T cells do not recognise and release cytotoxic 
granules towards target cells not expressing the specific peptide.  When the target 
cells were incubated with BU69 antibody conjugated with class-II peptides, there was 
an increase in the percentage of T cells positive for CD107 specific for the peptide, 
which had been conjugated to the antibody (Figure 5.12). The naturally processed 
minimal class-II peptide epitope DYSNTHSTRYV conjugated to the antibody does 
not elicit an IFN-γ response and after labelling with CD107 antibodies and there is 
almost no CD107 labelling on the CD4 T cells either, suggesting that the CD107 
assay is representative of the IFN-γ recognition assay. There is a large increase in 
CD107 labelling, between 10-15%, when target cells were incubated with the 
antibody conjugated with the extended peptides DDYSNTHSTRYVT, 
PDDYSNTHSTRYV, IPDDYSNTHSTRYV and LIPDDYSNTHSTRYV, cultured at  
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Figure 5.12 Determination of cytotoxic function of peptide-specific CD4 T cells using 
CD107 degranulation assay
Cells were stained with BU69 conjugated with HLA class II peptides DYSN - LIPDDYSN), 
control peptide (B-RPH) or unconjugated (DMSO) for 30 minutes, washed and incubated
overnight. The cells were cultured with T cells (without monensin), at two different E:T 
ratios (0.2:1 and 1:1) for 6 hours. After 6 hours the cells were stained with anti-CD107a and 
anti-CD107b antibodies for 30 minutes before being washed and analysed on the flow 
cytometer. Untreated target cells (Untreated) were used as a negative control to show that 
there was no degranulation towards the target cells. Peptide pulsed target cells (Peptide) 
were used as positive control to demonstrate the peptide specificity of the effector T cells.
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the lower E:T ratio. This is slightly lower than the CD107 labelling seen with T cells 
cultured with peptide-pulsed target cells as a positive control, but it is still increased 
in comparison with the background CD107 labelling. Degranulation frequency is 
similar when targets are incubated with T cells at a higher E:T ratio (1:1) but they are 
all decreased compared to the lower E:T ratio. This suggests that the CD107 
expressed at the cell surface has been internalised and degraded before labelling has 
occurred. These results are contradictory to previous results using a similar model of 
anti-CD19 antibody conjugated with tetanus toxin peptides (Eberl et al., 1998) where 
lysis of target cells was shown to be mediated by Fas:FasL and there was an absence 
of perforin-mediated lysis. This may be due to the use of different antibody clones or 
possibly due to the differential effects of using different peptides. 
 
These results correlate with T cell recognition data with the same peptides; they give 
an indication that, as well as being recognised by the CD4
+
 T cells and those specific 
T cells release IFN-γ at a very high concentration, the target cells can also be killed by 
specific T cell granular cytotoxicity.  These results reinforce the view that the slightly 
elongated peptides at both the amino and carboxy termini are better processed by the 
cell than the peptides that are shorter and closer to the naturally processed peptide 
antigen. Although the results suggest that labelling with the antibody-peptide 
conjugate could specifically target cells for CD4 T cell mediated lysis, the results 
need to be repeated using another cytotoxicity assay to validate this data and confirm 
killing. Importantly though, these results demonstrate that an antibody conjugated 
with class-II peptides could potentially target LCLs for specific lysis by the CD4
+
 T 
cells and, if this is true, means that peptide-conjugated antibodies could be used to 
target B cell lymphoma cells.  
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5.10.2 Novel Flow cytometric cell targeting assay 
In an attempt to confirm cytotoxicity, a novel flow cytometric based assay developed 
in our laboratory was employed as a readout of cell targeting.  By using the same 
target cell with peptide (stained with FITC) or without peptide (stained with APC), it 
was possible to determine peptide-specific responses using the decrease in FITC-
stained cells using the flow cytometer. This novel method also removes the possibility 
that responses seen are directed towards peptides naturally expressed by the target 
cells as there should be no decrease in the APC-stained cells.  Target cells were 
separated into 2 tubes, differentially labelled with either FITC or APC conjugated 
anti-CD45 antibodies and analysed using the flow cytometer (Figure 5.13 A-B) and 
the results used for the cell targeting assay (as described in materials and methods 
2.7.3).  
 
Addition of exogenous peptide caused a decrease in the percentage of target LCLs 
(CD45-FITC labelled) without decreasing the percentage of non-target LCLs (CD45-
APC labelled) (5.13 A). The principal of this assay is that it combines differentially 
labelled cell populations in the same well, with one cell population serving as a 
control and another population(s) serving as the target; killing is calculated by the 
reduction of target cells against the number of surviving control cells. 
 
There was little killing of non-target LCLs cultured without peptide after 6 hours 
demonstrating that there was little non-specific cell targeting of the untreated target 
cells (Figure 5.13 B-C). Addition of BU69 without a peptide or with an irrelevant 
peptide (biotin-RPH) did not decrease cell viability demonstrating that the addition of  
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Figure 5.13 Flow cytometry based cell targeting assay following staining with BU69 
conjugated to HLA class II peptides
Target LCLs were stained with one of two different anti-CD45 antibodies, conjugated with 
FITC or APC-H7, for 30 minutes and washed. Target cells stained with CD45-FITC were 
then stained with BU69 conjugated to HLA class II peptides, and the target cells stained 
with CD45-APC-H7 were left untreated. Cells were washed and after overnight incubation, 
the LCLs were washed again and cultured with T cells at two E:T ratios, 5:1 and 1:1. After 
6 hour co-culture, the cells were analysed on the flow cytometer (A-B) to determine the 
reduction in cell number between the BU69 and FITC stained cells and the untreated APC-
H7 stained cells. The results show the percentage of cells targeted after incubation with T 
cells for 6 hours (C).
No T cells + T cells; DYSN Peptide
+ T cells; BU69 + T cells; PDDYS-BU69+ T cells; RPH-BU69
A
B
C
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the antibody did not cause non-specific targeting by the CD4 T cells (Figure 5.13 B-
C). After labelling target cells with the DDYS_T conjugated BU69, there was an 
increased percentage of target cells killed at E:T ratio of 5:1 whereas there was no 
killing seen at an E:T ratio of 1:1. The untreated target cells (CD45 APC) remained at 
a similar percentage in all samples tested demonstrating that the CD4 T cells were 
specific for the BU69 incubated cells only.  When labelling target cells with the 
PDDYS conjugated BU69, there was an increase in cell targeting to 45% at 5:1 E:T 
ratio (Figure 5.13 B-C) and again there was no cell targeting when the E:T ratio was 
1:1. Similar to the other cultures analysed, there was no difference in the percentage 
of untreated target cells, demonstrating the peptide specificity of the T cells. These 
results demonstrate the potential cytotoxic activity of the peptide specific CD4 T cells 
which correlated with the previous degranulation assay (Figure 5.12) and also the 
IFN-γ recognition data. 
 
5.11 EBV as a model of antibody-antigen presentation 
The previous results have shown that there is a strong IFN-γ response to the HLA-
DRβ1*07 restricted peptide DYSN. However, all of the results shown above only use 
a single, CMV-derived peptide and therefore a single HLA allele. It was therefore 
important to ascertain whether the results are only seen using this peptide or using the 
HLA-DR7 allele. In order to prove that the previous results seen are not specific to a 
single peptide, a CD4 T cell clone (kind gift from Dr. H Long, University of 
Birmingham) specific for an HLA-DR52b-restricted, EBV-derived peptide 
PRSPTVFYNIPPMPLPPSQL (Long et al., 2005) was cultured. This peptide was 
synthesised with PDSPE- and -PPPAA elongations, at the amino and carboxy termini 
respectively, and a terminal cysteine residue at the carboxy terminus. The peptide was 
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conjugated to the BU69 antibody, as previously described, and conjugation confirmed 
as previously described using the biotinylated peptide.  
 
HLA-matched LCLs incubated with the peptide-conjugated BU69 were cultured with 
peptide-specific CD4
+
 T cells for 6 hours. There is an increase in IFN-γ production 
when target cells were pulsed with the viral peptide compared with the unpulsed 
target cells demonstrating that the T cells were peptide-specific and did not recognise 
target cells non-specifically (Figure 5.14). There was also an increase in IFN-γ when 
target cells were incubated with the peptide-conjugated antibody compared with the 
unlabelled target cells. These results confirm that both T cell recognition and antigen 
processing of antibody complexes are not specific for either the CMV-derived peptide 
or HLA-DR allele meaning that other peptides and HLA class-II alleles could be 
utilised in further studies.  Future therapy using this approach could utilise CD4 T cell 
responses to many different viruses. This would allow treatment of an increased 
number of patients as EBV is more prevalent in the population than CMV.  
 
Previous results suggest that conjugation of HLA class-II peptides to primary 
antibodies allows the peptide to be taken into the cell, processed and presented to 
CD4
+
 T cells in complex with HLA class-II. The positive results recorded with the 
BU69 antibody used LCLs from a lab donor and could be construed as a potential 
model for B cell lymphomas. However, CD70 itself is present on activated T cells 
(Brugnoni et al., 1997) and therefore, targeting this antigen may compromise the CD4 
T cells used for the recognition of the peptide.  As a result, attempts were made to try 
and find a different antibody that would specifically target B cells. 
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Figure 5.14 IFN-γ response to target cells stained with BU69 conjugated with EBV-
derived epitope
HLA-matched LCLs were stained with BU69 conjugated with the EBV-derived peptide PRS 
or irrelevant peptide (B-RPH) or without peptide (DMSO). After 30 minutes, cells were 
washed and incubated overnight. Peptide-specific T cells (E:T ratio - 1:5) were added and 
incubated for 6 hours before taking the supernatant to assay for IFN-γ by ELISA. Control 
wells containing peptide pulsed target cells without T cells (LCL + pep), target cells were 
pulsed with an irrelevant peptide and incubated with T cells (LCL + KYQ + T) and target 
cells cultured with peptide-specific T cells (LCL + T) were used to demonstrate that there 
was no spontaneous or non-specific release of IFN-γ. Peptide pulsed target cells cultured 
with peptide spefcific T cells (pLCL + T) were used to demonstrate the ability of the target 
cells to present the DYSN peptide. Error bars demonstrate mean + standard error mean, 
n=3 Data was analysed using unpaired t-test to determine statistical significance ** P<0.01.
**
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5.12 Generation of a model to screen large number of antibodies 
Peptide conjugation is not a laborious process and it would be possible to conjugate 
peptides to many antibodies. However, after the negative results from Rituximab 
conjugation, a method was developed that could rapidly assess many different 
antibodies in a single assay by conjugating HLA class-I and class-II peptides to a 
secondary antibody.  Antibodies which gave a positive result could then be 
conjugated with peptides directly in an attempt to define antibodies useful for this 
model. Previously, the best results had been seen using the slightly elongated class-II 
peptides DDYSNTHSTRYVT and PDDYSNTHSTRYV and as a result, it was 
decided to conjugate only PDDYSN to the secondary antibody.  To test the ability of 
the target cells to present the class-I peptides, the peptide with the similar elongations 
ARNLVPMVATV was also used. The antibodies of interest were specific for surface 
proteins expressed exclusively on B cells.  After labelling the cells with the 
unconjugated antibodies (BU12 (CD19), BU33 (CD21), Rituximab (CD20), BU69 
(CD70), A57H (IgG) and R8Z1E9 (IgG)), they were incubated with the peptide-
conjugated secondary antibodies.  There was no IFN-γ response when the secondary 
antibody was conjugated with either DMSO or ARLNVPMVATV (Figure 5.15 A), 
suggesting that the class-I peptides are not able to enter the class-I processing 
pathway after cross-linked antibodies are internalised by B cells.  This confirms the 
results from previous figures showing that the class-I peptides are not processed after 
they have been conjugated to the antibody. However, there was a strong IFN-γ 
response when cells, incubated with BU69 (CD70), BU12 (CD19) and BU33 (CD21), 
were incubated with the PDDYS-conjugated secondary antibody and a weaker IFN-γ 
response when cells were incubated with Rituximab. The positive IFN-γ response to 
BU69 is consistent with the previous results and therefore suggests that this method of  
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Figure 5.15 IFN-γ recognition of target cells stained with primary antibodies and a 
peptide-conjugated secondary antibody
Cells were stained with unconjugated primary antibodies (BU69 (anti-CD70), Rituximab 
(AntiCD20), BU12 (Anti-CD19), A57H, R8Z1E9 (both anti-IgG) and BU33 (Anti-CD21)) (A) 
or (anti-CD1a, anti-CD22, antiCD74, anti-CD79a and anti-CD79b) (B) for 30 minutes and 
washed before staining with a secondary antibody which had been conjugated with either 
HLA class I (ARNLV), class II peptide (PDDYSN), an irrelevant peptide (B-RPH) or 
unconjugated (DMSO) (A-B). After 30 minutes, the secondary antibody was washed off and 
the cells were incubated overnight. After washing, peptide-specific T cells (E:T ratio - 1:5) 
were added and the cells were cultured together for 6 hours before taking the supernatant 
to assay for IFN-γ production by ELISA.  Control wells containing peptide pulsed target 
cells without T cells (pLCL), unpulsed target cells (LCL), and target cells cultured with 
peptide-specific T cells (LCL + T) were used to demonstrate that there was no spontaneous 
or non-specific release of IFN-γ. Peptide pulsed target cells cultured with peptide spefcific T 
cells (pLCL + T) were used to demonstrate the ability of the target cells to present the 
DYSN peptide. Error bars demonstrate mean + standard error mean, n=3. Data was 
analysed using unpaired t-test to determine statistical significance * P<0.05, ** P<0.01 and 
*** P<0.001. 
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using a peptide-conjugated secondary antibody and looking for responses in cells 
incubated with an unconjugated primary antibody could be used for analysing a large 
number of antibodies quickly and easily. Another panel of antibodies were 
investigated using the HLA class-II peptide conjugated secondary antibody in order to 
determine if the previous results were similar with further B cell specific antibodies. 
Target LCLs were incubated with antibodies against CD1a (a transmembrane protein, 
structurally related to the MHC family not usually found on B cells) as a negative 
control, CD22 (belongs to a family of lectins and functions as an inhibitory receptor 
for surface Ig signalling), CD74 (the HLA Class-II invariant chain, functions to 
stabilise the HLA class-II molecule until peptide loading occurs) and CD79α and β 
(forms a complex with the BCR and generates a signal following activation of B cells 
through BCR engagement). There was no IFN-γ production when the cells were 
incubated with the secondary antibody containing the irrelevant peptide or without a 
peptide (Figure 5.15 B) demonstrating that there was very little background IFN-γ 
production throughout the assay. There was also very little IFN-γ production above 
the background when the secondary antibody conjugated to ARNLV was used either, 
further demonstrating that the class-I peptides cannot be processed in this way. Using 
the CD1a primary antibody as a negative control, there was a slight increase in IFN-γ 
production over background. The production of IFN-γ after labelling with CD79α and 
β was very similar to that seen after labelling with CD1a suggesting that there is no 
processing and presentation of the class-II peptide conjugated to these antibodies. 
When cells were incubated with the anti-CD74 antibody, there was a dramatic 
increase in IFN-γ production compared with the CD1a labelling. There was also a 
larger increase in IFN-γ production when cells had been incubated with the anti-CD22 
antibody. These results suggest that antibodies against CD22 and CD74 may be useful  
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Figure 5.16 IFN-γ recognition of target cells stained with further primary antibodies and a 
peptide-conjugatged secondary antibody
Target LCLs were stained with primary antibodies (anti-CD1a, anti-CD22, antiCD74, anti-CD79a 
and anti-CD79b) for 30 minutes (A), washed and then stained again with a secondary antibody 
conjugated with either an irrelevant peptide (B-RPH), ARNLVPMVATC or PDDYSNTHSTRYV. 
Cells were cultured overnight before the addition of peptide-specific T cells (E:T ratio - 1:5). Cells 
were then cultured for 6 hours and the supernatant taken to assay for IFN-γ production by ELISA.
Target LCLs were stained with anti-CD74 conjugated with class II peptides (DDYSN_T and 
PDDYSN), control peptide (B-RPH) or no peptide (DMSO). After 30 minutes, cells were washed 
and incubated overnight (B). The cells were then cultured with peptide-specific T cells (E:T ratio -
1:5) and the supernatant taken to assay for IFN-γ production after 6 hours by ELISA. T cells alone 
were culture to determine spontaneous IFN-γ release. Error bars demonstrate mean + standard 
error mean, n=3.  Target LCLs were stained with anti-CD22 conjugated with class II peptides 
(DDYSN_T and PDDYSN), control peptide (B-RPH) or no peptide (DMSO).  After 30 minutes, cells 
were washed and incubated overnight (C). The cells were then cultured with peptide-specific T 
cells (E:T ratio - 1:5) and the supernatant taken to assay for IFN-γ production after 6 hours by 
ELISA. Control wells containing peptide pulsed target cells without T cells (+ pep), unpulsed target 
cells (Alone), and target cells cultured with peptide-specific T cells (Alone + T) were used to 
demonstrate that there was no spontaneous or non-specific release of IFN-γ. Peptide pulsed target 
cells cultured with peptide spefcific T cells (+ pep + T) were used to demonstrate the ability of the
target cells to present the DYSN peptide. Error bars demonstrate mean + standard error mean, 
n=3 Data was analysed using unpaired t-test to determine statistical significance *** P<0.005 ** 
P<0.01 and * P<0.05.
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targets of as they are both expressed on B cells although CD74 is expressed on all 
cells expressing MHC class-II (Stein et al., 2007). 
 
5.13 Direct conjugation of antibodies with positive responses  
The previous data demonstrates that using a secondary antibody conjugated with 
peptides can induce T cell activation.  However, in order to determine whether the 
positive results seen with the secondary antibody can translate to direct conjugation, 
peptides were conjugated to BU12, BU33 and BU32 (another anti-CD21 antibody). 
There was no recognition of the LCLs incubated with BU12 (anti-CD19) conjugated 
to any of the HLA class-II peptides by the DYSN-specific T cells (Figure 5.16 A). 
The same results were seen for both BU32 and BU33 antibodies which had also been 
conjugated with the HLA class-II peptides. These results demonstrate that the peptide 
had not been presented by the cells, possibly due to lack of internalisation or lack of 
access to the MHC class-II processing pathway. These results are contradictory to 
previous results using anti-CD19 antibody conjugated with tetanus toxin peptides 
(Eberl et al., 1998) where there was a response seen with the anti-CD19 antibody. 
 
There are further studies published that show antibodies bound to CD21 (Tessier et al, 
2007) and CD19 (Ingle et al., 2008 & Gerber et al., 2009) are internalised after 
binding. However, the results shown in these previous studies demonstrate lack of 
CD19 internalisation when there is high surface expression of CD21. This may 
explain the negative results seen here as the target cells were strongly positive for 
both CD19 (90%) and CD21 less so (45%) (Figure 5.17), meaning that the lack of 
internalisation using BU12 (anti-CD19) may be due to expression of CD21. Despite 
the findings reported, the lack of T cell recognition may be due to lack of 
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Figure 5.17 CD19 and CD21 staining of LCLs
LCLs were stained left unstained (A-B Red), stained with isotype control antibodies (A-B 
Blue) or with antibodies against CD19 conjugated to PE (A Green) and CD21 conjugated to 
FITC (B Green). After 30 minutes, the antibodies were washed off and the cells were 
analysed on the flow cytometer. 
A B
CD19 CD21
Unstained
Anti-CD19 PE
Unstained
Anti-CD21 FITC
IsotypeIsotype
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internalisation or failure to enter the class-II antigen processing pathway possibly 
because the antibodies used for this experiment are from different clones and 
therefore could elicit a different biological response after binding. Once the HLA 
class-II peptides DDYS_T and PDDYS had been conjugated to anti-CD22 and anti-
CD74 as well as the control peptide biotin-RPH and DMSO, target LCLs were 
incubated with these antibodies to determine whether they produce a similar response. 
Cells incubated with anti-CD74 conjugated without a peptide or with an irrelevant 
peptide produced very little IFN-γ (Figure 5.16 B).  However, cells incubated with 
anti-CD74 conjugated to both of the class-II peptides demonstrated a large increase in 
IFN-γ production after incubation with DYS-specific T cells.  This suggests that the 
anti-CD74 antibody is efficiently internalised after binding to the surface CD74 and 
processed in the same way as BU69 allowing presentation of the peptides at the 
surface which can then be recognised by the peptide-specific CD4
+
 T cells. Cells were 
incubated with the anti-CD22 antibody conjugated with the class-II peptides as well 
as the irrelevant peptide and DMSO. There was very little IFN-γ produced when cells 
were incubated with the anti-CD22 antibody conjugated with any of the peptides, 
including the HLA class-II peptides (Figure 5.16 C). This suggests that the anti-CD22 
antibody behaves differently to the anti-CD74 antibody and either does not internalise 
after binding or is excluded from the class-II processing pathway therefore denying 
the conjugated peptides access to HLA class-II molecules.  These data would suggest 
that cross-linking is required for CD22 ligands to be directed toward the antigen 
processing machinery. 
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5.14 Targeted depletion of B cells in peripheral blood. 
Previous results have demonstrated that B cells incubated with antibody-peptide 
conjugates can be targeted by peptide-specific CD4 T cells when the target cells are 
the only cell present.  However, I wanted to determine whether the peptide-specific T 
cells could lyse the target B cells in PBMCs using the FACS-based targeting assay.  
The frequency of peptide-specific T cells in fresh PBMCs from the donor chosen was 
<1% and as a result of this, autologous peptide-specific T cells were added to increase 
the E:T ratio.  After labelling, the concentration of B cells in the untreated PBMCs 
was ~50% of the total CD3
-
 cells and the addition of 50,000 extra peptide-specific 
CD4
+
 T cells did not alter the percentage of the B cells suggesting there was little 
non-specific targeting of the PBMCs by the newly introduced T cells (Figure 5.18).  
Upon addition of the peptide-conjugated secondary antibody only (anti-mouse IgG), 
there was a decrease in the percentage of B cells (36%) suggesting that they were 
being targeted by CD4 T cells.  This decrease was surprising as the antibody should 
not be able to bind to the cells as it recognises mouse IgG and not human IgG.  
However, cells were not washed and it is possible that the secondary antibody could 
have been taken up by Fc receptors present on the surface of cells. Therefore, the 
peptides would then be processed and presented by these cells and this could account 
for the decrease in the percentage of B cells incubated only with the secondary 
antibody. When the cells were incubated with the specific primary antibodies BU12 
(CD19) or A57H (Human IgG) and then the peptide-conjugated secondary antibody, 
there was a further decrease in the percentage of B cells (70-76%) (Figure 5.18).  This 
potentially demonstrates an increase in B cell lysis by the peptide-specific CD4 T 
cells when there was a primary antibody specific for B cells present and that within an 
environment where there are many different types of leukocytes, the antibodies bind 
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Figure 5.18 B cell targeting in PBMCs spiked with peptide specific T cells using 
secondary antibody conjugated with HLA class II peptides
PBMCs were stained with either BU12 (anti-CD19) or A57H (anti-IgG), washed and then 
stained a second time with a peptide-conjugated (PDDYSNTHSTRYV) anti-mouse IgG 
antibody. The primary antibody would bind to the cell and the peptide-conjugated 
secondary antibody would bind to the primary antibody effectively coating the cell in 
peptide-conjugated antibody.  The frequency of DYSN-specific T cells in the donor PBMCs 
was very low and therefore cultured DYSN-specific T cells were added to the PBMCs to 
increase the E:T ratio.  After washing, the PBMCs with the added DYSN-specific T cells 
were left to incubate for 6 hours. The cells were stained using antibodies against CD3, CD4 
and CD19 and analysed on the FACS to determine the frequency of B cells present in each 
culture. The percentage of B cells present in the PBMCs was calculated as a percentage of 
CD3 negative cells as the DYSN-specific T cells added would alter the percentage of T 
cells in the culture and alter the percentage of B cells as a result. Therefore, the T cells 
were removed from the equation and the B cells calculated as a percentage of non-T cells.
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to their targets and direct an immune response against the targeted cells where 
previously only a single cell type was used.  Furthermore, this would suggest that if 
this work was to be moved into an animal model, it could potentially target a B cell 
tumour within all the other cells present in the haematopoietic system, although it 
must be remembered that a peptide-conjugated secondary antibody was used and as a 
result it is not a direct targeting assay. Ideally, this work would use a single antibody 
instead of having to use a primary antibody and a peptide-conjugated secondary 
antibody.  Future work will attempt to address this and use an antibody specific for B 
cells which has been directly conjugated with a viral peptide to determine if the same 
results are seen with this model. 
 
5.15 Testing Therapeutic Antibodies with Peptide-Conjugation 
All of the previous results have used LCLs as target cells and although they are a 
transformed B cell line, they are viewed as an lymphoma cell line and as a result of 
this, another cell line was sought which would provide a more accurate model for 
lymphoma in order to test another hypothesis; peptides conjugated to antibodies 
already used in therapy for patients of various cancers (including breast and non small 
cell lung carcinoma) and heamato-lymphoid malignancies (including chronic 
lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML)), could target 
malignant cells. The potential for peptides conjugated to the primary antibody to 
produce a positive IFN-γ response has been shown in previous results. Many of these 
cancers and leukaemias already have antibody therapies approved (Table 5.2) and it is 
possible that using the peptide conjugated antibodies could enhance the efficacy of 
such therapies and therefore work began to focus on either antibodies that have been 
approved for immunotherapy or those that could target surface proteins on malignant 
B cells.   
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Table 5.2 Current antibodies approved for immunotherapy
Shows the FDA-approved list of monoclonal antibodies for treatment in various indications. 
Table contents taken from Waldmann, TA. 2003. 
Transplant rejection
Cardiovascular disease
Transplant rejection
Non-hodgkin lymphoma
Transplant rejection
Autoimmune disorder
Respiratory syncitial virus
Breast cnacer
Acute myeloid leukemia
Chronic lymphocytic 
leukemia
Autoimmune disorder
Psoriasis
Non-hodgkin lymphoma
Non-hodgkin lymphoma
Colorectal cancer
Head and neck cancer
Multiple sclerosis
Colorectal cancer
Macular degeneration
Crohn’s disease
TCR:CD3
Glycoprotein 2a/3b
CD25
CD20
CD25
TNF-α signalling
RSV Protein Epitope
ErbB2
CD33
CD52
TNF-α signalling
CD11a
CD20
CD20
VEGF
EGF receptor
Alpha-4 integrin
EGF receptor
VEGF
TNF-α signalling
Murine
Chimeric
Humanised
Chimeric
Chimeric
Chimeric
Humanised
Humanised
Humanised
Humanised
Human
Humanised
Murine
Murine
Humanised
Chimeric
Humanised
Human
Humanised
Humanised
1986
1994
1997
1997
1998
1998
1998
1998
2000
2001
2002
2002
2002
2003
2004
2004
2006
2006
2006
2008
Muromonab-CD3
Abciximab
Daclizumab
Rituximab
Basiliximab
Infliximab
Palivizumab
Trastuzumab
Gemtuzumab
Alemtuzumab
Adalimumab
Efalizumab
Ibritumomab
tiuxetan
Tositumomab
Bevacizumab
Cetuximab
Natalizumab
Panitumumab
Ranibizumab
Certolizumab
pegol
TreatmentTargetAb TypeApproval 
Date
Name
TNF-α: Tumour necrosis factor alpha; VEGF: Vascular endothelial growth factor; EGF: Epidermal 
growth factor. 
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5.15.1 Labelling Burkitt‟s Lymphoma Cells with BU69-Peptide 
The results shown so far use BU69 conjugated with peptides and LCLs as the target 
cells to demonstrate the principle of the work. Ramos cell line is a human Burkitt‟s 
lymphoma cell line which is HLA-A2
-
 and more importantly HLA-DR7
+
 meaning 
that the cells could be targeted using the HLA class-II peptides. Firstly, the Ramos 
cell line was incubated with a commercial anti-CD70 antibody to determine whether 
the BU69 antibody could be used with these cells. After analysing Ramos cells using 
flow cytometery, they were strongly positive for surface CD70 expression (Figure 
5.19 A) and therefore the cells could be incubated with BU69 conjugated with class-II 
peptides to determine whether they could process and present the conjugated peptide 
in the same manner as previously shown.  The class-II peptide-conjugated anti-CD74 
was also used to stain the Ramos cells. After labelling, Ramos cells were cultured 
with the peptide-specific CD4 T cells and the supernatant taken to assay the 
production of IFN-γ after 6 hours. The Ramos cells pulsed with exogenous DYSN 
peptide were strongly recognised by the peptide-specific CD4 T cells (Figure 5.19 B) 
whereas the untreated Ramos cells were not recognised by the T cells.  This 
demonstrates the ability of Ramos cells to present the DYSN peptide to the T cells 
and that the T cells do not recognise the Ramos cells non-specifically. After labelling 
with either BU69 or anti-CD74 conjugated with the class-II peptides, there was no 
production of IFN-γ by the T cells. This demonstrated that there was no presentation 
of the peptide at the surface of the Ramos cells. This may be due to the inability of the 
Ramos cells to internalise the antibody although there may be a difference in the 
antigen processing by the Ramos cells that has prevented the expression of the peptide 
at the surface of the cell.  
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Figure 5.19 CD70 staining and IFN-γ release by Ramos cells stained with BU69 or 
anti-CD74
Ramos cells were left unstained (A Red), stained with  isotype control (A Blue) or stained 
with commercial anti-CD70-FITC antibody (A Green) for 30 minutes. Cells were washed 
and analysed on the flow cytometer. Ramos cells were stained with BU69 alone (DMSO) or 
peptide-conjugated BU69 or peptide conjugated anti-CD74 (B-RPH (control), DDYSN_T 
and PDDYSN) for 30 minutes, washed and incubated overnight. Peptide-specific T cells 
were added (E:T ratio - 1:5) for 6 hours before the supernatant was taken to assay for IFN-
γ production by ELISA (B). Target cells alone (Alone) and with T cells (Alone + T) 
demonstrate little IFN-γ production towards untreated target cells.  Addition of DYSN 
peptide (+ pep) did not increase the IFN-γ production until peptide-specific T cells were 
added to the culture (+ pep + T). Error bars demonstrate mean + standard error mean, n=3. 
Data was analysed using unpaired t-test to determine statistical significance.
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5.15.2 Targeting Breast Cancer Cells with Herceptin-Peptide 
As well as trying to target B cell lymphomas, there was the potential to target breast 
cancer as well. Herceptin is an antibody therapy for breast cancer which targets the 
Her2/neu receptor on breast cells and prevents growth factor binding, effectively 
starving the cancerous cell and preventing tumour growth (Goldenberg, 1999 and 
Hudis, 2007). The MCF-7 cell line used as a model for breast cancer was HLA-A2
+
 
but HLA-DR7
-
, therefore the class-I peptides but not the class-II peptides could be 
investigated. MHC class-I peptides were conjugated to Herceptin and used to stain 
MCF-7 cells. Assaying for IFN-γ showed that there was no recognition of the 
untreated MCF-7 cells (Figure 5.20), demonstrating that the T cells used in the assay 
did not recognise MCF-7 cells in a peptide independent manner. The NLV-specific 
CD8
+
 T cells can recognise MCF-7 cells pulsed with exogenous peptide 
demonstrating that the MCF-7 cells can present the peptide at the surface of the cells 
in complex with HLA-A2. However, there was no production of IFN-γ seen when 
cells were incubated with Herceptin conjugated with any of the HLA class-I peptides 
(<50pg/ml). There are previous publications suggesting Herceptin is quickly 
internalised after binding to the Her2/neu receptor (Mittendorf et al, 2006). Therefore, 
the lack of IFN-γ response to the antibody-peptide conjugate incubated cells is 
probably not due to the lack of internalisation.  
 
In order to test the class-II peptides in a breast cancer model, another cell line 
MDA.MB.231 was cultured which is HLA-A2
+
 and HLA-DR7
+
. The MDA.MB.231 
cells do not naturally express HLA class-II molecules at the surface but cells can be 
induced to express them by addition of IFN-γ to the culture media (Basham & 
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Figure 5.20 IFN-γ recognition of MCF-7 breast cancer cells stained with peptide-
conjugatged Herceptin
Breast Cancer cells, MCF-7, were stained herceptin unconjugated (DMSO) or conjugated 
to class I peptides (B-RPH, NLV, RNLV or RNLV_Q).  After 30 minutes, cells were washed 
and incubated overnight. Peptide-specific T cells were added (E:T ratio - 1:5) and the 
supernatant assayed for IFN-γ production after 6 hours by ELISA. Control wells containing 
peptide pulsed MCF-7 cells without T cells (pMCF-7 (NLV) only), unpulsed MCF-7 cells 
(MCF-7 only),  and MCF-7 cells cultured with peptide-specific T cells (MCF-7 + T (NLV) 
were used to demonstrate that there was no spontaneous or non-specific release of IFN-γ. 
Peptide pulsed MCF-7 cells cultured with peptide spefcific T cells (pMCF-7 + T (NLV)) were 
used to demonstrate the ability of the target cells to present the NLV peptide. Error bars 
demonstrate mean + standard error mean, n=3. Data was analysed using unpaired t-test to 
determine statistical significance.
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Merigan, 1983, Collins et al., 1984 & Gosselin et al, 1993). After treatment with IFN-
γ for 18 hours, to induce the expression of HLA class-II, cells cultured with T cells in 
the absence of peptide were not recognised.  However, when the treated cells are 
pulsed with exogenous DYSN peptide, there is an increase in cell recognition 
demonstrating that the IFN-γ treatment of cells has upregulated HLA class-II 
expression on the surface. However, when the IFN-γ treated cells are incubated with 
Herceptin, which has been tagged with HLA class-II peptides, there is no T cell 
response (Figure 5.21) above the background (Herceptin conjugated with SMCC but 
no peptide (DMSO)). This data suggests that there is no expression of the peptides at 
the cell surface. Since the cell line can express the HLA class-II peptide, and as CD4
+
 
T cells can recognise cells pulsed with peptide, this means that the cell line can be 
induced to express HLA class-II at the surface but it cannot process and present the 
peptide conjugated to Herceptin. The HLA class-I peptide conjugated Herceptin 
labelling was repeated using the MDA.MB.231 cell line but the results were similar to 
those seen with the MCF-7 cell line. Taken together, these results mean that the 
potential of this peptide-antibody therapy for breast cancer using Herceptin is low and 
as a result no further work was undertaken.  
 
5.16 Engineering Antibodies Encoding Viral Peptide Epitopes 
Previous results show peptides conjugated to antibodies can target B cells after 
processing and presentation of the viral peptide. I set out to test the hypothesis that B 
cells can process endogenous peptides derived from the CDR3 of immunoglobulin 
and present these peptides on the surface of the cell in complex with MHC molecules. 
By introducing a known viral peptide into the CDR3, I could determine the processing 
capability of B cells to present the CDR3-derived viral peptide. By doing so, the B  
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Figure 5.21 IFN-γ recognition of MDA-MB-231 cells stained with peptide conjugated 
Herceptin
MDA-MB-231 cells were stained with class II peptide conjugated herceptin (B-RPH -
IPDDYSN) or unconjugated herceptin (DMSO), washed and incubated overnight. Peptide-
specific T cells were added (E:T ratio - 1:5) and the supernatant assayed for IFN-γ
production after 6 hours by ELISA. Control wells containing peptide pulsed target cells 
without T cells (+ pep), unpulsed target cells (alone),  and target cells cultured with peptide-
specific T cells (Alone + T) were used to demonstrate that there was no spontaneous or 
non-specific release of IFN-γ. Peptide pulsed target cells cultured with peptide specific T 
cells (+ pep + T) were used to demonstrate the ability of the target cells to present the NLV 
peptide. Error bars demonstrate mean + standard error mean, n=3. Data was analysed 
using unpaired t-test to determine statistical significance.
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cell would become a target for CMV-specific T cells. The key question being: can 
CDR3-derived peptides be processed and presented by HLA molecules at the surface 
of the paternal B cell or are these peptides excluded from the HLA class I and II 
processing pathways in order to avoid being targeted.  
 
5.16.1 Mutating the CDR3 of Rituximab 
Rituximab, a chimeric antibody specific for CD20, was chosen as it is an approved 
therapeutic antibody which is routinely used to treat patients with B cell malignancies. 
The CMV-derived pp65495-503, HLA-A2 restricted peptide NLVPMVATV (Wills et 
al., 1996) was inserted into the CDR3 of the Rituximab sequence (Figure 5.22), 
labelled Rituximab-NLV. The assumption behind this work was that the default 
pathway for antibodies bound to a cell surface and internalised would be the class II 
processing pathway.  
 
5.16.2 Production of Rituximab-NLV 
Three different methods were employed to generate Rituximab-NLV, as discussed in 
materials and methods 2.6.3.4. Briefly, packaging cells in a single flask were 
transfected with both heavy and light chain in one tube with transfection reagent (A), 
packaging cells in a single flask transfected with heavy chain and light chain 
separately mixed with transfection reagent (B) and two flasks of packaging cells 
transfected with either the heavy or light chain and the media from the two flasks 
swapped so each cell line is transduced with both chains (C).  Once transduced, media 
taken from the flasks Rituximab-NLV A, B and C was purified and assayed for 
production of antibody by ELISA (Figure 5.23 A). There is no response seen using 
PBS as negative control and a large response seen when using Rituximab as positive 
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Figure 5.22 Sequence of the heavy chain of Rituximab containing viral epitope 
The sequence of Rituximab (A) (taken from www.drugbank.ca) with the CDR3 underlined 
and the sequence of Rituximab-NLV (B) with the viral epitope NLVPMATV in the CDR3.
QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDT
SYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTT
VTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDT
SYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCNLVPMVATVYWYFDVWGTGTT
VTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
A
B
 
 
Figure 5.23 Production and purification of Rituximab-NLV 
Media from transfected lenti-X 293T cells was purified using a protein G column as 
previously described (A). Transfected lenti-X 293T cells were grown in media containing 
IgG depleted FCS. The media was purified using a protein A column (B). The purified 
antibody was coated onto a 96 well plate and incubated for 60 minutes at 37°C. The plate 
was washed and a secondary antibody, mouse anti-human IgG was added for 60 
minutes at room temperature. The plate was washed and a third antibody was added, 
anti-mouse-HRP, for 60 minutes at room temperature. The plate was washed and TMB 
added to each well for 10-15 minutes at room temperature. Addition of 10% HCl stopped 
the reaction and the wells were read at absorbance of 450nm using the GloMax reader. 
(FT - Column wash flow through).
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control. There was no positive response seen against samples taken at different stages 
of the purification process suggesting that no antibody has been lost during the 
purification process. Although there is no response seen in the unpurified samples, 
there is a large response seen when the purified Rituximab-NLV was assayed from all 
3 flasks. After demonstrating that Rituximab-NLV had been purified successfully, the 
concentration of antibody was determined using the Qubit fluorimeter. The 
concentration of antibody contained in Rituximab-NLV B was slightly increased 
(350μg/ml) compared with the concentration from flasks A and C (300μg/ml) 
suggesting purification of the antibody had been successful. However, the protein 
concentration of Rituximab-NLV may be wrong due to the presence of bovine IgG in 
the media from the FCS used to culture the transfected cells. Therefore to remove this 
contaminant, the transfected cells were grown in media supplemented with FCS 
depleted of bovine IgG (kind gift from Dr M Goodall).  
 
After 5 days growth at 37°C, media from all 3 flasks was pooled and purified using a 
protein A column and tested using ELISA (Figure 5.23 B). The results are similar to 
the previous ELISA with no antibody lost during the purification and no response 
seen to the unpurified sample. There is a strong response seen from the purified 
sample similar to the positive control (Rituximab). The protein concentration from the 
sample was 100μg/ml, slightly decreased compared with previous results. This may 
be due to the removal of bovine IgG but may be due to decreased protein production 
by the transduced cells. The purified Rituximab-NLV was stored at 4°C until required 
for further experiments. 
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Figure 5.24 IFN-γ ELISPot of PBMCs stained with immune complexes of Rituximab and 
Rituximab-NLV formed with anti-kappa antibody
PBMCs were kept unfractionated (A-D) or depleted of B cells (E-H) using magnetic selection. 
Immune complexes were formed of Rituximab (C and G) and Rituximab-NLV (B and F) 
antibodies using mouse anti-kappa for 30 minutes at room temperature. The complexed
antibodies were added to 1x105 PBMCs previously plated in ELISpot wells. The cells were 
incubated overnight at 37°C without washing.  Cells were removed and the wells washed 5x 
in PBS and the secondary antibody (7-B6-1) added to each well. The wells were washed and 
the substrate added for 10-12 minutes before stopping the reaction with excess water. The 
wells were read in an ELISpot plate reader and the number of spots recorded. The 
background response to PBS (A and E) was determined and the response to NLV peptide (D 
and H) was recorded as positive control.
A B C D
E F G H
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5.16.3 Processing and Presentation of Rituximab-NLV 
After mutating Rituximab, producing Rituximab-NLV, the antibody no longer binds 
to CD20 and therefore cannot be taken into the cell to access the antigen processing 
pathway. As a result of this, Rituximab-NLV had to be taken into the cell via the Fc 
region and to facilitate this, it had to be made into an immune complex (see materials 
and methods 2.6.3.5). The immune complexes produced either by heating or by 
addition of an anti-kappa antibody were added to unfractionated PBMCs or PBMCs 
depleted of B cells and production of IFN-γ assayed by ELISpot.  
 
Using an anti-kappa antibody to form immune complexes of Rituximab and 
Rituximab-NLV, there was a strong IFN-γ response towards complexed Rituximab in 
whole PBMCs which was reduced significantly in the B cell depleted PBMCs (Figure 
5.24 C & G). Addition of immune complexed Rituximab-NLV to whole PBMCs also 
produced an IFN-γ response (B) which was somewhat weaker than the response to 
unmutated Rituximab. There was still a response seen when complexed Rituximab-
NLV was added to B cell depleted PBMCs (F). There was strong response seen to the 
NLV peptide-pulsed PBMCs with and without B cells (D & H) and very little 
response to untreated cells (A & E). After heating Rituximab-NLV, there were spots 
seen in wells containing both unfractionated PBMCs and B cell depleted PBMCs 
(Figure 3.25 B & E) although there were fewer spots seen in the B cell depleted 
PBMCs. Although not conclusive, these results suggest that there may be antigen 
processing of the Rituximab-NLV but further results are needed to confirm this. 
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Figure 5.25 IFN-γ ELISPot of PBMCs stained with immune complexes of Rituximab and 
Rituximab-NLV formed by heating
PBMCs were kept unfractionated (A-C) or depleted of B cells (D-F) using magnetic selection. 
Immune complexes were formed of Rituximab-NLV (B and E) by heating at 65°C for 30 
minutes. The complexed antibody was added to 1x105 PBMCs previously plated in ELISpot
wells. The cells were incubated overnight at 37°C without washing.  Cells were removed and 
the wells washed 5x in PBS and the secondary antibody (7-B6-1) added to each well. The 
wells were washed and the substrate added for 10-12 minutes before stopping the reaction 
with excess water. The wells were read in an ELISpot plate reader and the number of spots 
recorded. The background response to PBS (A and D) was determined and the response to 
NLV peptide (C and F) was recorded as positive control.
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5.17 Discussion 
In this chapter, an attempt was made to generate an antibody which was conjugated to 
a viral peptide to determine whether this conjugate could be used to deliver the 
peptide into the antigen processing pathway of the target cell. The hypothesis tested 
was: the peptide conjugated to the antibody would be processed by cellular machinery 
and presented at the surface of the target cell. This would allow targeted killing of 
cells bound by the antibody as peptide-specific CD8 or CD4 T cells would then 
recognise the peptide which had originally been conjugated to the antibody.  
 
After confirming that the conjugation of peptide to Rituximab was successful, cells 
were incubated with MHC class-I peptide and MHC class-II peptide-conjugated 
Rituximab. There was no response seen when target cells were incubated suggesting 
that there was no presentation of the peptide at the surface of the cell in complex with 
MHC molecules suggesting that the hypothesis is false. However, it was difficult to 
determine whether the lack of response was due to the peptide not entering the antigen 
processing pathway or due to lack of internalisation of Rituximab. Studies suggest 
that Rituximab is not internalised after binding to CD20 (Einfeld et al, 1988). 
Although there have been reports of a small percentage of Rituximab internalised 
after binding (Michel & Mattes, 2002 & Jilani et al., 2003), the lack of internalisation 
or inability to enter the antigen processing pathway are the most likely reasons for the 
lack of response.  I believe that in order for the peptides to enter either of the HLA 
processing pathways, the antibody must first be internalised by the cell whereupon the 
peptide can be cleaved from the antibody and processed. As a result of this, the 
hypothesis was re-tested using a different antibody, BU69, which had been shown to 
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be internalised quickly after binding to CD70 (Israel et al., 2005 and Adam et al., 
2006).  
 
After confirming that peptides have been conjugated to BU69, target cells were 
incubated with BU69 conjugated with either class-I or class-II peptides. There was a 
response seen when target cells were incubated with both class-I and class-II peptides 
suggesting that the hypothesis is true. These results suggest that target cells take up 
the antibody, cleave the peptide and process both class-I and II peptides for 
presentation that T cells can then recognise. The results also appear to suggest that 
amino acids flanking the naturally processed peptide sequence are important as the 
strongest T cell response is seen when the antibody has been conjugated with peptides 
elongated at both the carboxy and amino termini. Consequently, some of the weakest 
responses are seen with the shorter peptides and the naturally processed peptide. 
However, further experiments demonstrated that the positive initial results observed 
were as a result of excess, unconjugated free peptide binding to surface MHC on the 
target cells and therefore there was doubt as to whether there was antigen processing 
of the peptide conjugated to BU69. These results suggest that the hypothesis may not 
be true as first thought and that the response seen was a result of the unconjugated 
peptides.  
 
After removal of excess unconjugated peptides, a T cell response was seen using 
MHC class-II peptides only. The results shown here support previous results using 
similar peptide-conjugation technology where CD4 T cells in mice (Casten et al, 
1988) and humans (Eberl et al., 1998) could recognise target cells incubated with anti-
idiotype antibodies conjugated with antigenic peptides from either the tobacco 
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hornworm moth or tetanus toxin. These data suggest that the peptide conjugated 
antibody can gain access into the class-II processing pathway but not the class-I 
processing pathway. Uptake of extracellular protein is largely sequestered by the 
class-II processing pathway and the results shown here suggest that it can enter the 
class-II but not the class-I processing pathway. However, It may be possible that the 
antigen processing of the class-II pathway cleaves the bond between the antibody and 
the peptide whereas the class I processing pathway cannot break the bond. This would 
mean that the peptide-antibody complex could enter the class-I processing pathway 
but the conjugation technique may prevent correct processing. If this is the case, 
altering the conjugation could allow correct processing of the antibody-peptide 
conjugate and presentation of the class-I peptide on the cell surface. 
 
After showing that the class-II peptides were presented at the cell surface, further 
work was undertaken to determine the processing that was needed to present the 
peptide using inhibitors of antigen processing. The results showed that lactacystin and 
pepstatin had little effect on the production of IFN-γ suggesting that the peptide is not 
processed utilising either the proteasome or aspartyl proteases. However, the 
processing is partly due to the activity of thiol proteases as there was a small 
reduction in response when leupeptin was added. Proteases are found in the 
compartment associated with class-II processing and break down polypeptide chains 
at low pH. Therefore, the expectation would be that inhibition of proteases would 
have an effect on the antigen processing although this is not the case. It may be due to 
the presence and activity of other proteases that are not inhibited by either pepstatin or 
leupeptin. The response seen in the presence of 3-methyl adenine suggests that the 
autophagy pathway is not utilised by the antibody-peptide conjugate.  
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There is a decreased response when cells were cultured with cholroquine, suggesting 
that the antibody-peptide complex is taken up into a phagolysosome after 
internalisation and degraded using proteases (although not aspartyl proteases). The 
addition of chloroquine disrupts the pH in the lysosome preventing acidification and 
subsequently prevents protease activity. The activity of cholorquine appears to be 
irreversible as there is still a decreased response 24 hours after removal of the 
inhibitor. Addition of monensin to the media results in a decreased response after 6 
hours which is reversible and leads to an increased response after 24 hours. This may 
be explained by the fact that monensin is an inhibitor of the golgi complex and 
prevents transport of molecules to the surface of the cell. If this was to occur, there 
may be a backlog of HLA class-II molecules waiting to be transported to the surface. 
When the monensin was removed and the presentation pathway cleared, this backlog 
of HLA class-II molecules would then be expressed at the surface of the cell 
alongside the newly synthesised HLA class-II molecules. Therefore, the target cells 
would then have an increased expression of HLA class-II molecules, expressing the 
DYSN peptide, at the surface of the cell which the peptide-specific CD4 T cells can 
recognise and this could lead to an increase in IFN-γ production. These results 
demonstrate that the peptide-conjugated antibodies are processed and presented in the 
classical MHC class-II antigen processing pathway. Using an antibody which binds to 
HLA-DR, the results demonstrate a decreased response when HLA-DR is blocked, 
preventing T cells from accessing the peptide-MHC on the cell surface. This 
demonstrates that the peptide is being presented on the surface in complex with HLA-
DR, as it has been shown to do so in previous studies. Taken together, these results 
demonstrate that the antibody-peptide complex is processed in the classical class-II 
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processing pathway before presentation on the correct MHC class-II allele at the cell 
surface.  
 
A question that arose after these results was: Can a different peptide, from a different 
virus, elicit a similar response or is the response to peptide-conjugated antibody 
peptide specific? Conjugation of the EBV-derived, HLA-DR52b restricted peptide 
PRS (Long et al., 2005) to BU69 produced similar responses as that seen with the 
CMV derived peptide HLA-DR7 restricted peptide. This suggests that conjugation of 
any viral class-II peptide could elicit an immune response in this model and there is 
no restriction on where peptides are derived from. This means that if this is to be used 
in an in vivo setting, the peptide conjugated to the antibody could be generated after 
determining the immune response to different viruses from each patient, essentially 
tailoring the therapy to their immune system. 
 
After the failure with Rituximab and subsequent success seen with BU69, it is clear 
that different antibody targets will act differently and not all will be amenable to this 
system.  Using a secondary antibody conjugated with peptides would allow high-
throughput testing of this system to determine which antibodies would be useful.  This 
new system worked well with BU69 and there was a large response seen similar to the 
direct conjugation.  Using this new system, there was also a response seen using 
antibodies against CD19 and CD21 as well as Rituximab.  The positive result using 
Rituximab was unexpected as previously there was no response using the direct 
peptide conjugation. The positive response is possibly due to the forced internalisation 
due to cross-linking of the Fc region as has been published previously (Coffey et al., 
2004).  Therefore, this result suggests that a positive result seen with secondary 
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conjugation may not automatically translate to a positive result when tested with 
direct conjugation.  Positive results were also seen with BU12 (anti-CD19) and BU33 
(anti-CD21) when using secondary conjugation but when the same antibodies were 
tested with direct conjugation there was no response.  The lack of recognition most 
likely reflects failure of internalisation of the antibodies and therefore the peptides are 
not gaining access to the class-II processing pathway within the target cell. 
 
This confirms the previous result which shows that even if there is a positive response 
using secondary conjugation, it does not reveal which antibodies will be useful using 
direct conjugation.  This suggests that the use of the secondary antibody cross-links 
the primary antibody, causing internalisation of the complex and therefore allowing 
the peptide access to the antigen processing pathway.  When there is no cross-linking 
of the primary antibody, there is no internalisation and therefore no access to the 
antigen processing pathway for the conjugated peptide.  Previous studies have shown 
that cross-linking of an antibody bound to its antigen on the surface of the cell can 
cause internalisation of the whole complex (Coffey et al., 2004).  There is a high 
degree of probability that internalisation of the antibody is an important step in 
allowing the peptide access into the class-II antigen processing pathway.  
 
The results suggest that the assay using the peptide-conjugated secondary antibody to 
screen many antibodies at once may provide some antibodies as candidates but the 
positive results seen do not automatically translate into a positive result once the 
primary antibodies are directly conjugated with the peptides. It does however rule out 
some antibodies as those which do not produce a response using secondary 
conjugation do not produce a response using direct conjugation.  
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Until this point, the only antibody which had shown a positive response using direct 
conjugation was BU69 and as a result of this, the secondary conjugation system was 
used again to find potential antibodies specific for B cells which could produce a 
positive response.  Antibodies to CD22 and CD74 both showed responses using the 
secondary conjugation but only anti-CD74 antibody produced a positive response 
using direct conjugation.  This result was very important as it showed that this system 
is not limited to BU69 and can be used with other antibodies and secondly, it allowed 
specific targeting of a single cell type. Interestingly, CD74 is a therapeutic target 
found on many B cell malignancies (Pawlak-byczkowska et al, 1989 and Burton et al., 
2004) and therefore may represent a useful target for this model. 
 
Further experiments demonstrated firstly the ability of peptide-specific CD4 T cells to 
degranulate (CD107 assay) in response to peptide-antibody incubated cells and 
secondly to lyse peptide-antibody incubated cells whilst leaving untreated cells of the 
same type alone. The results from the degranulation assay demonstrate an increased 
degranulation when there were fewer peptide-specific T cells present. CD107 is 
internalised and degraded quickly after degranulation and normally, target cells are 
treated with monensin to prevent destruction of the antibody incubated CD107. This 
prevents degradation of the FITC-conjugated antibody, by neutralising the pH, 
allowing the signal to be read by the flow cytometer. In this assay, monensin was not 
used as there were concerns that this may have an adverse effect on the antigen 
processing, which would affect the presentation of the peptides conjugated to the 
secondary antibody. However, this means that the CD107 may be internalised and 
degraded before the cells were incubated with the antibody. It is possible that the 
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lower CD107 labelling on the cells at the higher effector to target ratio (1:1) means 
that the target cells are being killed quicker and therefore the CD107 is being 
internalised and degraded before the anti-CD107 specific antibodies are added. If 
there are fewer effector cells, the target cells will be killed over a longer period of 
time and therefore the CD107 expressed at the surface of the T cells, which are 
attacking the target cells, will be present for longer as the cells degranulate over a 
longer period of time. Therefore, when the anti-CD107 specific antibody is added 
after 24 hours, there is more CD107 still on the surface of the T cells at the lower E:T 
ratio (0.2:1). 
 
These results are very important and demonstrate the potential therapeutic 
possibilities of this system whereby specific cells can be targeted by peptide-antibody 
complexes and the resulting presentation of the peptide will render the target cell 
susceptible to peptide-specific CD4 T cells. Using this method, it may be possible to 
specifically target and kill malignant cells using different antibodies.  
 
Taking this forward, various malignant cell lines were targeted using available 
antibodies in an attempt to show lysis of these cells using the peptide-antibody 
complex.  Cell lines for Burkitt‟s lymphoma and breast cancer were targeted using 
peptide-antibody complexes but there was no response towards class-I or II peptides. 
These results suggest that the peptides are not presented at the surface of the cells 
possibly because the peptides do not gain access to the class-I or class-II processing 
pathways or because the peptides are discarded and therefore not presented at the 
surface.  Previous studies have shown the internalisation of Herceptin (Mittendorf et 
al, 2006) and previous results have shown internalisation of BU69.  This suggests that 
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the antigen processing is altered in different cell lines and the antigen processing is 
very important in this model. Although the initial attempts were unsuccessful, there is 
the possibility that malignant cells can be targeted once further investigation has been 
completed. 
 
The hypothesis behind this work was based around the ability of an antibody, 
chemically conjugated with a peptide, to cross the plasma membrane into the cell 
where the peptide would be separated from the antibody by cellular enzymes (Figure 
5.26). The peptide could then either pass from the endosome into the cytosol and gain 
access to the HLA class-I processing pathway, or it could be retained in the endosome 
and gain access to the HLA class-II processing pathway. This would require the cell 
to separate the peptide from the antibody and then process it, ready to be presented on 
the surface of the cell as part of a peptide-MHC complex. 
 
As a consequence of previous results, another hypothesis was suggested: an antibody 
containing an HLA-A2 binding peptide embedded within the CDR3 region could 
process and present the peptide. Or would the antibody be prevented from entering the 
antigen processing pathway? In order to answer these questions, another model was 
set up with an antibody containing a viral peptide within the CDR3. The antibody was 
produced using lentiviral transduction and assessed for uptake and presentation by 
professional antigen presenting cells. Initial results suggest that complexing the 
antibody may result in the presentation of the CDR3-derived viral epitope at the cell 
surface although this remains to be confirmed. Rituximab-NLV did not appear to bind 
to B cells due to the mutated heavy chain CDR3, although this was difficult to fully 
determine at the time. Therefore, the responses seen in unfractionated PBMCs and B 
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Figure 5.26 Potential antigen processing of the antibody-peptide conjugate
After internalisation, the peptide would be removed from the antibody in the endosome and 
passed into the cytosol. From there it would be processed by the proteasome and the 
peptides passed into the endoplasmic reticulum via TAP. The peptide then binds to HLA 
class I molecules and could then be expressed at the cell surface. The alternative would 
see the antibody-peptide complex broken down in the endosome. The endosome fuses 
with the compartment containing the MHC class II molecule folded with the invariant chain, 
which is removed before peptides can be loaded onto the class II molecule. After which, the 
peptide loaded class II molecules would be transported to the surface of the cell. 
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cell depleted PBMCs were assumed to be due to uptake of immune complexes via Fc 
receptors. The reduction in IFN-γ spots in B cell depleted PBMCs when complexed 
Rituximab-NLV was added may be a result of the removal of a large percentage of 
professional antigen presenting cells which would normally take up free antibody via 
their Fc receptors.  
 
Despite the results using Rituximab-NLV, the response to Rituximab in B cell 
depleted PBMCs casts some doubt on the validity of the results. Rituximab binds to 
CD20 and therefore when there are B cells present Rituximab would bind to these 
cells which could then be recognised by circulating NK cells leading to release of 
IFN-γ by NK cells. However, using B cell depleted PBMCs, there should have been 
no CD20 for Rituximab to bind to and therefore there could be no NK-mediated 
release of IFN-γ. Even if Rituximab was taken into the cell via Fc receptors, there 
should not be any peptides contained in Rituximab that could elicit a T cell response. 
Therefore, the presence of IFN-γ spots in the B cell depleted PBMCs casts doubt on 
the validity of the results seen with Rituximab-NLV. However, if the results seen 
when Rituximab-NLV was added to PBMCs are correct, the immune complex would 
have been taken into the antigen presenting cell by Fc receptor uptake and the 
antibody processed by the cell resulting in the presentation of CDR3-derived epitopes 
at the cell surface. This would mean that circulating antibodies, once taken into 
professional antigen presenting cells, can be processed and CDR3-derived peptides 
presented at the surface of the cell. This would give a clear indication as to why the B 
cell repertoire is edited to remove B cell receptors which contain HLA-binding 
epitopes within their CDR3. 
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5.18 Conclusion 
In this chapter, the hypothesis tested was that antibodies containing viral epitopes 
could be internalised by target cells and the epitope processed and presented at the 
surface in complex with MHC class-I or II. Initially, using Rituximab the results were 
negative but this was possibly due to the lack of internalisation of the antibody. When 
using BU69, which is known to be internalised, there is expression and recognition of 
MHC class-II peptides by peptide specific CD4
+
 T cells but there is no expression or 
recognition of MHC class-I peptides. The peptide appears to enter the classical MHC 
class-II processing pathway before presentation at the surface of the cell. This 
phenomenon is not restricted to CMV-derived peptides nor is it restricted by MHC 
class-II allele as shown by the positive response to the EBV-derived HLA-DR52-
restricted peptide also producing a response. In an attempt to find more antibodies that 
could lead to presentation of the conjugated peptide, only anti-CD74 produced a 
positive response demonstrating that it is not BU69 specific. The results shown may 
be very important in an immunotherapeutic setting and as a result of this, two 
different malignancies were targeted, breast cancer and Burkitt‟s lymphoma. 
Although initial results using both class-I and class-II peptides showed poor results, 
there are a lot of avenues left to explore.  
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6.  General Discussion 
 
There are an enormous number of potential lymphocyte receptors available to the 
immune system using gene segment re-arrangements, 10
18
 in T cells and 10
16
 in B 
cells.  Despite this, the number of functional receptors present in the periphery is 
thought to be around 25x10
6
 (Arstila et al., 1999) due to the inability to pair and non-
functioning of many of the estimated receptors.  However, it is thought that ~98% of 
all lymphocytes generated are deleted during positive and negative selection in either 
the thymus or bone marrow (Janeway et al, 2001).  Selection processes are known to 
be dependent on the ability of lymphocytes to recognise and react to non-self proteins 
only and in the case of T cells, their ability to weakly recognise MHC class-I or class-
II.  This study suggests that there could potentially be a 3
rd
 selection process, 
dependent on CDR3 sequence, through which B cells must pass before populating the 
periphery.  The potential process of immunoediting of B cells would be a novel 
selection process which has not been previously described (Figure 6.1 A-B).  In this 
model, B cells are forced to present peptides from their CDR3 on the surface and any 
peptides recognised by bone-marrow resident T cells would result in the B cell being 
killed by the T cell, either through Fas:FasL interaction or through perforin/granzyme 
mediated lysis.  The interaction between B and T cells at this stage of maturation may 
or may not be an absolute requirement for B cells to pass this stage of selection.  If no 
interaction occurs, B cells may either die by neglect if T cell interaction is a necessity, 
or they could exit the bone marrow and populate the periphery if T cell interactions 
are not required. 
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Figure 6.1 Model of B cell selection demonstrating 3rd selection step
B cells normally undergo positive and negative selection in the bone marrow to remove 
autoreactive B cells before they populate the periphery (A). Data previously shown suggested a 3rd
selection step during B cell maturation in the bone marrow dependent on the CDR3 sequence of 
each B cell clone (B). B cells containing a potentially immunogenic HLA-binding peptide in the 
CDR3 which could be recognised by bone marrow resident T cells would be deleted in the bone 
marrow at this stage of maturation.
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Data presented demonstrates the potential for a process of editing of the B cell 
repertoire in four HLA alleles suggesting that the phenomenon seen is not an artefact 
of HLA prediction algorithms used in the study although the results seen are not 
statistically significant.  One of the main problems with peptide prediction analysis is 
that none of the algorithms available for epitope prediction are perfect and there will 
always be limitations associated with each.  However, similar results seen with 2 
algorithms across the 4 HLA alleles investigated suggest that the results seen may be 
valid.  The results seen here were restricted to analysis of 4 different HLA types and it 
may be possible that editing or selection of lymphocytes occurs in an HLA-restricted 
manner.  This may be true as the results shown for BCR and TCR were not fully 
consistent across all HLA types tested and this may mean that the selections observed 
may be restricted to certain HLA alleles or that some algorithms are more accurate 
than others. 
 
There may also be a selection pressure on T cells during development based on their 
CDR3 sequence. However, in contrast to B cells, there appears to be immunoselection 
of T cells containing an HLA-binding peptide within the CDR3. This 
immunoselection of T cells was also shown in different HLA alleles suggesting that 
the results are not an artefact of the prediction algorithms.   
 
It is attractive to propose that the observed reduction in B cell HLA-restricted CDR3-
derived peptides acts as a mechanism to limit the development of auto-immune 
disease.  However, a previously published theory of T-B interactions (João, 2007) 
suggests that B cells could present CDR3-derived peptides on their surface which 
mediate immune regulation.  Presentation of these peptides would (i) shape the TCR 
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repertoire and (ii) 'gently' stimulate T cells and this B:T cell interaction may be 
required to prevent T cell death by stimulating the TCR to provide continuous 
survival signals.  However, results shown here would appear to contradict this theory 
because there appears to be a lack of CDR3-derived peptides in the BCR due to 
editing of the B cell repertoire removing B cells bearing CDR3 with self-HLA 
binding peptides.  In this study the cellular basis underpinning this immunoediting has 
not been investigated.  However, it is attractive to postulate that there is interaction 
between B and T cells, as previously suggested, but instead of shaping the TCR 
repertoire in the thymus and stimulating T cells in the periphery, the interaction of B 
and T cells occurs in the bone marrow and shapes the BCR repertoire.   
 
This model (Figure 6.1) may provide explanations for diseases which arise as a 
consequence of either a decreased number of CD8 T cells or a deficiency in CTL 
cytotoxicity. Firstly, patients with an unusually low number of CD8 T cells do not 
present with increased viral infections as may be expected but often present with 
bronchial problems including bronchitis, bronchiectasis and bacterial infections of the 
respiratory tract (Sugiyama et al, 1986; Plebani et al., 1996; de la Salle et al., 1999 & 
Moins-Teisserenc et al., 1999) which are classical signs of antibody deficiency. The 
theory postulated above may explain why a lack of T cells can lead to antibody 
deficiency because B cells require T cell interaction to mature fully and exit the bone 
marrow. This would suggest that B cells require signals from the T cell interaction to 
exit the bone marrow. Patients with a deficiency in CD8 T cells would therefore 
present with decreased numbers of B cells and consequently with bronchial problems 
due to antibody deficiency.  
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Secondly, mutations in either Fas or FasL are responsible for auto-immune 
lymphoproliferative syndrome (ALPS) (Rieux-Laucat et al., 1995 & Drappa et al, 
1996). Patients present with hypergammaglobulinemia and increased lymphocyte 
counts suggesting there is a problem preventing the maturation and homeostasis of B 
cells. This may be explained by the inability of Fas-mediated killing of B cells which 
present potentially immunogenic CDR3-derived peptides by bone-marrow derived T 
cells. This scenario would suggest that B cells do not require T cell interactions to 
allow their exit from the bone marrow and it is the Fas-mediated killing deficiency in 
T cells which is the cause of the increased lymphocyte count and 
hypergammaglobulinemia.  
 
Initial results suggested that there may be an immunoediting process in B cells of 
healthy donors and it would be interesting to determine if there could be a similar 
process in malignant B cells.  There is a decrease in the frequency of CDR3-derived 
HLA-binding peptides in malignant B cells and therefore potentially a process of 
immunoediting of the B cell repertoire. If this is true, it would remove potentially 
tumour-specific T cell targets and may provide a reason as to why many previous 
results studying the T cell immune response towards the idiotype from B cell 
malignancies have been poor (Timmerman et al., 2002 & Levy et al, 2008).  These 
results would suggest that targeting B cell malignancies with anti-idiotypic T cells 
would prove to be very difficult and would fail to elicit a response in the majority of 
patients.   
 
Furthermore, it has been suggested that T cells require constant stimulation through 
TCR engagement to prevent apoptosis (Tanchot et al, 1997).  Contradictory to the 
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published hypothesis (João, 2007) which suggests B cell CDR3-derived peptides 
provide this stimulation, the lack of T cell epitopes found within the CDR3 of the 
BCR suggests that the published hypothesis of shaping the TCR repertoire may not be 
true.  A second competing theory can be suggested using the results shown here.  
There is an apparent stage of immunoselection of T cells bearing a TCR containing 
CDR3-derived peptides and these may be presented on the surface of the T cell, as 
shown previously. This may provide the interaction needed to (i) shape the TCR 
repertoire and (ii) keep T cells alive in the periphery.  T cells would be selected in the 
thymus if they presented a CDR3-derived peptide recognised by other T cells present 
in the thymus and in this way, the TCR repertoire could be shaped.  The presentation 
of the CDR3-derived peptide by memory T cells in the periphery would be recognised 
by CDR3-peptide specific T cells and this interaction could gently stimulate the T 
cells (as described in the published hypothesis) to prevent the onset of apoptosis.   
 
Many previous studies have investigated immune responses towards B cell idiotypic 
peptides (Hsu et al., 1997, Berger et al., 1998 & King et al., 1998).  One of these 
studies, Berger et al., 1998, attempted to prove the presence of an idiotypic peptide on 
the surface of the T cell with encouraging results.  However, there have been no 
previous studies investigating the processing and presentation of CDR3-derived 
peptides in B or T cells.  As part of this report, attempts were made to generate 
models of antigen processing and presentation of CDR3-derived epitopes in both B 
and T cells.  As part of these models, functional TCRs and BCRs were transduced 
into target cells using bicistronic lentivirus vectors.  Previously, similar bicistronic 
lentivirus vectors had been used to express TCRs in T cells (Joseph et al., 2008) with 
good transduction efficiency.  Whilst every attempt was made to make both models as 
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physiologically relevant as possible, there are issues with the generation of the 
models.  Firstly, the cells are being infected with lentivirus which may alter the 
repertoire of peptides expressed at the cell surface.  Secondly, after synthesis of the 
introduced TCR inside the cell, the protein may be broken down immediately and 
presented at the cell surface, therefore not entering the normal pathway of a TCR 
protein chain.  Despite these potential problems, these models may provide an 
interesting insight into the antigen processing and presentation capabilities of (i) T 
cells in presenting TCR CDR3-derived peptides and (ii) various cell types in 
presenting Ig CDR3-derived peptides.  Results shown here are similar to previous 
studies which suggest that CDR3-derived peptides are presented at the surface of T 
cells and B cells.  However, further investigation of the antigen processing and 
presentation of these proteins may provide useful data for future idiotype studies. 
 
The knowledge that there is immunoediting of B cells led to the hypothesis that B 
cells expressing a BCR containing potentially immunogenic CDR3-derived peptides 
are removed to prevent the initiation of an auto-immune reaction after cellular uptake 
of antibody.  Previously, the results suggested that CDR3-derived peptides could be 
processed and presented on the surface of the cells which can be recognised by 
peptide-specific T cells.  The expression of these peptides appears to result in the 
production of IFN-γ by T cells suggesting that there is a T cell response towards the 
peptide, thus, showing that there can be a strong immunogenic response towards 
peptides derived from the CDR3.  The above hypothesis was therefore reversed to 
suggest that antibodies encoding immunogenic epitopes could be used to specifically 
target cells for lysis by CD4 or CD8 T cells.  Initial results shown here suggest that 
this system could be extremely useful in targeting malignant cells using antibodies 
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already available.  Despite previous studies utilising this technique (Casten et al, 1988 
& Eberl et al., 1998), there has not been any studies in the past 10 years using this 
approach to target malignant cells.  Whether this is due to the lack of positive results 
seen using malignant cells or lack of useful antibodies is impossible to ascertain.  
Initial results using peptide-conjugated BU69 staining Ramos cells produced negative 
results suggesting that these malignant cells differ in their antigen processing and 
possibly presentation pathway compared to the positive results seen when using 
LCLs.  This has previously been shown to happen for the antigen processing of MHC 
class I peptides in melanoma (Kageshita et al, 1999), renal cells (Seliger et al., 1996) 
and in other cell types (Cordon-Cardo et al., 1991).  Although these reports show 
deficiencies only in MHC class I processing, the results shown here suggest that 
malignant B cells also alter the MHC class II antigen processing capabilities 
apparently preventing processing of the T cell epitope.   
 
The results produced demonstrate that conjugation using MHC class I peptides does 
not result in recognition by peptide-specific CD8 T cells.  This is most probably 
because the peptide-conjugated antibody is an extracellular antigen and will therefore 
naturally enter the MHC class II processing pathway.  Therefore, in order to present 
the MHC class I peptide, the antibody complex would need to be cross-presented to 
allow the peptide to move from the endosome into the cytosol/endoplasmic reticulum 
and enter the MHC class I processing pathway.  There are very few cells which have 
the ability to cross-present antigens and it has been shown that LCLs cannot cross-
present exogenous antigen (Münz et al., 2000). However, one cell type which has 
shown the ability to cross-present exogenous antigen is dendritic cells (Lizée et al., 
2003).  Therefore, by using DCs loaded with class I peptide conjugated antibody, it 
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may be possible to demonstrate the presentation of class I peptides at the cell surface 
and ascertain if cross-presentation is required for this.  If this is the case, the potential 
for class I peptide-conjugated antibodies in treating malignancies may be reduced.  
However, the use of class II peptide-conjugated antibodies in treating B cell 
malignancies is a very attractive option and it may be possible to treat other 
malignancies. 
 
The results shown here may also provide an explanation for the onset of adverse 
events including fever, chills and myalgia after administration of antibody therapies 
such as Rituximab (Maloney et al., 1997) and intravenous immunoglobulin (IvIg) 
(Duhem et al, 1994). There have been previous suggestions that the adverse effects 
are due to complement after infusion (van der Kolk et al, 2001). However, these 
adverse effects only occur in a small subset of patients treated and therefore, although 
there is an increase in complement proteins after treatment, it may not completely 
solve the issue. An interesting theory regarding the adverse effects is the role of 
CDR3-derived peptides and the T cell responses directed towards them. Data 
presented possibly demonstrates the ability of cells to process and present peptides 
from within the CDR3 region at their surface. This may also occur when antibodies 
are administered to patients whereby the peptides from the CDR3 could potentially be 
presented at the surface of the cell. It could offer an explanation as to why the adverse 
effects are seen in only a small subset of patients because the potentially 
immunogenic peptides present could only be presented by a restricted number of HLA 
alleles. Therefore, the adverse effects seen may be due to HLA restriction and patients 
could be HLA typed before the antibody was administered to determine if they might 
present with complications following therapy. It may be possible to investigate this in 
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the future by HLA typing patients known to have presented with adverse effects and 
to determine if there are common HLA alleles between patients. By doing so, patients 
could be given alternative therapy that would prevent the onset of any adverse events. 
 
The data shown suggests that there could be an overall scenario whereby B cells 
undergo editing in the bone marrow before populating the periphery (Figure 6.2 A). T 
cells do not appear to undergo a selection process during maturation in the thymus. If 
a B cell containing a CDR3-derived peptide reaches the periphery, it could become 
activated and produce antibodies containing the CDR3-derived peptide. Other cell 
types could take up this antibody and present the CDR3- derived peptide at the cell 
surface for recognition by T cells (Figure 6.2 B) leading to the initiation of an immune 
reaction against the original B cell. However, this finding can be used to target 
specific cells for T cell mediated lysis by conjugating a viral peptide to an antibody. 
This technology could be a very important immunotherapeutic tool in the future. 
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Figure 6.2 Overview of CDR3-derived sequence lymphocyte selection and CDR3 peptide 
antigen processing
B cells undergo immunoediting in the bone marrow and B cells without HLA-binding CDR3-derived
peptides populate the periphery (A). T cells may undergo a process of enrichment of HLA-binding
CDR3-derived peptides and there is no immunoediting in the T cell repertoire (A). B cells which
contain an HLA-binding CDR3-derived peptide could produce antibodies which are bound by Fc
receptors, internalised, processed and presented by the cell, leading to the potential initiation of an
immune response (B).
Bone Marrow Thymus
Periphery
Bone Marrow
B cell expressing BCR not containing
HLA-binding peptide
B cell expressing BCR containing
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Appendix - A1 
 
Sequences of Immunoglobulin Heavy Chain CDR3 from Healthy Donors 
 
Ig Heavy Chain Sequence V Region J Region 
ADDTAVYYCARQVYCGGDCFSTDSEFDLWGQGTVVTVSSASPT 
RAEDTAVYYCARSTVDTAMAFDYWGQGTLVTVSSASTKG 
TAADTAVYYCARNARTPDIRGRGTLVTVSSASPTSPKV 
TAADTAVYYCARDPGGGGSGSYFDYWGQGTLVTVSSASPTSP 
VEDTAVYFCARTQYDRSGYYYWYFDHWGRGTLVTVSSASPTSP 
AADTAVYYCARAPRMYGDNTHREFDHWGQGTLVTVSSASTKG 
RSDDTAVYYCARDLDLTGAYYGMDVWGQGTTVTVSSASTKGP 
RIEDTAVYYCVISSGYYNAAGWGQGALVTVSSASTKGPSVFPL 
ADTAVYYCARDREDSSGYYPEGFDYWGQGTLVTVSSASTKGPS 
VTAADTAVYYCARVVAAAANFDYWGQGTLVTVSSGSASAPT 
TAADTAMYFCVRQMVRDGYDFWGQGTLVTVSSASTKGPSVF 
RAEDTAVYYCARDSESFGPYYSGMDVWGQGTSVTVSSASTKGP 
RAEDTAVYYCEAVGRGYSFDYWGQGTLVTVSSASTKGPSVFP 
RAEDTGVYYCARDRSSWYQYYYGMDVWGQGTTVTVSSASTK 
AADTAVYYCVRHNDIAVAFRRGYLDYWGPGTQVTVSSASTKGP 
ASDTAMYYCARQGGTATTLGGVWFDPWGQGTLVTVSSASTKG 
KPEDTGVYYCTTGPMRCSGDNCVFDYWGQGTLVTVSSASPTSP 
DTAVYYCTRDPSRCSGGSCYNYYGMDVWGQGTTVTVSSGSAS 
TAMYKCVREPAVVPAAFRPKFSEDWYFDLWGRGTLVTVSSAST 
 
DTAIYFCVRQRCEARDCYIGNNFYYMDVWGTGTTVTVSSASPTS 
TAADTAVYYCARIKYTHGWFGFDPWGQGTLVTVSSASTKGPSV 
TAADSATYFCARGFTYGPDLDSWGQGIQVTVSSASPTSPKVFP 
ADTAVYYCARLIAAAGPGAGTRGRFDPWGQGTLVTVSSASTKG 
LKTEDTAVYYCTRVGVRFVTSGWGRGTVVTVSSGSASAPTL 
KTEDTGVYYCSTDRDFWRGWNGLDVWGQGTTVIVSSASTKGP 
TAADTAVYYCARERDAFDIWGQGTMVTVSLGSASAPTLFP 
TAADTAVYYCARDSGYRPFDYWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCVRDRDGVAGVYWGQGTLVTVSSGSASAPT 
KTEDTAVYYCTTVPYYDSGGLDYWGQGTLVTVSPGSASAPT 
DTAMYFCARQEADKDMVEQYYFPYWGQGTLVTVSSASTKGP 
TAVYYCARWRGYYDSSGYYDNWFDPWGQGTLVTVSSGSASA 
3-11*01 
3-21*01 
2-23*01 
4-61*01 
3-53*01 
3-7*01 
1-2*02 
3-30*01/07 
4-59*02 
4-31*03 
4-39*01 
3-33*01 
3-30*01 
3-21*01 
4-39*02 
5-51*01 
3-15*07 
3-49*04 
3-30*04 
 
1-69*03 
4-59*01 
4-31*03 
4-59*01 
3-49*04 
3-15*01 
4-59*01 
4-61*01 
3-7*01 
3-15*01 
5-a*03 
4-59*01 
3*01 
4*02 
2*01 
4*02 
2*01 
5*02 
6*02 
4*02 
4*02 
4*02 
4*02 
6*02 
4*02 
6*02 
4*02 
5*02 
4*02 
6*02 
2*01 
 
6*03 
5*02 
4*02 
5*02 
4*02 
6*02 
3*02 
4*02 
4*02 
4*02 
4*02 
5*02 
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TAADTAVYYCARRRVLGGLDPWGPGILVTVSSASTKGPSVFPK 
RAEDTAVYYCARDLLVVGSRGGFDSWGQGTLVTVSSGSASAP 
TATDTAVYYCARTLSASYAQADFWGQGTLVTVSSGSASAPTLFP 
RAEDTAVYYCASKSDWFDLWGQGTLVTVSSGSASAPTLFP 
RAEDTAVYYCARDLEDYGGILDYWGQGTLVTVSSGSASAPTL 
TAADTAVYYCARGSGGRSTNWFDPWGQGTLVTVSSASPTSPK 
TAADTAVYFCVRRRASHGGVWFDSWGQGNLVTVSSASPTSP 
RAEDTAIYYCAKAVGDSGYFQPLNWWGQGTLVTVSSASTKGP 
VTAADTAVYYCAISSYSSRYYYYYMDVWGKGTTVTVSSGSAS 
TAADTAVYYCARDSSGYYYVERWGQGTLVTVSSGSASAPTL 
QASDTALYYCGRHLYGPVSPLDDWGQGTQVTVSAASPTSPKV 
RAEDTAVYYCARDKATMVRHIWFDPWGQGTLVTVSSGSASA 
LRAEDTAVYYCASGAIYRAFDYWGQGTLVTVSSGSASAPTLFP 
TAVYYCARDVELNYDSSGYLGAFDIWGQGTMVTVSSGSASAP 
TAADTAVYYCARDDSSGYSNWFDPWGQGTLVTVSSGSASAP 
 
RSDDTAVYYCARGYSSSWSLRAEYFQHWGQGTLVTVSSGSAS 
RAEDTAIYYCARPQKAMVNWGYFDYWGQGTLVAVSSGSASA 
DTAMYYCAICLSCDFWSGYPYYFDYWGQGSLVSVSSASTKGP 
TAVYYCARDPGEYSSSSGVYYYYGMDVWGQGTTVTVSSGSAS 
TAVYYCAREQTYSSGWYLAMVTNQNDLDVWGQGTTVTVSSAS 
DTAVYYCARILLFSPFGEPPDYYYGMDVWGQGTTVTVSSGSAS 
RDDDTAVYYCARDYGFKLDYWGKGTPVTVSSGSASAPTLFP 
TAADTAVYYCARDSSGYYYVERWGQGTLVTVSSGSASAPTLFP 
RAEDTAVYYCAKVGGYCTNGVCIDYWGQGTLVTVSSGSASAP 
AEDTAVYYCAKVMVEMATIGNYFDYWGQGTLVTVSSASTKG 
ADDTAVYFCGKDAFSYDLSSHLYHIKDWGQGTLVTVSSASTKG 
LTVDDTGVYFCARGLSSGFYYRYGLDVWGQGTTVTVSSASPT 
LRAEDTAIYYCARAHGSGWHTDFFDYWGQGTLVTVSSASTKG 
LRAEDTAVYYCAKVRRGGDCFDYWGQGTLVSVSSGSASAP 
LRVDDTGVYYCARGDGYNWGLFRYWGQGTPVTVSSASPTSP 
LRAEDTAVYYCARDPGGRYINNWFDPWGQGTLVTVSSGSAS 
LTVDDTGIYFCARGLSSGFYYRYGLDVWGQGTTVTVSSASP 
ADTAVYYCARAPRMYGDNTHREFDHWGQGTLVTVSSASTKG 
ISLRDDDAAVYFCARGDNNWAEGKYWGQGTRVTVSSGSASA 
EDTAVYYCARDGAVVTPNWVAFDIWGQGTMVTVSSGSASAP 
LRAEDTAVYYCARDYYGGLDSWGQGTLVTVSSASPTSPKVF 
4-4*07 
3-7*01 
4-59*01 
3-23*01/04 
3-21*01 
4-59*01 
4-59*04 
3-23*01/04 
4-59*01 
4-61*01 
5-51*01 
3-48*03 
3-33*01 
3-48*03 
4-39*01 
 
1-2*02 
3-7*01 
5-51*03 
1-69*06 
3-30*09 
4-39*01 
3-7*01 
4-61*01 
3-30*18 
3-30*03 
3-23*01 
3-21*01 
3-23*01/04 
3-23*04 
3-48*03 
3-33*01 
3-21*02 
3-7*02 
3-7*01 
3-33*01 
3-30*01 
5*02 
4*02 
4*02 
4*02 
4*02 
5*02 
5*01 
4*02 
6*03 
4*02 
4*02 
5*02 
3*02 
4*02 
5*02 
 
1*01 
4*02 
4*02 
6*02 
6*02 
6*02 
4*02 
4*02 
4*02 
4*02 
4*02 
6*02 
4*02 
4*02 
4*02 
5*02 
6*02 
5*02 
4*02 
3*02 
5*02 
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LRAEDTAVYYCAKGRGGYDEDDAFDVWGQGTMVTVSSASPTS 
VAPADTAFYYCARVRGDIDAFDIWGQGAMVTVSSASTKGPSV 
VTAADTAAYYCARGGYDILTGYAKVFDYWGQGTLVTVSSGSAS 
LRVEDTAVYYCAREAVVVPGRPDYWGQGTLVTVSSASPTSP 
LRTEDTALYYCAKRADYGTNSGAFDIWGQGTLVTVSSASTKGP 
EDTAVYYCARVPCGGVGSCKFRWFDPWGQGTLVTVSSASTKGP 
LRAEDTAVYYCAKRRIVGGTVFDYWGQGTLVTVSSASPTSPK 
LRAEDTAVYYCAREYYGNYYWGQGTLVTVSPASPTSPKVFP 
LRAEDAAIYYCARSGTDRPNLLDIWGQGTMVTVSSASTKGPS 
LRAEDTALYYCAKRRGGNSGPFDYWGQGTLVTVSSASTKGPS 
LRSEDMAVYYCVREFYGDLMWGQGTLVTVSSASPTSPKVF 
DTAIYFCARDLATDFDWSLGPAAGFDIWGQGTMVTVSSTSPTSP 
LRAEDTALYYCARVGSSWKFDYWGQGTLVTVSSASTKGPSVFP 
SAVYYCTRGGLTSEKFSVYHGGMDVWGQGTTVTVSSASTKG 
AVYYCARGSDYSNPQTPRDRYNYFYGMGVWGPGTTVTVSSAS 
LRADDTGLYYCANWDLRSDYWGQGTLVTVSSASPTSPKVFP 
LRAEDTAVYFCVSTLTVRPEAGAFHYWGHGTLVTVSSASTKG 
LRAEDTAIYYCAKFRYDYGDYYGIDYWGQGTLVTVSSASPTSP 
LRVEDTAVYYCAREAIVVPGRPDYWGQGTLVTVSSASTKGPS 
LRVEDAAIYYCVRDFYGGKSDYLDYWGQGTLVTVSSASTKG 
VRPDDTARYFCAKPGSGYEGAFDTWGQGALVTVSSAPTKGPS 
LRAEDTAVYYCAREYYGNYYWGQGTLVTVSPASPTSPKVFP 
LTAADTAVYFCARDVRSNYFDNWGQGIAVSVSSASPTSPKVFP 
LKPEDTAVYYCISSGYCSDGRCYRYWGPGTLVTVASASPASPKV 
VTAADTAVYYCARTIGSGSYIDFWGQGALVTVSSASTKGPSVFP 
IEDTAIYYCASNWGSGSPRVHEGAFDIWGQGTKVSVSSASTKG 
LRAEDTALYYCARVGSSWKFDYWGQGTLVTVSSASTKGPSVF 
 
LRVEDTAVYYCARDGPNDSWPLDHWGQGTLVTVSSASTKGPS 
LKAEDTAVYYCAKIRYCGADCYESFEIWGQGTMVTVSSASPT 
LTVDDTALYYCAREKPAGLVTLDPWGQGTLVTVSSASPTSP 
LKSEDTVVYYCMSYESREYFDGFDRWGQGTVVTVSSASPTS 
VTAADTAVYFCARESGIAAAGTLDSWGQGILVTVSSASPTS 
EDTAVYYCARDFIAARPALARISFDYWGQGTLVTVSSASTKG 
LSTEDTAMYYCARGSRGQPCDYWGQGTLVTVSSGSASAPTL 
VTAADTAVYYCARHLSGRDYWGQGTLVTVSSGSASAPTLFP 
 
3-23*01 
4-59*01 
4-39*01 
3-7*01 
3-23*01/04 
3-11*01 
3-23*/0104 
3-48*01 
3-74*01 
3-23*04 
3-30*09 
3-7*01 
3-23*01 
4-61*02 
4-61*02 
3-11*01 
3-21*01 
3-23*01 
3-7*01 
3-30-3*01 
3-23*01/04 
3-48*01 
4-61*02 
3-49*03 
4-4*02 
3-15*01 
3-23*04 
 
3-30*14 
3-23*01/04 
3-7*01 
3-15*07 
4-59*01 
3-33*03 
3-72*01 
4-39*01 
 
3*01 
3*02 
4*02 
4*02 
3*02 
5*02 
4*02 
4*02 
3*02 
4*02 
5*02 
3*02 
4*02 
6*02 
6*02 
4*02 
4*01 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
3*02 
4*02 
 
4*02 
3*02 
4*02 
3*02 
4*02 
4*02 
4*02 
4*02 
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TAIYYCARHVSDLRVPTDLGDYYYAMDFWGQGTTVTVSSAS 
LRGEDTAMYYCAKWDGYGSDWGQGTLVTVSSASPTSPKVFP 
LKASDTAMYYCARRSSGWYGTGFDPWGQGTLVTVSSASTKG 
AADTAVYYCARRYTSGWYQDWYFDLWGRGTLVTVPSASPT 
VTAADTAVYFCARAYGDYENWFDPWGQGTLVTVSSASTKGP 
LRASDTAMYYCARVTSYSSSFYFDYWGQGTLLTVSSGSASAP 
RTDDAGVYYCTRGSILWFGTSGWYYDLWGRGSLVTVSSASPT 
LKTEDTAVFYCTTDYYDSTGSYLMDYWGQGTLVTVSSASPTS 
LRAEDTAVYYCARATREADYWGQGTLVTVSSGSASAPTLF 
VTAADTAMYFCARPRRTLPNTEPFIFDVWGQGTMVTVSSAS 
LRAEDTAVYYCARGGATAYYYYYYMDVWGKGTTVTVSSA 
VTAADTAVYFCARGSGWYDYWGQGTLVTVSSASPTSPKVFP 
LRVEDTAVYYCARDYYGALEPAACSDYWGQGTLVTVSSPST 
 
LASEDTAVYYCARAQSLYGAGSFAGYWGQGSLVTVSSASPTSP 
LRAEDTAVYYCARDLYCRTGTCNHYPDYWGQGTLVTVSSAS 
LRGEDTAVYYCARDLNTSGDYWGQGTLVTVSSGSASAPTLFP 
LRAEDTAVYYCATNSGWRFEYWGQGTLVTVSSASTKGPSVFP 
LRVEDTAVYYCAKEKGLHLPFDYWGQGTLVTVSSGSASAPTLFP 
LKASDTAMYYCARHRFEQQLGYYFDYWGQGNLVTVSSRSASA 
VTAADTAVYYCARADTASRHWDVWGQGTTVTVSSASTKGPSV 
LRAEDTAVYYCARQSSFDYWGQGTLVTVSSASTKGPSVFP 
SDDTAVYYCARVGGLCGGGSCRHYFDFWGQGTLVTVFSGSA 
LRAEDTAVYYCARGQTMIVVAPITSFDYWGQGTLVTVSSGSA 
VTAADTAVYYCARDFSGSYRKTAFDVWGQGTMVTVSSGSAS 
DTAVYYCARGGDHADPFNHRHTAPGGFDYWGQGTLVTVSSG 
TALYYCARDARPPYCSEGICRPDAFGIWGQGTMVTVSSGSA 
LRADDTAVYYCARWRISYHSSGFYAHLDSWGQGSLVTVSSAS 
LRADDTALYYCARVSIPFPDWFDPWGQGTLVTVSSASTKGP 
LRAEDTAVYYCTRDLIIGSGSNDFWGQGTLVTVSSASPTSPKVF 
VTAADTALYYCARATSGSYSPGYFDARGRGTMVTVSSASPT 
LRAEDTAVYYCAKDGGGVNGYYYGMDVWGQGTTVTVSSGS 
LRAEDTAVYYCAKSVAPDFFGSEDYFDYWGQGTLVTVSSTS 
LRGEDTAVCYCSFTLDFWGQGALVTVSSASTKGPS 
LRVEDTAIYYCTRDGPAQSPWGQGTLVTVSSASTKGPSVF 
LRAEDTAVYYCASVSSNGWGFDYWGQGTLVTVSSASPTSPK 
LGAEDSAVYYCAKWPSDLLRQGSFDYWGQGALVTVSSAST 
5-a*01 
3-23*04 
5-a*01 
4-59*01 
4-30-2*01 
5-a*01 
3-74*01 
3-15*01 
3-11*03 
4-61*01 
3-74*01 
4-59*01 
3-7*01 
 
1-46*01 
3-21*01 
3-48*01 
3-7*01 
3-23*01 
5-51*03 
4-4*07 
3-33*01 
1-2*02 
3-23*01/04 
4-39*07 
4-59*01 
4-61*02 
3-21*01 
3-23*01 
3-74*01 
4-61*01 
3-23*04 
3-30*03 
3-7*01 
3-53*01 
3-74*02 
3-23*01/04 
6*02 
4*02 
5*02 
2*01 
5*02 
4*02 
2*01 
4*02 
4*02 
3*01 
6*03 
4*02 
4*02 
 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
4*03 
4*02 
4*02 
4*02 
3*01 
4*02 
3*02 
4*02 
5*02 
4*02 
3*01 
6*02 
4*02 
4*02 
5*02 
4*02 
4*02 
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LRSDDTAVYYCAKDLGSSNAFHIWGQGTMVTVSSASPTSPKVF 
 
DTAVYYCAKDYYDSSGPQSYYYYGMDVWGQGTTVTVSSGSA 
LRAEDTAIYYCAKRRGLEVPDWSFDLWGRGTLVTVSSASTKG 
VTAADTAVYYCARAMITSRAFDFWGQGTLVTVSSASPTSPKVF 
EDTAVYYCSSTYTTMVRGVIRRAFDYWGQGTLVTVSSASTK 
LKIEDTAVYYCTTGASDGSYYKTDSWGQGTLVTVSSASTKGP 
VTAADTAVYYCARLMAVAGRLDVWGQGTTVTVSSGSASAP 
LRVEDTAVYYCARGQWLVFRGQGALVTVSSGSASAPTLF 
TAVYYCAIEYRPPPMARGGTGYSYGMDVWGQGTTVTVSSGSA 
LRAEDTAVYYCTKTLVAAAGQSWGQGTLVTVTSASPTSPKVFP 
LRSEDTAVFYCARLVGSSEFFAFDIWGQGTMVTVSSASTKGP 
LRAEDTAVYYCARLFQEGDSRDRHFDLWGRGTLVTVSSAST 
LRAEDTAVYYCVRADDGDYQTLNWGQGTLVTVSSASTKGPS 
LRAEDTAVYYCAKGDLPMVRAPAGYWGQGTLVTVSSGSAS 
VTAADTAVYYCAGVPMGGSSSGAFDIWGQGTMVIVSSGSAS 
SDTAMYYCARHREGEDQIYYYYGLDVWGQGTTVTVSSASTK 
ADTAVYYCARLHRDKRDYYYYYGMDVWGQGTTVTVSSGSA 
VTAADTAVYYCAGRFFVRSEPGMDVWGQGTTVIVSSASPTSP 
VTAADTAVYYCARNFYYSMDVWGQGTTVTVSSASTKGPSVFP 
LTPDDTAMYYCVSFSGMGEGTLVTVSSGSASAPTLFP 
VTAADTAVYYCARERLREEGLFDPWGQGILVTVSSASTKGPS 
LRDEDAAVYFCARESAATGTRYFDYWGQGTLVTVSSGSASA 
LRAEDTAVYSCARELGGDDVFDIWGQGTVVTVSSGSASAPTLF 
LKIEDTALYYCTTDWGSGTNPKIAFDLWGQGTMVTVSSASPT 
 
LKTEDTAVYYCTRRVGRARRLNWFDPWGQGTLVTVSSASTKG 
LRVEDTAVYFCAKDLRPGSVVTQLDHWGQGTLVTVSSASTKG 
LRVEDTALYYCASHKGVSYYGAFDFWGRGTAVSVSSASTKG 
LRAEDTAVYYCVRELFDYTGPWGYWGQGTLVAVSSASPTSP 
VTAADTAVYYCARGNPTPTMYGLYYWGQGTLVTVSSASTKG 
DTARYFCARAGYYDFWSQFLKGMDVWGQGTTVTVSSASTKG 
LRLEDTALYYCVKSSRQQGLAYYDYWGRGTLVTVSSASTKG 
LRAEDTAVYYCAKLVYSGSYHFDYWGQGTLVTVSSASTKG 
LTAEDTAVYYCAREWRAFDIWGQGTRVTVSSASPTSPKVFP 
VTAADTAVYYCTRGSGYGADAGTFDPWGQGTLVTVSSGSASA 
VTAADTAVYYCAREYYSGGWLRTDYWGQGILVTVSSASTKG 
1-2*02 
 
3-48*02 
3-23*01/04 
4-4*07 
3-15*01 
3-15*01 
4-59*01 
3-7*01 
3-23*01/04 
3-7*01 
1-69*06 
3-7*01 
3-74*01/02 
3-23*01 
4-59*01/03 
5-a*03 
4-39*01 
4-4*02 
4-4*02 
1-2*02 
4-4*02 
3-74*01/02 
3-33*01 
3-15*01 
 
3-49*04 
3-30*03/18 
3-30*04 
3-7*01 
4-4*02 
4-b*01 
3-9*01 
3-23*01/04 
3-21*01 
4-61*01 
4-59*01 
3*02 
 
6*02 
2*01 
4*02 
4*02 
4*02 
3*01 
4*02 
6*02 
1-1*01 
3*02 
2*01 
4*02 
4*02 
3*02 
6*02 
6*02 
6*02 
6*02 
5*02 
5*02 
4*02 
3*02 
3*01 
 
5*02 
4*02 
3*02 
4*02 
4*02 
6*02 
4*02 
4*02 
3*02 
5*02 
4*02 
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DTAMYYCARHEGERGLWFGELPYYFDYWGQGTLVTVSSGSAS 
LKTEDTAVYYCNTWVAVGGLMFDYWGQGTLVTVSSASTKG 
VTAADTALYYCARIIDGYIMVPFDYWGQGILVTVSSASPTSPK 
VTAADTAVYYCASRDGHSIDYWGQGVLVTVSSASPTSPKVFP 
LRAEDTAVYYCVRSGYGPRYYFDCWGQGTLVTVSSAPTKG 
YYCARDMVVFGGINVDTPMITLLPGWFDPWGQGARVTVSSAST 
LRLEDTALYYCVKSSRQQGLAYYDYWGRGTLVTVSSASTKG 
VTPEDTAVYYCARDNYGMDVWGQGTSVTVSSGSASAPTLF 
ATAADTAVYYCARDRGGVGASDAFDIWGQGTMVTVSSASPTS 
LRAEDTAVYYCARDRNDIWSGYLLGWFDLWGRGTLVTVSSASP 
LRAEDTAVYYCARDRGEDNPIDYWGQGTLVTVSSASPTSPKVF 
VTAADTAVYYCVRDCGWLVSGDAFDTWGQGTMVTVSSASTK 
 
LRAEDTAVYYCVRGGVLGATDYWGQGTLVTVSSASTKGPSVFP 
AEDTAIYYCAREVGYVSPSSWAIDAFDVWGQGTMVTVSSASTK 
LRSEDTAVYYCARGRRDGYNPFDYWGQGTLVTVSSGSASAP 
LTAEDTATYYCARLSVTYGWEFLDYWGRGTLVTVSSASPTSP 
LRAEDTALYYCAVDVSSSPTLWGQGTLVTVSSGSASAPTLFP 
VTAADTAVYYCARLPPPGSGSYFDPWGQGVLVTVSSGSASAP 
ADTAVYYCARAEYCTGGVCYGPRHLDNWGQGTLVTVSSASPTS 
VTAADTAVYYCATYYIGLTGLHWYFDVWGLGSLVTVSSPSPTS 
ADTAVYYCARRKYYFDSSGLILDTFDIWGQGTMVTVSSGSASA 
LRAEDTAVYYCASVRLALSSTALDYWGQGTLVTVSSASTKG 
LQASDSAMYFCARSPIPWGNLWSGAQLDYWGQGTLVTVSSASP 
VTAADTAVYYCARGKPTTVFDYWGQGTLITVSSASTKGPSVFP 
VTAADTAVYYCGTDSTGWLGYGIDVWGPGTTVTVSSASPTSP 
VTAADTAIYMCARVIRTGEGGRGYFDLWGRGTLVTVSSASPTS  
a 
VRPDDTARYFCAKPGSGYEGAFDTWGQGALVTVSSAPTKGPSV 
LRAEDTAIYFCARVFYDGRGSHHYYFDFWGQGTLVTVSSASTK 
VTPADTAVYYCARDDFWSGTHWFDPWGQGTLVTVSSASPTSPK 
LRAEDTAVYYCAKNYDFWSTYYFDYWGQGTLVTVSSGSASAP 
ADTAVYYCARGLYYYGSGSLGYCYDMDVWGQGTTVTVSSGSA 
LTVADTAVYYCVRVRKERGGSLDDWGQGTTVTVSSASTKGPS 
VTAADTAVYYCARGPGRGYADYWGQGTLVTVSSGSASAPTLF 
 
EDTAVYYCAREGDPSGSGTYLDAYDIWGQGTMVTVSSGSASAP 
5-51*01 
3-15*01 
4-61*01 
4-4*06 
3-7*01 
4-59*01 
3-9*01 
6-1*01 
4-59*01 
3-7*01 
3-33*01 
4-b*02 
 
3-74*01/02 
3-48*03 
1-69*01 
3-48*03 
3-23*04 
4-59*03 
4-61*01 
4-61*01/08 
4-b*01 
3-48*03 
5-51*01 
4-4*02 
4-4*02 
4-4*02 or 
4-61*03 
3-23*04 
3-11*03 
4-61*08 
3-23*01/04 
4-59*01 
4-4*02 
4-59*01 
 
3-48*03 
5*02 
4*02 
4*02 
4*02 
4*02 
5*02 
4*02 
6*02 
3*02 
2*01 
4*02 
3*02 
 
4*02 
3*01 
4*02 
4*02 
4*02 
5*02 
4*02 
2*01 
3*02 
4*02 
4*02 
4*02 
6*02 
2*01     
at 
4*02 
4*02 
5*02 
4*02 
6*02 
4*03 
4*02 
 
3*02 
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VTAADTAIYYCVQGDSLVAFDVWGQGTLVTVSSASPTSPKVFP 
TGVYFCAREGIYSYSSGSIWGSRTYNGMDAWGKGTTVIVAPAST 
LTAEDTAMYYCARRGANRDFAFDVWGPGTMVTVSSASPTSPK 
LKASDTAMYYCARHKSGVTTVTTLDYWGQGTLVTVSSGSASA 
LRPEDTATYFCAKGDFGSSQYYFDYLGQGTLVTVSSASPTSPK 
VTAADTATYYCMRSGYSGGGHWGQGKLVTVSSASTKGPSVFP 
LTAEDTALYYCAKDLVGEHTYWGQGTLVTVSSASPTSPKVFP 
VTAADTAVYYCARADGATVTYWYFDLWGRGTLVTVSSGSASA 
VTAADTAVYYCARGSNSWSFDYWGQGTLVTVSSGSASAPTLFP 
VTAADTAVYYCARLRGNYFPDVWGKGTTVTVSSGSASAPTLFP 
at 
VTAADTAVYYCARHGSHWTFDSWGQGTLVTVSSGSASAPTLFP 
LRAEDTAVYYCASGYSAYALGYWGQGTLVTVSSGSASAPTLFP 
VTAADTAVYYCARYGSGSYHFDYWGQGILVTVSSASPTSPKVFP 
LRAEDTAVYYCARTSNFGDYPIDYWGQGTQVTVSSASPTSPKVF 
VTAADSATYFCARGFTYGPDLDSWGQGIQVTVSSASPTSPKVFP 
VTAADTAVYYCARDLGYSYSYYFDSWGQGTLVTVSSGSASAP 
VTAADTAMYFCARDHTYSGRGGMDVWGPGTTVAVSSASPTSP 
AADTAVYYCARQTYYYDSSGNYYLDYWGQGTLVTVSSGSAS 
VTAADTAVYYCAREKWELHTRAFDIWGQGTMVTVSSGSASAPT 
VTAADTATYYCMRSGYSGGGHWGQGKLVTVSSASTKGPSVFP 
VTAADSATYFCARGFTYGPDLDSWGQGTQVTVSSASPTSPKVFP 
 
4-4*07 
3-33*01 
3-11*03 
5-a*01/03 
3-23*04 
4-31*06 
3-23*01/04 
4-59*01 
4-59*01 
4-59*02 or 
4-61*08 
4-59*01 
3-74*02 
4-59*01 
3-21*02 
4-31*03 
4-61*01 
4-31*06 
4-59*01 
4-59*01 
4-31*06 
4-31*03 
3*01 
6*04 
3*01 
4*02 
4*02 
5*02 
4*02 
2*01 
4*02 
6*03     
at 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
6*02 
4*02 
3*02 
5*02 
4*02 
 
Sequences from data set were compared with known Ig sequences to determine variable 
region and joining region usage (Imgt.cines.fr - version 3.2.16 (Accessed 24 September 2010) 
(Brochet, X et al, 2008)). 
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Appendix – A2 
 
Table of Immunoglobulin CDR3-Derived Peptides Predicted to bind to HLA 
Alleles from SYFPEITHI and BIMAS 
 
HLA-A1
+
  HLA-A1
-
  HLA-A2
+
  HLA-A2
-
  
YYDSGGLDY 
LRDEDTAVY 
LRDEDAAVY 
RTEDTALYY  
KTEDTAVYY 
KTEDTGVYY 
RSEDMAVYY 
RADDTGLYY 
CSDGRCYRY 
RSEDTAVFY 
RLEDTALYY 
TSEDTAIYF 
RAEDTAVYY 
MVEQYYFPY 
RAEDTAIYY 
RVEDTAVYY 
RPEDTAVYY 
RAEDAAIYY 
RAEDTALYY 
RAEDTAMYY 
YGDYYGIDY 
RVEDAAIYY 
KPEDTAVYY 
TIEDTAIYY 
RAEDTAIYY 
KIEDTAVYY 
EGEDQIYYY 
TPDDTAMYY 
KIEDTALYY 
SYDLSSHLY 
LRDDDAAVY 
PTDLGDYYY 
RSDDTAVYY 
DSESFGPYY 
SGDNCVFDY 
KTEDTAVYY 
RSEDTAVYY 
TVDDTALYY 
KSEDTVVYY 
STEDTAMYY 
RTDDAGVYY 
KTEDTAVFY 
ASEDTAVYY 
TSDDTAVYY 
RADDTALYY 
RAEDTAVYY 
GADDTAVYY 
DLDLTGAYY 
RIEDTAVYY 
YCEAVGRGY 
RAEDTGVYY 
KPEDTGVYY 
RAEDTAIYY 
FGEPPDYYY 
RVDDTGVYY 
TVDDTGIYF 
RPDDTAIYY 
RVEDTAVYY 
SLRDDDAAV 
YQYYYGMDV 
DLWGRGTLV 
AMYYCAICL 
QTYSSGWYL 
KVMVEMATI 
DLWGRGSLV 
TLPNTEPFI 
SLYGAGSFA 
GIWGQGTMV 
ALYYCAKDL 
TVTYWYFDL 
 
GLDPWGPGI 
DILTGYAKV 
TLNWGQGTL 
HLYGPVSPL 
DLMWGQGTL 
LMWGQGTLV 
RIIDGYIMV 
ALYYCAVDV 
TLWGQGTLV 
GLILDTFDI 
RLALSSTAL 
YIGNNFYYM 
DLWGQGTLV 
AIYYCAKAV 
LATDFDWSL 
GLTSEKFSV 
GVWGPGTTV 
DLWGQGTMV 
RVHEGAFDI 
WLVFRGQGA 
YCARGQWLV 
LVGSSEFFA 
GLYYWGQGT 
SQFLKGMDV 
AVYYCNTWV 
YVSPSSWAI 
TLWGQGTLV 
YMCARVIRT 
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RVEDTALYY 
TAEDTAVYY 
RLEDTALYY 
TPEDTAVYY 
KAEDTAVYY 
RGEDTAMYY 
NTEPFIFDV 
RGEDTAVYY 
HTAPGGFDY 
RADDTAVYY 
RGEDTAVCY 
RVEDTAIYY 
GAEDSAVYY 
TAEDTATYY 
RAEDTALYY 
GVEDTAVYY 
TAEDTAMYY 
TAEDTALYY 
RADGATVTY 
 
 
 
 
HLA-B7
+
  HLA-B7
-
  HLA-B8
+
  HLA-B8
-
  
APRMYGDNT 
AVYYCARDL 
AAGWGQGAL 
AVAFRRGYL 
AVYYCARIL 
EPPDYYYGM 
CARDYGFKL 
GVYFCARGL 
CARDYYGGL 
CARGGYDIL 
CVREFYGDL 
AVYFCVSTL 
EVPDWSFDL 
LVFRGQGAL 
AVYYCTKTL 
DPSGSGTYL 
RPGSVVTQL 
GVYWGQGTL 
VPYYDSGGL 
FPYWGQGTL 
AVYYCARDL 
AVYYCARTL 
CAREKPAGL 
AARPALARI 
AVYYCARHL 
RPRRTLPNT 
CARDYYGAL 
AVYYCTRDL 
AVCYCSFTL 
CAKWPSDLL 
RERLREEGL 
CARLRGNYF 
CAREKWELH 
ELHTRAFDI 
CAKEKGLHL 
CAKWPSDLL 
CAKRRGLEV 
DSRDRHFDL 
CARDKATMV 
DARGRGTMV 
CARDRNDIW 
CARDRGEDN 
CARHKSGVT 
 
CAKVRRGGD 
CAKGRGGYD 
CAKRRIVGG 
CAKRRGGNS 
CAKFRYDYG 
SPRVHEGAF 
CAKIRYCGA 
CAREKPAGL 
TPRDRYNYF 
VRKERGGSL 
DIRGRGTLV 
CARDREDSS 
CARDRSSWY 
CARDYGFKL 
CARDYYGGL 
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DSRDRHFDL 
CARNFYYSM 
AVYSCAREL 
SVTYGWEFL 
GVCYGPRHL 
AVYYCARGL 
 
AVYYCAKDL 
AVYYCVREL 
NPTPTMYGL 
TVTYWYFDL 
 
CARGGYDIL 
CARDYYGAL 
CARGKPTTV 
 
 
 
 
Key 
 
Peptides predicted to bind to:  SYFPEITHI 
    Both Algorithms 
    BIMAS 
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Appendix – A3 
 
Sequences of immunoglobulin heavy chain CDR3 from CD27
-
 B cell receptors 
from one healthy donor 
 
Sequence V Region J Region 
RVEDTAVYYCAKGGWLENWGQGTLVTVSSGSASAPTLF 
AEDTAVYYCAKDSPGGSSSWYVGYYYGMDVWGQGTTVTVSSGSAS 
SSEDTAVYYCAREDPDSYYDDYWGQGTLVTVSSWSASAPTLF 
TAADTAVYYCARERDNDGMDVWGQGTTVTVSSGSASAPTLF 
RSDDTAVYYCARTFGHRHDAFDIWGQGTMVTVSSGSASAPTLF 
TAADTAVYYCARVERTITVVKFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDSSELWPTGWFDPWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCAKVSLRAPRSWVWFDPWGQGTLVTVSSGSASAPTLF 
EDTAVYYCARDNVVEYQLPQSLDYYYGMDVWGQGTTVTVSSGSAS 
TAADTAVYYCARRGQWLVKGWFDPWGQGTLVTVSSGSASAPTLF 
PEDTAVYYCARYIAVAEFDYWGQGTLVTVSSGSASAPSLF 
TAADTAVYYCARDSGSGYSSGWYDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARHFKQQRPNWFDPWGQGTLVTVSSGSASAPTLF 
TATDTAIYYCSRHGSWLQPQNGFDVWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARARGYEPFDYWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCAKFGLAGITVAGNDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDRYGDYGAVNWFDPWGQGTLVTVSSGSASAPTL 
TAADTAVYYCARVNVRGWKIYYGMDVWGQGTTVTVSSGSASAPTL 
TAADTAVYFCARISGYDIDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCATRRIAAAGIVYWGQGTLVTVSSGSASAPTLF 
TATDTAMYYCARHGSWLQAQIGFDIWGQGTMVSVSSASPTSPTLF 
TAADTAVYYCARARGGYYDSGEFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARTGRAYSSGWIDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARRLGGSFSTLYYFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGLAATPVDFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGRVPAVVGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARREGTDAFDIWGQGTMVTVSSGSASAPTLF 
TAADTAVYYCARVSDMTFDPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCAREGGAATLSFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDPAAAGRFAPSGFDYWGQGTLVTVSSGSASAPTL 
3-23*01/04 
3-23*01/04 
1-46*01/03 
4-59*01 
1-18*01 
4-31*03 
4-59*01 
3-30*03/18 
1-69*01 
4-4*02 
6-1*01 
4-59*01 
4-39*01 
4-39*01 
4-59*01 
3-30*03/18 
4-61*02 
4-59*01 
4-59*01 
4-31*03 
4-39*01 
4-59*01 
4-31*03 
4-39*01 
4-59*01 
4-59*01 
4-39*01 
4-4*02 
4-59*01 
4-61*01 
4*02 
6*02 
4*02 
6*02 
3*02 
4*02 
5*02 
5*02 
6*02 
5*02 
6*02 
4*02 
5*02 
3*01 
4*02 
4*02 
6*02 
6*02 
4*02 
4*02 
3*02 
4*02 
4*02 
4*02 
4*02 
5*02 
3*02 
5*02 
4*02 
4*02 
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TAADTAVYYCARDRGGNLLDMHYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARAPQLWLIDPWGQGTLVTVSSGSASAPTLF 
DTAVYYCARGGVGYCSGGSCQTDYYYGMDVWGQGTTVTVSSGSAS 
TAADTAVYYCARVGLERQYYYYYGMDVWGQGTTVTVSSGSASAPT 
TAADTAVYYCARGGAYNWNDVNFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARYYVWGSYHDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDRRVEMATIIYYYGMDVWGQGTTVTVSSGSASAP 
TAADTAVYYCARASIAAAGVSDIWGQGTMVTVSSGSASAPTLF 
TAADTAVYYCARDGARYYYGMDVWGQGTTVTVSSGSASAPTLF 
TAADTAVYYCARAKRGGAARLVWFDPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGGSGWYYFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARVKLLMDYSNYGHWFDPWGQGTLVTVSSGSASAP 
TAADTAVYYCARVSFGSSLYYFDYWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCARGGGGRCLRMDVWGQGTTVTVSSGSASAPTLF 
TAADTAVYYCAREVRYGSGSFSMDVWGQGTTVTVSSGSASAPTLF 
TAADTAVYYCARVGASSGADYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGMGSSSPIDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGPRFDPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARTITIFGVPPPGWFDPWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCARDVGAKLFDYWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCAKDQGELHDAFDIWGQGTMVTVSSGSASAPTLF 
RAEDTAVYYCARGKSYYDSIGVGTLVTVSSGSASAPTLF 
TAADTAVYYCARDRDIFTWGQGTLVTVSSGSASAPTLF 
TPEDTAVYYCARDRFGELLRPYYYYGMDVWGQGTTVTVSSGSASAP 
RAEDTAVYYCASSYDYVWGSYRSFAPEDYWGQGTLVTVSSGSASAP 
TAADTAVYYCARVGSSWYSRWFDPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCAAGGSYGVGPANWFDPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARQVITARHSDYWGQGTLVTVSSGSASAPTLF 
RAEDTAVYYCARVSRFLEWLPSGSIDYWGQGTLVTVSSGSASAPTLF 
KTEDTAVYYCTRVRDIAVAGPVDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGDLTLDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCAREKVYYGMDVWGQGTTVTVSSGSASAPTLF 
RSEDTAVYYCARAPRNIVVVIAMPSGAFDIWGQGTMVTVSSGSASAP 
TAADTAVYYCVRAMLGVPAFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARALPIDYYGSGSYIDYWGQGTLVTVSSGSASAPTLF 
4-61*01 
4-59*01 
4-59*01 
4-59*01 
4-59*01 
4-59*01 
4-61*01 
4-59*01 
4-59*01 
4-59*01 
4-59*01 
4-59*01 
4-59*01  
3-11*01 
4-59*01 
4-4*02 
4-59*01 
4-59*08 
4-59*01 
3-74*01/02 
3-23*01/04 
3-11*01 
4-59*01 
6-1*01 
3-74*01/02 
4-59*01 
4-30-4*01 
4-39*01 
3-74*01 
3-49*04 
4-59*01 
4-59*01 
1-8*01 
4-4*02 
4-30-4*01 
4*02 
5*02 
6*02 
6*02 
4*02 
4*02 
6*02 
3*02 
6*02 
5*02 
4*02 
5*02 
4*02 
6*02 
6*02 
4*02 
4*02 
5*02 
5*02 
4*02 
3*02 
4*02 
4*02 
6*02 
4*02 
5*02 
5*02 
4*02 
4*02 
4*02 
4*02 
6*02 
3*02 
4*02 
4*02 
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RSEDTAVYYCARDLWFLENLYYFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARSGYFPGGFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARHAPDLVVVVDNWFDPWGQGTLVTVSSGSASAPTL 
TAADTAVYYCARNRAVAGTKGFDYWGQGTLVTVSSGSASAPTLF 
RSEDTAVYYCARAPLGAGYFVDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARGSKWELLLDWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDMFFGVAPDAFDIWGQGTMVTVSSGSASAPTLF 
TAADTAVYYCARAEAAGMVHNDAFDIWGQGTMVSVSSGSASAPTLF 
TAADTAVYYCARAPIRPHPFDLWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARDSGSGYSSGWYDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARANYILEWLIDYWGQGTLVTVSSGSASAPTLF 
ADTAVYYCARYHYYYDSSGYYPETNWFDPWGQGTLVTVSSGSASA 
TAADTAVYYCARDIERFLRPWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARARGYEPFDYWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARERIYKNAGGLLSDWGQGTLVTVSSGSASAPTLF 
TAADTAVYYCARAGATDIAVAGYYFDYWGQGTLVTVSSGSASAPTL 
TAADTAMYYCARVGSYGYHDWGQGALVTVSSGSASAPTLF 
LRAEDTAVYYCAKVMVEMATIGNYFDYWGQGTLVTVSSASAPTLF 
1-46*01/03 
4-4*02 
4-39*01 
4-4*02 
1-69*01 
4-39*01 
4-59*01 
4-61*02 
4-59*01 
4-59*01 
4-59*01 
4-31*03 
4-4*02 
4-59*01 
4-59*01 
4-4*02 
4-59*01 
4-59*01 
4*02 
4*02 
5*02 
4*02 
4*02 
4*02 
3*02 
3*02 
4*02 
4*02 
4*02 
5*02 
5*02 
4*02 
1*01 
4*02 
4*02 
6*02 
 
Sequences from data set were compared with known Ig sequences to determine variable 
region and joining region usage (Imgt.cines.fr - version 3.2.16 (Accessed 24 September 2010) 
(Brochet, X et al, 2008)). 
 
 
.   
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Appendix – A4 
 
Sequences of immunoglobulin heavy chain CDR3 from CD27+ B cells from 
healthy donors 
 
Sequence V Region J Region IgA/G 
RPEDTAVYFCAKAPGGNFGDYSEALDVWGQGTTVIVSSASTKGPS 
TAADTALHYCARDDISDPSFDLWGRGTLVTVSSASTKGPS 
TAADTAVYFCARGPRAYCRGGNCLVPLRWGQGTLVTVSSASPTS 
SDTAMYYCVRHRRIELSNGDNLFHGMDLWGQGTTLTVSAASPTS 
AADTAVYYCTRTPRHGYCSSTSCYGEFDYWGQGTPVTVSSASTKG 
RAEDTAVYYCARDGWIATSKYRLDSWGQGTLVTVSSASTKGPSV 
KASDTAMYYCARYHNTWYGDSWGQGTLVTVSSASTKGPSVF 
TAADTAVYYCARGRDYGEFDSWGQGTLVTVSSASTKGPSV 
TAADTAVYYCARAALMVRGHAFEIWGQGTLVAVSSASPTSPSV 
RAEDTAVYYCARDLSWQLFDYWGQGALVTVSSASTKGPSV 
TDEDTAVYFCARGHPGYTFAYWGQGTPVTVSSASTKGPS 
TAADTAIYYCARAIVAIGVVGDWFDPWGRGTLLIVSSASTKGPS 
TAEDTAVYSCARGRRVGALSYFDSWGQGSLVTVSSASTKGPS 
AADTAVYYCARDPRAYYYDSSASSGFDSWGQGTLVTVSSASTKG 
TAADTAVYYCARGLGYCIDGVCHLFDYWGQGALVTVSSASPTSP 
RTEDTAVYYCARDYGGNLDLWGQGIVVTVSSASTKGPK 
TAADTAVYYCARRSDIWHAFDPWGPGTMVTVSSASTKGPS 
TAADTAVYYCAGSGNYYYLQYWAQGSQVTVSSASPTSPS          
attack 
TAADTAVYYCARDHSLGWWYVWGQGTLVTVSSASTKGPS 
RAEDTAVYYCAKLGEHSSLGLDVWGQGTTVTVSSASTKGPS 
RAEDTAIYYCAKGSHSSWSFFDFWGQGTLVTVASTSPTSPS 
TAADTAVYYCARGQWETWFDLWGQGTLVTVSSASTKGPS 
TAADTAFYYCARIHCGVGICYWDWGQGTLVTVSSASTKGPS 
TAADTAVYYCARGDLRGGSFYGGYDHWGQGILVTVSSASTKGP 
TTADTAVYFCARGQLMGPWGRGTLVTVSSASTKGPS 
GAEDTADYYCARGKLNDYGLDVWGQGTTVTVSSASTKGPS 
TAADTAVYYCARRSDIWHAFDPWGPGTMVTVSSASTKGPS 
AEDTAVYYCARCDCSGSCYLRAHCGMDVWGQGTTVIVSSASPTS 
TAADTAVYYCARDYGGYWGQGTLVTVSSASTKGPS 
3-30*03/18 
4-39*01 
4-31*01 
5-a*01 
4-61*01 
3-30*15 
5-51*01 
4-31*01 
4-4*07 
3-74*01/02 
4-59*02 
4-61*01/03 
3-23*01/04 
4-59*01 
4-59*01 
3-30*01 
4-39*01 
4-59*01 or 
4-61*01 
4-61*01/03 
3-74*01/02 
3-23*04 
4-b*01 
4-b*02 
4-30-4*03 
4-59*01 
3-74*01/02 
4-39*01 
3-21*01 
4-59*01 
3*01 
2*01 
4*02 
6*02 
4*02 
4*02 
4*02 
4*02 
3*02 
4*02 
4*02 
5*02 
4*02 
5*01/02 
4*02 
4*02 
3*01/02 
1*01    
at 
5*02 
6*02 
4*02 
5*02 
5*02 
5*02 
4*02 
6*02 
3*01/02 
6*02 
4*02 
IgG 
IgG 
IgA 
IgA 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
IgG 
IgA       
attt 
IgG 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
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RAEDTAVYYCIMMTVGWGHGTLVTVSSASTKGPS 
AADTAVYYCARFRVGATATLGDYYFDSWGQGTLVTVSSASPTSP 
NAADTAVYFCARGPRAYCRGGNCLVPLRWGQGTLVTVSSASTKG 
TAADTAVYFCARGPRLMVYARFDNWGPGTLVTVSSASTKGPS 
ADTAIYYCARDFRQLDTRYKHHYYGMDAWGQGITVTVSSASPTS 
RAEDTAVYYCARVPLGQWLVGADWGQGTLVTVSLASTKGPS 
RAEDTAVYFCARGAYGKFYFDYWGQGTLVTVSSASTKGPS 
TALYYCVKDRGVGGVLRYYDWLHSFDCWGQGTLVTVSSASTKG 
RAEDTAVYYCAKKYDNRSPSFDYWGQGSLVTVSSASTKGPS 
KTEDTAVYYCARAPCSNDICHLLNWGQGTLVTVSSASTKGPS 
TTADTAVYFCARGQLMGPWGRGTLVTVSSASTKGPS 
RAEDTAVYYCARDERGYTTSCIDYWGQGTLVTVSSASTKGPS 
RAEDTAVYYCARGLISGSQSAGGMDVWGQGTTVTVSSASPTSPS 
RPEDTAVYFCAKAPGGNFGDYSEALDVWGQGTTVIVSSASTKGPS 
TSEDTAVYYCARGRDGYIRGLFDYWGQGILVTVSSASTKGPS 
ADTAVYFCARGGASRESSGWNQVHGLDVWGQGTSVIVSSASPTS 
TAADTAVYYCARDRATNSRYFYGLDVWGQGTTVIVSSASTKGPS 
TAADTAVYFCARGPRAYCRGGNCLVPLRWGQGTLVTVSSASTKG 
RAEDTAVYYCAKDQGSGWGGDAFDIWGQGTMVTVSSASTKGPS 
DTAVYYCGRETEPSSDYFSAQPGWPYFDHWGQGALVTVSSASTK 
RAEDTAVYYCARDLSWQLFDYWGQGALVTVSSASTKGPS 
TVADTAVYFCARGKEWLPDNWFDPWGQGILVTVSSASTKGPS 
RSEDTAVYYCARASMLLDWGQGTLVAVSSASTKGPS 
TAADTAVYYCARGDLRGGSFYGGYDHWGQGILVTVSSASTKGPS 
TAADTAVYYCAVTTTSTGASEIWGPGTMVTVSSASPTSPS 
RAEDTAVYFCARGAYGKFYLDYWGQGTLVTVSSASTKGPS 
ADTAVYYCAKIAIFQHVNLPYYYYAMDDWGQGTKVTVSSASTKG 
TAADTAVYYCARGRDYGEFDSWGQGTLVTVSSASTKGPS 
TAADTAVYYCARDRRPGGSPHYDYWGQGTLVTVSSASTKGPS 
TAEDTAVYSCARGRRVGALSYFDSWGQGSLVTVSSASPTSPS 
TAADTAVYYCARRSDIWHAFDPWGPGTMVTVSSASPTSPS 
TAVYYCANNYYDFRRGYPDPTYYGMDVWGQGTTVTVSSASTKG 
RAEDTAVYFCAKARTTVTTWDYWGQGTLVTVSSASTKGPS 
TAADTAVYFCARAESAGYYYYDFWGQGTLVTVSSASTKGPS 
AVYYCARDPKQSVDGSDFYSYHYGMDVWGQGTTVTVASASPTS 
3-74*01 
4-61*01/08 
4-31*03 
4-b*02 
4-4*07 
3-74*01/03 
3-74*01/02 
3-9*01 
3-23*04 
3-72*01 
4-59*01 
3-21*01 
3-48*03 
3-30*03/18 
1-69*01 
4-4*07 
4-61*01 
4-31*04 
3-30*03/18 
3-33*05 
3-74*02 
4-4*07 
1-8*01 
4-30-4*03 
4-4*07 
3-74*01/03 
4-4*07 
4-31*01 
4-61*01 
3-23*04 
4-39*01 
1-69*01 
3-23*04 
4-4*07 
3-48*01/02 
5*01/02 
4*02 
4*02 
4*02/03 
6*02 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
4*02 
6*02 
3*01 
4*02 
6*02 
6*02 
4*02 
3*02 
4*02 
4*02 
5*02 
4*02 
5*02 
3*02 
4*02 
6*02 
4*02 
4*02/03 
4*02 
3*01/02 
6*02 
4*02 
4*02 
6*02 
IgG 
IgA 
IgG 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgA 
IgA 
IgG 
IgG 
IgG 
IgA 
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EDTAVYYCALQPTHSSMGTRTISGRITDYWGQGTLVTVSSASTKG 
RAEDTAVYYCARDLSWQLFDYWGQGALVTVSSASTKGPS 
TTEDTAVYYCTTITGWDRTKFDTWGRGTLVTVSSASTKGPS 
TVADTAVYFCARGKEWLPDNWFDPWGQGILVTVSSASPTSPS 
AVYYCARGLRTRGPAIFGVVMPLRLHFGLDVWGQGTTVTVSSAST 
GAEDTAVYYCVKCHVVAAGWCNFFDPWGQGTLVTVSSASPTSPS 
RAEDTAVYYCARAFQGVILDYWGQGTLVTVSSASTKGPS 
TAADTAIYYCARGKSVVGATDDYFDYWGQGALVTVTSASTKGPS 
RSEDTAVYYCARYSGTYYPSYFDQWGQGTLVTVSSASTKGPS 
TAADTAVYYCARRSDIWHAFDPWGPGTMVTVSSASPTSPS 
TAVYYCANNYYDFRRGYPDPTYYGMDVWGQGTTVTVSSASTKG 
TAADTAVYYCAVTTTSTGASEIWGPGTMVTVSSASPTSPS 
TTADTAVYFCARGQLMGPWGRGTLVTVSSASTKGPS 
KSEDTAVYYCATKHCGGGNCHFQIFDFWGQGVLVSVSSASPTSPS 
DTAVYYCARDGMAEGVGRYHYYYGVDVWGQGTTVTVSSASTK 
RVEDTGVYYCARGLRYLYGLDVWGQGTTVTVSSASTKGPS 
TAADTAVYYCARGGMLIQEWSNLYSWGQGTPVIVSSASTKGPS 
TAADTAVYYCARGERSIDWYFDLWGRGTLVTVSSASTKGPKV 
TAADTAVYYCARQDTTGVFAYWYFDVWGRGTLVTVSSASPTSPS 
RAEDTAVYYCARDDFGDQSLLDYWGQGTLVTVSSASTKGPS 
RVEDTGTYYCARGGGQTWGQGVLVTVSSASPTSPS 
TAADTAVYYCARDYSANSRYFDYWGQGTLVAVSSASTKGPS 
RASDTATYYCARHLVPDLVREFYYYALDVWGHGTTVTVSSASTK 
RVEDTAIYYCASDEAEQLVAYQHGMDFWGLGTTVTVSSASTKGP 
RVDDTAVYYCARARPGSYGLDIWGQGIVVIVSSASPTSPS 
STEDTAVYYCARPGPNGSGKEDVFDLWGQGTMVAVSSASTKGPS 
3-7*01 
3-74*01/03 
3-15*01 
4-4*07 
1-8*01 
3-23*01/04 
3-74*03 
4-61*08 
1-69*01 
4-39*01 
1-69*01 
4-4*07 
4-61*07 
3-15*01 
4-59*01 
3-74*01/02 
4-59*01 
4-59*01 
4-59*01/03 
3-21*01 
3-74*01/03 
4-59*01 
5-51*02 
3-30*03/18 
3-74*01/03 
3-30*01/15 
4*02 
4*02 
4*02 
5*02 
6*02 
5*02 
4*02 
4*02 
4*02 
3*01/02 
6*02 
3*02 
1*01 
4*02 
6*02 
6*02 
4*02 
2*01 
2*01 
4*02 
5*02 
4*02 
6*02 
6*02 
3*02 
3*01/02 
IgG 
IgG 
IgG 
IgA 
IgG 
IgA 
IgG 
IgG 
IgG 
IgA 
IgG 
IgA 
IgG 
IgA 
IgG 
IgG 
IgG 
IgG 
IgA 
IgG 
IgA 
IgG 
IgG 
IgG 
IgA 
IgG 
 
Sequences from data set were compared with known Ig sequences to determine variable 
region and joining region usage (Imgt.cines.fr - version 3.2.16 (Accessed 24 September 2010) 
(Brochet, X et al, 2008)). 
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Appendix – A5 
 
Sequences of T cell receptor β-chain CDR3 from healthy donors 
 
Sequence V 
Region 
J 
Region 
QTSVYFCASSYGARGNTEAFFGQGTRLTVVEDLNKVFPP 
LGDSALYFCASSVGKSYEQYFGPGTRLTVTEDLKNVFPP 
PSQTSVYFCASSYGDGTYEQYFGPGTRLTVTEDLKNVFPP 
QPEDSALYLCASSQAGYSYNEQFFGPGTRLTVLEDLKNVFPP 
PSQTSVYFCASSETSGRSDEQFFGPGTRLTVLEDLKNVFPP 
ELGDSALYFCASSVTQGKSCEQYFGPGTRLTVTEDLKNVFPP 
KLEDSAMYFCASSDRGQPQHFGDGTRLSILEDLNKVFPP 
QQEDSAVYLCASSSRGLGSPLHFGNGTRLTVTEDLNKVFPP 
ELGDSALYFCASSVEESHNEQFFGPGTRLTVLEDLKNVFPP 
SSQTSVYFCAISETGTATDTQYFGPGTRLTVLEDLKNVFPP 
ELGDSALYFCASSVGQGKSYEQYFGPGTRLTVTEDLKNVFPP 
ELGDSALYFCASSVAPTPTRNEQFFGPGTRLTVLEDLKNVFPP 
PSQTSVYFCASSYGDGTYEQYFGPGTRLTVTEDLKNVFPP 
KLEDSAMYFCASSPGGTRQPQHFGDGTRLSILEDLNKVFPP 
SSQTSVYFCAISEKGFEQYFGPGTRLTVTEDLKNVFPS 
QQEDSAVYLCASSLQTSGVNEQYFGPGTRLTVTEDLKNVFPP 
QQEDSAVYLCASSLQPSGINEQYFGPGTRLTVTEDLKNVFPP 
SPEDSSIYLCSADFRGEQYFGPGTRLTVTEDLKNVFPP 
QTSVYFCAISTQYFGPGTRLTVLEDLKNVFPP 
 
TERGDSAVYLCASSPDLIYEQYFGPGTRLTVTEDLKNVFPP 
QQEDSAVYLCASSPDLIYEPTFGPGTRLTVTEDLKNVFPP 
QSSFYICSAVPAATTVNNYGYTFGSGTRLTVVEDLNKVF 
PSQTSVYFCASSYGGDGYTFGSGTRLTVVEDLNKVFPP 
EQRDSAMYRCASSLAGEGYEQYFGPGTRLTVTEDLKNVFPP 
QQEDSAVYLCASSPELITEQAFGPGTRLTVTEDLKNVFPP 
QQEDSAVYLCASSPGLLYTGYFGPGTRLTVLEDLKNVFPP 
PSQTSVYFCASSYGGTEAFFGQGTRLTVVEDLKNVFFP 
SSQTSVYFCAISAPDRVGETQYFGPGTRLLVLEDLKNVFPP 
QQEDSAVYLCASSGDLIYRYFGPGTRLTVTEDLKNVFPP 
PSQTSVYFCASSYGGEGTTPGSGTRLTVVEDLNKVFPP 
EQRDSAMYRCASSLGQGNEQFFGPGTRLTVLEDLKNVFPP 
6-6*01 
9*02 
6-5*01 
4-3*01 
6-1*01 
9*03 
2*01 
7-2*01 
9*02 
10-3*02 
13*01 
13*01 
6-6*04 
2*02 
10-1*02 
7-8*01 
7-2*01 
29-1*01 
10-3*03 
 
7-3*05 
7-2*01 
20-1*02 
6-5*01 
7-7*01 
7-2*01 
7-8*01 
6-5*01 
10-3*01 
7-2*03 
6-1*01 
7-6*01 
1-1*01 
2-7*01 
2-7*01 
2-1*01 
2-1*01 
2-7*01 
1-5*01 
1-6*01 
2-1*01 
2-3*01 
2-7*01 
2-1*01 
2-7*01 
1-5*01 
2-7*01 
2-7*01 
2-7*01 
2-7*02 
2-3*01 
 
2-7*01 
2-1*01 
1-2*01 
1-2*01 
2-7*01 
2-7*01 
2-3*01 
1-1*01 
2-5*01 
2-7*01 
1-2*01 
2-1*01 
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QQEDSAVYLCASSPRGGGVGNTIYFGEGSWLTVVEDLNKVFPP 
EQRDSAMYRCASSLQGTNTGELFFGEGSRLTVLEDLKNVFPP 
QQEDSAVYLCASRGVGSPLHFGNGTRLTVTEDLNKVFPP 
PSQTSVYFCASNSPGQGRTPLHFGNGTRLTVTEDLNKVFPP 
EQRDSAMYRCASSPAGASNQPQHFGDGTRLSILEDLNKVFPP 
APSQTSVYFCASSPRGYNEQFFGPGTRLTVLEDLKNVFPP 
SSQTSVYFCAIKADTLTDTQYFGPGTRLTVLEDLKNVFPP 
TQQEDSAVYLCAIKPDLIYEFGPGTRLTVTEDLKNVFPP 
 
LELGDSAVYFCASSQMRERTETQYFGPGTRLLVLEDLKNVFPP 
LQPEDSALYLCASSREAGYEQYFGPGTRLTVTEDLKNVFPP 
PEDSSFYICSARDPREAYTGELFFGEGSRLTVLEDLKNVFPP 
AELEDSGVYFCASSQYRYNEQFFGPGTRLTVLEDLKNVFPP 
KNPTAFYLCASTRLAGQPQHFGDGTRLSILEDLNKVFPP 
SPEDSSIYLCSVEGLAGGDEQFFGPGTRFTVLEDLKNVFPP 
EDSGVYFCASSQLLAGGSIEGGRSYNEQFFGPGTRLTVLEDLK 
APSQTSVYFCASTLTVNTGELFFGEGSRLTVLEDLKNVFPP 
SEPRDSAVYFCASSLRSGGAGTGELFFGEGSRLTVLEDLKNVF 
 
APSQTSVYFCASSEGASGANVLTFGAGSRLTVLEDLKNVFPP 
LQPEDSALYLCASSPGLGGNTGELFFGEGSRLTVLEDLKNVFPP 
TKLEDSAMYFCASSSDRNTEAFFGQGTRLTVVEDLNKVFPP 
LELGDSAVYFCASSQARVTSGVSSYNEQFFGPGTRLTVLEDLN 
APSQTSVYFCASSYEGTSYNEQFFGPGTRLTVLEDLKNVFPP 
AELEDSGVYFCASSLQGIPYEQYFGPGTRLTVTEDLKNVFPP 
LGDSALYFCASSLVGSGGAQEQFFGPGTRLTVLEDLKNVFPP 
ELGDSALYFCASSVLLAGDNEQFFGPGTRLTVLEDLKNVFPP 
TEQRDSAMYRCASRTTGYTEAFFGQGTRLTVVEDLNKVLPP 
TSSQTSVYFCAIWREGDTQYFGPGTRLTVLEDLKNVFPPA 
ELEDSGVYFCASSQDWLGTGPNYNSPLHFGNGTRLTVTEDL 
LQPEDSALYLCASSPGLGARTGELFFGEGSRLTVLEDLKNVFPP 
TKLEDSAMYFCASSESGLAGNTGELFFGEGSRLTVLEDLKNV 
AQKNPTAFYLCASSIGGQIYTEAFFGQGTRLTVVEDLNKVFPP 
SEPRDSAVYFCASSRQVNEQFFGPGTRLTVLEDLKNVFPP 
ELEDSGVYFCASSQDLWTPGGNYNSPLHFGNGTRLTVTEDLN 
ELGDSALYFCASSGGRSYEQYFGPGTRLTVTEDLKNVFPP 
 
7-2*04 
7-7*01 
7-2*01 
6-1*01 
7-7*01 
6-5*01 
10-3*03 
7-2*03 
 
3-1*02 
4-3*01 
20-1*01 
14*01 
19*01 
29-1*01 
14*01 
6-5*01 
12-4*01 
 
6-1*01 
4-3*01 
2*02 
3-1*02 
6-5*01 
14*01 
9*03 
9*01 
7-7*01 
10-3*02 
14*01 
4-3*04 
2*01 
19*01 
12-4*01 
14*01 
9*02 
 
1-3*01 
2-2*01 
1-6*02 
1-6*01 
1-5*01 
2-3*01 
2-3*01 
2-7*01 
 
2-5*01 
2-7*01 
2-2*01 
2-1*01 
1-5*01 
2-1*01 
2-1*01 
2-2*01 
2-2*01 
 
2-6*01 
2-2*01 
1-1*01 
2-1*01 
2-1*01 
2-7*01 
2-1*01 
2-1*01 
1-1*01 
2-3*01 
1-6*01 
2-2*01 
2-2*01 
1-1*01 
2-1*01 
1-6*01 
2-7*01 
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TDRWDTAVYLCASSPYSGTSSTREQFFGPGTRLTVLEDLKNVF 
ELGDSALYFCASSPGTSGREVGTQYFGPGTRLTVLEDLKNVF 
QQEDSAVYLCASSPPGQASYGYTFGSGTRLTVVEDLNKVFPP 
QQEESAVYLCASSFIAGENYNEQFFGPGTRLTVLEDLKNVFPP 
ELGDSALYFCASSPRDAANYGYTFGSGTRLTVVEDLNKVFPP 
ELGDSALYFCASSVGPFSLDEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCAQTPDWAGEGGYTFGSGTRLTVVEDLNKVFP 
TERGDSAVYLCASSLIGGTRFTGELFFGEGSRLTVLEDLKNVF 
TQQEDSAVYLCASSPPGQASYGYTFGSGTRLTVVEDLNKVFP 
LQPEDSALYLCASSQEFSGYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASSYTVPWTGDEQYFGPGTRLTVTEDLKNVFPP 
TQQEDSAVYLCASSPPGQASYGYTFGSGTRLTVVEDLNKVFPP 
VPSQTSVYFCASSGGGATDTQYFGPGTRLTVLEDLKNVFPP 
TQQEDSAVYLCASSFITRLSYNEQFFGPGTRLTVLEDLKNVFP 
TCSQTLVYFCAISVQGAEETQYFGPGTRLLVLEDLKNVFPP 
QQEDSAVYLCASSRPGPLSQETQYFGPGTRLLVLEDLKNVFPP 
TERGDSAVYLCASSPYSGTSSTREQFFGPGTRLTVLEDLKNVF 
DSALYFCASSSPRGVPGANVLTFGAGSRLTVLEDLKNVFPP 
TQQEDSAVYLCASSSGTSAEQFFGPGTRLTVLEDLKNVFPP 
TSSQTSVYFCAISGPGAGSYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCANGVMGGYNEQFFGPGTRLTVLEDLKNVFPP 
TQQEDSAVYLCASSLGISYNEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSYGGSLADGYTFGSGTRLTVVEDLNKVFPP 
APSQTSVYFCASSPSGGHYNEQFFGPGTRLTVLEDLKNVFPP 
 
APSQTSVYFCASSYSGADEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASAPTGGGGDEQFFGPGTRLTVLEDLKNVFPP 
ATRSQTSVYFCASNPLGGSGYGYTFGSGTRLTVVEDLNKVFPP 
APSQTSVYFCASSYGGQGGQPQHFGDGTRLSILEDLNKVFPP 
APSQTSVYFCASSYDGNTEAFFGQGTRLTVVEDLNKVFPP 
APSQTSVYFCASSPVSGSGSYGYTFGSGTRLTVVEDLNKVFPP 
TEQRDSAMYRCASSLGGILDNSPLHFGNGTRLTVTEDLNKVF 
TEQRDSAMYRCASSLGETQYFGPGTRLLVLEDLKNVFPP 
TSSQTSVYFCAIRGGGEETQYFGPGTRLLVLEDLKNVFPP 
APSQTSVYFCASSYRDYSPLHFGNGTRLTVTEDLNKVFPP 
TSSQTSVYFCASRPGLGPLHFGNGTRLTVTEDLNKVFPP 
APSQTSVYFCASSPTSGGTTDTQYFGPGTRLTVLEDLKNVFPP 
11-2*01 
9*01 
7-2*01 
7-8*01 
13*02 
9*02 
6-5*01 
7-3*05 
7-8*03 
4-2*01 
6-5*01 
7-2*04 
6-4*01 
7-2*01 
10-3*02 
7-2*02 
7-3*01 
9*01 
7-8*01 
10-3*02 
6-1*01 
7-2*01 
6-5*01 
6-6*01 
 
6-5*01 
6-5*01 
10-2*01 
6-5*01 
6-5*01 
6-5*01 
7-6*01 
7-6*04 
10-3*02 
6-5*01 
10-3*02 
6-5*01 
2-1*01 
2-3*01 
1-2*01 
2-1*01 
1-2*01 
2-7*01 
1-2*01 
2-2*01 
1-2*01 
2-7*01 
2-7*01 
1-2*01 
2-3*01 
2-1*01 
2-5*01 
2-5*01 
2-1*01 
2-6*01 
2-1*01 
2-7*01 
2-1*01 
2-1*01 
1-2*01 
2-1*01 
 
2-1*01 
2-1*01 
1-2*01 
1-5*01 
1-1*01 
1-2*01 
1-6*01 
2-5*01 
2-5*01 
1-6*02 
1-6*01 
2-3*01 
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APSQTSVYFCASAPQGGYEQYFGPGTRLTVTEDLKNVFPP 
ELGDSALYFCASSLEGQSYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASRPRTGAYEQYFGPGTRLTVTEDLKNVFPP 
ASSQTSVYFCASSHRDPGADTQYFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSYRRTSGGVYEQFFGPGTRLTVLEDLKNVFPP 
LQPEDSALYLCASSLGVTEAFFGQGTRLTVVEDLNKVFPP 
QRTEQRDSAMYRCASSLARILDNSPLHFGNGTRLTVTEDLNKV 
ESATSSQTSVYFCAISQKGDQYFGPGTRLLVLEDLKNVFPP 
APSQTSVYFCASSPVSGSGSYGYTFGSGTRLTVVEDLNKVFP 
AELEDSGVYFCASSDGSGANVLTFGAGSRLTVLEDLKNVFPP 
 
AELEDSGVYFCASSQDMPGEQYFGPGTRLTVTEDLKNVFPP 
LELEDSALYLCASSLQGSYEQYFGPGTRLTVTEDLKNVFPP 
ELGDSALYFCASSVGAGQGGTYEQYFGPGTRLTVTEDLKNVF 
APSQTSVYFCASRRMGGSYEQYFGPGTRLTVTEDLKNVFPP 
KLEDSAMYFCASSEALRATQYFGPGTRLLVLEDLKNVFPP 
NRETRHCISAPAVSLGNEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASSSVIAGAGTGELFFGEGSRLTVLEDLKNVFPP 
HPEDSSFYICSAPAPGARSYTDTQYFGPGTRLTVLEDLKNVFPP 
SEPRDSAVYFCASSLTGGAYEQYFGPGTRLTVTEDLKNVFPP 
PNQTALYFCATSVSGDNEQFFGPGTRLTVLEDLKNVFPP 
TSSQTSVYFCATSSGEGTDTQYFGPGTRLTVLEDLKNVFPP 
VRGDSAAYFCASSLAPSRATIDNEQFFGPGTRLTVLEDLKNV 
VVRGDSAAYFCASSQFPGQASYNSPLHFGNGTRLTVTEDLNK 
APSQTSVYFCASSPQGGYGYTFGSGTRLTVVEDLNKVFPP 
TQQEDSAVYLCASSSTGFKEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASNPDRGIYNEQFFGPGTRLTVLEDLKNVFPP 
 
ASSQTSVYFCASSDKGTSGGTNEQFFGPGTRLTVLEDLKNVF 
APSQTSVYFCASSFTYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASSYSRGNEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSYRAGVTEAFFGQGTRLTVVEDLNKVFPP 
TERGDSAVYLCASSLTSGSYNEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASRYSTDTQYFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSPYRADQPQHFGDGTRLSILEDLNKVFPP 
APSQTSVYFCASRPAGIPNTGELFFGEGSRLTVLEDLKNVFPP 
APSQTSVYFCACLGSGRLLEQFFGPGTRLTVLEDLKNVFPP 
6-6*01 
9*01 
6-5*01 
10-1*02 
6-2*01 
4-1*01 
7-7*01 
10-3*02 
6-1*01 
14*02 
 
14*01 
5-8*02 
9*02 
6-1*01 
2*01 
 
6-2*01 
20-1*01 
12-4*01 
24-1*01 
10-3*01 
18*01 
18*01 
6-5*01 
7-2*01 
6-1*01 
 
10-1*01 
6-6*01 
6-6*01 
6-5*01 
7-3*01 
6-2*01 
6-2*01 
6-6*01 
6-2*01 
2-7*01 
2-7*01 
2-7*01 
2-3*01 
2-1*01 
1-1*01 
1-6*02 
2-5*01 
1-2*01 
2-6*01 
 
2-7*01 
2-7*01 
2-7*01 
2-7*01 
2-5*01 
2-7*01 
2-2*01 
2-3*01 
2-7*01 
2-1*01 
2-3*01 
2-1*01 
1-6*02 
1-2*01 
2-7*01 
2-1*01 
 
2-1*01 
2-7*01 
2-1*01 
1-1*01 
2-1*01 
2-3*01 
1-5*01 
2-2*01 
2-1*01 
 338 
TRSQTSVYFCASQPDSAYNEQFFGPGTRLTVLEDLKNVFPP 
IPNQTALYFCATGQGYNEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSPPAGTREQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASSYSQGGYEQYFGPGTRLTVTEDLKNVFPP 
GDSALYFCASSPLQFLAKNIQYFGAGTRLSVLEDLKNVFPP 
APSQTSVYFCASSRLLAGVDEQFFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCASRGGTGSTGELFFGEGSRLTVLEDLKNVFPP 
 
TSSQTSVYFCASRDIRTEAFFGQGTRLTVVEDLNKVFPP 
PEDSALYLCASSQEGGIAQYFGPGTRLTVLEDLKNVFPP 
APSQTSVYFCARHRQGATGELFFGEGSRLTVLEDLKNVFPP 
APSQTSVYFCASSQGQWEETQYFGPGTRLLVLEDLKNVFPP 
APSPTYVYLCASSYSSRGGSDTEAFFGQGTRFTVVEDLNKVF 
APPQTSVYFCASRRNTGELFFGEGSGLTVLEDLKNVFPP 
APSQTSVYFCASNVQGSTEAFFGQGTRLTVVEDLNKVFPP 
APSQTSVYFCASSYPRGGTMAQYFGPGTRLLVLEDLKNVFPP 
APSQTSVYFCASSFYPRSVKNIQYFGAGTRLSVLEDLKNVFPP 
TSSQTSVYFCAISDRVSYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASNVQGSTEAFFGQGTRLTVVEDLNKVFPP 
GDSALYFCASSSGQKNTEAFFGQGTRLTVVEDLNKVFPP 
APSQTSVYFCASIRQGATEAFFGQGTRLTVVEDLNKVFPP 
TQQEDSAVYLCASSLGLAGGGAETQYFGPGTRLLVLEDLK 
PEDSALYFCASRQGETQYFGPGTRLLVLEDLKNVFPP 
 
APSQTSMYLCASSLVPGDFYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASSRQGRLGYTFGSGTRLTVVEDLNNVFPP 
AIPNQTALYFCATSDLTPGANVLTFGAGSRLTVLEDLKNVFPP 
LELGDSAVYFCASSRSTGGSYEQYFGPGTRLTVTEDLKNVFPP 
APSQTSVYFCASSYVSQNNEQFFGPGTRLTVLEDLKNVFPP 
LQPEDSALYLCASSLTQAYEQYFGPGTRLTVTEDLKNVFPP 
LGDSALYFCASSVGGSTDTQYFGPGTRLTVLEDLKNVFPP 
TEQGDSAVYLCASSLVAGEQYFGPGTRLTVTEDLKNVFPP 
10-2*01 
24-1*01 
6-5*01 
6-5*01 
9*02 
6-5*01 
6-5*01 
 
10-3*01 
4-3*01 
6-6*01 
6-6*01 
6-5*01 
6-2*01 
6-3*01 
6-3*01 
6-1*01 
10-3*02 
6-5*01 
9*02 
6-5*01 
7-2*01 
4-3*01 
 
6-6*01 
6-5*01 
24-1*01 
3-1*02 
6-6*01 
4-3*01 
9*01 
7-4*01 
2-1*01 
2-1*01 
2-1*01 
2-7*01 
2-4*01 
2-1*01 
2-2*01 
 
1-1*01 
2-3*01 
2-2*01 
2-5*01 
1-1*01 
2-2*01 
2-2*01 
2-5*01 
2-4*01 
2-7*01 
1-1*01 
1-1*01 
1-1*01 
2-5*01 
2-5*01 
 
2-7*01 
1-2*01 
2-6*01 
2-7*01 
2-1*01 
2-7*01 
2-3*01 
2-7*01 
 
Sequences from data set were compared with known TCR sequences to determine variable 
region and joining region usage (Imgt.cines.fr - version 3.2.16 (Accessed 24 September 2010) 
(Brochet, X et al, 2008)). 
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Appendix – A6 
 
Table of T Cell Receptor CDR3-Derived Peptides Predicted to bind to HLA 
Alleles from SYFPEITHI and BIMAS 
 
HLA-A1
+
  HLA-A1
-
  HLA-A2
+
  HLA-A2
-
  
YGDGTYEQY 
VLEDLKNVF 
ISEKGFEQY 
SPDLIYEQY 
SADFRGEQY 
VTEDLKNVF 
KLEDSAMYF 
ELEDSGVYF 
VTEDLNKVF 
SQDMPGEQY 
SSRQGRLGY  
VTEDLKNVF 
ILDNSPLHF 
VTEDLNKVF 
ELEDSGVYF 
KLEDSAMYF 
 
SLIGGTRFT 
SVLEDLKNV 
GLAGGGAET 
SMYLCASSL 
DLTPGANVL 
YLCASSPEL 
YLCASSPDL 
AMYRCASSL 
YLCASSPGL 
LVLEDLKNV 
YLCAIKPDL 
ALYFCASSV 
ALYFCASSL 
YLCASSLGV 
ALYLCASSL 
YLCASSLGL 
TVTEDLKNV 
TVVEDLNKV 
TVLEDLKNV 
SILEDLNKV 
LIYEFGPGT 
YLCASSFIA 
YLCASSFIT 
LVYFCAISV 
YLCASSSGT 
YLCASSLGI 
TLTVNTGEL 
ALYFCASSL 
GLGGNTGEL 
GLGARTGEL 
GLAGNTGEL 
CISAPAVSL 
SLAPSRATI 
TVVEDLNKV 
ALYFCASSV 
SILEDLNKV 
LVLEDLKNV 
YLCASSPGL 
ALYLCASSL 
ALYFCATSV 
TVTEDLKNV 
TVLEDLKNV 
SVLEDLKNV 
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HLA-B7
+
  HLA-B7
-
  HLA-B8
+
  HLA-B8
-
  
APSQTSMYL 
GPGTRLTVL 
APSPTYVYL 
GPGTRLLVL 
AVYLCASSL 
QPEDSALYL 
AVYFCASSL 
AAYFCASSL 
WPRHPADSA 
CASSPLQFL 
ASRRNTGEL 
AVYLCASSL 
GPGTRLTVL 
GPGTRLLVL 
SPGQGRTPL 
GPGTRFTVL 
QPEDSALYL 
SSRGLGSPL 
AVYLCASSL 
SPEDSSIYL 
QAFGPGTRL 
ASRGVGSPL 
SVYFCASTL 
AVYFCASSL 
ASRPGLGPL 
GLGARTGEL 
GPGTRLTVL 
GPGTRFTVL 
GAGSRLTVL 
GPGTRLLVL 
FCAIKADTL 
 
GPGTRLTVL 
CASSRPGPL 
GPGTRLLVL 
GAGTRLSVL 
CASSRQGRL 
GAGSRLTVL 
 
 
Key 
 
Peptides predicted to bind to:  SYFPEITHI 
    Both Algorithms 
    BIMAS 
 
 
 
